var title_f40_43_41648="Nasolabial folds";
var content_f40_43_41648=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F77905&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F77905&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 522px\">",
"   <div class=\"ttl\">",
"    Nasolabial folds",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 502px; height: 302px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAEuAfYDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDsFUYyaI+GoIz9KcVK4IrwrWPohsy7j9KEj4qVV3deKXvgdKA8hgU9hxUco59qnY4HXioJWB+7Q2UkQkYannAHPWo+d3v6VPHFkZcc0k77FNW3EUZXphaYWwcAcVLtOOTxTX27TtGT6mmSRsyikAL9OBRswASKlVl28KcUgsNWMA4J61Mqnbtz+FMjQlw2KuQhCx3cMaaE9CNIhj52x7VLE8cO5cnJp0sS5DREk1C20k5PNGqFuTYj4dTlqcpwx3EAHtVAsV5XpT3kHGTk4qosUombrBzMSB0qCBtw5p902Ufvms+GVg208VnLe5olpYvzRgqO1Ubq1Eg+7we9XkYHaDyKtLF5gPA6U0rhflOHvdNxIdorPn0dnzkHFeiSadmLfsBNZ11biLC7fnPUU+Vo051LQ4bTfDEMVz58i7iDxmup0+IRuVUcD0pHfau3b82elWrONyCQACewpXu9SJaK5KjEttBJJOK0oUxDkgjJ7UlvbKgEkgwfQVd8tnOOgxwM1qonK53ZUC/MinIXOSTS3KqrhEbOR1z0qdoFIO5ycdB6Vl3M5XcqDk9zQ42GtSneqBIc/eFZUqtK3CkY6cdK0rgSvEpkAXBzkdTUcW5nYH7vc/0rJrWxpeyKEFpGZN789uauTW4SPMqZIIHy/wAP0q7bC327lUNu4KYz/OrCKHjb930YEeg9q0irKxm3dnF6zZFnIyVZj8vvXPT2skO7J/GvQtQi89XbaAFPUVzep2gYHAGV4yaiVzWCOB1awDOJVYBu9a/hd1V1354OCKfq1odvyAZI9OlZens1pPmXn1wapSuikj2rRYY44luCwO4cKfSqN8Y/NfyxjmuXsddyEQyYAHAzU02phjwxxTlO6shRptO7JL6RVBzjI6Vxuu6gFRgfvdBV3V9TCBiTiuSlaS8m7kE8VEY31ZqtCC2haabIBJJr0/wXbmziG4csOlc1ommCNkZhk12WnyiF1xVOVndilquVHW285AwtaFrKXADtz0BrnIJ/nzmtO2lDcMStCd2Z8uhty2yMoUPz71nXtoUwB+lWISeAz5B6GpZVZWGPmFNolXizCms+5/Gqc0G0nvXRXELY3HpWbcRjeTjmspRNYyuYjDnGKhuANhzkVqPCMkjqKozqeQwyKjUsx2yDz0odTj+lWpEAPFQMnPXpUobREp2tgjipAMnIqKQ06FznnpTJsTAZWonYjjtUgOG9jVa5JVsjpT2JsTsvGRwaqTtgnPWpVnynBqtP8+exob7AvMgmdQnvVbn71Dn5iDSOcJxTi7iloKTnmiohIcUU7kNHu4HFPRfl5qJCTkmpCcDitLisJS7Dt4oBI7UKxJxSKGMuRzTGUdutWWAPFIYwKbGmRQxBQWPWnFhj3p4XJxSeWoO480vQbdxgGQdxqFyOgHSp5OBkcVXxlsnOBSYJCiIyY44qxBbg9uBS27BgeMAVL5mflUYFNWE77DmVYsDgsfTtSCIJ8xHWnKjde/apWBIx/FVWuQ9CCN3MnOFT09aiYKjO/Y06ZskqOo61SmkBG09FpNlRiLM/AVelNd1jhAHLGnwKrKzPVS4kUAhevYmpWmo7X0KtxIu/FZ07YcstXXVeD1PrVK9QyDCNt9am9y7WHw3JKjZg1ejutpXnHtXPgvbnAGR61Il4gzuOTS5rFqKZ0Uup5lVGHy/WqGp3ibwYvmJ44NY7ztKx8rJq3Z2s8zhZIwPfPWnzuWhLioaiafbNdTlnyMGultLQQggKCe1Q6fZm1BLHhjxnsK1YVUDcPmLCtIxsc1SfMVD8q4xhs9+1TQp5cYYtyanESyBmC/UntT3jVsep9e1bJ3MGrFS4QEEoSCeCKy7xdsRLEFtuAB2rVVwJChOZDwMdKoXiK0MhXChWweOpol3Ki+hhSGWRPukr/KtC3hVLdUYbuchtvf0qKFGEhDHrxx0q5Gu1h5R+ZTznpis0upUpEljb/M+IxhjuBxyKt3SBLVto2heWA6k1LbbpgAhAGevenNE5EhkGFJwvOa1S0MnLU5ydRParKAcAcqBWJdQFxIyj5OxPFdXJFI0bZhKjPAH8WO+KzdSQKq4Hyjls1lNHTCRx97Z/uhyp47Vy95p7+UzEqGXpXcXCh0DxYaM9KyLi13KW468isb2NPM42JpInG4EAj72alk1PauA2a0rmycyujINp5FUZNOhDbXTcR6VSkupakZczPdt82cGtPT7RI1B705oI4wBHGST2p8BZXxjApykugK71ZtWa7cVprjg1jwybQK0LebcoB7VjKRSRpQzMhrXtr4HAI49awgQRjNPilMZAPIoUrA1c6+3mVgMGtGBxt+Zua5C2vwhCk8VuW12rgYFaxmQ43NhmGDgk5qo1qdxLEYNWYpEIGcg0+ZgcLtJB7ir0ZnexhyxhJNy81Tudr5xjPpWxcRhQQo4qhNCuMgVk00bJpmK6DJ4qk5HmEHita6t2IJjNZEysjnd1rNuxoo3RWuAQeOlLC+Ux6UuS2eKiUbWPbNNMlrQtxgdaivF+XjpUcbEE46UXEm6LjtVaWI2M0SFJiM8VMzioNu4s2KZuycZwalCkRzY3E1GXp7r82KgdSZQoqloJ6jlUEk0VLImxQDRTsRc9xRsZqZMEZqA4FPQ46mrQEwIJpvAYkVGzfNgGnIM0bjSJCvGc807OFPc01CSfWpGXbg96LAIPlGCOTSAZJOOKXaxOaV8hcL1obAhc5bgcUpG8bQABRyR0FTRRcZJpLUp6DI4yoywwoqwVULlRyacqF1+Y9OgqQpIYzgYAHWrSIbGBtmDUBY7mkJpFl2ROrct61RnuCsfyjipcrIaiK77Y2buaz5H3EAZPrRJLIRg/lT7dSVyx96j4jT4Syzf6OM8VRkAY4qxK+8d+KqO4XORk0paiirDJtoXArPkDDJzwauMWbJPFQ+XvYBhmpZRnYZiRglTSpph88bWG09jW20KNjHSpo41WYYAp2J57bFey02KAZVcsetadtEqvyAAKlROflqaCJS3qc9jVxjqYSn3HOoK4IyDT4lU/Kgxt7mpGGeBgL61EplWRmZgUyNtaGd7k2GXOB8mMntUN1I2wgFgD1YcAVaGxl3sw9APekJGx1kX5e3FUBQjhRSXUnceSc5qG4jWZNmQQeTxVkkKCoAHeoMjftB5I9KL9xNW1MzJWf7nAHXHGKghkZ55VAHI4FaTwW8oMT52sM45yait4Y7eRFSNmbdt47D3poVy9p0cixr5iFV7jNaR2FcDAAPrUKMCPmX5sZI9PaiGGNGeRnOG5w3QfSrWmiI31IrkqwwysPpxWDexqXfCk7uDnit+R4zIyKcyBckHsKyNQh+Q/K3pkGon5m1NnNvbBBlQNvoKoyW48skAAVumFIoxGg2j9apmIbXAPB71g0bNnPXUSvuyRlRwaxLhBluxAzXVTwK3y9fese7gCycDjvUNdykzD2h1yp59qfEoGCBlver81omxGjHB6ioGj28g/hSehadyNc7uRirtvk1AvT5hUkbbH9qllJmhk7eOtPUFl5qusgzipkcE7c0MaZG7FDjNaWmagUYKzVlzpye9VWmMbcDmmh7no9pfGRRtwa2ra6OzlBXm2hag/mYdsV2NpceYow2DW0JWMpwRozYkf7nX0qndRBOn5VagkCZLsSBUNzIh5Bzmqk01cmK10MuZsN0rJuoQ0hNbsiqW3dxWdcqC5GOaxkbR0MOVMMQOKruCM5rTuI8DOOapOmOetTsNmezsr+1DNxx0NFwpBPpVbeVGD0pksSTKEgdKrRn95z0qxcH5QQc1XuGG0FadjK4ucuTUUD5uuelMZsJweaYpwc96pEtl28YM/HSiq5bOCaKpq5KaPcRIrnjtUi4PJPSq+wI+B09aeBjvT2GiwuDg96kHfFVEzmrKZHFK5RLECDnFOkJzyaVGwM0x+T0wKoFuSwlutLPkrhRj1ogYAinlgX56UMOpDHHuYZPAqwMBSV7frT4go6DrTUyXJPQU0kDdxshkIUr1NSXEhEQUv060SMpj+XjFZU7GQksxCCm3YIx5iOacENt6HvVCafnFJczBQQOlUof3jFiTisL3djeySL0Kh2yT0qVic4FQwbVHzE0ssoXnOBQzK+opB5J6VD5ZlJIIAFSGT5c5/CmxOH+7RoF9BJFUfKetIsQKEEZJqXAZjxyKkRCxG04FFib6DraFYYgFNPigHnFiTz+VSrGFwGPNThAik8nNUkQ5DInDM2FIC8ZNT2kSwh2Uk7uSarljKWBT92OpxVhGDQphdq+/WtF3M2uhNEm75m/h6UjoTIGAz2pxBVFCPjBycd6Z5UoYNGGfc2SWOAoqkib6liNEXJB6etLLL5icquR3oUkKMpnPc1SnuGiiLKhyOdq9TRewbkcyBskEg9MVFEmUIYfMDViHbIA7BsHkZpif8fLcAgDqaku+lhyRBFXGBjgVFGQtxIAP3g5x61MGWQqCCpDY6frRuQ3G3BPH3jVGRP5fVmAHv61KqMAGKqQOeTTVUMpIznPXtTidhOeTjpmqERSMJQ525I56VnzFpIsOFDDrzxir0376MgEpkYIDVTWJI0C8txt+Y5z+NEmVEyri1DsSOcDGfSs6ePyxgj8K2ZSY5QNhxk529qpXUalgWBOecetYyN0zHuIiqb0A2nvWFIjq5OPMBPOTjFdc0aiNkK4xWRNboNw6ehqQuYghypweKzrqMqPlXkGtORZFkbghc/nThGsi5P0qPItO2pkRJuXJGDT1jycH86uTQbZMDqai+zsGGD0qWi+YgVXXPWpVJ3dacpy+xuMGkuF2NleaVilImVsj5uahljUnOKAcpmkSYFttJFXIVzDIGHaus0S/SUAE4NczIAw9h6U2yuzaXQIPy5rRMb1R6bFIcYwCDT1iSVhkYxWVpd8siDHOa01kVsgZDVotTGzRXvUVG+TPFU3iMi7+MitN4yY8vVeRFVMLUtalp6GFcAjqKoXCEEEZ2961rlC0nA4qu67gVxULUu5jXka7QQeKyZW2kg9DW3ep8mB1FZE6ZAx1oe5LWhSB65PFVHfBIJqW53AnHbrVCQ5bOacdTOStqP3nf7U4bmcEdKqyvgDFXYsrb7sc1okZSZYc5UcUVHbNuB3Cigg9x39zRvywFMbk0yIHzCWNBoi4n3hzVlmAHAqopzU6njmgCWN+1SLl+3FQxpjmrIB2gimUPOEHTmkCFhk07OVzU0RURY709wvYWIk9RwOwpcEP6J60x2cRfIMVDM5eH5mxVCtcW5Cxx/Kck1i3bbQdx/Crcsy44zketZF7KMMSeTWU2awVindMZCB61LACMADgVStwZZcnoK1Il+UlaiITfQa52qc9aY8fnBGOcCnIwdyOWIqR324U9T0FNkJixRA/e6elTJGq5IHAqFA4JB4FTIjHrSRLFgG9zxVpYxGhJHJohRVQ8ck0rFgcnAUdzWkUQ5EUe95chgYxxj3q6SCFHU1Ws0KodzBgTnirUeGbpntiqehCfUcgKrgAEnpRKyiNyFLN3xUihl+8BgU5WLRZ4UZ7darfQTfUr26yy7QAyAcnI6+1aO4qmCMtjqaiOcZBKAdajkaRpFIlOMYI9atdiHqLLckbQ+A3TpVUjgnIIPvR5fnEo8m9l569B6UXduUg2wtsJ6NgcCpaL2I5bhY5BCqknbuwO1RgKdrMep45oAYg4OexzUjKqrwMr6jqKl6jWhJGcuxKjA5XnrUiBmZsrknt6VUt5I0IXcx9yOlSSlXlAV2XnJK9xQpXJcWW9xB8tiAvoKlXapGRuOOPeqjRk3CSrMQmMbfU+9SCRdvG7Oau5CFLKSVk2oPSmT7IyDwSTxgdKruircGdpX3YwFzxj6VDeXIRMIG3Hqc0uZFqN2RToEcGRvmPAJ4BqOaMn5gR0/ComkZpUJcMoAGG6/WrZZSgHCj09aV7lNNGPfthlCAZPWsSVW8xs8Z4PFdFfRqcLwBnNZ1xAPLO089vpWT3NItWOfuo2D7QeO1VoZRvKA5PcelaN5EMB8kBetVTGEKsFxnvUdCitMSJsk5wKlRVYA7gCabdx4IkU847VVBfoM8DNGwdB0iBZdx5FOADHg5BqJpiyKp6CkSUKfl6UDTGyIVc46U0x45xye9WWdXj9DTQAydamxfNchAwtVblT6VdZMAY5qKdMrn0qbmqZpeHL7jyywBFdjbS7lBbB968uWU21ysgzjPNdzo94k8SlW61tFktHQq4CEj5hVeYmYABSM0RkL1JxU5lVUyBVb7k7GbOuxSGFZgYqxz0rbljEuWas66hQHI4rNp3uUn3Mu7XgnHXpWOyFXJNbN05BA6iqMyYzil1BmDfqFckdDWFMSshFdFfrnJHWsC9jPLdxVRZD2KxfJrSt2LxAdqxg+4+9aliW2Ba0ehjuaEcXtxRVyCNvLHrRRYnU9cZSHpnzGTAqSd/3vHFQ+ZiQYqWNMuIO1OBNQKWZwe1XEWmUmWYeU6VJHknGOKigHynmrceNuFphccIuMmiNe9LtcsOeKkHT0HrTC5E0mZNoHy+tQThS/ByPQVPMyuoVOAKpuPLVhkZ9aGykUbsquexrB1GZQgVOXar2pTBFOCSe+aybRWnuN7fdHSsG7myWly1bqYoM4yTVyxJYZcHHpUkMJ9KtLCQAKpGcmVljIc7RgGlmQIwONz9BU4Pz4XtTkhO5nY8mqSuZuVhqQkrubrUrBljLKMkdBSkFkAQ/nSxKUTDtubuTVpGLkx8eQoJ/GnBRIcFcqajZh0HNWUx5SjGD7UIOhA3yHCD2FTwHapbHNIw3K4XG89z2oTBIG7IHvQk2xN6EiRuSxJ3D0PamGZUlRGRiXz0HAxTYGM0ZJLKrdsYNSIAu/ILA9Miq2JWpJOylQyZc54HSlc4wCCS36VFuAPynJHXFRCfzJnUE7hjPpRzFWJvkwQV2v3KjrVWdwkeS4x0/+tSuVUuRlSTknFVryMSQsCAR1wKhyNFEZPO0ab4vmYEDGcdaHnZQuflY9h3pkId0HzZPcClcFpNm1h1A/wAc1LkPl1JY515JULzyOuRRLKFbK84PHOBVfGZVXBB29cf1ply8asqs4Ut93Pc1LkyrIvR3XzEFRg8cHpUnnLu3A4HQk9qpBBjKKfTmpDGwbIJwcdBVczJ5ETtOMlB82e9Vp5UaI7cOQcemKkjQMCR1zzzUU0ZYMF+Ujj/69NNhYzIZofMfy5Fz0OPWrsTLgDcHK8jJxVOe2jlj2r/FkMw4P1qFBJEV2t93j60LQtxui7e/cBGODnnrVOdg6sq8HFK25kBmwHPYVAibck8buevSlclLQyZFmRNjkOck9O1QswljK4+cdqvXPEvzHaDx9aqxqqXGAOOxzUFEbw8JzzjkVXaPG4kcdKvMN0vBxjpUNwTsdeM9OlNITMCaJplKhimDnI60wb1ZQBu9TUpjdJ5Czgj0qOCRHmZRnI60vIEWLaQsGWRDjsak2bEIHf1pjyhIz25qeCYTDBIGBQ9RrQdHHujxjpUEseCasRsyybWwBijbv5x+FTY1TMa7izmrXh65aGTy2PGePapLhBsNZUpa3kV1OMGiOm5ad0em2r7olIO6r++NkCOuK5bQbvzLdG3cmui8weXvIzWyIe5LKFVSE6YrLuQGXODxWiAZY9+7FVbtCUIXBoaBGJOofOKqtH+7Yn8K1XjVY8DrVG5Uon9Kze42YFzH8/NYuoxYLACuhu1LkHFY98AA3ekiJHKv+7mIrb0o7mBrDv8AiUkVraG/AFbPa5mdGjnPA4opLYqQaKgWh6lOrGSmheQatuu/moTgcVZmmTxnOMVP5hUAAZNVoR6Vdto8nJqS0XLYZQFhU6MFPSoM4IFWUXJFWP1F3OWzjij95u+ZflqVWUE5OAKilcyZw2FFVYaIJtqknIB9Ky7uUbSQcmrlyU2Egkmsa8mCrz09KykaxRj6nKzEKO9aGmWxWJSaz4kM93k8gGuhjAWML6VmkVKVtB0ZwxFWHHycd6rADcCKlJKgbulWkYzaEiiWM8Ckk3OhDZAqaRirLx1qOU437uw4xVrsYtkEXmLKckeWBwKntoSgd5WLl+ee1RLHvgXflSeSBVyMmQADjHTNUiWQnLjcgAx61YjcgZOAuOTUccQZQjZbHU+tOnKKnlkgn09/SmkSyKGdlMjPgQgcN6mhwVkEkfGcZBPQe1SJFtU5XjGcCmzYDpGSoLLnBPNC0Ha4lt+7LvGr4kOfnPSraD90QWBpAmACSOB60wuNuCNq5xjNJtlRiOOCMdBjHFOC4XPHuarGbawVOQDjjtTWvN8ZClV7ckDNJGvsyZkEjFW+UetLFaqu9XOcc8mq6TsMPnJ/2cnFSPOfPLSZXqCegzT5e42nsg2IkhOCO4GKJChIODxxSTurKrowbjbwe5GaqR30SqgbIY4+b0qXCxShctmEGMDkEdCKgvrcfumXaSpyGI6VYMimInJYE8dic/rUc0iJB+8A6ZG49qfJoRqmLAY1klV2JwARxmkkKbgd3UHAzWVNqCxyXRUZKqAc8c1Qmvp/tbFeMEYIbpkU7K1jVUmzY4DqQ7bc4IB6+lUrm88t2zgtyOD2rJlu7kb1RXyCOuAfSqj3Em8LJGxbBH61Lj2NY0+rN9HDKRwSBTSijDMxG7tWTaXYV1LE9O9TateRMqeWRkJyB60mrIlw1sXpSr48rHpk1TucxZyxIPp2rPiuWQ8McE5A/CnS3PmRgMMYrOSYOnZl6XZIoUqM44JrMuItk3yk5HJxT4p+duMjHBp8kgLDt60r33IceV6FVJCVLYwVOMetI9woLBwOelEqKxZecGq16geM7RwPSi5DWpXuIUYmRB1FZEDlLvBHX2rVlk2Ww4yRVRVWVsj5TTFaxPcIstufesyPz4FAIJwcD6VotheGNRTOmMkcCgLlqQkqrnjip4cE1UeRXhVgamSQIoIHWluyk9B90gAC4Gax76EkEHrW1s8x9xNUtQGHz2pM0gyLw1eGOUwt2rvrdleLg15ZPut7hZY+uea7jRbppIVbOcj1raDCW9zflYxICoyPakK70J2kU2KbLBcj8atzKypnjGKpom5kugyTnpVC4IcHmtOTaSePmqhJB8rHFZW7F+piS8yFT+FYN+hDsp6V0N2ChzisbUMMxPQ1JLRyOoxBXNWNFbDgUurLlQR1qDSX2XAzWv2TNnVKCDx0IoqSMhsY9KKgk9bBO2mKmcsaeWGSKegAWrRkMgJ3YNasBCrjvWdbLucn0rRjTOaEUWIwCc1Mh+YU23TahzUsYBye9WkVcQp5hOeBVeV4wxjBFS3UgDBQTuPYVUdFQE9z1NUCZUvZAqlV6VzmoTHORzWxqTgAhe9Ye3fOF64rCWrOiOxY0uJs7zxW1tPlkjrUVtGFjBFXbdS/HahK5nJ9SupKIMqSxNWkGMbh70PhZVUCluIjtLgkEDirSsYSlcqXFwfMVAhOT19KRZg023Gcd6X7qfMcn1qlcMSyNGW5PYUyWasuBGWxnAp9u/y5HSqbMRE4cnD8fSpIGCIoByp4AHahvUEroun5QNvU+lMWNDPuUg+p9TSiYBcYOOlRxyqpwMAilfsVytkhmQOUJw1QXLoJAxQZA61VuJhl29D1FQ+eAV8xhgnBNCu9zWNOxaW6RsE7vXio5JGYFwflGcgfzrPknClQj4BJGcVBLdqrMuGlYrtJPQVdkbKHVF8zbd5JTdvBOTnj0psFyFddzIEQkZwM5z6GqK6gX6QLkkZ2DnA44pzlneQm2IVD91+Mexqkuw+XuXVuN0Mi+a7vtxheAAD3P+FK8ku8uvkonOSTu61RkZVkbNuI0dcjknH0pUcGCSOOJYt5ADP98/hVBYkaWZC0MlypfAKxqu/cccAGqFx5r26SToVThAxI6jtVv7NapayztKXmj6KvAzVR98jQwrCSoUsAzYyfWly9y4vsLFqKwcQR3DlRkktgZ/AVBHdb2P2gSMrJ1DHK81oQM73kkUrxxjygZFQenY1S/tCKC6u5ChII+VQOM9qOXuO99kVdkBtZ5TI6sWwqnOCP8agl8kRb0lfBxgYP480+CQusDzRkwKxzkcEnrTi8UunTbUCop4YjqxPQUcug22txbhY33rJLIyADy2Q8fjUV5C6XWIZxtI2jqe1SrbmeRBFEohiiDPt4LH/9dWJ3BlR0ZECRAb8ZAJH86OXuRezsjEc3seFUgnB5XsM96jgklaKTLcDkmrV8kcWnLiU+YxOQD296it7ZTp5dXKspywPT2qXHU1voPA/cqwYKSMkdximF5C2FB3AZI9qIlkYGYk7FAwx6Ux5jKmOnJJc81NiR8cg5znIGT7CnSThkzuGCTg1RmkjKyGIuTgBieKqCYgx4X5FGTnvScUybXNVZz5gA5xTHnV3Iz+VZvmmNBIrdck0wF9ykZ6ZNZumQ43LM+cHjGaqAGN8qetTySbUOe9VSc9SeelZvQhx0LE0fmgbWw2O5qCEgqVfp3qPceFPX1qvfSBIyVPOapO5m7rQ0AAECr07Vdt5BwCOlZtoS9upBycVds13nB6DrQ9HoCehcPyZOetVbr5+O9SzZWUc8U1l3IcCm0aQ1Mm7iDqa0fDl2AfJY4IqtNGSKq2b/AGbUFPY0oOzLaurHo1uiuqt1Iq/jcmMnFY+mS7gOTzWyJCY+ma1T7mb0Kcsew5HNU55dvQVoSxk5x1rNu0IOTUvQa1MrU0yMjpXP3oBb3rpLlCenIrC1BFzgfeFQxnL6knLYrKtDtuRn1rdu1wxDd6w2BS4/Gri7omR1lo4CAnpiiobHm3U5oqLMi57U4yeKeBwB606FMkk0mMuSK0MESWy7WrSVDtGOtUbdPmBNakByM4wKcdSnoESP36VMAVB4pyY3jninykbeOtUloO5VlVQC3f1rNunOSc8dqtyF5GKnhB1NZ94wA+UZqZS0NIrUybx/lY55qtYxHduY9TTrjPmAN3PStGyRcDIrPc2loi7boCmMfLUxbYVC8Zp1qA7Mo7VLIgC9MkVSRzOQ6KMNyaZKQTtzx3p3m7U2kc00qAhPrWnQy6mfOhEmM5AqtukyMIFGe/pVi7k8tdw+bHFReYWUOeDiovYu1x1wjTIE3EA9cVOjLbqARkAdaqLMc5biq89yTuTFCuy4x6FqW+XqOBnpVSS72FvMyD3+lZ8bSMJFZcNnNOuCrR736bcH3NXFaXOhRSJJ7zK/J0Ix+NQGRi4JHmEcgDpin2htxEoZSCT989PwqsZWiuSkiErk8jqKtWLXZFnzHQcfKwBYHHOajBeOJpCvOenUGq9yWGw20hkRfm3Y5BqdLsJIskShuMNG3IqlZlJaXRLFlp1ZF8kyYAI4ANPS6SK8uEmcvKVI3Mcjd65qmXWRJN7bMfMoXpWfNM6OkoXAHBP1ovYap8xrW8rHcs7M8oU7Tnt2xRbyrLqENxMxI3AEHmqsMIkJnUlunft6Utwy52gFMfcx2+tHmHLrZGvq8yrLlUEcb8sqcgDtWT9rYyW8it8yAr17VXeeREOWzz+dUWcRyrz8rHiic+o4UbKzNezjmvJp3VtrtwecYGKptbebdGMv8i4yxOM4rQ06RIV3O6jJycmor+dC/moQOp46Z9annT3GviaQuqOLiOCC1j2RB8KSMZ7Ump2qQtbWqZk+YZQY5qn9sYvAHYYXpn1rUimjDIRjfuyXIpqalcTi42RUu40sW2hf9MkyNuflRR/Oq0T26ab5tyHJ3khezGpdWuEjR2j+aaTILnsKoWLpPGDMu+NPup2J96q6ewKOl2IUWeP7XNGEhThQFxvP+FLawvLA00wKQFtw9Ce34Ut9vuYooVchIxnaOmT1qORZpQIslUGAFFIL3LUEL30BSMswUmSTnAAFUr1ZWiPkx7I+x9RWhOzx2S20C/J1d8dT6VWu0lktt0kue2OmB6USFF9TCYqmB94nsKVU/dsZB8xPHsKvNALOAOGUzt0GPuj/ABqBbYt++kJKjoOufWp5QbTK8iodpTmNTj61FLdDfKiLkMRg065XgbQdorNQYlJY4UVIcty2ku8MCc4PFQ5JfOeKjifcW28Z4zSytsCqO3SplG6IasyWVzkVBJ86kYzTFdmY7uQKkjBwSeAaxtYznEn099ilFByOa0YGZcY4zWZbNtfHqa1MDzYzuwFFNamD0JpyzyqAMAdalHQACpI4t4JJ69KmWHy0GRk9zQzSLsZVypUE9zWPdrhdw+8DXQ3eDkKKyrlOOlS+5qmb/hq/EkKA9R1rronyOOhrzfQGEV4UzjNd5YuSAoPNaxdzOW5anZgMgZxVG6G4c961drMCpGKz723LDCnkU2QtDLkiOw+tYV5HiQk4zXRuCiEHnisLUIyzE1jI2WpzOppySO1c5dcuT6V0+oDk5rnbtQpz71cGTJGrpErNBj0oqlpcpVWANFNmNrH0UhAU0kQ60hwM+tPRcDNNmcS1AmQK0I8Bdpqra9KtKBnmmtChdhI+XpUzbVj5FNPy4OeBUUkhcEr0q7pIdrla9YlcLwO9ZkuDyCKt3bNIwQHArOuyLcEA5OKxctTZR0KcsPm3QOc4rUtoduM1R0qMyMXatjbjbS31FOXQkiUA/Lx61LG28njFJEOfanbwsgHFWjnkV7gbTwM1EXcHGPlNWpcEkjpVO4fYhxTYrlKbDvt7Z5qvdlV2kfdFOlYplycZ6VnXV2BhCc5qNHoa04tjnnJl29AaiuX3hWDfN3qFfnUkDoetRuG3bsZHp2rZKx0RjqWI2aeZjuBwMcDFW4rY3CiMIVUAlmPSspN4cGJsK3zGtuG5mjtwCh2kdB3qoy11NJRstDDmf7NMYWDBe+elLcBnZH3Z3dumRUsxadv38eIgeMDpVjyAEDJzgcEU0rlPQjtpXt2dxCPKcYIAyKglKblaMDjkqwpWuvs7EMcZ6isy91VBzuGaXMNIvSTRsfnVV9cVDdPFNEVXaoAwMVz9zfNKD5YJz6U22kIBDRyO5UgYbAB9aWvVmii+hfi1JrJ/LeVRt5BPeh9aidvnIyfSs2e0ac5ljHJqxbaRCSWdWJFRZdy+Xq0Svq0ZJ2oXrJvtRkaYfKw74I6V0aabAIwFXIzV8adbpECIkLe45qrIlyaOSW/d0AZW9ADU0jXCR7AAFODyc1uSWUP2gYVc4/WnS2KgfMgAx1FCjDexN2c0s0hKEjI9K05Lx7W2jZnV1YZCq2SPrVuGwVo+QOScU9tNh24IBNF12G1rqzmbzVZJFIWM89zTV1qS3g2+X83TgVuNpiknaowDVW60xWAKqM0k7FtRehmW+v7VxIpB78dat22rm4kDlgiL0yetQzaaoH3efQis+4tCiZC/lVc66oh0b7M6GTVNwBaQY7Y71dgU3UYYMigDPJrgnikjOVcjHSq893qC/dmYqO3SqTizOVKS2O7uHXIE7L17VG1zCuVEny9AK4BdSuAcSlqu2l+p/iwe5NPlb2IemjOsuHSaMIi4RR+ZrKvICE3cKo7U22vYy4AfPvVudxMowRiot3KjK2hlKCoJY4z2qTO6Ppz60SQt5o28inHESBSfnP6UWCQxl2qMd+ppWmACoDwKj8wAHJz6Cq6sWYluMVEo3MpGlbDLAmr4cKRuyaoWbKY+eDVhy2AVrB6GUkblpIHCk9BWkB5yfL0WsWxDPGqscD1rdtUVY8qc57U1qTsVrm3XBZRj1rFvY8t8oroZzlMHrWVcckgDrSZcWYcgMEqyJXa6BdLcQo2fmFcvcwfLgjmk0a6e2uwmSATTg+jCSvqekxSY+9yKrXeQN0dNs2MsY5yDzVvYSMYzWjZCMiYAIGPWsXURkcV0N0mSRjGKxrqMsxrJm0TktQjyrHvXOXiHBFdhqEJyfSuV1JdjkUReominZkozc0U2E4JzRVvcxPpILh+asqN7cdBUPfmrtonHNUZrQfC5j6iraqzgMBgmkijXPzdKsjaAQOtUlpqNsjMZx8x4qtMwC4j6VZnz5eM1QuGAXC9qUmawVypM2GJY1lXp3HBOWPatMqHBZutZUAM2oHHKrWL0NTX06HZGoxV5k96IF2qM05sAH1qzmbuxqkBcd6YeZMYpFB3ZJ60EAt97BFWQxsuUBx3qs7ZU7utWJBvGCc1Qu5fLRwaXQVrszb994xnp2rEmBkbA4I71Pe3I2HBw1Zkc7SNjvmiK6nbTi0Xo5miUoT1qKW4YEr/C1QSMUcEjNPtgsjkN+FW9TojFbmnZHYRvAKYxzV03AC4ZvlHSs2SSOCMBmxWHqGqhMqGzmldvYhrmOguL2OME7s+1YN54h8likX5CstRc3kgAyie/WpxpZUrtXk9Se9PXqXCCvZkP2m51E5ZSqnpzzUsOmE8tyfeug0/SmSAtt+Y9Ce1aFppjBwZvug9Kdmac8ImHa6UNgOOT2xV5NN2n5Uwcc10aGOE4VFFMB3sREhcnrjoKNEZ+2kzLTSSWAIANT/2XDGxMkoQDqPWtRrWdgoZwoxjavWo00pGB8w4zxgnn8qNOxm6j7mTIltHIoV+M8BRmmuST8sbsPTPWtl9GRdmwcA9TxiporJY4/wCFuefn6UD9pG2hzz27PtIjCEHtSTwP0x06cd66CKGIl9sTMQ2Dz096uiwbPzRr5eOODkUrO2hLq2OKSCRFKoSrE8A0SCY5BByB1Gea666tli2goEyMZxVSKOKeWSKMxMVAyo4NJItVtLs5E+cVbCt8xqN43UZZcGu2GnoxAUH5R+dZeo2DmaRWUbQflI7ihp7lKvFuxybtnJYdPSq8yIQChB9q6K401UizsOCcVmXdlx8nUHpUc3Q1Uoy2Ma5tonXlQD9Kz7jS1dAR8pNbN1BIvDKceh5qNSfJ6dOxqroey0OTutMkj5xuX1qk1qpPA59BXbFEkjPVTnoeQazbuwUSDYuHP5VabRLd9zlJbaWM/u3ZafBf3VucOCV9RXQmPepjmUZHeq0losWWChl7iqUzGUUxbLUoZAAz4J9afMYwS+7cO1VH02C6TMY2t7VTlgurKTB/eJ70XRnqi3JIXPAwKG+UhiPl71SS/SSRVcFG7g1PdTFk2g/LTaJvcuWtwvmbRW1bEFSAM+9c/pqbzuPbvXQWpUKDnmsqkOpnJrY0IUeOHAGSa1bddkaMxwap2x8xRmr5jyg68VjsZ3uNDFnOORUEsOX3dKtW6YJ6801xmcKKnYpMpSwb88dqxJ4/LmDDqDXU3IAIwO1Yl5DvdiaT0ZpE6fQ5S0CMDnjmt6J9sZbPNcR4cumSQxE8+9dZGzbcda2TurkNajrgqUJ71iXi8E45rWkjJyTxVC6xjHpWbNIo5vUOpyK5HVoyXLAcV1+qcNkVzuopujOKSZTOak60U+Zefeit0zE+mQuSKvRrgVXiAJzV2Jcn2qTIWNiWFWSQuDVfaQxAp5jfyseverWiG9yKeUuT6VUmI2knirPl7Bk8nsKpXAJ5Y1EjWNuhRu58IVTqan0q08tNxHJ5qnGvn3mB90VvwIFUCoWruE3ZWJQuEzUEvzLhetWH+7xUGRu461RiVn3qee1KVDENyDinTE5wRSFgMYpoT2AgbRnrWXqK4QgHmr0srKelZOoTbgTkZptX0CC1ucjqDMspUggVURn3Ar09avXzebKFI6nmoZIhDwDx6VaWh3RYqYlYBj060+TZCu7dyKYsiopJxWbLJPezeVAh5OM9hSZqpMh1LU97hIwzSHgAVPpumuxEk6lpGPQ9q3NL0OC2UvIu6Xux5Jq/DtReB8+eB6CqSsJyT0QlrYxwDcwy/wBOlXYooY5cugIwCKijd3mIP50v7xrgqBnHSneyJ9TSaZRExJx6AVCPOlkG3cB7VYtbUsymTpWkIkCj0FS5XI5lEy7eyBkYvuPuelaMUKRR7ipY8cY61ZhUKGJ4GKlVGYfuwpQjhj696SM5TbKUsmyQKsb5Izu7D8aSNTFmVnkeVj90DAWr5tweoOSOveligDHBOTnnvmqZHMiG2DYJJDMTkB+cVJw452K69TjiniIhsHAj9B1qRFCL8i8nkZoTbC6KzL+8KxyY3Dk4OKfGxKuJpG9FwetTED+JcAVEXUqSDz3GTzQ7Be5RudzACPcT2JINVGiaSXBUq6jb8oxir6qN7bunselTwQjbt5xndkYqYvUpySRj2qSQQSI0rPyzBmOG65x/SgyySMQNjEHn2X/GtN7cMpAIPvVMWyQ73XKuwy5AwT+Ip7kXRQvWGwnaCB1IFYjp50wdSDEy8V0Uyb0Lqp2MMruGM/hWXJauJlMYATq309qxkbQaSKElupySATWfNp6LG20c55relURr0JrP3HJDHAPfFRzmqb3Rz1xZso+QcVn3CyM5yevbHSurVUwysfxIrOnt0C7jwfWrUylUs9Tnmhbln44496hk4zxwa25LbdkEdBWddWhVsYwPerv2HzKW5lmIxyb0OOelPkw4Ifn2qzPbsDkdAeakeAS4IAB7USZOhg6ppccyh4xg+tczcNc2z7XyUBrvZo2SH+YrDu4ElDMRyaqnUsyZRuippWoKRsJAz610NhMvmbVbI9a4m6tWhbfFx7Vb0rVPKkCynFbtKepyyTiek2bhDwetbaSh1UHqK5fSrmOdFOc1vWb75cKOlYThYzuXww39KgI/elwOatRqFBJ5NMkyvOK55aFxG7A33utZ97HyBWggOTzUU8XmDPpUvU0Whhwn7PeK+cDNdhZP5gDK2Qa5W+hG3I6itnSZMQRjPNXB9AkupvFtysHrMugCvFbCIskfqayr1DGSByKctAgznr6IFiD0rn7zaCy9RXTXpzn1rmr8YY1BpuczdpiU44oqzeRhmBxRWqkTZH0pbj1q9CBmq1uBgetWFBHIpnPuTbCHBqRiSuMUyNi4yaczELVpg0VZjtXB6msW9mIVlXqeK0bhiS5JrGkOZVPvWUmbQRe0218tQWHJ5rSCgVFb8oKnUAmhabGTd2OfAGBUJQZzipjgio2dRxTuSV5TyRjIqB3VOlSXD4U4rIac7GZjkjtTRLVyzPOuG5rnNWcgEoeKuXU/yMc1zl9OzZ5+UVdjenHqV3mXHPLVG25uS3HpVR5cvkdKs2ytMNxyEH61e250pW2Gxx+c5VSQB1Nb+l20cUYMajjqapWVvu4x35rpLO3EUSgDAalcJyUUPMS7lPYDFRtZg3LEfd9qk1BzEigdScZqxp0bbCW5J9ahy1sZaqPMVxbDcdvAq1ZwBCcgEjrU/lgS4weasRxbWX5evWpbvuLm0Gx/vIwVBHpmnuUGA7jIPrVmG3xKxJPI6HtT/ssAHliNMA5Ax0OaaRnzDbaBo0yzGQMe4/SrTMFDYUjsBUojKIqADnmotwc5cc5zirtYlO4i7CuPmyB1PNPVxHgMSMntQq7juXACnBJPSoZ5QnJIOD/nFD01Y99CaQEtuXCqD6ZJqJmO5WyVYnoODTkcODubaT0OaiyJMonz+/8A9ejmuNIbcSfKN25t3XviopMsBsO0Y5yOlWUZR8qjBHAIPJqvcKVlZMEE8ZpNXQ0+gwvldzk+9PiYBGLN83Ye1VZAY/ljB/4FyKjlm8qX7sbBl2tg9PcVHNYfLfYum52x4AGPcUuGkiPKgfe9OKqw7IyWmJUY4FKsgY/J8pPr3pqXclpdB0w3KC2AD0qCWIfNjpjFW0CIFP3hj5SR1qK6jLpnGWOMHpim0Cl0MqSL5igG76VktAHDEKw2uQQRXRSQjeAuF2jJIPWq1wmQoQ5HU+9ZygjRTtscvcp8jjG/PGB6VVlaMr5Ldhmt25jCiR3GAeeKyp7dnAdBtJwfmHOKz5bFt3M6SUJGScAA9T3pJ1EgPQ8ZFTywESk4GwDpjvUF0rJGzIBntQmK5EbcNE68Enn6VVWAqMHGAauQyM0ojKt0zntU0igA8DFU5X3HexlXUavER+tYdzCCDtHHeuinUgbcYzWS6Ylxjg0lKwJtHNXVuVJyMisy6s1YZArq7qMZII4rLlgHNbQqNMbSkjN0rULjTpgsmTHnrXouhalHcoGVgK8/ntyynaM4osrmaxkG0kDPIrbmUjmnS7HsMUwIXHNSyjzGGDxXLeH9YjuUAJAauigdcEs30rCcSYsnC844pcgIRT4SpU4Gc1FPmNSR1NZJWNDOu4wCfSmaa5W62Z47Cp5gzR5PWqEZaO5Vh1qdmaRV0djaShclqbeYkUtgYNVoXD2+D96mSMyx7d3HpWrehMVrcyL9cbsVz18gKH1rqL2PKHPeubvxtJBrLY1MCaPP1oq3Io65oq7szPoSEdMVcRT+FVoVwtWkPT2rQwuSqArY6CoZ3y+F+7Uj4Oaglfy05FNsFuZuoOR8oqpbqC4B61PMPMlLN0pbGMFyfesb3Zs9FY0IhhRxUi8ZxSEccUM2OBVGW4jnOarOdpOKfJJt61VluFOc0nqBDcu2f9msq4nWIEbQAeamvbtUDHcAB61yGsauzNtU9fSrjccY33J9TvQudprAnnMrEK3WklSa7IWInHc1q6RohVg0mS3vW9lHc1T7Fey04ld8xxkcA1sw2e2BcDgVqQWAzlhx0q+0EbJhRgLUt31H7RLRGbptqCcgcCtaQbAoPIFSWkaRRg5HNTSlWQYA3Vm3oZufMyvJAspBcDC8irEUaPFmFhn16inqo8tQ+OeKnSJYk2xqFUHoKSE23oR2qMiDzSHIOCQOtWdu0k9c9KQD5lBz61PuBjAI71VgJk+bhsA9qcxAYZBHGOBmoEk9cjFPDDkb+hqk9CLWELbc5Psd1NL9QxypGflqKUoWO449M80wuW+6MgdKlyNEgTOSZMseenNTKNyjHzkjnNJGSGIeQKvtSAg7mjYbBxxxSWg9xpdS+1QxA6qDUyoHXkoB1wKqssyyExr8hGfrUsEkm9F2RqQOc/1oj5g12HyoECshO3H8PNMIYxblc+WOxPOaknmV3G6YAgcqOhNV7iQBEynznoVzVNolJlfPmKxYMgHTHc1X3bXG5RsIPfBNTMNj723Ae3eq07s0i7HH4jn8KxbNEhkis0St5hAP8LdaaZtsZXzOnfvimySnYQ3zuTwG7U2R8RJGyCJ+5PYUX7DL5uGKoof5c9cUTNjd8wViepNVI5IxCCG+YKMsOhqZ1MjqSVYH5j2FXe5naxKeFY5B55NVpBjkY2KMEipJd3mlRt29flPFQ3LqqAbwV7jFDkJFOQFhk5KnoDVG4Riw2KAB1zV6RgVXblV96yrxnUt5bHdnv0qG0aJN7EV1ACTJu4zjFZl4rGRvL5Hce3rWtFyuZCCMdKa0QkJeMD3FLcHoY9uuy7XnAYHGalkUjIf72e3pTZziWMlCu1s4qeZwV+UYJHFSN33KLlT8p6EYyKzbyIICR94VfuGMbINvU9qqXoYMWTkd6VxLcypAsvBPI61Tmh3Bgoya0zBHvLYw561WGI5DvH0q09S0zKSPlhg5plzbggHHJ61dlBS4BHQ06VP3WTir5rEy3MaJpLWTdGSMV2Xh/UmvI1DNhh1rlposetQ2VxJZ3iujEKetWncyqLqj123lG0LTrg5YYGaxdOvPMiRgQSe9a6SDAHUmsZJkxZDcHaM4qpLHnaQOc1rSIpjBbFUmXMmB0qXobRLNi5DDcMrU83zscDiobYFUNXYUzHk9avdD21M+5x5XPWud1NQykgV0N9xkCsO8A2MKjcrbU5x/vUUXBxIaKtENn0XHwAKnXCqfWoN3NSIcnJrUwHg4GT1NV5gXfnpSyFmkx0FBO1TntUN30LStqQNGpVqZaAL0olclDtpbZSBmovqN7F4YxzUEuOcU8nIqvO4UdabZCKl2/wApAPNYt3MyxlQTmrV1MzTBV6Vh65ctEQq/eNKOoPQydQuZZZ1iXJGaSHSzI+XBJ960tKsi7+ZN941uxWoVCccmtb9ClKxl2WmqgxtxWnaQokjBx9KnijG3B6g08R/vCcdqV+onJsjkZxhUAC+tPhVlXLcikkOxwrjqKfEGzj+AGi4mPRMjOAR1x6UshjSUIhAOM1MiA4BOBUMluPtZdep4/Cl0CK1J8AsqsM981aPCkZ4NRbkDJuA44p6ZwwPTrTTKsMXdjGckcjFTQ5bIY89qSMZY7eoHWnoSFJHBplNgxYHkc0SABc4GetOlwo3SDJHeovKLZbDAY9f5U32JI3IdWIGw56mmMdyjyzll/CnuAzAEsNvOOtN3KhBC4z0rNs0RKM+X91tw5zTJQ4yU4B/hoadz8p3DB5boKiw5UEcof4ie9KQ0i0Qw2lnbpwKTeuwNyjg8MwyaYiMVVSxIz/DVsBQMBcqR99uopq5D0KrhVYkRtj/nr1JqDeh2pxu+8N/GK03hEgCtIAvfI61nXytGHKhJChA+UcYqpKyuVBqWhS8x4nJ+/L2weMfSo/Pkb76DceQMYxViVHSPeEUkjjFRyESeWInB29VrLY00ZXUry8q5GMD2NRthmInyRngHnH40/BFyUCFVJz6YqWa17Kz5A6kdaV3bQlpIrhgm6OJVD9wehFTPN5qII0DDPbjFVbgSREsu/GMEsORVb7TEm3Mr59TxRzW3FyX1Rph49zKm5S5x97NRzKwAXbn/AGiKihl8mdpIdrZHzBv51N9tDZG0h26CrZnqtiF13HPyso9DVN4A8jHP0GKtn5ASF2s/XnmkVvlAOSfWle+5V7FRbdI0bA3MetJMMIxAClhVpQFJKkEn1qlcNuJ3EgdhSuFrsybobrhEA49aWfhW3gZU4H0qbGzMknI3ccdBVOd98uScKe1IuxSnV3AKsOucEVXnOVXHUHkVefBcMOMHFVrlchnHBHakTYzLjCkstMv4xJtYDBA5FSXXyqMDhqkuADyB2waYGOVLgg/eFLIN1tt/ipQ22Zu9NCFXYA5zyKpMUmUFO8Mp+8DUMsXykY5FX5YQsgcd+tRXeCCR1qr6i3Nzw3N5luqN1HFdjbKqxc8mvOdAna3vFz90mvQoZUaPdnOR2obJasyaV8gDpURAB4oU+Y2fSpQoIJxxWZqtC0mPJUAcmpo1IJGOtPjjXyEx1pd2wZqrE3ujO1CPaCTXN3rYJGK6a/YvknpXNajgE1PUtbHM3Y/eGilu+ZDiirTJZ9F4pqbg3XinHmkDYfArU5ycAN+FRupbipFIDdOtSomMmk1cFKxUdVAK96WFQoxTLlgWAXrS5IiJAzUdSm9BZWCg1m3LlwcdKsM52ksKotOG3DHAqXqNaFK4/d5YnmshYvtd2CwyFNX72UyNtWjToyrHiktBtFuO3C/dGKtINy9eKY2QmDwTU9ugWHk5Jq0ZsjXhgMVKD8+49BTRgGmMeSB0NK5VhjjdIWPQ9KniGRgdRULYLgZ4qRSY3BGSGp3GkSRktEWPBBqRCoO4nJPSq7SZjKnOKlgYY2kdKL6mli0ApzvXPfpSNGwySeOuKRX9s0kzyLGfLwxI707k6osRFVQv2IxTHZg+eQnamwnKZAyQMEe9SBeMydSeg7UbrQSHxcKC43A+tPjJDfNg5+76VXyOQD8p4zUj7cKE+92ouNoCuMg4B6jAqo7BleM7vk5JFW5ASoBOMfxetV9hZpASEHp6e9DHEjhiMzBXJx6elTMFLqFcsg4O0UsYVYl8o7mJ5z6etIwkWTCAEHqaSRV7iI7w7hGu3nAJGaI3MTgvKuw8AEE5NMmkWOQqzNgjAC1HFH5cisxTb12k5IoHa61Lc0hkj8uVSTjKhciqrBdqsd6oeOT3qaOLzJDJDOcZ/iPBpSUlG5ggRMZA6g+tKSuJaFaE5mk8wD5RwSe1Mkt1aV90RBPIOamdkYblRiyjG7196TEobYAZSPXsKSjfQq/UpJmSZ96/uwMBgeKj8xhGG5wp2kq3GKnEJR3MiMoH3dv9aquFy5t1UgjPPWqjHuPcjuLyJpVErOV6hwOntWY3lyzvGMAEblDDrVm6jZG+6x5yVPce1VJRmHeoY/Nxt6ihxuyrJLQSCVkX584BwVI5x7GrdqY2kMikuo/gJ/lVFvMCMAMtzgj0piTNuUkiLcdrEDipd42uS43L11coApKlgp5BPSmRXI3+Zk7G6Cs65lxIySHkdu9MjuCke0jKnoe9Z82ocmhrl9zkjIA7VFPtKndyOlRQyAJtLHBGee1RtJtJBOT6nvVE2I5lPl7RtPP6VmTjNxk9u1X53XBYA76zGOHDckEcg0MpCud7BV4xzmqty+Dg8g+lTmXgZHTioGUFM4796mwWIWQeWwIznge1U9x2uhPNTzM6yZY5ANVp0BJIJ3daZLRQZT5nPSp3KZQimsAz8jnGKHUhNpHIqkJor3B/enHQ1HJHuANSP0JNIDlPpQIqhWRwR611Wg3m4COQ89q5zbkZHWrumThJgp65607jaudvG2CcDirCMDHjGO9Z9pMVAJOQau792AOlSwiadmfMUDOMVIsW6TBPFRWZ4xViRGGDmrWqE9zNv0G0j0rlNSOHOK6jUGPzYPFcrqBAc81L3KWxhXWd/FFNum/eUVWorn0SDuHWnQgFveq8Z4qaOTY1aHPYuRAZ5FOIYcDoaijYt0qbcQvvRcVim8GGbJpoyFxnrVi4bEZx1NUznaDmobs9C0ror3zeXGT1rJmlBXIGM9a05DuByM+lZF4kgyMYzWbZUYkUSB34q/AgjHA71DYwFcE1e2Dmmhshb525FShiFPHFPBU1EeSVFMlIWIZPPenFcKT1pViCgHNL2I9aQyCNMtk9KsBP3gIPFGVEdIsp34A46U0VuDxnJPUelORAo9xUiMQpB5piZ8zFMaZNHhRkng0vRjxkU51BXavNJtyuMnNP0EOUFcnIAPWlfcV4PWoUyPlPI9TT9xUbWHPrSuMXG3AYdOfrVhVYkEHlh+VVpJcSbQOmAanaWOK2aRjzg8U42bJlcjMzGXO4bR+lVWu8+bsGMnknvVZC8hXrz0FT+UqEDG7J5PrTWxSikMMsj5PTHoKmbMojV2OV/u0RHeW2MpAPJ7D2qbKCRCeEcDG2qSuVzJFcqFIM0r46AAZxTnhWQlyGZsY9CatSFljkYRDIxt9uaarSvGRO6qW+UYHNJxWwKXUiCSQMrxbtwXJVumaXzN0bvHGQerDHBNSwwNECRuLdFJNQwBmV0kcbiTgjj8KXLqO6eo2d5Jo/3a47MvSkgWYLGplUYB5PcUSbnYuxMZC8A85pIAJQI2OVIJDentUpXYPYbdXAMcnmP5hHYd/eql6yOiGJChyACevNFv5cSSRMBG7nMb/zpt/IJIoomG6ToSvQEVSlpqFrOyKIlfZskChg+Mf0qrFuimJKZi3E7lOea1LVn80l7ZhlsMT3xTyEEMipGA552qeuO9Na9RylbSxkXMTzK+QAy/MpXuPeq0+9I1WUKVYZ4Gea0GtvN3kMyBugbpVG4jWOMCTJZRkHv9KTQLsUZR5qDeo3Zxn2qtC3lyeRNjYehzVlowFWYSMUPb0qlcyh0DFfmB6LWTiXctb/AJmHPyjqKPvR5b5s1nQXY3NGT846E/yq1DMPLZh91TyPSpRLuiYSgMdwIFUrlAz5XOKekg8wgd+TSvtCNlsnqKe4XsyjcBvLz374pIAXjAyc9c0spy2TzmplULHlfukfjQlqEnoULrCkHqcYNVAVQk96ttltxPPPQ1XZQzEYGRQTYqoDl5D36UrZYEnrU6IDuB6AVAxwQe3SgNynJw+B0qNsK+PWrE0R3g54NRyxjgk1SFYWIjvUf3LhSKevGAeKXyskEUDR0VnP8qBjxWzFKpUY61zFvKBGFPBrYsZQSM1II6WxfBGelaDEMc9hWfY7AoPrU12/yFVOBWsdEZvVmXqcgG7HrXK6jk5NdJegDJJzXN6m4yfSoZeiMOY5Y55oolb09aKdiWz39JCCKm6kGq6VKjYNaGFzQhbaBUrP8nFV4DvFPdiBiga1I3w2Rmq0zbY+TzTpGIBqo7l846Cs2zRIkXIjyRVC43O+Owq2Q7oOcCotmCah3GhI/lxUmD2pgAOTnpSbyre1NCaBhge9RocNSvOCMYpm75abGkThy5x2FSxDJ56VBGPlzjqKfGeaSB+Qsi7nx2xUaFg2cd6m4DjPWkf5Qx29TxVIafQkV8inbcEGowcJnFPDbwAODQ2CRNHMQOmBQrFicVWmLKMKKmjyBkHkChXbHbS42XzEdNoyvU5qV3LQ7xjPTFQzyb3KjHoaNpC7c5H8qL9heogOOepHrUc0xMYj75yfakf5ZCoIz3qe2t8RMwHPU0JN6BcgiO1twGX6+gFPZguVPL45B9KexXYPkLMDwB61EFaGMPcFWlblyBgLzwK2jHQbepbh5gGzC5/gPerEjTQoGAVOcKB296gsjE5a4mbaq9CeMVPIVRkm8wtCp4HUmtL2iZ21Ktw0rtsYMrkfM2fSpoJ3UMgjyQM5PUZqK8jHnBt/l4G9+fypLWNQshkYpkdc/M4rFN3L0sOZw0e4yFyGxz0FTtbpkMN4bHBUVBMoDr9mJw4GQQODSm5xdKTJkkYIHApOSW49XsRSSmOBlGHAPLnkgVW+0rvVSCiZyCO9XXRNrm1IJzyG6VBPE8M8czxLFHwH+XI+tTZspWIzbRyTOFJOOQMdKZA9uzSxGP5h/EOO1Sy7o7uQJIFMq4XPQ+lUrd98UpuVMTk7cg5puNtSdy3DcvLFIqAckbSRWeFEJdwN7Anr2q3GpjaWWOVi6DByOoqF5MtJyoSUA9aL9xrS9itJLBHJEFbcshzjOce1QXoWSN38vkHae1TiBTA0LKodX3DHPFVdeinRV8tjtAHy9DRra41a6RVS1BtSJZMHqD6isW4hdGyqhj64z1rYsXZtyMwBBGQfSqtwGhvVcruRG+6DtJHrRa6TKWjaOfuomgud+0ADhsd6UyspcFhscc5HNaU75MqD7sn3sjP61kXMLK42kMinpWb02H6kYuWTYijhT171clmLfLtwuMgmqkkASdWVvkfHWnzMyfITuC9j6UrWE3fYc5UqgBztpzO24AkgCmuymRTFhcjBqAyEu8bNuK9xQTe5NKnysVP51XdDlH74p0rEMu7PIyKjDEHDflQBC5JLBTwOtREgsuAdpqZXAlb+VNdAX46DoKEBHKoVth5HrUVwmEGelSy8jOKgmY4UHkGmhMjA3Lk0oZk+lBADADkUs3JAUdKZSJlYE9a2NMYFwpOKxoo8sDV2zY+bjpU9RNnb2rqFC56VNcHcvy1lWj/KMHJNXi/A9K0v0MtjP1HKxmuVv2J5NdHrEuVIHSuVvWJ4qepaehQkbNFMK8mitDNs+hEbjFJuwfemA/NxRIMc1XQyLsEu2p9+4cVnRkkVZjJHepfYtISc4XmqYDhv9mrk6ZUc0zHAFZvQu+hGrDkdhVadscL+dWnG0VWccYqGyoojwSvBp5BCE9qanPFSO2YcU0EitsO3J6UsKEnimGQ4INTWrdhVMpJ2JBuB2ntUgTauT60MNoz1JqQfOMGgljCMyKFPWpJFKtgnNQxDEuKmZ8HB5oTC2o9lGOfSowArgdaiaU+YR2zUicvj05obHaw+QhnUdMVHI2z6HtTtmec81FKepPOMUADKQvmrx7HvSyXAjQAgnvio3kZ5AvG0dqibM7AMeh7U/QW+5LbqZH3HGTzirkzGNSFbnuelQxR+X0I3ZxUzR7p03HIPOK0jHQHuVwZFywGSD09KcA1xIVMQ8th84Pc1LOrEE7sDPb0qS3wknkpkBOSfWrt0Q76XLFvEIf8AWhfmHJ254oSVyWPyGFfuj3ptzcNG3yovlgfMD1NVSpmtk8rEY6t70OSRKjfVljytiLvAZ25OO9JM/lzR4ijdQOTnJFT7VWMO+S6qBxVeS0jIUvkJKcfL1qUuw009weceUI3Uea2QAO9ERjx/q1B/hB55qiwaGYAYOzO0nqO1a8O0r8iD72Mn17ms0+ZjkuUrXG4ny5EYM3JC8AVAjyGVhK2VK42nnpV64LWsqIx8xpDyW9Kzr+2CySlGKmE5+tW01qOLVrEFxI88kYtiRIq8ZHTjmnWtvHvIKl2YHJPQGoLS6aRwcbXQEgg1OZjPIiw/u8D5/c1nGd3cck17o15XS1k8oNuLEHcO1V7topgg8s4IxwMYNbJmW6t5kVADGo5Pesy7x5SEgB14JHerlG3UiLXYpW87RxCRF/eIdrbu49qqXLLI7I7MWOHX2rRdGHmRkKVYk454GKx7p1jiTaDuVimc9RUt2RpHV6Fe4t3SSSRP9Z0+XvSMVkMLyj5uM5rVt1USDIz5ig/TFU7+NY1DnoTggU5aIXNd2Kt5EDOpCYDZGBWTLbxvKdxKqepHWtq5RkhwzbqyZgyyuMjjmolqxrYxo4fJnJZmdMnCv2pt4GSZXxlH9K0LuINDuHXNV7j51CP2OOO1LyBFJWZWdOMN0ptuALpfMX5SDkmkuUMXl85zT51O2NgfvCi1hXHzFdwznA6GoZ2bIZeAe9PQb38snIIp8a4iMbc4NINioxIkDKPmx3qKSVkJGOf5VddNwHqDUU8S4Gevc01oBXVvk+vWo5FPlkjtUgXD8djTroYHHpTQinEoz8x5qcY+tRbfmUip4h+95pjuPzsXK9aLR/32TUVw2SQBTIDht1TYDrbRyqBs8VehkL8npWDZSlkA5xWi8jJHhT2qluZyK2rSgk46VzV1J3rVvXJVia5+7cliBVJak30EJxiimbcqKKsD/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The lines extending from the lateral nasal alae to the lateral mouth are nasolabial folds.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_43_41648=[""].join("\n");
var outline_f40_43_41648=null;
var title_f40_43_41649="Patient information: Aortic coarctation in adults (The Basics)";
var content_f40_43_41649=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/17179\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?24/38/25187\">",
"         Aortic coarctation",
"        </a>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?33/58/34722\">",
"         Patient information: High blood pressure in adults (The Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Aortic coarctation in adults (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/aortic-coarctation-in-adults-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H15992583\">",
"      <span class=\"h1\">",
"       What is aortic coarctation?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Aortic coarctation",
"      <strong>",
"      </strong>",
"      is a heart defect that causes the heart&rsquo;s largest vessel, called the &ldquo;aorta&rdquo;, to narrow (",
"      <a class=\"graphic graphic_figure graphicRef65713 \" href=\"mobipreview.htm?24/38/25187\">",
"       figure 1",
"      </a>",
"      ). People with this condition are born with it. But they might not find out that they have the condition until they are adults. People with aortic coarctation often also have a heart valve problem.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H15992598\">",
"      <span class=\"h1\">",
"       What are the symptoms of aortic coarctation?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Most people with aortic coarctation do not have any symptoms. But often they have high blood pressure. If their high blood pressure is not treated, symptoms can include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Trouble breathing, especially when exercising",
"       </li>",
"       <li>",
"        Headache",
"       </li>",
"       <li>",
"        Leg cramps",
"       </li>",
"       <li>",
"        Fatigue",
"       </li>",
"       <li>",
"        Nosebleeds",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      People with aortic coarctation usually have high blood pressure in their arms (especially the right arm) but low blood pressure in their legs. Also, their pulse is much weaker in the groin area than in the neck or arms.",
"     </p>",
"     <p>",
"      A less common but serious problem that can happen in people with aortic coarctation is a bleed inside the head due to an enlarged blood vessel.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H15992613\">",
"      <span class=\"h1\">",
"       Are there tests for aortic coarctation?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. The doctor will do an exam and measure your pulse and blood pressure in your arms and legs. Other tests include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        An electrocardiogram &ndash; This test measures the electrical activity of the heart. It is also called an &ldquo;ECG&rdquo; or &ldquo;EKG.&rdquo;",
"       </li>",
"       <li>",
"        An echocardiogram &ndash; This test uses sound waves to take pictures of your heart and aorta.",
"       </li>",
"       <li>",
"        An MRI or CT scan &ndash; These tests can take pictures of your aorta as well as the blood vessels in the head.",
"       </li>",
"       <li>",
"        A cardiac catheterization - During this test, the doctor inserts a thin tube into a blood vessel in your leg or arm and advances the tube to your aorta. Then the doctor injects a dye that shows up on an X-ray. This dye can show how much your aorta has narrowed.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H15992628\">",
"      <span class=\"h1\">",
"       How is aortic coarctation treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The type of treatment you have depends how much your aorta has narrowed, your symptoms, and your age. Treatments include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Angioplasty&nbsp;&ndash; A doctor puts a thin tube into a blood vessel in the leg or arm and advances the tube to the aorta. Then the doctor inflates a balloon inside the aorta to widen it. In some cases, the doctor props open the aorta using a mesh tube called a &ldquo;stent.&rdquo;",
"       </li>",
"       <li>",
"        Surgery&nbsp;&ndash; Different types of surgery can fix the narrowed aorta. The surgeon might remove the narrowed part of the aorta. In some cases, he or she uses a plastic tube called a &ldquo;graft&rdquo; or a piece of another one of your blood vessels to fix the aorta.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H15992643\">",
"      <span class=\"h1\">",
"       What if I want to get pregnant?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Women with aortic coarctation who want to get pregnant should talk to their doctor about the risks. Most women who have been treated can have a baby safely. &nbsp;",
"     </p>",
"     <p>",
"      In some women who have not been treated for aortic coarctation, pregnancy can be dangerous and in rare cases, fatal. The most common problem is high blood pressure. If a women&rsquo;s blood pressure stays in a normal range during her pregnancy, she can be treated for the condition after she delivers. But if her blood pressure gets too high, she might need to deliver early or get treatment before giving birth.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H15992660\">",
"      <span class=\"h1\">",
"       What will my life be like?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Many people with aortic coarctation are able to live normal lives. But high blood pressure and aortic coarctation can return after treatment. So you will need to see your doctor and get tested again at least every 5 years. Also, you should check with your doctor about what types of exercise you can do.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H15992675\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?33/58/34722?source=see_link\">",
"       Patient information: High blood pressure in adults (The Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"mobipreview.htm?40/43/41649?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 17179 Version 2.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-115.25.216.6-12D3B89698-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_43_41649=[""].join("\n");
var outline_f40_43_41649=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15992583\">",
"      What is aortic coarctation?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15992598\">",
"      What are the symptoms of aortic coarctation?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15992613\">",
"      Are there tests for aortic coarctation?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15992628\">",
"      How is aortic coarctation treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15992643\">",
"      What if I want to get pregnant?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15992660\">",
"      What will my life be like?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15992675\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/17179\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?24/38/25187\">",
"      Aortic coarctation",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?33/58/34722?source=related_link\">",
"      Patient information: High blood pressure in adults (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f40_43_41650="Volumetric modulated arc therapy";
var content_f40_43_41650=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F55906&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F55906&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Volumetric modulated arc therapy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 400px; height: 362px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The system is equipped with imaging tools that help clinicians visualize tumor targets and normal tissue, and their movement between and during fractions. The integration of this technology in the gantry enables physicians to perform imaging with the patient in the treatment position at the time of treatment to optimize patient setup before therapy.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Modified&nbsp;with permission from: Elekta Synergy&reg;",
"     <a href=\"file://www.elekta.com/healthcare_international_elekta_synergy.php\">",
"      file://www.elekta.com/healthcare_international_elekta_synergy.php",
"     </a>",
"     .",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_43_41650=[""].join("\n");
var outline_f40_43_41650=null;
var title_f40_43_41651="Esophageal perforation PA";
var content_f40_43_41651=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F60957&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F60957&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Esophageal perforation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 276px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Chest film from a patient with Boerhaave's syndrome reveals air under both diaphragmatic leaflets.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Robert E Mindelzun, MD, Department of Radiology, Stanford University.",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 450px\">",
"   <div class=\"ttl\">",
"    Normal chest radiograph",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 371px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Posteroanterior view of a normal chest radiograph.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Carol M Black, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_43_41651=[""].join("\n");
var outline_f40_43_41651=null;
var title_f40_43_41652="Methazolamide: Drug information";
var content_f40_43_41652=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Methazolamide: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?20/0/20484?source=see_link\">",
"    see \"Methazolamide: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F10415504\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Neptazane&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F194139\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Methazolamide&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F194154\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Carbonic Anhydrase Inhibitor;",
"     </li>",
"     <li>",
"      Diuretic, Carbonic Anhydrase Inhibitor;",
"     </li>",
"     <li>",
"      Ophthalmic Agent, Antiglaucoma",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F194142\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Glaucoma:",
"     </b>",
"     Oral: 50-100 mg 2-3 times/day",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F194143\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F194121\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 25 mg, 50 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neptazane&trade;: 25 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neptazane&trade;: 50 mg [scored]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F194109\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F194124\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of chronic open-angle or secondary glaucoma; short-term therapy of acute angle-closure glaucoma prior to surgery",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F194160\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Methazolamide may be confused with methenamine, metolazone",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Neptazane&trade; may be confused with Nesacaine&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F194152\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Confusion, drowsiness, fatigue, fever, malaise, seizure",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Erythema multiforme, photosensitivity, rash, Stevens-Johnson syndrome, toxic epidermal necrolysis, urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Electrolyte imbalance, metabolic acidosis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Appetite decreased, diarrhea, melena, nausea, taste alteration, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Crystalluria, glycosuria, hematuria, polyuria, renal calculi",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Agranulocytosis, aplastic anemia, bone marrow depression, hemolytic anemia, leukopenia, pancytopenia, thrombocytopenic purpura",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Fulminant hepatic necrosis, hepatic insufficiency",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Flaccid paralysis, paresthesia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Myopia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Otic: Hearing disturbance, tinnitus",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Anaphylaxis, hypersensitivity",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F194127\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Marked kidney or liver dysfunction; adrenal gland failure; cirrhosis; hyperchloremic acidosis; hyponatremia; hypokalemia; long-term treatment of angle-closure glaucoma",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F194113\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CNS effects: May impair mental alertness and/or physical coordination.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Electrolyte disturbance: Initially, potassium excretion may be increased; periodically monitor serum electrolytes and signs of hypokalemia in at risk patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sulfa allergy: Chemical similarities are present among sulfonamides, sulfonylureas, carbonic anhydrase inhibitors, thiazides, and loop diuretics (except ethacrynic acid). Use in patients with sulfonylurea allergy is not specifically contraindicated in product labeling, however, a risk of cross-reaction exists in patients with allergy to any of these compounds; avoid use when previous reaction has been severe. Discontinue if signs of hypersensitivity are noted.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Diabetes: Use with caution in patients with prediabetes or diabetes mellitus; may see a change in glucose control.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with hepatic impairment; may precipitate hepatic encephalopathy. Use is contraindicated in patients with marked liver impairment or cirrhosis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Respiratory disease: Use with caution in patients with respiratory disease such as emphysema or pulmonary obstruction; may precipitate or aggravate respiratory acidosis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Aspirin (high dose): Use with caution in patients taking high dose aspirin concurrently; may lead to severe adverse effects including death, coma, tachypnea, anorexia, and lethargy.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299682\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F194117\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alfuzosin: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha-/Beta-Agonists: Carbonic Anhydrase Inhibitors may decrease the excretion of Alpha-/Beta-Agonists.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Dipivefrin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amifostine: Antihypertensives may enhance the hypotensive effect of Amifostine.  Management: When amifostine is used at chemotherapy doses, antihypertensive medications should be withheld for 24 hours prior to amifostine administration. If antihypertensive therapy can not be withheld, amifostine should not be administered.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amphetamines: Carbonic Anhydrase Inhibitors may decrease the excretion of Amphetamines.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticonvulsants (Barbiturate): Carbonic Anhydrase Inhibitors may enhance the adverse/toxic effect of Anticonvulsants (Barbiturate). Specifically, osteomalacia and rickets.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticonvulsants (Hydantoin): Carbonic Anhydrase Inhibitors may enhance the adverse/toxic effect of Anticonvulsants (Hydantoin). Specifically, osteomalacia and rickets.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antihypertensives: May enhance the hypotensive effect of other Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CarBAMazepine: Carbonic Anhydrase Inhibitors may increase the serum concentration of CarBAMazepine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Carbonic Anhydrase Inhibitors: May enhance the adverse/toxic effect of other Carbonic Anhydrase Inhibitors. The development of acid-base disorders with concurrent use of ophthalmic and oral carbonic anhydrase inhibitors has been reported. Management: Avoid concurrent use of different carbonic anhydrase inhibitors if possible.  Monitor patients closely for the occurrence of kidney stones and with regards to severity of metabolic acidosis.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Diazoxide: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Flecainide: Carbonic Anhydrase Inhibitors may increase the serum concentration of Flecainide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypertensive Properties): May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypotensive Properties): May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hypotensive Agents: May enhance the adverse/toxic effect of other Hypotensive Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lithium: Carbonic Anhydrase Inhibitors may decrease the serum concentration of Lithium.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the orthostatic hypotensive effect of Orthostatic Hypotension Producing Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Memantine: Carbonic Anhydrase Inhibitors may decrease the excretion of Memantine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MetFORMIN: Carbonic Anhydrase Inhibitors may enhance the adverse/toxic effect of MetFORMIN. Specifically, the risk of developing lactic acidosis may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methenamine: Carbonic Anhydrase Inhibitors may diminish the therapeutic effect of Methenamine.  Management: Consider avoiding this combination. Monitor for decreased therapeutic effects of methenamine if used concomitant with a carbonic anhydrase inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylphenidate: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentoxifylline: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phosphodiesterase 5 Inhibitors: May enhance the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Primidone: Carbonic Anhydrase Inhibitors may enhance the adverse/toxic effect of Primidone. Specifically, osteomalacia and rickets. Carbonic Anhydrase Inhibitors may decrease the serum concentration of Primidone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prostacyclin Analogues: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QuiNIDine: Carbonic Anhydrase Inhibitors may decrease the excretion of QuiNIDine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RiTUXimab: Antihypertensives may enhance the hypotensive effect of RiTUXimab.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salicylates: May enhance the adverse/toxic effect of Carbonic Anhydrase Inhibitors. Salicylate toxicity might be enhanced by this same combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Phosphates: Diuretics may enhance the nephrotoxic effect of Sodium Phosphates. Specifically, the risk of acute phosphate nephropathy may be enhanced.  Management: Consider avoiding this combination by temporarily suspending treatment with diuretics, or seeking alternatives to oral sodium phosphate bowel preparation. If the combination cannot be avoided, hydrate adequately and monitor fluid and renal status.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trientine: Carbonic Anhydrase Inhibitor Diuretics may decrease the serum concentration of Trientine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Yohimbine: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F194118\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F10450004\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic in animal studies; however, there are no adequate and well-controlled studies in pregnant women.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F194145\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F194128\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Methazolamide Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     25 mg (100): $143.62",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50 mg (100): $287.26",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Neptazane Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     25 mg (90): $156.25",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50 mg (90): $312.50",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F10450007\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     CBC and platelet count (baseline and periodically), serum electrolytes (periodically)",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F194129\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Glaumetax (AR);",
"     </li>",
"     <li>",
"      Mezomine (KP);",
"     </li>",
"     <li>",
"      Neptazane (FR)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F194112\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Noncompetitive inhibition of the enzyme carbonic anhydrase; thought that carbonic anhydrase is located at the luminal border of cells of the proximal tubule. When the enzyme is inhibited, there is an increase in urine volume and a change to an alkaline pH with a subsequent decrease in the excretion of titratable acid and ammonia.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F194126\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: Slow in comparison with acetazolamide (2-4 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Peak effect: 6-8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: 10-18 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Slow",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : 17-23 L",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: ~55%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Slowly from GI tract",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: ~14 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (~25% as unchanged drug)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9625 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0502-210.101.131.231-1C6C0C3C8D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_43_41652=[""].join("\n");
var outline_f40_43_41652=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10415504\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194139\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194154\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194142\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194143\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194121\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194109\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194124\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194160\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194152\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194127\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194113\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299682\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194117\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194118\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10450004\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194145\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194128\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10450007\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194129\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194112\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194126\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9625\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9625|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?20/0/20484?source=related_link\">",
"      Methazolamide: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f40_43_41653="Loratadine and pseudoephedrine: Drug information";
var content_f40_43_41653=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Loratadine and pseudoephedrine: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?18/57/19349?source=see_link\">",
"    see \"Loratadine and pseudoephedrine: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?17/29/17877?source=see_link\">",
"    see \"Loratadine and pseudoephedrine: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F190101\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Alavert&trade; Allergy and Sinus [OTC];",
"     </li>",
"     <li>",
"      Claritin-D&reg; 12 Hour Allergy &amp; Congestion [OTC];",
"     </li>",
"     <li>",
"      Claritin-D&reg; 24 Hour Allergy &amp; Congestion [OTC];",
"     </li>",
"     <li>",
"      Loratadine-D 12 Hour [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F190102\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Chlor-Tripolon ND&reg;;",
"     </li>",
"     <li>",
"      Claritin&reg; Extra;",
"     </li>",
"     <li>",
"      Claritin&reg; Liberator",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F190119\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Alpha-/Beta- Agonist;",
"     </li>",
"     <li>",
"      Decongestant;",
"     </li>",
"     <li>",
"      Histamine H;",
"      <sub>",
"       1",
"      </sub>",
"      Antagonist",
"     </li>",
"     <li>",
"      Histamine H;",
"      <sub>",
"       1",
"      </sub>",
"      Antagonist, Second Generation",
"     </li>",
"     <li>",
"      Piperidine Derivative",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F190104\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Seasonal allergic rhinitis/nasal congestion:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oral: 1 tablet every 12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Extended release: 1 tablet daily",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F190113\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?17/29/17877?source=see_link\">",
"      see \"Loratadine and pseudoephedrine: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Seasonal allergic rhinitis/nasal congestion: Children &ge;12 years: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F190105\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F190106\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Claritin-D&reg; 12-Hour: 1 tablet daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Claritin-D&reg; 24-Hour: 1 tablet every other day",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F190107\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Should be avoided.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F190092\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, extended release: Loratadine 10 mg and pseudoephedrine sulfate 240 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Alavert&trade; Allergy and Sinus: Loratadine 5 mg and pseudoephedrine sulfate 120 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Claritin-D&reg; 12 Hour Allergy &amp; Congestion: Loratadine 5 mg and pseudoephedrine sulfate 120 mg [contains calcium 30 mg/tablet]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Claritin-D&reg; 24 Hour Allergy &amp; Congestion: Loratadine 10 mg and pseudoephedrine sulfate 240 mg [contains calcium 25 mg/tablet]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Loratadine-D 12 Hour: Loratadine 5 mg and pseudoephedrine sulfate 120 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F190081\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F190094\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Temporary relief of symptoms of seasonal allergic rhinitis, other upper respiratory allergies, or the common cold",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F7914564\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Claritin-D&reg; may be confused with Claritin-D&reg; 24",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Claritin-D&reg; 24 may be confused with Claritin-D&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F190117\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F190097\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to loratadine, pseudoephedrine, or any component of the formulation; use with or within 14 days of MAO inhibitors",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F190084\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular disease: Use with caution in patients with cardiovascular disease (including hypertension and ischemic heart disease).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Diabetes: Use with caution in patients with diabetes mellitus.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with hepatic impairment; dosage adjustment recommended.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Increased intraocular pressure/glaucoma: Use with caution in patients with increased intraocular pressure or glaucoma.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Prostatic hyperplasia/urinary obstruction: Use with caution in patients with prostatic hyperplasia and/or GU obstruction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment; dosage adjustment recommended.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Thyroid dysfunction: Use with caution in patients with thyroid dysfunction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Use with caution in the elderly; may be more sensitive to adverse effects.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Safety and efficacy have not been established in children &lt;12 years of age.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Claritin-D&reg; 24-Hour: Patients with swallowing difficulties (eg, upper GI narrowing or abnormal esophageal peristalsis) should not use Claritin-D&reg; 24-Hour.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Self-medication (OTC use): When used for self medication (OTC), notify healthcare provider if symptoms do not improve within 7 days or are accompanied by fever. Discontinue and contact healthcare provider if nervousness, dizziness or sleeplessness occur.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F190114\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to individual components.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F190088\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acetylcholinesterase Inhibitors (Central): Anticholinergics may diminish the therapeutic effect of Acetylcholinesterase Inhibitors (Central). Acetylcholinesterase Inhibitors (Central) may diminish the therapeutic effect of Anticholinergics. If the anticholinergic action is a side effect of the agent, the result may be beneficial.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aclidinium: May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha1-Blockers: May diminish the hypertensive effect of Alpha-/Beta-Agonists. Similarly, Alpha-/Beta-Agonists may antagonize hypotensive effects of Alpha1-Blockers. Alpha1-Blockers may diminish the vasoconstricting effect of Alpha-/Beta-Agonists. Similarly, Alpha-/Beta-Agonists may antagonize Alpha1-Blocker vasodilation.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amiodarone: May increase the serum concentration of Loratadine. Management: Due to reported QT interval prolongation and Torsades de Pointes with this combination, consider an alternative to loratadine when possible.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amphetamines: May diminish the sedative effect of Antihistamines.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antacids: May decrease the excretion of Alpha-/Beta-Agonists.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Aluminum Hydroxide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticholinergics: May enhance the adverse/toxic effect of other Anticholinergics.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP2D6 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AtoMOXetine: May enhance the hypertensive effect of Sympathomimetics. AtoMOXetine may enhance the tachycardic effect of Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Benzylpenicilloyl Polylysine: Antihistamines may diminish the diagnostic effect of Benzylpenicilloyl Polylysine.  Management: Suspend systemic H1 antagonists for benzylpenicilloyl-polylysine skin testing and delay testing until systemic antihistaminic effects have dissipated. A histamine skin test may be used to assess persistent antihistaminic effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Benzylpenicilloyl Polylysine: Alpha-/Beta-Agonists may diminish the diagnostic effect of Benzylpenicilloyl Polylysine.  Management: Consider use of a histamine skin test as a positive control to assess a patient's ability to mount a wheal and flare response.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Betahistine: Antihistamines may diminish the therapeutic effect of Betahistine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bromocriptine: Alpha-/Beta-Agonists may enhance the adverse/toxic effect of Bromocriptine. Including increased blood pressure, ventricular arrhythmias, and seizure.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine.  Management: Consider reduced doses of CNS depressants used in combination with buprenorphine.  Consider avoiding other CNS depressants in patients thought to be at high risk of buprenorphine overuse or self-injection.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cannabinoids: May enhance the tachycardic effect of Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Carbonic Anhydrase Inhibitors: May decrease the excretion of Alpha-/Beta-Agonists.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Brinzolamide; Dorzolamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Droperidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ergot Derivatives: May enhance the hypertensive effect of Alpha-/Beta-Agonists. Ergot Derivatives may enhance the vasoconstricting effect of Alpha-/Beta-Agonists.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Ergoloid Mesylates.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     FentaNYL: Alpha-/Beta-Agonists (Indirect-Acting) may decrease the serum concentration of FentaNYL. Specifically, fentanyl nasal spray serum concentrations may decrease and onset of effect may be delayed.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hyaluronidase: Antihistamines may diminish the therapeutic effect of Hyaluronidase.  Management: Patients receiving antihistamines (particularly at larger doses) may not experience the desired clinical response to standard doses of hyaluronidase.  Larger doses of hyaluronidase may be required.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iobenguane I 123: Sympathomimetics may diminish the therapeutic effect of Iobenguane I 123.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ipratropium (Oral Inhalation): May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the hypertensive effect of Alpha-/Beta-Agonists (Indirect-Acting).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrosine: CNS Depressants may enhance the sedative effect of Metyrosine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mirtazapine: CNS Depressants may enhance the CNS depressant effect of Mirtazapine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Inducers: May decrease the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inducers may also further limit the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Inhibitors: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inhibitors may also enhance the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramlintide: May enhance the anticholinergic effect of Anticholinergics. These effects are specific to the GI tract.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: CNS Depressants may enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Specifically, the risk of psychomotor impairment may be enhanced.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serotonin/Norepinephrine Reuptake Inhibitors: May enhance the tachycardic effect of Alpha-/Beta-Agonists. Serotonin/Norepinephrine Reuptake Inhibitors may enhance the vasopressor effect of Alpha-/Beta-Agonists.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Oxybate: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Spironolactone: May diminish the vasoconstricting effect of Alpha-/Beta-Agonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sympathomimetics: May enhance the adverse/toxic effect of other Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tiotropium: Anticholinergics may enhance the anticholinergic effect of Tiotropium.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem dose to 1.75 mg for men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F12808380\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Ethanol: May increase CNS depression; monitor for increased effects with coadministration. Caution patients about effects.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16323330\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablet, 12-hour",
"     </b>",
"     (Alavert Allergy/Sinus Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5-120 mg (12): $8.10",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablet, 12-hour",
"     </b>",
"     (Claritin-D 12 Hour Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5-120 mg (20): $18.86",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablet, 12-hour",
"     </b>",
"     (KLS AllerClear D-12HR Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5-120 mg (30): $18.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablet, 24-hour",
"     </b>",
"     (Claritin-D 24 Hour Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10-240 mg (10): $12.80",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablet, 24-hour",
"     </b>",
"     (Clear-Atadine D Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10-240 mg (10): $18.90",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablet, 24-hour",
"     </b>",
"     (Wal-itin D 24 Hour Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10-240 mg (10): $10.99",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F190099\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Airet (CO);",
"     </li>",
"     <li>",
"      Aldisa-SR (ID);",
"     </li>",
"     <li>",
"      Alergicol LP (PE);",
"     </li>",
"     <li>",
"      Allerpid (MY);",
"     </li>",
"     <li>",
"      Bonalerg - D (GT);",
"     </li>",
"     <li>",
"      Carinox (MY);",
"     </li>",
"     <li>",
"      Clariflu (MX);",
"     </li>",
"     <li>",
"      Clarifriol (MX);",
"     </li>",
"     <li>",
"      Clarinase (AE, BH, CY, EG, HK, ID, IL, IQ, IR, JO, KP, KW, LB, LY, MY, OM, PH, QA, SA, SY, TH, TW, VE, YE);",
"     </li>",
"     <li>",
"      Clarinase 24 Hour Extended Release (MY, SG);",
"     </li>",
"     <li>",
"      Clarinase 24 Hour Relief (AU);",
"     </li>",
"     <li>",
"      Clarinase Repetabs (CL, NZ, TH);",
"     </li>",
"     <li>",
"      Clarityne (MX);",
"     </li>",
"     <li>",
"      Clarityne D Repetabs (CO, PE);",
"     </li>",
"     <li>",
"      Clarityne-D (CR, DO, GR, GT, HN, NI, PA, PY, SV, UY);",
"     </li>",
"     <li>",
"      De-Cold (SG);",
"     </li>",
"     <li>",
"      Dimegan D (MX);",
"     </li>",
"     <li>",
"      Gralddep (MX);",
"     </li>",
"     <li>",
"      Larotin D (EC);",
"     </li>",
"     <li>",
"      Lertamine D (MX);",
"     </li>",
"     <li>",
"      Lorfast-D (IN);",
"     </li>",
"     <li>",
"      Lorimox (MX);",
"     </li>",
"     <li>",
"      Minlife-P (TW);",
"     </li>",
"     <li>",
"      Rhilor D (PK);",
"     </li>",
"     <li>",
"      Rhinos SR (ID);",
"     </li>",
"     <li>",
"      Sensibit (MX);",
"     </li>",
"     <li>",
"      Theraflu (MX);",
"     </li>",
"     <li>",
"      Zoratadine-P (MY)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F190096\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10204 Version 46.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0502-201.77.166.39-59FAC149C3-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_43_41653=[""].join("\n");
var outline_f40_43_41653=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F190101\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F190102\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F190119\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F190104\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F190113\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F190105\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F190106\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F190107\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F190092\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F190081\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F190094\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7914564\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F190117\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F190097\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F190084\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F190114\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F190088\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12808380\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16323330\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F190099\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F190096\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10204\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10204|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?18/57/19349?source=related_link\">",
"      Loratadine and pseudoephedrine: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?17/29/17877?source=related_link\">",
"      Loratadine and pseudoephedrine: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f40_43_41654="Medical management of symptomatic aortic stenosis";
var content_f40_43_41654=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Medical management of symptomatic aortic stenosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/43/41654/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/43/41654/contributors\">",
"     Catherine M Otto, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/43/41654/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/43/41654/contributors\">",
"     William H Gaasch, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/43/41654/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/43/41654/contributors\">",
"     Susan B Yeon, MD, JD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?40/43/41654/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 29, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Aortic valve replacement is the mainstay of treatment of symptomatic aortic stenosis (AS). Aortic valve replacement offers substantial improvements in symptoms and life expectancy. Medical therapy may not prolong life in patients with aortic stenosis and has limited utility in treating symptoms.",
"   </p>",
"   <p>",
"    In patients who are candidates for surgical intervention and are awaiting surgery, medical therapy to optimize hemodynamics in the pre-operative setting may be needed. However, when severe symptoms are present, it may be prudent to admit the patient to the hospital and perform surgery urgently as there is a high risk of cardiac death once severe symptoms are present.",
"   </p>",
"   <p>",
"    Longer-term palliative medical management of symptomatic aortic stenosis is appropriate for patients who are not candidates for aortic valve surgery due to coexisting medical conditions and in patients who have refused aortic valve replacement.",
"   </p>",
"   <p>",
"    This topic will discuss medical management of patients with symptomatic aortic stenosis and possible indications for aortic valvuloplasty. Indications for aortic valve surgery, methods of aortic valve replacement, and management of asymptomatic aortic stenosis are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/8/31881?source=see_link\">",
"     \"Indications for valve replacement in aortic stenosis in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/37/11865?source=see_link\">",
"     \"Surgical valve replacement in aortic stenosis in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/62/2025?source=see_link\">",
"     \"Medical management of asymptomatic aortic stenosis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     SETTINGS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Aortic valve replacement is recommended for patients with symptomatic aortic stenosis (AS). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/8/31881?source=see_link\">",
"     \"Indications for valve replacement in aortic stenosis in adults\"",
"    </a>",
"    .) However, patients with symptomatic AS in the following settings may require temporary or indefinite medical management:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Comorbid conditions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Aortic valve replacement may not be appropriate in some patients with symptomatic aortic stenosis due to certain severe comorbid conditions, such as malignancy. In some cases, aortic valve replacement may be deferred only temporarily while a treatable condition (eg, infection) is managed and controlled.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     High risk patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some patients are not candidates for valve replacement due to a very high risk for operative mortality and morbidity. Some of these patients may be candidates for transcatheter aortic valve implantation if that procedure is approved by the FDA. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/5/7252?source=see_link\">",
"     \"Estimating the mortality risk of valvular surgery\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/37/11865?source=see_link\">",
"     \"Surgical valve replacement in aortic stenosis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Patient refusal",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some patients with symptomatic aortic stenosis may refuse aortic valve replacement despite adequate counseling on the potential benefits and risks of aortic valve replacement and deferral of surgery.",
"   </p>",
"   <p>",
"    Care should be taken to ensure that aortic valve surgery is offered to all appropriate patients with symptomatic AS with adequate discussion of estimated risks. Of concern are reports that substantial numbers of patients with symptomatic AS with reasonable estimated operative risks are not referred for aortic valve surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/43/41654/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/8/31881?source=see_link\">",
"     \"Indications for valve replacement in aortic stenosis in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/5/7252?source=see_link\">",
"     \"Estimating the mortality risk of valvular surgery\"",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Patients awaiting valve replacement",
"    </span>",
"    &nbsp;&mdash;&nbsp;In general, medical intervention prior to aortic valve replacement should be minimized in patients with symptomatic AS. Most medical interventions carry the risk of destabilizing the patient. Patients with the onset of mild symptoms may be scheduled electively for valve replacement. However, those with frank heart failure, angina, or syncope should be hospitalized while awaiting valve replacement. The management of critically ill patients is discussed below. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Critically ill patients awaiting valve replacement'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Management of pregnant patients with symptomatic aortic stenosis is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/25/27032?source=see_link&amp;anchor=H9#H9\">",
"     \"Pregnancy in women with a bicuspid aortic valve\", section on 'Bicuspid aortic stenosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     MEDICAL MANAGEMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Severe symptomatic inoperable AS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     General considerations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Aortic valve surgery for symptomatic AS effectively treats symptoms and prolongs life and should be considered in all patients. In contrast, when valve replacement is not possible or is refused by the patient, medical therapy may not prolong life and has potential harm. The goals of medical therapy are to treat concurrent cardiovascular conditions, prevent or treat superimposed diseases that often exacerbate the effects of valve obstruction, maintain optimal loading conditions, and treat symptoms. In addition, the physician should provide both the patient and family counseling about the expected disease course, treatment options, and end-of-life preferences.",
"   </p>",
"   <p>",
"    No endocarditis prophylaxis is indicated for patients with aortic stenosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/43/41654/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Adults with severe symptomatic AS should only engage in mild physical activity as symptoms will be precipitated by even moderate physical exertion.",
"   </p>",
"   <p>",
"    Since patients with calcific aortic valve disease commonly have concurrent atherosclerotic disease including coronary artery disease, evaluation for and management of associated cardiovascular risk factors (eg, hyperlipidemia) is recommended. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/62/2025?source=see_link&amp;anchor=H11#H11\">",
"     \"Medical management of asymptomatic aortic stenosis in adults\", section on 'Coronary artery disease'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/60/40906?source=see_link\">",
"     \"Secondary prevention of cardiovascular disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    At present, statin therapy solely to treat or prevent progression of aortic stenosis (ie, in the absence of coexisting atherosclerotic vascular disease or other indications) cannot be recommended. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/62/2025?source=see_link&amp;anchor=H3#H3\">",
"     \"Medical management of asymptomatic aortic stenosis in adults\", section on 'Prevention of disease progression'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Medical therapy for coronary artery disease, and atrial fibrillation should be continued in adults with aortic stenosis, both in those with and without symptoms. An appropriate goal for patients with atrial fibrillation is rate control with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    beta blockers. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/62/2025?source=see_link\">",
"     \"Medical management of asymptomatic aortic stenosis in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/50/12074?source=see_link\">",
"     \"Control of ventricular rate in atrial fibrillation: Pharmacologic therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Management of loading conditions and symptoms",
"    </span>",
"   </p>",
"   <p>",
"    Even in the absence of an acute illness, adults with severe symptomatic inoperable AS may have fewer symptoms and less frequent hospitalizations if loading conditions can be optimized. This includes treatment of hypertension and maintaining a normal volume status.",
"   </p>",
"   <p>",
"    Treatment of hypertension in severe symptomatic AS is challenging. Concomitant hypertension and AS present a double load for the left ventricle, which may adversely affect ventricular function [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/43/41654/abstract/4\">",
"     4",
"    </a>",
"    ]. The combination of hypertension and AS may lead to development of symptoms as an earlier stage of AS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/43/41654/abstract/5\">",
"     5",
"    </a>",
"    ]. However, no specific treatment regimen for patients with aortic stenosis with hypertension has been established.",
"   </p>",
"   <p>",
"    Various medical therapies pose a risk of destabilizing the patient with aortic stenosis:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Diuretics reduce preload, on which the patient may depend for maintenance of cardiac output. Therefore, diuretics should be used with caution.",
"     </li>",
"     <li>",
"      Beta blockers reduce contractility which may pose a risk for the overloaded left ventricle. While low dose beta blockers may be considered in patients with asymptomatic hypertension (particularly in the setting of atrial fibrillation), beta blockers should be avoided in patients with symptomatic aortic stenosis and heart failure.",
"     </li>",
"     <li>",
"      Vasodilators (such as",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?14/57/15254?source=see_link\">",
"       hydralazine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?11/24/11656?source=see_link\">",
"       nitroglycerin",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?12/5/12377?source=see_link\">",
"       nifedipine",
"      </a>",
"      ) in the presence of a fixed valvular stenosis may reduce systemic blood pressure and reduce coronary artery perfusion pressure. These agents should be avoided or used with caution. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Critically ill patients awaiting valve replacement'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Despite these concerns, cautious treatment of hypertension starting with low doses and titrating slowly as needed to optimize loading conditions is appropriate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/43/41654/abstract/6\">",
"     6",
"    </a>",
"    ]. Angiotensin converting enzyme (ACE) inhibitors are used by some [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/43/41654/abstract/6\">",
"     6",
"    </a>",
"    ]. Since experience in AS patients is limited, calcium channel blockers should be used with caution.",
"   </p>",
"   <p>",
"    For management of patients who have had symptoms of heart failure, we suggest a combination of a diuretic and an ACE inhibitor. These should be started at low doses with gradual titration.",
"   </p>",
"   <p>",
"    Treatment is improved if patients are educated and involved in following daily weights and signs of decompensation. In addition, patients should be educated about the effects of sodium intake, changes in elevation with travel, and other factors that may lead to clinical decompensation. Frequent physician or nurse visits are needed for patient monitoring.",
"   </p>",
"   <p>",
"    Even with optimal care, adults with severe symptomatic inoperable AS will have exacerbations of symptoms and frequent hospitalizations. Symptoms of dyspnea and chest pain are treated as described above, within the end-of-life care parameters set by the patient. Dizziness and pre-syncope typically are exertional and can be avoided by decreasing physical activity and instructing the patient to stop and sit (or lie) down when symptoms occur. Palliative care includes symptomatic treatment for symptoms of dyspnea and angina. In addition, end-of life discussions and counseling are appropriate. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/37/2650?source=see_link\">",
"     \"End of life considerations for heart failure patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Prevention and treatment of concurrent conditions",
"    </span>",
"   </p>",
"   <p>",
"    Many adults with severe symptomatic aortic stenosis have relatively stable symptoms with decompensation triggered by an intercurrent illness such as influenza, anemia, pulmonary embolism, etc. Optimal preventative care can prevent recurrent hospitalizations. These measures include pneumococcal vaccination, annual influenza vaccination, routine preventative care examinations, and treatment of any noncardiac conditions.",
"   </p>",
"   <p>",
"    When clinical decompensation occurs, in addition to treating the disease process, patients may be effectively managed by supportive care during the acute illness. Medical therapy focuses on decreasing cardiac workload by reducing fever, controlling heart rate and blood pressure, correction of anemia, and administration of oxygen. Volume status should be carefully monitored with cautious replacement of fluid or gentle diuresis, as needed. With severe AS, patients are very sensitive to small changes in preload, often called a \"narrow preload window.\" An increase in LV volume in a stiff hypertrophied LV results in a rapid rise in diastolic pressure and symptoms of pulmonary congestion. Conversely, when filling volumes are too low, the small LV does not fill adequately with a fall in forward stroke volume and signs of low output failure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22998847\">",
"    <span class=\"h2\">",
"     Medical management in patients awaiting surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;In general, medical intervention prior to aortic valve replacement should be minimized in patients with severe or symptomatic AS. Most medical interventions carry the risk of destabilizing the patient:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Diuretics reduce preload, on which the patient may depend for maintenance of cardiac output.",
"     </li>",
"     <li>",
"      Vasodilators in the presence of a fixed valvular stenosis may reduce systemic blood pressure and reduce coronary artery perfusion pressure.",
"     </li>",
"     <li>",
"      Positive inotropic agents such as",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/57/25494?source=see_link\">",
"       dobutamine",
"      </a>",
"      must be used with caution; tachycardia (with reduced cardiac output) and myocardial ischemia (due to increased oxygen demand) may occur.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Critically ill patients awaiting valve replacement",
"    </span>",
"   </p>",
"   <p>",
"    Some critically ill patients with AS are hemodynamically unstable prior to surgery and at high risk for mortality during the operation. This is especially true in patients with left ventricular dysfunction, who may present with heart failure, and those with coronary disease, who may present with unstable angina. It would be desirable to stabilize such patients prior to surgery, but these are precisely the patients at highest risk of further decompensation with injudicious medical intervention.",
"   </p>",
"   <p>",
"    Percutaneous balloon valvotomy may reduce the aortic valve gradient and can potentially improve symptoms prior to aortic valve replacement. However, this procedure is associated with high morbidity and only transient efficacy. This was illustrated in a series of 21 patients with AS and cardiogenic shock who underwent balloon valvotomy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/43/41654/abstract/7\">",
"     7",
"    </a>",
"    ]. After the procedure, there were significant increases in mean aortic pressure (from 77 to 116 mmHg), aortic valve area (from 0.48 to 0.84 cm2), and the cardiac index (from 1.84 to 2.24). However, nine of the patients died in the hospital during or after the procedure. In addition, vascular complications occurred in five patients, and stroke, cholesterol emboli, and aortic regurgitation occurred in one patient each.",
"   </p>",
"   <p>",
"    Because of these limitations, balloon valvotomy should be considered only in selected clinical settings. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Possible indications for aortic valvotomy'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Although data are limited,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21302?source=see_link\">",
"     nitroprusside",
"    </a>",
"    may be useful in improving ventricular performance prior to surgery in an attempt to reduce surgical risk. The use of nitroprusside was evaluated in a study of 25 patients with severe AS and depressed left ventricular function who were not hypotensive; nitroprusside was administered during continuous hemodynamic monitoring with a pulmonary artery catheter [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/43/41654/abstract/8\">",
"     8",
"    </a>",
"    ]. During nitroprusside treatment, there were significant increases in cardiac index (1.60 to 2.52",
"    <span class=\"nowrap\">",
"     L/min",
"    </span>",
"    per m2) and stroke volume (from 32 to 54 mL) and significant reduction in mean arterial pressure (81 to 69 mmHg) and systemic vascular resistance. Five patients died in the hospital and 13 underwent successful aortic valve replacement.",
"   </p>",
"   <p>",
"    Although no complications occurred, the use of vasodilator therapy in such patients is associated with a risk of hypotension and hemodynamic collapse, and it is unclear from this uncontrolled study whether the surgical outcomes were improved [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/43/41654/abstract/9\">",
"     9",
"    </a>",
"    ]. This approach should be undertaken only with careful hemodynamic monitoring by experienced clinicians.",
"   </p>",
"   <p>",
"    A potential alternative approach is use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/57/25494?source=see_link\">",
"     dobutamine",
"    </a>",
"    in such patients, although use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21302?source=see_link\">",
"     nitroprusside",
"    </a>",
"    or dobutamine in critically ill patients with AS requires intensive monitoring.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     POSSIBLE INDICATIONS FOR AORTIC VALVOTOMY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Percutaneous aortic balloon valvotomy is a procedure in which one or more balloons are placed across the stenotic aortic valve and inflated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/43/41654/abstract/10\">",
"     10",
"    </a>",
"    ]. The aim is to relieve the stenosis, presumably by fracturing calcific deposits within the valve leaflets. Stretching of the annulus and separation of the calcified commissures also may contribute. Early changes after successful valvotomy include a moderate reduction in the transvalvular pressure gradient and an often dramatic improvement in symptoms; however, the postprocedure valve area rarely exceeds 1.0 cm2 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/43/41654/abstract/10,11\">",
"     10,11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Serious complications (stroke, aortic regurgitation, myocardial infarction) occur in approximately 10 to 20 percent of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/43/41654/abstract/10-12\">",
"     10-12",
"    </a>",
"    ]. Furthermore, restenosis and clinical deterioration occur in most cases within 6 to 12 months and the long-term outcome resembles the natural history of untreated AS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/43/41654/abstract/11,13\">",
"     11,13",
"    </a>",
"    ]. Repeat balloon valvotomy can be performed, but most patients fail within six months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/43/41654/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Based upon these observations, the 2006",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    guidelines concluded that balloon valvotomy is NOT a substitute for valve replacement in adults, although selected young adults without valve calcification may represent an exception&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/43/41654/abstract/3\">",
"     3",
"    </a>",
"    ]. In addition, balloon valvotomy is frequently used in children with valvar AS. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/58/7078?source=see_link&amp;anchor=H9#H9\">",
"     \"Treatment of bicuspid aortic valve stenosis in adults\", section on 'Balloon valvotomy in young adults'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/28/38345?source=see_link&amp;anchor=H18#H18\">",
"     \"Valvar aortic stenosis in children\", section on 'Balloon valvotomy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although the evidence is not well established, the guidelines noted two specific settings in adults in which balloon valvotomy might be reasonable [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/43/41654/abstract/3\">",
"     3",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      As a bridge to surgery in hemodynamically unstable patients who are at high risk for aortic valve replacement. However, mortality remains high in these patients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/43/41654/abstract/7\">",
"       7",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Critically ill patients awaiting valve replacement'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Use for palliation in patients with serious comorbid conditions that prevent performance of aortic valve replacement.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, there are two other settings in which balloon valvotomy has been considered:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      As a bridge to delivery to symptomatic pregnant women. Although there are case reports suggesting success, balloon valvotomy can induce aortic regurgitation even in experienced hands, the postdilation bicuspid aortic valve remains susceptible to infective endocarditis irrespective of its functional state, the ascending aorta still harbors an abnormal media, and recurrent stenosis is common within 6 to 12 months. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?26/25/27032?source=see_link\">",
"       \"Pregnancy in women with a bicuspid aortic valve\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In patients who require urgent noncardiac surgery. However, the",
"      <span class=\"nowrap\">",
"       ACC/AHA",
"      </span>",
"      guidelines concluded that most asymptomatic patients with severe AS can undergo urgent noncardiac surgery at relatively low risk with careful intraoperative and postoperative management, including monitoring of anesthesia and careful attention to fluid balance [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/43/41654/abstract/3,15,16\">",
"       3,15,16",
"      </a>",
"      ]. Balloon valvotomy was not recommended; aortic valve replacement should be considered if preoperative correction of AS is warranted [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/43/41654/abstract/3\">",
"       3",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?13/14/13544?source=see_link\">",
"       \"Noncardiac surgery in patients with aortic stenosis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Recent improvements in both balloon technology and procedural technique may lead to a resurgence in the clinical application of balloon valvotomy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/43/41654/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?35/53/36690?source=see_link\">",
"       \"Patient information: Aortic stenosis (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Symptomatic aortic stenosis (AS) is an indication for aortic valve replacement and medical therapy has limited utility in treating symptoms. However, medical management may be required in patients who are not candidates for surgery (either due to comorbid conditions or patient refusal to undergo valve replacement). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Settings'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Palliative care for severe symptomatic inoperable AS includes the following (see",
"      <a class=\"local\" href=\"#H8\">",
"       'Medical management'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Treatment of concurrent cardiovascular conditions such as atrial fibrillation and coronary artery disease.",
"     </li>",
"     <li>",
"      Management of loading conditions and symptoms. Careful treatment of hypertension is appropriate. For patients with heart failure, we suggest a combination of a diuretic and an ACE inhibitor. These should be started at low doses with gradual titration.",
"     </li>",
"     <li>",
"      Prevention and treatment of concurrent conditions.",
"     </li>",
"     <li>",
"      End-of-life discussions and counseling.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In critically ill patients with severe AS, attempts to medically stabilize the patient should be undertaken with caution. In these patients, we recommend prompt aortic valve replacement. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Critically ill patients awaiting valve replacement'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/43/41654/abstract/1\">",
"      Bach DS, Siao D, Girard SE, et al. Evaluation of patients with severe symptomatic aortic stenosis who do not undergo aortic valve replacement: the potential role of subjectively overestimated operative risk. Circ Cardiovasc Qual Outcomes 2009; 2:533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/43/41654/abstract/2\">",
"      van Geldorp MW, van Gameren M, Kappetein AP, et al. Therapeutic decisions for patients with symptomatic severe aortic stenosis: room for improvement? Eur J Cardiothorac Surg 2009; 35:953.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/43/41654/abstract/3\">",
"      Bonow RO, Carabello BA, Chatterjee K, et al. 2008 Focused update incorporated into the ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease): endorsed by the Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Circulation 2008; 118:e523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/43/41654/abstract/4\">",
"      Pibarot P, Dumesnil JG. New concepts in valvular hemodynamics: implications for diagnosis and treatment of aortic stenosis. Can J Cardiol 2007; 23 Suppl B:40B.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/43/41654/abstract/5\">",
"      Antonini-Canterin F, Huang G, Cervesato E, et al. Symptomatic aortic stenosis: does systemic hypertension play an additional role? Hypertension 2003; 41:1268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/43/41654/abstract/6\">",
"      Carabello BA, Paulus WJ. Aortic stenosis. Lancet 2009; 373:956.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/43/41654/abstract/7\">",
"      Moreno PR, Jang IK, Newell JB, et al. The role of percutaneous aortic balloon valvuloplasty in patients with cardiogenic shock and critical aortic stenosis. J Am Coll Cardiol 1994; 23:1071.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/43/41654/abstract/8\">",
"      Khot UN, Novaro GM, Popovi ZB, et al. Nitroprusside in critically ill patients with left ventricular dysfunction and aortic stenosis. N Engl J Med 2003; 348:1756.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/43/41654/abstract/9\">",
"      Zile MR, Gaasch WH. Heart failure in aortic stenosis - improving diagnosis and treatment. N Engl J Med 2003; 348:1735.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/43/41654/abstract/10\">",
"      Nishimura RA, Holmes DR Jr, Reeder GS. Percutaneous balloon valvuloplasty. Mayo Clin Proc 1990; 65:198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/43/41654/abstract/11\">",
"      Lieberman EB, Bashore TM, Hermiller JB, et al. Balloon aortic valvuloplasty in adults: failure of procedure to improve long-term survival. J Am Coll Cardiol 1995; 26:1522.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/43/41654/abstract/12\">",
"      Percutaneous balloon aortic valvuloplasty. Acute and 30-day follow-up results in 674 patients from the NHLBI Balloon Valvuloplasty Registry. Circulation 1991; 84:2383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/43/41654/abstract/13\">",
"      Litvack F, Jakubowski AT, Buchbinder NA, Eigler N. Lack of sustained clinical improvement in an elderly population after percutaneous aortic valvuloplasty. Am J Cardiol 1988; 62:270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/43/41654/abstract/14\">",
"      Ferguson JJ, Garza RA. Efficacy of multiple balloon aortic valvuloplasty procedures. The Mansfield Scientific Aortic Valvuloplasty Registry Investigators. J Am Coll Cardiol 1991; 17:1430.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/43/41654/abstract/15\">",
"      Christ M, Sharkova Y, Geldner G, Maisch B. Preoperative and perioperative care for patients with suspected or established aortic stenosis facing noncardiac surgery. Chest 2005; 128:2944.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/43/41654/abstract/16\">",
"      Torsher LC, Shub C, Rettke SR, Brown DL. Risk of patients with severe aortic stenosis undergoing noncardiac surgery. Am J Cardiol 1998; 81:448.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/43/41654/abstract/17\">",
"      Hara H, Pedersen WR, Ladich E, et al. Percutaneous balloon aortic valvuloplasty revisited: time for a renaissance? Circulation 2007; 115:e334.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8130 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-202.43.93.2-49404BB9CF-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_43_41654=[""].join("\n");
var outline_f40_43_41654=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H15\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      SETTINGS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Comorbid conditions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      High risk patients",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Patient refusal",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Patients awaiting valve replacement",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      MEDICAL MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Severe symptomatic inoperable AS",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - General considerations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Management of loading conditions and symptoms",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Prevention and treatment of concurrent conditions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22998847\">",
"      Medical management in patients awaiting surgery",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Critically ill patients awaiting valve replacement",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      POSSIBLE INDICATIONS FOR AORTIC VALVOTOMY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/50/12074?source=related_link\">",
"      Control of ventricular rate in atrial fibrillation: Pharmacologic therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/37/2650?source=related_link\">",
"      End of life considerations for heart failure patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/5/7252?source=related_link\">",
"      Estimating the mortality risk of valvular surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/8/31881?source=related_link\">",
"      Indications for valve replacement in aortic stenosis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/62/2025?source=related_link\">",
"      Medical management of asymptomatic aortic stenosis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/14/13544?source=related_link\">",
"      Noncardiac surgery in patients with aortic stenosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?35/53/36690?source=related_link\">",
"      Patient information: Aortic stenosis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/25/27032?source=related_link\">",
"      Pregnancy in women with a bicuspid aortic valve",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/60/40906?source=related_link\">",
"      Secondary prevention of cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/37/11865?source=related_link\">",
"      Surgical valve replacement in aortic stenosis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/58/7078?source=related_link\">",
"      Treatment of bicuspid aortic valve stenosis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/28/38345?source=related_link\">",
"      Valvar aortic stenosis in children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f40_43_41655="Brain tumor headache";
var content_f40_43_41655=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Brain tumor headache",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/43/41655/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/43/41655/contributors\">",
"     Christine L Lay, MD, FRCPC",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/43/41655/contributors\">",
"     Christina Sun-Edelstein, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/43/41655/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/43/41655/contributors\">",
"     Jerry W Swanson, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/43/41655/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/43/41655/contributors\">",
"     April F Eichler, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?40/43/41655/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 3, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H20626022\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Headache is one of the most common complaints encountered in clinical medicine. Though the vast majority of headaches are caused by primary headache disorders, more ominous etiologies, such as cerebral neoplasm or metastatic disease, may also be heralded by headache. This topic will review headache related to brain tumors. Other clinical aspects of brain neoplasms are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/3/25657?source=see_link\">",
"     \"Clinical presentation and diagnosis of brain tumors\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/42/8874?source=see_link\">",
"     \"Risk factors for brain tumors\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The approach to evaluating headache in adults and children is reviewed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/51/34615?source=see_link\">",
"     \"Evaluation of headache in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/8/35977?source=see_link\">",
"     \"Approach to the child with headache\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/49/39704?source=see_link\">",
"     \"Evaluation of the adult with headache in the emergency department\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/52/14153?source=see_link\">",
"     \"Emergent evaluation of headache in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4462249\">",
"    <span class=\"h1\">",
"     MECHANISMS OF HEADACHE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Traction on the large blood vessels and dura as well as direct compression of cranial and cervical nerve fibers by the tumor itself are the likely mechanisms for headaches attributed to brain tumors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/43/41655/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. Of note, the brain parenchyma is insensitive to pain. Structures that are sensitive to pain include the following [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/43/41655/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The large arteries at the base of the brain and the first few centimeters of their immediate branches",
"     </li>",
"     <li>",
"      The meningeal arteries",
"     </li>",
"     <li>",
"      The large venous channels of the brain and dura",
"     </li>",
"     <li>",
"      Parts of the dura, including the tentorium and the diaphragma sellae",
"     </li>",
"     <li>",
"      Cranial nerves that carry pain fibers (V, VII, IX, X)",
"     </li>",
"     <li>",
"      Skin and subcutaneous tissue, muscle, vessels, and periosteum of the skull",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Tumors and other mass lesions can cause headache by direct pressure on any of the above structures. Pain arising from the intracranial cavity is a form of visceral pain, and therefore referred to more superficial structures; it is not perceived as coming directly from the compressed region [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/43/41655/abstract/4\">",
"     4",
"    </a>",
"    ]. In general, unilateral lesions refer pain ipsilaterally, supratentorial lesions refer pain to the frontal regions, and posterior fossa masses refer pain to the occiput [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/43/41655/abstract/4\">",
"     4",
"    </a>",
"    ]. However, these associations have poor localizing value in clinical practice. As an example, in a study that evaluated 37 patients with infratentorial tumors, 73 percent of patients had headache in the frontal, temporal,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    parietal regions, while nuchal and occipital pain occurred in only 27 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/43/41655/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Acute or severe headache from a brain tumor can potentially be caused by elevated intracranial pressure resulting from hydrocephalus, mass effect of the tumor itself, or hemorrhage into or around the tumor [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/43/41655/abstract/6\">",
"     6",
"    </a>",
"    ]. A tumor can distort or displace structures distant from its locale, resulting in referred pain that does not correspond with its location. In such cases of \"distant traction,\" elevated intracranial pressure may be the cause of the headache [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/43/41655/abstract/7\">",
"     7",
"    </a>",
"    ]. However, the relationship between elevated intracranial pressure and headache in brain tumor remains uncertain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/43/41655/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4463038\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Headache at presentation is observed in approximately 20 percent of patients with brain tumor, and headache occurs during the course of the disease in 48 to 60 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/43/41655/abstract/9-11\">",
"     9-11",
"    </a>",
"    ]. Several reports have noted that a prior history of headache is a probable risk factor for headache associated with brain tumor [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/43/41655/abstract/11,12\">",
"     11,12",
"    </a>",
"    ], though this may apply only to a longstanding primary headache history and not to a remote history [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/43/41655/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The most frequent primary intracranial tumors are gliomas, meningiomas, and pituitary adenomas. The most frequent sources of metastatic tumors are lung and breast cancer, followed by malignant melanomas and carcinomas of the kidney, and gastrointestinal tracts [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/43/41655/abstract/13,14\">",
"     13,14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Though headache is a common symptom of brain tumor, it is infrequently seen in isolation, as described in the following sections. Furthermore, among all patients with headache who have normal neurologic examinations, the prevalence of intracranial neoplasm is exceedingly low [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/43/41655/abstract/15\">",
"     15",
"    </a>",
"    ]. In contrast, the prevalence of intracranial involvement is relatively high in patients with known systemic malignancy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/58/6057?source=see_link\">",
"     \"Overview of the clinical manifestations, diagnosis, and management of patients with brain metastases\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20626029\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The features of brain tumor headache are generally nonspecific and vary widely with tumor location, size, and rate of growth [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/43/41655/abstract/6,11,15\">",
"     6,11,15",
"    </a>",
"    ]. The headache is usually bilateral, but can be on the side of the tumor [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/43/41655/abstract/14,16\">",
"     14,16",
"    </a>",
"    ]. Supratentorial tumors impinging on structures innervated by the ophthalmic division of the trigeminal nerve may produce a frontotemporal headache, while posterior fossa tumors compressing the glossopharyngeal and vagus nerves can cause occipitonuchal pain. There is generally little radiation, except in posterior fossa tumors. Nausea",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    vomiting accompany the headache in 40 to 60 percent of adult patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/43/41655/abstract/5,9,12\">",
"     5,9,12",
"    </a>",
"    ]. Headache exacerbation with Valsalva, change in position, or exertion occurs in a substantial minority of patients.",
"   </p>",
"   <p>",
"    The evidence regarding the phenotypes of brain tumor headache is inconsistent.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a series of 111 patients with primary and metastatic brain tumors, 53 had headache attributed to the brain tumor [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/43/41655/abstract/12\">",
"       12",
"      </a>",
"      ]. The headache related to brain tumor was described as similar to tension-type headache in 41 patients (77 percent), similar to migraine (although with atypical features) in five patients (9 percent), and was unclassifiable in seven patients (13 percent).",
"     </li>",
"     <li>",
"      A later prospective study of 85 patients with brain tumor-associated headache found that tension-type headache criteria were met in nearly 40 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/43/41655/abstract/17\">",
"       17",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Another prospective report that analyzed 98 patients with tumor-associated headache noted that it was not possible to classify the headache phenotype as a primary headache syndrome for more than one-half of the cases [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/43/41655/abstract/11\">",
"       11",
"      </a>",
"      ]. In those that could be classified, the most common syndromes were episodic tension-type headache and episodic migraine without aura.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other studies have also reported tumors that produced migraine-like headaches with visual aura [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/43/41655/abstract/18-21\">",
"     18-21",
"    </a>",
"    ]. In addition, brain tumor headache can also mimic cough or exertional headache [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/43/41655/abstract/22,23\">",
"     22,23",
"    </a>",
"    ], stabbing headache [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/43/41655/abstract/24\">",
"     24",
"    </a>",
"    ], cluster headache [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/43/41655/abstract/25-27\">",
"     25-27",
"    </a>",
"    ], cluster variants such as short-lasting unilateral neuralgiform pain with conjunctival injection and tearing (SUNCT) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/43/41655/abstract/28\">",
"     28",
"    </a>",
"    ], and chronic paroxysmal hemicrania [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/43/41655/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Though headache is a common symptom of brain tumor, it is infrequently seen in isolation. In the majority of cases, brain tumor headache is associated with other neurologic symptoms such as seizures or focal weakness. In pediatric patients with brain tumor, isolated headache at presentation has been reported in 0 to 1 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/43/41655/abstract/30,31\">",
"     30,31",
"    </a>",
"    ]. Among adults, only 2 to 16 percent of patients with brain tumor present with headache alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/43/41655/abstract/12,17,32-34\">",
"     12,17,32-34",
"    </a>",
"    ]. Isolated headache of more than 10 weeks duration is seldom caused by brain tumor [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/43/41655/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The classic \"brain tumor triad,\" comprising nocturnal or early morning occurrence,",
"    <span class=\"nowrap\">",
"     nausea/vomiting,",
"    </span>",
"    and severe nature, has not been borne out as a typical pattern in modern studies. In one series of 53 adults with brain tumor headache, this triad occurred in only nine patients (17 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/43/41655/abstract/12\">",
"     12",
"    </a>",
"    ]. Morning worsening of headache was observed in 19 (36 percent). The patients described most headaches as \"moderate to severe,\" rather than severe. In children, the prevalence of nocturnal or morning headaches appears to be higher than in adults [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/43/41655/abstract/30,35\">",
"     30,35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20626036\">",
"    <span class=\"h2\">",
"     Tumor type and location",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tumor location and pathology may influence the presentation of the headache. Primary brain tumors and metastatic tumors are equally likely to cause headache [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/43/41655/abstract/12,36,37\">",
"     12,36,37",
"    </a>",
"    ]. In general, slow-growing supratentorial tumors, such as low-grade gliomas, cause headache less frequently than tumors with more rapid growth. With slower-growing tumors, seizures are more common than headaches [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/43/41655/abstract/10\">",
"     10",
"    </a>",
"    ]. Meningiomas are usually slowly progressive, and cause headaches significantly less often than gliomas. Headache occurs in approximately one-third of patients with supratentorial meningiomas [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/43/41655/abstract/12,16\">",
"     12,16",
"    </a>",
"    ]. The meninges may also be involved in diffuse tumor infiltration (leptomeningeal carcinomatosis), which results in a generalized headache.",
"   </p>",
"   <p>",
"    Tumors in the posterior fossa, such as medulloblastomas and ependymomas, cause headache in 60 to 83 percent of patients, and earlier in the clinical course than supratentorial ones [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/43/41655/abstract/36-38\">",
"     36-38",
"    </a>",
"    ]. Though a study of brainstem gliomas, excluding ependymomas, found only 44 percent of patients with headache [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/43/41655/abstract/39\">",
"     39",
"    </a>",
"    ], this lower figure might reflect the slower growth of low-grade gliomas or the presence of other symptoms that led to diagnosis before the onset of headache [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/43/41655/abstract/8\">",
"     8",
"    </a>",
"    ]. Within the posterior fossa, location seems to be a more important determinant of headache than tumor type, probably because posterior fossa lesions tend to obstruct cerebrospinal fluid pathways early and lead to increased intracranial pressure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/43/41655/abstract/4\">",
"     4",
"    </a>",
"    ]. Headache is the first symptom of posterior fossa tumors in most cases, with the notable exception of cerebellopontine angle tumors. Many of those tumors are vestibular schwannomas, which usually present with hearing loss or tinnitus before the onset of headache. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/18/40232?source=see_link\">",
"     \"Vestibular schwannoma (acoustic neuroma)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Within the sellar and parasellar regions, tumors in adults do not often present with headache, despite the sensitivity of the diaphragma sellae to pain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/43/41655/abstract/40\">",
"     40",
"    </a>",
"    ]. These tumors, usually pituitary adenomas and craniopharyngiomas, are usually heralded by the presence of visual or endocrine symptoms. Nevertheless, headache is a common accompaniment of pituitary tumors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/43/41655/abstract/41\">",
"     41",
"    </a>",
"    ]. In one study of 63 patients with pituitary tumors, the prevalence of headache was 70 percent, but there was no relationship between headache features and pituitary volume [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/43/41655/abstract/42\">",
"     42",
"    </a>",
"    ]. In children, however, headache is usually the presenting complaint, as they are often unaware of the other symptoms.",
"   </p>",
"   <p>",
"    Third ventricle tumors, such as colloid cysts, are associated with paroxysmal headaches. Patients report sudden onset of severe headache, which reflects blockage of the cerebrospinal fluid pathway by the tumor in a ball-valve mechanism. The headache can be worsened or relieved by changes in position. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/19/12601?source=see_link&amp;anchor=H11#H11\">",
"     \"Thunderclap headache\", section on 'Colloid cyst of the third ventricle'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20626043\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Though only a small minority of patients with headache have brain tumor as the cause, it is crucial to recognize those headache characteristics that are associated with tumors. Because of the variable nature of headache among patients with brain tumor, the diagnosis of headache attributed to brain tumor should be considered in patients who complain of a headache with any of the following \"red flags\" [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/43/41655/abstract/40\">",
"     40",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Acute, new, usually severe headache or headache that has changed from previous patterns",
"     </li>",
"     <li>",
"      New headache onset in an adult, especially over 50 years of age",
"     </li>",
"     <li>",
"      Headache in the elderly or in children",
"     </li>",
"     <li>",
"      Headache on exertion, onset at night, or onset at early morning",
"     </li>",
"     <li>",
"      Headache that is progressive in nature",
"     </li>",
"     <li>",
"      Headache associated with fever or other systemic symptoms",
"     </li>",
"     <li>",
"      Headache with meningismus",
"     </li>",
"     <li>",
"      Headache with new neurologic signs",
"     </li>",
"     <li>",
"      Precipitation of head pain with the Valsalva maneuver (by coughing, sneezing, or bending over)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In patients with any of the above complaints, further investigation with neuroimaging should be pursued.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20626050\">",
"    <span class=\"h2\">",
"     Neuroimaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Head CT or MRI is indicated whenever there is reasonable clinical suspicion that the headache is due to an intracranial mass lesion. A meta-analysis of patients with migraine and normal neurologic examinations found that the rate of intracranial lesions of only 0.2 percent (ie, 2 per 1000) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/43/41655/abstract/43\">",
"     43",
"    </a>",
"    ]. However, in patients with non-acute headache, the odds of finding a significant abnormality on neuroimaging were significantly increased in those with a rapidly increasing headache frequency, focal neurologic signs, headache causing awakening from sleep, and lack of coordination [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/43/41655/abstract/43,44\">",
"     43,44",
"    </a>",
"    ]. Though CT is sufficient in showing a majority of neoplasms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/43/41655/abstract/45\">",
"     45",
"    </a>",
"    ], it is the consensus of expert opinion that the sensitivity of MRI exceeds that of CT imaging, particularly for posterior fossa and dural based abnormalities [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/43/41655/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H90700163\">",
"    <span class=\"h2\">",
"     Diagnostic criteria",
"    </span>",
"    &nbsp;&mdash;&nbsp;Proposed diagnostic criteria for headache attributed to intracranial neoplasm have been developed by the International Headache Society [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/43/41655/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For headache attributed directly to neoplasm, the diagnostic criteria are as follows [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/43/41655/abstract/47\">",
"     47",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A) Headache with at least one of the following characteristics and fulfilling criteria C and D:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Progressive",
"     </li>",
"     <li>",
"      Localized",
"     </li>",
"     <li>",
"      Worse in the morning",
"     </li>",
"     <li>",
"      Aggravated by coughing or bending forward",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      B) Intracranial neoplasm shown by imaging",
"     </li>",
"     <li>",
"      C) Headache develops in temporal (and usually spatial) relation to the neoplasm",
"     </li>",
"     <li>",
"      D) Headache resolves within seven days after surgical removal or volume-reduction of neoplasm or treatment with glucocorticoids",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For headache attributed to carcinomatous meningitis, diagnostic criteria are the following [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/43/41655/abstract/47\">",
"     47",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A) Diffuse or localized headache fulfilling criterion C",
"     </li>",
"     <li>",
"      B) Carcinomatous meningitis proven by (repeated) cerebrospinal fluid examination",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      dural enhancement on MRI",
"     </li>",
"     <li>",
"      C) Headache develops",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      deteriorates with advancing disease; however, the headache may improve temporarily with intrathecal chemotherapy or glucocorticoid treatment",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For headache attributed to hypothalamic or pituitary hyper- or hyposecretion, diagnostic criteria are as follows [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/43/41655/abstract/47\">",
"     47",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A) Bilateral, frontotemporal",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      retro-orbital headache fulfilling criteria C and D",
"     </li>",
"     <li>",
"      B) At least one of the following:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Prolactin, growth hormone and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?1/62/2023?source=see_link\">",
"       adrenocorticotropic hormone",
"      </a>",
"      hypersecretion associated with microadenomas &lt;10mm in diameter",
"     </li>",
"     <li>",
"      Disorder of temperature regulation, abnormal emotional state, altered thirst and appetite and change in level of consciousness associated with hypothalamic tumor",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      C) Headache develops during endocrine abnormality",
"     </li>",
"     <li>",
"      D) Headache resolves within three months after surgical resection or specific and effective medical therapy",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For headache attributed to increased intracranial pressure or hydrocephalus caused by neoplasm, the following diagnostic criteria apply [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/43/41655/abstract/47\">",
"     47",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A) Diffuse non-pulsating headache with at least one of the following characteristics and fulfilling criteria C and D:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Associated with nausea",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      vomiting",
"     </li>",
"     <li>",
"      Worsened by physical activity",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      manoeuvres known to increase intracranial pressure (such as Valsalva manoeuvre, coughing or sneezing)",
"     </li>",
"     <li>",
"      Occurring in attack-like episodes (Onset of headache can be sudden (thunderclap headache) and, in such cases, associated with loss of consciousness)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      B) Space-occupying intracranial tumor demonstrated by CT or MRI and causing hydrocephalus (eg, colloid cyst of the third ventricle)",
"     </li>",
"     <li>",
"      C) Headache develops",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      deteriorates in close temporal relation to the hydrocephalus",
"     </li>",
"     <li>",
"      D) Headache improves within seven days after surgical removal or volume reduction of tumor",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20626064\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to differentiating between tumor headaches and primary headache disorders, other etiologies must be considered in evaluating a patient with headache [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/43/41655/abstract/8\">",
"     8",
"    </a>",
"    ]. Other space-occupying lesions such as abscesses and subdural hematoma can present with a similar clinical picture to intracranial neoplasm, as can stroke and subarachnoid hemorrhage. The possibility of systemic disorders (ie, thyroid disease, hypertension, pheochromocytoma), temporal arteritis, and traumatic head injuries should be taken into account as well. Idiopathic intracranial hypertension (formerly referred to as pseudotumor cerebri or benign intracranial hypertension) presents with headache as well.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20626071\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of brain tumors is reviewed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/58/6057?source=see_link\">",
"     \"Overview of the clinical manifestations, diagnosis, and management of patients with brain metastases\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/26/39335?source=see_link\">",
"     \"Management of vasogenic edema in patients with primary and metastatic brain tumors\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/26/13736?source=see_link\">",
"     \"Overview of the management of central nervous system tumors in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/36/44616?source=see_link\">",
"     \"Treatment of benign (WHO grade I) meningioma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/2/4133?source=see_link\">",
"     \"Systemic treatment of recurrent meningioma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/25/42391?source=see_link\">",
"     \"Adjuvant chemotherapy for malignant gliomas\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/38/4712?source=see_link\">",
"     \"Adjuvant radiation therapy for malignant gliomas\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/35/44601?source=see_link\">",
"     \"Treatment of brain metastases in favorable prognosis patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/43/15029?source=see_link\">",
"     \"Management of malignant gliomas in elderly patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In general, the treatment of brain tumor headache depends on tumor type, the functional status of the patient, and the extent of disease progression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/43/41655/abstract/6\">",
"     6",
"    </a>",
"    ]. Early on, glucocorticoids and simple analgesics often provide good symptom relief while the patient awaits definitive treatment. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/26/39335?source=see_link&amp;anchor=H3#H3\">",
"     \"Management of vasogenic edema in patients with primary and metastatic brain tumors\", section on 'Glucocorticoids'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Depending on the patient&rsquo;s prognosis, tumor type, and tumor location, treatment of the tumor itself may involve chemotherapy, surgery, radiation therapy, or a combination of the above. However, in many patients with metastatic brain tumors, life expectancy is limited and treatment is palliative. Pain should be managed aggressively with simple analgesics, narcotics, and glucocorticoids. Consultation with a palliative care team is encouraged.",
"   </p>",
"   <p>",
"    Tumor treatment itself may cause headache [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/43/41655/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Radiotherapy is associated with acute (within two weeks) and subacute (after one to six months) radiation encephalopathy, manifest by new or worsening headache, focal neurologic symptoms and signs, and nausea and vomiting. Nevertheless, acute encephalopathy with whole brain radiotherapy is rare with modern treatment techniques. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?36/22/37226?source=see_link&amp;anchor=H4#H4\">",
"       \"Complications of cranial irradiation\", section on 'Acute encephalopathy'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?36/22/37226?source=see_link&amp;anchor=H13#H13\">",
"       \"Complications of cranial irradiation\", section on 'Somnolence and the somnolence syndrome'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?36/22/37226?source=see_link&amp;anchor=H14#H14\">",
"       \"Complications of cranial irradiation\", section on 'Transient focal neurologic symptoms'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Chemotherapeutic agents may also induce headaches in patients with brain tumors.",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/47/11000?source=see_link\">",
"       Temozolomide",
"      </a>",
"      , which is commonly used to treat malignant gliomas, has been associated with headache in up to 22 percent of patients [53]. In addition, intrathecal infusions of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      and cytosine arabinoside can cause aseptic meningitis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/43/41655/abstract/48-50\">",
"       48-50",
"      </a>",
"      ]. Antiemetics used in conjunction with chemotherapy, such as",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?21/2/21544?source=see_link\">",
"       ondansetron",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/50/32550?source=see_link\">",
"       granisetron",
"      </a>",
"      , are reported to cause headache in 14 to 39 percent of patients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/43/41655/abstract/51,52\">",
"       51,52",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Postcraniotomy headache is another potential complication of brain tumor treatment. One study found that the majority of patients who undergo craniotomy had headaches similar to tension-type headache or site-of-injury headache, most of which resolved [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/43/41655/abstract/53\">",
"       53",
"      </a>",
"      ]. Surgery can also result in cerebrospinal fluid leakage and subsequent low pressure headache [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/43/41655/abstract/54\">",
"       54",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?0/20/330?source=see_link\">",
"       \"Pathophysiology, clinical features, and diagnosis of spontaneous low cerebrospinal fluid pressure headache\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4462344\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Traction on the large blood vessels and dura as well as direct compression of cranial and cervical nerve fibers by the tumor itself are the likely mechanisms for headaches attributed to brain tumors. (See",
"      <a class=\"local\" href=\"#H4462249\">",
"       'Mechanisms of headache'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Headache at presentation is observed in approximately 20 percent of patients with brain tumor, and headache occurs during the course of the disease in 48 to 60 percent. Though headache is a common symptom of brain tumor, it is infrequently seen in isolation. Furthermore, among all patients with headache who have normal neurologic examinations, the prevalence of intracranial neoplasm is very low. (See",
"      <a class=\"local\" href=\"#H4463038\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Though only a minority of patients with headaches have brain tumor, it is crucial to recognize those headache characteristics that may be more commonly associated with tumors. The features of brain tumor headache are generally nonspecific and vary widely with tumor location, size, and rate of growth. The headache is usually bilateral, but can be on the side of the tumor. Brain tumor headache often resembles tension-type headache, but may resemble migraine or a variety of other headache types. (See",
"      <a class=\"local\" href=\"#H20626029\">",
"       'Clinical features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Brain tumors should be considered in patients presenting with headaches associated with meningismus, focal neurologic signs, fever, or systemic symptoms. New-onset headaches in adults over age 50 should prompt further work-up as well. A prior history of headache does not rule out the possibility of brain tumor, and indeed, a change in headache pattern is a diagnostic \"red flag.\" (See",
"      <a class=\"local\" href=\"#H20626043\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Brain MRI is the diagnostic test of choice in evaluating for brain tumor, especially if a posterior fossa or dural-based abnormality is suspected. (See",
"      <a class=\"local\" href=\"#H20626050\">",
"       'Neuroimaging'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Treatment of brain tumor headache depends on tumor type, the patient&rsquo;s functional status, and the extent of disease progression. In cases where treatment is palliative, pain should be managed aggressively with simple analgesics, opioids, glucocorticoids, and the assistance of a palliative care team. (See",
"      <a class=\"local\" href=\"#H20626071\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/43/41655/abstract/1\">",
"      Northfield DWC. Some observations on headache. Brain 1938; 61:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/43/41655/abstract/2\">",
"      Ray BS, Wolff HG. Experimental studies on headache. Pain-sensitive structures of the head and their significance. Arch Surg 1940; 41:813.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/43/41655/abstract/3\">",
"      Dalessio DJ. Mechanisms of headache. Med Clin North Am 1978; 62:429.",
"     </a>",
"    </li>",
"    <li>",
"     Edmeads J. Brain tumors and other space-occupying lesions. In: Blue Books of Practical Neurology: Headache, Butterworth-Heinemann, Newton 1997. p.313.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/43/41655/abstract/5\">",
"      Pfund Z, Szap&aacute;ry L, J&aacute;szber&eacute;nyi O, et al. Headache in intracranial tumors. Cephalalgia 1999; 19:787.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/43/41655/abstract/6\">",
"      Loghin M, Levin VA. Headache related to brain tumors. Curr Treat Options Neurol 2006; 8:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/43/41655/abstract/7\">",
"      Goffaux P, Fortin D. Brain tumor headaches: from bedside to bench. Neurosurgery 2010; 67:459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/43/41655/abstract/8\">",
"      Purdy RA, Kirby S. Headaches and brain tumors. Neurol Clin 2004; 22:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/43/41655/abstract/9\">",
"      Jaeckle KA. Causes and management of headaches in cancer patients. Oncology (Williston Park) 1993; 7:27.",
"     </a>",
"    </li>",
"    <li>",
"     Forsyth PA, Ponser JB. Intracranial neoplasms. In: The Headaches, 2nd edition, Olesen J, Tfelt-Hansen P, Welch KMA (Eds), Raven Press, New York 2000. p.849.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/43/41655/abstract/11\">",
"      Valentinis L, Tuniz F, Valent F, et al. Headache attributed to intracranial tumours: a prospective cohort study. Cephalalgia 2010; 30:389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/43/41655/abstract/12\">",
"      Forsyth PA, Posner JB. Headaches in patients with brain tumors: a study of 111 patients. Neurology 1993; 43:1678.",
"     </a>",
"    </li>",
"    <li>",
"     Salcman M, Kaplan R. Intracranial tumors in adults. In: Comprehensive textbook of oncology, Moossa A, Robson M, Schimpff S (Eds), Williams and Wilkins, Baltimore 1986. p.617.",
"    </li>",
"    <li>",
"     Schoenberg B. Nervous system. In: Cancer epidemiology and prevention, Schotterfeld D, Joseph F (Eds), WB Saunders, Philadelphia 1982. p.968.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/43/41655/abstract/15\">",
"      Kirby S, Purdy RA. Headache and brain tumors. Curr Neurol Neurosci Rep 2007; 7:110.",
"     </a>",
"    </li>",
"    <li>",
"     Lavyne MH, Patterson RH. Headache associated with brain tumor. In: Wolff&rsquo;s headache and other head pain, 5th edition, Dalessio D (Ed), Oxford University Press, New York 1987. p.343.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/43/41655/abstract/17\">",
"      Schankin CJ, Ferrari U, Reinisch VM, et al. Characteristics of brain tumour-associated headache. Cephalalgia 2007; 27:904.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/43/41655/abstract/18\">",
"      Pepin EP. Cerebral metastasis presenting as migraine with aura. Lancet 1990; 336:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/43/41655/abstract/19\">",
"      PEARCE JM, FOSTER JB. AN INVESTIGATION OF COMPLICATED MIGRAINE. Neurology 1965; 15:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/43/41655/abstract/20\">",
"      Debruyne J, Crevits L, Vander Eecken H. Migraine-like headache in intraventricular tumours. Clin Neurol Neurosurg 1982; 84:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/43/41655/abstract/21\">",
"      Schlake HP, Grotemeyer KH, Husstedt IW, et al. \"Symptomatic migraine\": intracranial lesions mimicking migrainous headache--a report of three cases. Headache 1991; 31:661.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/43/41655/abstract/22\">",
"      SYMONDS C. Cough headache. Brain 1956; 79:557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/43/41655/abstract/23\">",
"      Rooke ED. Benign exertional headache. Med Clin North Am 1968; 52:801.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/43/41655/abstract/24\">",
"      Mascellino AM, Lay CL, Newman LC. Stabbing headache as the presenting manifestation of intracranial meningioma: a report of two patients. Headache 2001; 41:599.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/43/41655/abstract/25\">",
"      Porta-Etessam J, Ramos-Carrasco A, Mart&iacute;nez-Salio A, et al. Clusterlike headache as first manifestation of a prolactinoma. Headache 2001; 41:723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/43/41655/abstract/26\">",
"      Tajti J, Sas K, Szok D, et al. Clusterlike headache as a first sign of brain metastases of lung cancer. Headache 1996; 36:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/43/41655/abstract/27\">",
"      Masson C, Lehericy S, Guillaume B, Masson M. Cluster-like headache in a patient with a trigeminal neurinoma. Headache 1995; 35:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/43/41655/abstract/28\">",
"      Massiou H, Launay JM, Levy C, et al. SUNCT syndrome in two patients with prolactinomas and bromocriptine-induced attacks. Neurology 2002; 58:1698.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/43/41655/abstract/29\">",
"      Medina JL. Organic headaches mimicking chronic paroxysmal hemicrania. Headache 1992; 32:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/43/41655/abstract/30\">",
"      The epidemiology of headache among children with brain tumor. Headache in children with brain tumors. The Childhood Brain Tumor Consortium. J Neurooncol 1991; 10:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/43/41655/abstract/31\">",
"      Wilne SH, Ferris RC, Nathwani A, Kennedy CR. The presenting features of brain tumours: a review of 200 cases. Arch Dis Child 2006; 91:502.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/43/41655/abstract/32\">",
"      Iversen HK, Strange P, Sommer W, Tyalve E. Brain tumor headache related to tumor size, histology, and location. Cephalalgia 1987; 7 (Suppl 6):394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/43/41655/abstract/33\">",
"      V&aacute;zquez-Barquero A, Ib&aacute;&ntilde;ez FJ, Herrera S, et al. Isolated headache as the presenting clinical manifestation of intracranial tumors: a prospective study. Cephalalgia 1994; 14:270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/43/41655/abstract/34\">",
"      Davies E, Clarke C. Early symptoms of brain tumours. J Neurol Neurosurg Psychiatry 2004; 75:1205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/43/41655/abstract/35\">",
"      Rossi LN, Vassella F. Headache in children with brain tumors. Childs Nerv Syst 1989; 5:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/43/41655/abstract/36\">",
"      Kunkle EC, Ray BS, Wolff HG. Studies on Headache: The Mechanisms and Significance of the Headache Associated with Brain Tumor. Bull N Y Acad Med 1942; 18:400.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/43/41655/abstract/37\">",
"      Suwanwela N, Phanthumchinda K, Kaoropthum S. Headache in brain tumor: a cross-sectional study. Headache 1994; 34:435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/43/41655/abstract/38\">",
"      Lyons MK, Kelly PJ. Posterior fossa ependymomas: report of 30 cases and review of the literature. Neurosurgery 1991; 28:659.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/43/41655/abstract/39\">",
"      Guillamo JS, Monjour A, Taillandier L, et al. Brainstem gliomas in adults: prognostic factors and classification. Brain 2001; 124:2528.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/43/41655/abstract/40\">",
"      Purdy RA. Clinical evaluation of a patient presenting with headache. Med Clin North Am 2001; 85:847.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/43/41655/abstract/41\">",
"      Benitez-Rosario MA, McDarby G, Doyle R, Fabby C. Chronic cluster-like headache secondary to prolactinoma: uncommon cephalalgia in association with brain tumors. J Pain Symptom Manage 2009; 37:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/43/41655/abstract/42\">",
"      Levy MJ, J&auml;ger HR, Powell M, et al. Pituitary volume and headache: size is not everything. Arch Neurol 2004; 61:721.",
"     </a>",
"    </li>",
"    <li>",
"     Frishberg BM, Rosenberg JH, Matchar DB, et al. Evidence-based guidelines in the primary care setting: Neuroimaging in patients with nonacute headache. file://www.aan.com/professionals/practice/pdfs/gl0088.pdf (Accessed on October 14, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/43/41655/abstract/44\">",
"      Silberstein SD. Practice parameter: evidence-based guidelines for migraine headache (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2000; 55:754.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/43/41655/abstract/45\">",
"      Lear J, Weston P. CT scanning and pseudotumour cerebri. Lancet 1994; 343:1638.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/43/41655/abstract/46\">",
"      Practice parameter: the utility of neuroimaging in the evaluation of headache in patients with normal neurologic examinations (summary statement). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 1994; 44:1353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/43/41655/abstract/47\">",
"      Headache Classification Subcommittee of the International Headache Society. The International Classification of Headache Disorders: 2nd edition. Cephalalgia 2004; 24 Suppl 1:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/43/41655/abstract/48\">",
"      Yung WK, Albright RE, Olson J, et al. A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. Br J Cancer 2000; 83:588.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/43/41655/abstract/49\">",
"      Middleton MR, Grob JJ, Aaronson N, et al. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol 2000; 18:158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/43/41655/abstract/50\">",
"      Plotkin SR, Wen PY. Neurologic complications of cancer therapy. Neurol Clin 2003; 21:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/43/41655/abstract/51\">",
"      Kalaycio M, Mendez Z, Pohlman B, et al. Continuous-infusion granisetron compared to ondansetron for the prevention of nausea and vomiting after high-dose chemotherapy. J Cancer Res Clin Oncol 1998; 124:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/43/41655/abstract/52\">",
"      Einhorn LH, Nagy C, Werner K, Finn AL. Ondansetron: a new antiemetic for patients receiving cisplatin chemotherapy. J Clin Oncol 1990; 8:731.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/43/41655/abstract/53\">",
"      Gee JR, Ishaq Y, Vijayan N. Postcraniotomy headache. Headache 2003; 43:276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/43/41655/abstract/54\">",
"      Mokri B. Posture-related headaches and pachymeningeal enhancement in CSF leaks from craniotomy site. Cephalalgia 2001; 21:976.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 14113 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-60.18.131.125-92069A6D88-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_43_41655=[""].join("\n");
var outline_f40_43_41655=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H4462344\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20626022\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4462249\">",
"      MECHANISMS OF HEADACHE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4463038\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20626029\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20626036\">",
"      Tumor type and location",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20626043\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20626050\">",
"      Neuroimaging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H90700163\">",
"      Diagnostic criteria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20626064\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20626071\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4462344\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/25/42391?source=related_link\">",
"      Adjuvant chemotherapy for malignant gliomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/38/4712?source=related_link\">",
"      Adjuvant radiation therapy for malignant gliomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/8/35977?source=related_link\">",
"      Approach to the child with headache",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/3/25657?source=related_link\">",
"      Clinical presentation and diagnosis of brain tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/22/37226?source=related_link\">",
"      Complications of cranial irradiation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/52/14153?source=related_link\">",
"      Emergent evaluation of headache in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/51/34615?source=related_link\">",
"      Evaluation of headache in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/49/39704?source=related_link\">",
"      Evaluation of the adult with headache in the emergency department",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/43/15029?source=related_link\">",
"      Management of malignant gliomas in elderly patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/26/39335?source=related_link\">",
"      Management of vasogenic edema in patients with primary and metastatic brain tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/58/6057?source=related_link\">",
"      Overview of the clinical manifestations, diagnosis, and management of patients with brain metastases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/26/13736?source=related_link\">",
"      Overview of the management of central nervous system tumors in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/20/330?source=related_link\">",
"      Pathophysiology, clinical features, and diagnosis of spontaneous low cerebrospinal fluid pressure headache",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/42/8874?source=related_link\">",
"      Risk factors for brain tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/2/4133?source=related_link\">",
"      Systemic treatment of recurrent meningioma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/19/12601?source=related_link\">",
"      Thunderclap headache",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/36/44616?source=related_link\">",
"      Treatment of benign (WHO grade I) meningioma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/35/44601?source=related_link\">",
"      Treatment of brain metastases in favorable prognosis patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/18/40232?source=related_link\">",
"      Vestibular schwannoma (acoustic neuroma)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f40_43_41656="Levothyroxine: Drug information";
var content_f40_43_41656=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Levothyroxine: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?13/20/13638?source=see_link\">",
"    see \"Levothyroxine: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?30/47/31480?source=see_link\">",
"    see \"Levothyroxine: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5709010\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F188360\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Levothroid&reg;;",
"     </li>",
"     <li>",
"      Levoxyl&reg;;",
"     </li>",
"     <li>",
"      Synthroid&reg;;",
"     </li>",
"     <li>",
"      Tirosint&reg;;",
"     </li>",
"     <li>",
"      Unithroid&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F188361\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Eltroxin&reg;;",
"     </li>",
"     <li>",
"      Euthyrox;",
"     </li>",
"     <li>",
"      Levothyroxine Sodium;",
"     </li>",
"     <li>",
"      Synthroid&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F188382\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Thyroid Product",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F188365\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Doses should be adjusted based on clinical response and laboratory parameters.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Hypothyroidism:",
"     </b>",
"     Adults, healthy adults &lt;50 years of age, children in whom growth and puberty are complete, and older adults who have been recently treated for hyperthyroidism or who have been hypothyroid for only a few months):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Oral:",
"     </i>",
"     ~1.7 mcg/kg/day; usual doses are &le;200 mcg/day (range: 100-125 mcg/day [70 kg adult]); doses &ge;300 mcg/day are rare (consider poor compliance, malabsorption, and/or drug interactions). Titrate dose every 6 weeks.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Patients &gt;50 years or patients with cardiac disease: Refer geriatric  dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      I.M., I.V.:",
"     </i>",
"     50% of the oral dose; alternatively, some clinicians administer up to 80% of the oral dose.",
"     <b>",
"      Note:",
"     </b>",
"     Bioavailability of the oral formulation is highly variable, but absorption has been measured to be ~80%, when the oral tablet formulation was administered in the recommended fasting state (Dickerson, 2010; Fish, 1987).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Severe hypothyroidism:",
"     </b>",
"     Oral: Initial: 12.5-25 mcg/day; adjust dose by 25 mcg/day every 2-4 weeks as appropriate",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Subclinical hypothyroidism (if treated):",
"     </b>",
"     Oral: 1 mcg/kg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      TSH suppression:",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Well-differentiated thyroid cancer:",
"     </i>",
"     Highly individualized; Doses &gt;2 mcg/kg/day may be needed to suppress TSH to &lt;0.1 mIU/L in intermediate- to high-risk tumors. Low-risk tumors may be maintained at or slightly below the lower limit of normal (0.1-0.5 mIU/L) (Cooper, 2009).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Benign nodules and nontoxic multinodular goiter:",
"     </i>",
"     Routine use of T",
"     <sub>",
"      4",
"     </sub>",
"     for TSH suppression is not recommended in patients with benign thyroid nodules. In patients deemed appropriate candidates, treatment should never be fully suppressive (TSH &lt;0.1 mIU/L) (Cooper, 2009; Gharib, 2010). Avoid use if TSH is already suppressed.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Myxedema coma or stupor:",
"     </b>",
"     I.V.: 200-500 mcg, then 100-300 mcg the next day if necessary; smaller doses should be considered in patients with cardiovascular disease",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F188377\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?30/47/31480?source=see_link\">",
"      see \"Levothyroxine: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Hypothyroidism:",
"     </b>",
"     Infants and Children: Doses should be adjusted based on clinical response and laboratory parameters.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      Oral:",
"     </i>",
"     Daily dosage based on body weight and age as listed below:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1-3 months: 10-15 mcg/kg/day; if the infant is at risk for development of cardiac failure, use a lower starting dose of 25 mcg/day; if the initial serum T",
"     <sub>",
"      4",
"     </sub>",
"     is very low (&lt;5 mcg/dL) begin treatment at a higher dosage of 50 mcg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     3-6 months: 8-10 mcg/kg/day",
"     <b>",
"      or",
"     </b>",
"     25-50 mcg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     6-12 months: 6-8 mcg/kg/day",
"     <b>",
"      or",
"     </b>",
"     50-75 mcg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1-5 years: 5-6 mcg/kg/day",
"     <b>",
"      or",
"     </b>",
"     75-100 mcg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     6-12 years: 4-5 mcg/kg/day",
"     <b>",
"      or",
"     </b>",
"     100-125 mcg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &gt;12 years: 2-3 mcg/kg/day",
"     <b>",
"      or",
"     </b>",
"     &ge;150 mcg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Growth and puberty complete: 1.7 mcg/kg/day; refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Hyperactivity in older children may be minimized by starting at",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      4",
"     </sub>",
"     of the recommended dose and increasing each week by that amount until the full dose is achieved (4 weeks).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Children with severe or chronic hypothyroidism should be started at 25 mcg/day; adjust dose by 25 mcg every 2-4 weeks.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      I.M., I.V.:",
"     </i>",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F188366\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Doses should be adjusted based on clinical response and laboratory parameters.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Hypothyroidism:",
"     </b>",
"     Elderly patients may require &lt;1 mcg/kg/day:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Oral:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     &gt;50 years without cardiac disease",
"     <b>",
"      or",
"     </b>",
"     &lt;50 years with cardiac disease: Initial: 25-50 mcg/day; adjust dose by 12.5-25 mcg increments at 6- to 8-week intervals as needed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     &gt;50 years with cardiac disease: Initial: 12.5-25 mcg/day; adjust dose by 12.5-25 mcg increments at 4- to 6-week intervals (many clinicians prefer to adjust at 6- to 8-week intervals).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Patients with combined hypothyroidism and cardiac disease should be monitored carefully for changes in stability.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      I.M., I.V.:",
"     </i>",
"     Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Myxedema coma:",
"     </b>",
"     <i>",
"      I.V.",
"     </i>",
"     : Refer to adult dosing; lower doses may be needed.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F16265597\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F16265598\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F188330\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, soft gelatin, oral, as sodium:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tirosint&reg;: 13 mcg, 25 mcg, 50 mcg, 75 mcg, 88 mcg, 100 mcg, 112 mcg, 125 mcg, 137 mcg, 150 mcg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution, as sodium: 100 mcg, 200 mcg [DSC], 500 mcg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral, as sodium: 25 mcg, 50 mcg, 75 mcg, 88 mcg, 100 mcg, 112 mcg, 125 mcg, 137 mcg, 150 mcg, 175 mcg, 200 mcg, 300 mcg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Levothroid&reg;: 25 mcg, 75 mcg, 88 mcg, 100 mcg, 112 mcg, 125 mcg, 137 mcg, 150 mcg, 175 mcg, 200 mcg, 300 mcg [scored]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Levothroid&reg;: 50 mcg [scored; dye free]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Levoxyl&reg;: 25 mcg, 75 mcg, 88 mcg, 100 mcg, 112 mcg, 125 mcg, 137 mcg, 150 mcg, 175 mcg, 200 mcg [scored]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Levoxyl&reg;: 50 mcg [scored; dye free]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Synthroid&reg;: 25 mcg, 75 mcg, 88 mcg, 100 mcg, 112 mcg, 125 mcg, 137 mcg, 150 mcg, 175 mcg, 200 mcg, 300 mcg [scored]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Synthroid&reg;: 50 mcg [scored; dye free]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Unithroid&reg;: 25 mcg, 75 mcg, 88 mcg, 100 mcg, 112 mcg, 125 mcg, 150 mcg, 175 mcg, 200 mcg, 300 mcg [scored]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Unithroid&reg;: 50 mcg [scored; dye free]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F188314\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Excludes capsule",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F188334\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oral: Administer in the morning on an empty stomach, at least 30 minutes before food.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Capsule: Must be swallowed whole; do not cut, crush, or attempt to dissolve capsules in water to prepare a suspension.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tablet: May be crushed and suspended in 5-10 mL of water; suspension should be used immediately. Levoxyl&reg; should be administered with a full glass of water to prevent gagging (due to tablet swelling).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Nasogastric tube: Bioavailability of levothyroxine is reduced if administered with enteral tube feeds. Since holding feedings for at least 1 hour before and after levothyroxine administration may not completely resolve the interaction, an increase in dose (eg, additional 25 mcg) may be necessary (Dickerson, 2010).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Parenteral: Administer doses &le;100 mcg I.V. over 1 minute.",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F188389\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Do not mix I.V. solution with other I.V. infusion solutions.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F188333\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Replacement or supplemental therapy in hypothyroidism; pituitary TSH suppression",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F7789483\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Management of hemodynamically unstable potential organ donors increasing the quantity of organs available for transplantation",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F188391\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Levothyroxine may be confused with lamoTRIgine, Lanoxin&reg;, levofloxacin, liothyronine",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Levoxyl&reg; may be confused with Lanoxin&reg;, Levaquin&reg;, Luvox&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Synthroid&reg; may be confused with Symmetrel&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Administration issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Significant differences exist between oral and I.V. dosing. Use caution when converting from one route of administration to another.",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Other safety concerns:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       To avoid errors due to misinterpretation of a decimal point, always express dosage in mcg (",
"       <b>",
"        not",
"       </b>",
"       mg).",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F188380\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Angina, arrhythmia, cardiac arrest, flushing, heart failure, hypertension, MI, palpitation, pulse increased, tachycardia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Anxiety, emotional lability, fatigue, fever, headache, hyperactivity, insomnia, irritability, nervousness, pseudotumor cerebri (children), seizure (rare)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Alopecia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Fertility impaired, menstrual irregularities",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal cramps, appetite increased, diarrhea, vomiting, weight loss",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Liver function tests increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Bone mineral density decreased, muscle weakness, tremor, slipped capital femoral epiphysis (children)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Dyspnea",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Diaphoresis, heat intolerance, hypersensitivity (to inactive ingredients, symptoms include urticaria, pruritus, rash, flushing, angioedema, GI symptoms, fever, arthralgia, serum sickness, wheezing)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Levoxyl&reg;: Choking, dysphagia, gagging",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F188337\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to levothyroxine sodium or any component of the formulation; acute MI; thyrotoxicosis of any etiology; uncorrected adrenal insufficiency",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     Capsule: Additional contraindication: Inability to swallow capsules",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F188318\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Adrenal insufficiency: Use with caution in patients with adrenal insufficiency; symptoms may be exaggerated or aggravated.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Benign thyroid nodules: Appropriate use: Routine use of T",
"     <sub>",
"      4",
"     </sub>",
"     for TSH suppression is not recommended in patients with benign thyroid nodules. Treatment should never be fully suppressive (TSH &lt;0.1 mIU/L) (Gharib, 2010; Cooper, 2009).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     - Use of T",
"     <sub>",
"      4",
"     </sub>",
"     is often physician-dependent and may be considered in select patients, including patients who reside in iodine-deficient areas, young patients with small thyroid nodules, and patients with nonfunctioning nodular goiters (Gharib, 2010).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     - Use should be avoided in postmenopausal women, men &gt;60 years of age, patients with cardiovascular disease, osteoporosis, or systemic illness, and patients with large thyroid nodules or long-standing goiters, or low-normal TSH levels (Gharib, 2010).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular disease: Use with caution and reduce dosage in patients with angina pectoris or other cardiovascular disease; chronic hypothyroidism predisposes patients to coronary artery disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Diabetes: Use with caution in patients with diabetes mellitus and insipidus; symptoms may be exaggerated or aggravated.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Myxedema: Use with caution in patients with myxedema; symptoms may be exaggerated or aggravated.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Osteoporosis: Long-term therapy can decrease bone mineral density. Postmenopausal women and women using suppressive doses should receive the lowest dose necessary for clinical response.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Use with caution; decrease initial dose; suppressed TSH levels may increase risk of atrial fibrillation and mortality secondary to cardiovascular disease. (Gharib, 2010; Parle, 2001).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Levoxyl&reg;: Product may rapidly swell and disintegrate causing choking or gagging (should be administered with a full glass of water); use caution in patients with dysphagia or other swallowing disorders.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Weight reduction (unlabeled use):",
"     <b>",
"      [U.S. Boxed Warning]: Thyroid supplements are ineffective and potentially toxic when used for the treatment of obesity or for weight reduction, especially in euthyroid patients. High doses may produce serious or even life-threatening toxic effects particularly when used with some anorectic drugs (eg, sympathomimetic amines).",
"     </b>",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299600\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F188323\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aluminum Hydroxide: May decrease the serum concentration of Levothyroxine. Management: Separate administration of oral levothyroxine and aluminum hydroxide by at least 4 hours.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bile Acid Sequestrants: May decrease the serum concentration of Thyroid Products. Management: Administer oral thyroid products at least 4 h prior to colesevelam, and at least 1 h before or 4-6 h after cholestyramine.  Specific recommendations for colestipol are not available. Monitor for decreased concentrations/effects of the thyroid product.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Polystyrene Sulfonate: May decrease the serum concentration of Thyroid Products. Management: To minimize risk of interaction, separate dosing of oral calcium polystyrene sulfonate and thyroid products (eg, levothyroxine) or administer calcium polystyrene sulfonate rectally. Monitor for signs/symptoms of hypothyroidism with concomitant use (oral).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Salts: May diminish the therapeutic effect of Thyroid Products. Management: Separate the doses of the thyroid product and the oral calcium supplement by at least 4 hours.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CarBAMazepine: May decrease the serum concentration of Thyroid Products.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Estrogen Derivatives: May diminish the therapeutic effect of Thyroid Products.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosphenytoin: May decrease the serum concentration of Thyroid Products. Phenytoin may also displace thyroid hormones from protein binding sites.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iron Salts: May decrease the serum concentration of Levothyroxine. Management: Separate oral administration of iron salts and levothyroxine by at least 4 hours.  Separation of doses is not required with parenterally administered iron salts or levothyroxine.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Ferumoxytol; Iron Dextran Complex; Iron Sucrose.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lanthanum: May decrease the serum concentration of Thyroid Products. Management: Administer oral thyroid products at least two hours before or after lanthanum.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Multivitamins/Minerals (with ADEK, Folate, Iron): May decrease the serum concentration of Levothyroxine. Management: Separate oral administration of iron-containing multivitamins and levothyroxine by at least 4 hours.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Orlistat: May decrease the serum concentration of Levothyroxine. Management: Separate administration of oral levothyroxine and orlistat  by a least 4 hours. Monitor patients closely for signs and symptoms of hypothyroidism.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenytoin: May decrease the serum concentration of Thyroid Products. Phenytoin may also displace thyroid hormones from protein binding sites.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Raloxifene: May decrease the absorption of Levothyroxine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifampin: May decrease the serum concentration of Thyroid Products.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sevelamer: May decrease the serum concentration of Levothyroxine. Management: Consider separating administration of sevelamer and levothyroxine by at least several hours whenever possible in order to decrease the risk of a significant interaction.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Iodide I131: Thyroid Products may diminish the therapeutic effect of Sodium Iodide I131.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Polystyrene Sulfonate: May decrease the serum concentration of Thyroid Products. Management: To minimize risk of interaction, separate dosing of oral sodium polystyrene sulfonate and thyroid products (e.g., levothyroxine) or administer sodium polystyrene sulfonate rectally. Monitor for signs/symptoms of hypothyroidism with concomitant use (oral).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sucralfate: May decrease the serum concentration of Levothyroxine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Theophylline Derivatives: Thyroid Products may increase the metabolism of Theophylline Derivatives.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Dyphylline.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Thyroid Products may enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F188355\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Food: Taking levothyroxine with enteral nutrition may cause reduced bioavailability and may lower serum thyroxine levels leading to signs or symptoms of hypothyroidism. Soybean flour (infant formula), cottonseed meal, walnuts, and dietary fiber may decrease absorption of levothyroxine from the GI tract. Management: Take in the morning on an empty stomach at least 30 minutes before food. Consider an increase in dose if taken with enteral tube feed.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F188326\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     A (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F188341\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;\">",
"     Endogenous thyroid hormones minimally cross the placenta; the fetal thyroid becomes active around the end of the first trimester. Levothyroxine has not been shown to increase the risk of congenital abnormalities.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Uncontrolled maternal hypothyroidism may result in adverse neonatal outcomes (eg, premature birth, low birth weight, and respiratory distress) and adverse maternal outcomes (eg, spontaneous abortion, pre-eclampsia, stillbirth, and premature delivery). To prevent adverse events, normal maternal thyroid function should be maintained prior to conception and throughout pregnancy. Levothyroxine is considered the treatment of choice for the control of hypothyroidism during pregnancy. Due to alterations of endogenous maternal thyroid hormones, the levothyroxine dose may need to be increased during pregnancy and the dose usually needs to be decreased after delivery.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F188371\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/use caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F188342\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Endogenous thyroid hormones are minimally found in breast milk. The amount of endogenous thyroxine found in breast milk does not influence infant plasma thyroid values. Levothyroxine was not found to cause adverse events to the infant or mother during breast-feeding. Adequate thyroid hormone concentrations are required to maintain normal lactation. Appropriate levothyroxine doses should be continued during breast-feeding.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F188343\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Should be taken on an empty stomach, at least 30 minutes before food.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F188340\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Tirosint Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     13 mcg (28): $35.16",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     25 mcg (28): $35.16",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50 mcg (28): $35.16",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     75 mcg (28): $35.16",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     88 mcg (28): $35.16",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mcg (28): $35.16",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     112 mcg (28): $35.16",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     125 mcg (28): $35.16",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     137 mcg (28): $35.16",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     150 mcg (28): $35.16",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution (reconstituted)",
"     </b>",
"     (Levothyroxine Sodium Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mcg (1): $91.81",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     500 mcg (1): $240.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Levothroid Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     25 mcg (100): $21.94",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50 mcg (100): $24.20",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     75 mcg (100): $26.66",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     88 mcg (100): $27.32",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mcg (100): $27.60",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     112 mcg (100): $29.92",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     125 mcg (100): $32.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     137 mcg (100): $19.54",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     150 mcg (100): $32.96",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     175 mcg (100): $37.24",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     200 mcg (100): $40.84",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     300 mcg (100): $56.78",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Levothyroxine Sodium Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     25 mcg (100): $29.57",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50 mcg (100): $33.57",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     75 mcg (100): $37.08",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     88 mcg (100): $39.61",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mcg (100): $38.02",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     112 mcg (100): $46.16",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     125 mcg (100): $46.78",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     137 mcg (100): $47.44",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     150 mcg (100): $48.15",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     175 mcg (100): $57.25",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     200 mcg (100): $57.37",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     300 mcg (100): $78.10",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Levoxyl Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     25 mcg (100): $43.69",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50 mcg (100): $49.60",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     75 mcg (100): $54.82",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     88 mcg (100): $55.75",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mcg (100): $56.18",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     112 mcg (100): $64.97",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     125 mcg (100): $65.87",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     137 mcg (100): $66.78",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     150 mcg (100): $67.80",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     175 mcg (100): $80.58",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     200 mcg (100): $80.74",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Synthroid Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     25 mcg (90): $61.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50 mcg (100): $81.29",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     75 mcg (100): $90.65",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     88 mcg (90): $77.92",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mcg (100): $94.03",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     112 mcg (90): $76.80",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     125 mcg (100): $92.64",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     137 mcg (90): $79.64",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     150 mcg (100): $95.08",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     175 mcg (90): $95.36",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     200 mcg (100): $114.20",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     300 mcg (90): $130.04",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Unithroid Direct Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     25 mcg (84): $35.18",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50 mcg (84): $35.18",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     75 mcg (84): $35.18",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     88 mcg (84): $35.18",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mcg (84): $35.18",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     112 mcg (84): $35.18",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     125 mcg (84): $35.18",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     150 mcg (84): $35.18",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     175 mcg (84): $35.18",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     200 mcg (84): $35.18",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     300 mcg (84): $35.18",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Unithroid Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     25 mcg (100): $26.40",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50 mcg (100): $29.98",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     75 mcg (100): $33.11",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     88 mcg (100): $33.70",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mcg (100): $33.94",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     112 mcg (100): $39.24",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     125 mcg (100): $39.78",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     137 mcg (90): $34.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     150 mcg (100): $40.95",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     175 mcg (100): $48.67",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     200 mcg (90): $34.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     300 mcg (90): $34.00",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F188328\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Thyroid function test (serum thyroxine, thyrotropin concentrations), resin triiodothyronine uptake (rT",
"     <sub>",
"      3",
"     </sub>",
"     U), free thyroxine index (FTI), T",
"     <sub>",
"      4",
"     </sub>",
"     , TSH, heart rate, blood pressure, clinical signs of hypo- and hyperthyroidism; TSH is the most reliable guide for evaluating adequacy of thyroid replacement dosage. TSH may be elevated during the first few months of thyroid replacement despite patients being clinically euthyroid. In cases where T",
"     <sub>",
"      4",
"     </sub>",
"     remains low and TSH is within normal limits, an evaluation of &ldquo;free&rdquo; (unbound) T",
"     <sub>",
"      4",
"     </sub>",
"     is needed to evaluate further increase in dosage",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Infants: Monitor closely for cardiac overload, arrhythmias, and aspiration from avid suckling",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Infants/children: Monitor closely for under/overtreatment. Undertreatment may decrease intellectual development and linear growth, and lead to poor school performance due to impaired concentration and slowed mentation. Overtreatment may adversely affect brain maturation, accelerate bone age (leading to premature closure of the epiphyses and reduced adult height); craniosynostosis has been reported in infants. Treated children may experience a period of catch-up growth. Monitor TSH and total or free T",
"     <sub>",
"      4",
"     </sub>",
"     at 2 and 4 weeks after starting treatment; every 1-2 months for first year of life; every 2-3 months during years 1-3; every 3-12 months until growth completed. Perform routine clinical examinations at regular intervals (to assess mental and physical growth and development).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Adults: Monitor TSH every 6-8 weeks until normalized; 8-12 weeks after dosage changes; every 6-12 months throughout therapy",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F188331\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Pediatrics: Cord T",
"     <sub>",
"      4",
"     </sub>",
"     and values in the first few weeks are much higher, falling over the first months and years. &ge;10 years: ~5.8-11 mcg/dL (SI: 75-142 nmol/L). Borderline low: &le;4.5-5.7 mcg/dL (SI: 58-73 nmol/L); low: &le;4.4 mcg/dL (SI: 57 nmol/L); results &lt;2.5 mcg/dL (SI: &lt;32 nmol/L) are strong evidence for hypothyroidism.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Approximate adult normal range: 4-12 mcg/dL (SI: 51-154 nmol/L). Borderline high: 11.1-13 mcg/dL (SI: 143-167 nmol/L); high: &ge;13.1 mcg/dL (SI: 169 nmol/L). Normal range is increased in women on birth control pills (5.5-12 mcg/dL); normal range in pregnancy: ~5.5-16 mcg/dL (SI: ~71-206 nmol/L). TSH: 0.4-10 (for those &ge;80 years) mIU/L; T",
"     <sub>",
"      4",
"     </sub>",
"     : 4-12 mcg/dL (SI: 51-154 nmol/L); T",
"     <sub>",
"      3",
"     </sub>",
"     (RIA) (total T",
"     <sub>",
"      3",
"     </sub>",
"     ): 80-230 ng/dL (SI: 1.2-3.5 nmol/L); T",
"     <sub>",
"      4",
"     </sub>",
"     free (free T",
"     <sub>",
"      4",
"     </sub>",
"     ): 0.7-1.8 ng/dL (SI: 9-23 pmol/L).",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F188344\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Berlthyrox (DE);",
"     </li>",
"     <li>",
"      Cynocuatro (MX);",
"     </li>",
"     <li>",
"      Droxine (AU, NZ);",
"     </li>",
"     <li>",
"      Elthyro (TH);",
"     </li>",
"     <li>",
"      Elthyrone (BE);",
"     </li>",
"     <li>",
"      Eltroxin (AE, BD, BF, BH, BJ, BM, BZ, CH, CI, CL, CY, CZ, DK, EG, ET, GB, GH, GM, GN, GY, HK, IL, IQ, IR, JO, JP, KE, KW, LB, LR, LY, MA, ML, MR, MU, MW, NE, NG, OM, PH, PK, QA, SA, SC, SD, SL, SN, SR, SY, TH, TN, TW, TZ, UG, YE, ZA, ZM, ZW);",
"     </li>",
"     <li>",
"      Eurolev (PH);",
"     </li>",
"     <li>",
"      Euthyrox (AR, AT, BE, BG, BR, CH, CL, CZ, DE, EE, ID, MY, PH, PL, RU, SE, SG, TH, VE);",
"     </li>",
"     <li>",
"      Eutirox (BB, BS, CN, CR, DO, ES, GT, HN, IT, JM, MX, NI, NL, PA, PE, SV, TT);",
"     </li>",
"     <li>",
"      Eutroxsig (AU, NZ);",
"     </li>",
"     <li>",
"      Levaxin (SE);",
"     </li>",
"     <li>",
"      Levhexal (MX);",
"     </li>",
"     <li>",
"      Levothyrox (FR);",
"     </li>",
"     <li>",
"      Levotirox (IT);",
"     </li>",
"     <li>",
"      Levotiroxina (EC);",
"     </li>",
"     <li>",
"      Narval (UY);",
"     </li>",
"     <li>",
"      Oroxine (AU, MY);",
"     </li>",
"     <li>",
"      Pondtroxin (TH);",
"     </li>",
"     <li>",
"      Synox (IN);",
"     </li>",
"     <li>",
"      Synthroid (BR, CO, KP, NZ);",
"     </li>",
"     <li>",
"      Synthyroxine (KP);",
"     </li>",
"     <li>",
"      T4 (PY);",
"     </li>",
"     <li>",
"      T4KP (TH);",
"     </li>",
"     <li>",
"      Thevier (DE);",
"     </li>",
"     <li>",
"      Thyradin S (JP);",
"     </li>",
"     <li>",
"      Thyrax (BE, CZ, ID, PH, PT);",
"     </li>",
"     <li>",
"      Thyrax Duotab (BF, BJ, CI, ET, GH, GM, GN, KE, LR, MA, ML, MR, MU, MW, NE, NG, SC, SD, SL, SN, TN, TZ, UG, ZM, ZW);",
"     </li>",
"     <li>",
"      Thyrex (AT);",
"     </li>",
"     <li>",
"      Thyro-4 (GR);",
"     </li>",
"     <li>",
"      Thyrosit (TH);",
"     </li>",
"     <li>",
"      Thyroxin (FI);",
"     </li>",
"     <li>",
"      Thyroxin-Natrium (NO);",
"     </li>",
"     <li>",
"      Tiroidine (MX);",
"     </li>",
"     <li>",
"      Tiroxin (CO)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F188317\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Levothyroxine (T",
"     <sub>",
"      4",
"     </sub>",
"     ) is a synthetic form of thyroxine, an endogenous hormone secreted by the thyroid gland. T",
"     <sub>",
"      4",
"     </sub>",
"     is converted to its active metabolite, L-triiodothyronine (T",
"     <sub>",
"      3",
"     </sub>",
"     ). Thyroid hormones (T",
"     <sub>",
"      4",
"     </sub>",
"     and T",
"     <sub>",
"      3",
"     </sub>",
"     ) then bind to thyroid receptor proteins in the cell nucleus and exert metabolic effects through control of DNA transcription and protein synthesis; involved in normal metabolism, growth, and development; promotes gluconeogenesis, increases utilization and mobilization of glycogen stores, and stimulates protein synthesis, increases basal metabolic rate",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F188336\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: Therapeutic: Oral: 3-5 days; I.V. 6-8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Peak effect: I.V.: 24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Oral: Erratic (40% to 80% [per manufacturer]); may be decreased by age and specific foods and drugs",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: &gt;99% bound to plasma proteins including thyroxine-binding globulin, thyroxine-binding prealbumin, and albumin",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic to triiodothyronine (T",
"     <sub>",
"      3",
"     </sub>",
"     ; active); ~80% thyroxine (T",
"     <sub>",
"      4",
"     </sub>",
"     ) deiodinated in kidney and periphery; glucuronidation/conjugation also occurs; undergoes enterohepatic recirculation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: Oral tablets: 64% (nonfasting state) to 79% to 81% (fasting state)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, serum: 2-4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: Euthyroid: 6-7 days; Hypothyroid: 9-10 days; Hyperthyroid: 3-4 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (major route of elimination; decreases with age); feces (~20%)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Bauer LA, &ldquo;Simulations of Levothyroxine Bioavailability Using a Single Dose Protocol,&rdquo;",
"      <i>",
"       Am J Ther",
"      </i>",
"      , 1995, 2:414-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?40/43/41656/abstract-text/11850686/pubmed\" id=\"11850686\" target=\"_blank\">",
"        11850686",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Berkner PD, Starkman H, and Person N, &ldquo;Acute L-Thyroxine Overdose: Therapy With Sodium Ipodate: Evaluation of Clinical and Physiologic Parameters,&rdquo;",
"      <i>",
"       J Emerg Med",
"      </i>",
"      , 1991, 9(3):129-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?40/43/41656/abstract-text/2050969/pubmed\" id=\"2050969\" target=\"_blank\">",
"        2050969",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Binimelis J, Bassas L, Marruecos L, et al, &ldquo;Massive Thyroxine Intoxication: Evaluation of Plasma Extraction,&rdquo;",
"      <i>",
"       Intensive Care Med",
"      </i>",
"      , 1987, 13(1):33-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?40/43/41656/abstract-text/3558934/pubmed\" id=\"3558934\" target=\"_blank\">",
"        3558934",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cooper DS, Kloos RT, Mazzaferri EL, et al,  &ldquo;Revised American Thyroid Association Management Guidelines for Patients With Thyroid Nodules and Differentiated Thyroid Cancer,&rdquo;",
"      <i>",
"       Thyroid",
"      </i>",
"      , 2009, 19(11):1167-214.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?40/43/41656/abstract-text/19860577/pubmed\" id=\"19860577\" target=\"_blank\">",
"        19860577",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      de Groot JW, Zonnenberg BA, Plukker JT, et al,  &ldquo;Imatinib Induces Hypothyroidism in Patients Receiving Levothyroxine,&rdquo;",
"      <i>",
"       Clin Pharmacol Ther",
"      </i>",
"      , 2005, 78(4):433-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?40/43/41656/abstract-text/16198662/pubmed\" id=\"16198662\" target=\"_blank\">",
"        16198662",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dickerson DN, Maish GO 3rd, Minard G, et al, &ldquo;Clinical Relevancy of Levothyroxine &ndash; Continuous Enteral Nutrition Interaction,&rdquo;",
"      <i>",
"       Nutr Clin Pract",
"      </i>",
"      , 2010, 25(6):646-52.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?40/43/41656/abstract-text/21139130/pubmed\" id=\"21139130\" target=\"_blank\">",
"        21139130",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Escalante DA, Arem N, and Arem R, &ldquo;Assessment of Interchangeability of Two Brands of Levothyroxine Preparations With a Third-Generation TSH Assay,&rdquo;",
"      <i>",
"       Am J Med",
"      </i>",
"      , 1995, 98(4):374-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?40/43/41656/abstract-text/7709950/pubmed\" id=\"7709950\" target=\"_blank\">",
"        7709950",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Fish LH, Schwartz HL, Cavenaugh J, et al, &ldquo;Replacement Dose, Metabolism, and Bioavailability of Levothyroxine in the Treatment of Hypothyroidism,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 316(13):764-70.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?40/43/41656/abstract-text/3821822/pubmed\" id=\"3821822\" target=\"_blank\">",
"        3821822",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gharib H, Papini E, Paschke R, et al, &ldquo;American Association of Clinical Endocrinologists, Associazione Medici Endocrinologi, and European Thyroid Association Medical Guidelines for Clinical Practice for Diagnosis and Management of Thyroid Nodules,&rdquo;",
"      <i>",
"       Endocr Pract",
"      </i>",
"      , 2010, 16(Supp 1):1-43.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?40/43/41656/abstract-text/20497938/pubmed\" id=\"20497938\" target=\"_blank\">",
"        20497938",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gorman RL, Chamberlain JM, Rose SR, et al, &ldquo;Massive Levothyroxine Overdose: High Anxiety - Low Toxicity,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 1988, 82(4):666-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?40/43/41656/abstract-text/3174321/pubmed\" id=\"3174321\" target=\"_blank\">",
"        3174321",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gupta VD, &ldquo;Stability of Levothyroxine Sodium Injection in Polypropylene Syringes,&rdquo;",
"      <i>",
"       Int J Pharm Compound",
"      </i>",
"      , 2000, 4(6):482-3.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Helfand M and Crapo LM, &ldquo;Monitoring Therapy in Patients Taking Levothyroxine,&rdquo;",
"      <i>",
"       Ann Intern Med",
"      </i>",
"      , 1990, 113(6):450-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?40/43/41656/abstract-text/2143640/pubmed\" id=\"2143640\" target=\"_blank\">",
"        2143640",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Johnson DG and Campbell S, &ldquo;Hormonal and Metabolic Agents,&rdquo;",
"      <i>",
"       Geriatric Pharmacology",
"      </i>",
"      , Bressler R and Katz MD, eds, New York, NY: McGraw-Hill, 1993, 427-50.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kulig K, Golightly LK, and Rumack BH, &ldquo;Levothyroxine Overdose Associated With Seizures in a Young Child,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 1985, 254(15):2109-10.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?40/43/41656/abstract-text/4046139/pubmed\" id=\"4046139\" target=\"_blank\">",
"        4046139",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Liwanpo L and Hershman JM, &ldquo;Conditions and Drugs Interfering With Thyroxine Absorption,&rdquo;",
"      <i>",
"       Best Pract Res Clin Endocrinol Metab",
"      </i>",
"      , 2009, 23(6):781-92.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?40/43/41656/abstract-text/19942153/pubmed\" id=\"19942153\" target=\"_blank\">",
"        19942153",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mandel SH, Magnusson AR, Burton BT, et al, &ldquo;Massive Levothyroxine Ingestion: Conservative Management,&rdquo;",
"      <i>",
"       Clin Pediatr (Phila)",
"      </i>",
"      , 1989, 28(8):374-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?40/43/41656/abstract-text/2758719/pubmed\" id=\"2758719\" target=\"_blank\">",
"        2758719",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mayor GH, Orlando T, and Kurtz N, &ldquo;Limitations of Levothyroxine Bioequivalence Evaluation: Analysis of an Attempted Study,&rdquo;",
"      <i>",
"       Am J Ther",
"      </i>",
"      , 1995, 2:417-32.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?40/43/41656/abstract-text/11850687/pubmed\" id=\"11850687\" target=\"_blank\">",
"        11850687",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Parle JV, Maisonneuve P, Sheppard MC, et al, &ldquo;Prediction of All-Cause and Cardiovascular Mortality in Elderly People from One Low Serum Thryotropin Result: A 10-year Cohort Study,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 2001, 358(9285):861-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?40/43/41656/abstract-text/11567699/pubmed\" id=\"11567699\" target=\"_blank\">",
"        11567699",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rosendale JD, Kauffman HM, McBride MA, et al, &ldquo;Aggressive Pharmacologic Donor Management Results in More Transplanted Organs,&rdquo;",
"      <i>",
"       Transplantation",
"      </i>",
"      , 2003, 75(4):482-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?40/43/41656/abstract-text/12605114/pubmed\" id=\"12605114\" target=\"_blank\">",
"        12605114",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rosengard BR, Feng S, Alfrey EJ, et al, &ldquo;Report of the Crystal City Meeting to Maximize the Use of Organs Recovered From the Cadaver Donor,&rdquo;",
"      <i>",
"       Am J Transplant",
"      </i>",
"      , 2002, 2(8):701-11.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?40/43/41656/abstract-text/12243491/pubmed\" id=\"12243491\" target=\"_blank\">",
"        12243491",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Salim A, Martin M, Brown C, et al, &ldquo;Using Thyroid Hormone in Brain-Dead Donors to Maximize the Number of Organs Available for Transplantation,&rdquo;",
"      <i>",
"       Clin Transplant",
"      </i>",
"      , 2007, 21(3):405-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?40/43/41656/abstract-text/17488392 /pubmed\" id=\"17488392 \" target=\"_blank\">",
"        17488392",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sanders LR, &ldquo;Pituitary, Thyroid, Adrenal and Parathyroid Diseases in the Elderly,&rdquo;",
"      <i>",
"       Geriatric Medicine",
"      </i>",
"      , 1990, 475-87.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sawin CT, Geller A, Hershman JM, et al, &ldquo;The Aging Thyroid. The Use of Thyroid Hormone in Older Persons,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 1989, 261(18):2653-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?40/43/41656/abstract-text/2709545/pubmed\" id=\"2709545\" target=\"_blank\">",
"        2709545",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Singh N, Singh P, and Hershman J. &ldquo;Effect of Calcium Carbonate on the Absorption of Levothyroxine,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2000, 283:2822-25.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?40/43/41656/abstract-text/10838651/pubmed\" id=\"10838651\" target=\"_blank\">",
"        10838651",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Stockley IH,",
"      <i>",
"       Drug Interactions",
"      </i>",
"      , 5th ed, London, UK: Pharmaceutical Press, 1999.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Strong DK, Decarie D, and Ensom MHH, &ldquo;Stability of Levothyroxine in Sodium Chloride for IV Administration,&rdquo;",
"      <i>",
"       Can J Hosp Pharm",
"      </i>",
"      , 2010, 63(6):437-43.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Tunget CL, Clark RF, Turchen SG, et al, &ldquo;Raising the Decontamination Level for Thyroid Hormone Ingestions,&rdquo;",
"      <i>",
"       Am J Emerg Med",
"      </i>",
"      , 1995, 13(1):9-13.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?40/43/41656/abstract-text/7832964/pubmed\" id=\"7832964\" target=\"_blank\">",
"        7832964",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Watts NB, &ldquo;Use of a Sensitive Thyrotropin Assay for Monitoring Treatment With Levothyroxine,&rdquo;",
"      <i>",
"       Arch Intern Med",
"      </i>",
"      , 1989, 149(2):309-12.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?40/43/41656/abstract-text/2644903/pubmed\" id=\"2644903\" target=\"_blank\">",
"        2644903",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9557 Version 42.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-61.234.146.186-7705E05A5A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_43_41656=[""].join("\n");
var outline_f40_43_41656=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5709010\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F188360\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F188361\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F188382\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F188365\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F188377\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F188366\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16265597\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16265598\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F188330\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F188314\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F188334\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F188389\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F188333\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7789483\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F188391\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F188380\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F188337\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F188318\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299600\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F188323\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F188355\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F188326\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F188341\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F188371\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F188342\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F188343\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F188340\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F188328\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F188331\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F188344\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F188317\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F188336\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9557\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9557|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?13/20/13638?source=related_link\">",
"      Levothyroxine: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?30/47/31480?source=related_link\">",
"      Levothyroxine: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f40_43_41657="Normal membranes";
var content_f40_43_41657=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F51447%7EOBGYN%2F54320&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F51447%7EOBGYN%2F54320&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Normal membranes",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Image courtesy of Drucilla Roberts, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Chorioamnionitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 392px; height: 261px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Light micrograph illustrating leukocytes extending through the full thickness of choriamniotic membrane.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Drucilla J Roberts, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_43_41657=[""].join("\n");
var outline_f40_43_41657=null;
var title_f40_43_41658="PJS duodenal polyp Light";
var content_f40_43_41658=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F81889%7EGAST%2F69268&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F81889%7EGAST%2F69268&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1107px;\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Duodenal Peutz-Jeghers polyp",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 284px; height: 394px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Low power view of a duodenal Peutz-Jeghers polyp shows a tree-like proliferation of smooth muscle lined by normal small intestinal epithelium; the overlying epithelium is normal.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Robert Odze, MD.",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 517px\">",
"   <div class=\"ttl\">",
"    Normal small intestine",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 517px; height: 168px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Low (left) and high (right) power views of the normal villous architecture of the small intestine. The high power view shows the enterocytes and interspersed goblet cells (arrows).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Robert Odze, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1108px;\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Colonic Peutz-Jeghers polyp",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 397px; height: 288px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAEgAY0DASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6DK984pQBtzkgD3phzknv/X3pwG7GBwfbBrxT0rC4HGR7ilJOCOQPTNNOfQjH+fzpOMdyc9x1qRofkHIJ/MdaaCAVJ4PqOmKQZHTP9KUtg8c+/b8aSGLxtBPBI60EkdCfUkGm5HP9B1pGJ25zz3H+FUFhWOGweDnNN5OAe/agkZ4z27ZoI+XkkgmmAbt3PU+g9KATnOQTjGc8flSHOWOeKGC8gAjj86EOw4Hqc9Pxo3Nzx9eelNxuOP4hzQw/dvIWVYl++7Haq/UmgHZbhnHqPXBozkjBz756VxvjXxxb6Fp8B0x4L68nbbHgbh1/hXjcx/AD1rjz8RvGMkF0tro2mRyQjc8l/gNCByxZEJJ7dM12U8DVqR5tEvP/ACNo0JzXNFHsORgen1/zik3DDc5ycV41B8Xru+itNPghthfXUTSPqERB8hRwTHEcbm6kZIqbxZ8VrqybTV8O3FjcKRsuDcQmTewGeSOd3c+laf2ViOblaEqU3sj1kMPtkpJ/5ZRg57k9Ki1fUrHRrJ7vV7uKztVHVm+ZvQKvUk14PqHxq8Q29w8jXGkWbRhJvstvB5hulHVWYkeWD78+lc5qfivQ9RvBqpXVG1GUtcHT5MzQeaOQPMOPlHXGO1b08oqc37x6eX/Bt+o6dPmlabsvvPRNW+NLpe+RpGh2kMTP5SS6vdBWZvQopO3/AAIqfwV448Ra7rt9JqF1bfYLSIuLSyg8uHzuixvI2GbJ7DNcd8IINO1S+1W41Yx3zfZy4ZAuxfMJLHDdADkevFUvBhsYdavmSRrvTtOmmV0i+UhUyUY5PzYP413SwdBKUIQs0lrvv6nWqFHa13/XnZ/cdjP8RfGGnXmp6bdTaLd3FjcFbi48pU2IOW8pOPMYLnI7GvULjxXocWmPqUt9stEVGkAXfIqN0YqueM/lXg/hDwY/iWKS+DSXckbt+7XBntwp4faSBycA5OcE8VZjlvvDf2jSdTuYo4rlGEF2kBxKuPuRuewPVSBzznisq2CoVZKEdJLdLS4nhoPya3t/wT3jRNc0rXoZZtD1CK/iiAEvlhlMec4DAjIJweDWl8wUE5CnkZ7/AEr520nxbJpvhXSdI0C7kgv4riRnu4trthsHCr/y05U5zjGa9b+G2q6jrVjd3WoWqLAzb0vRc+Z9pl6EKuP3aDGAvOPWvOxeXyoJy6ee5yzoyhruu/8AX9anXE5HOcegoPTk9ffFcT4l+I2n+G9RtbXVdOvdrx7rpoSHks3LAKGXoykHOQScdq6zT9RsdUtvtOlXkF5bZ2mWHlVOOn1/lXHPD1IRU5LRmbut0WQSDk4z60biRwST04PNKRu+bB45Hv8A/WobI27eD2z3rHyAXLDueOnv9BS72BOHY496jkkjhXfKyxx93kYKq54Gc+p4p5yGAJwR2PWjUNByyP3kYsT1zS72OMk/jTAQc8dacD0ANDbCw8HJyaTGAOoFJn8/ejdx6554FSIUjvijgD2zmkJIGR06n/61AOR6+2OaAFz6/Wl9fWkBz68dfalHXIx3oEHfvjrSHA6inHAA/P6U1m2jJ+76Dr+FAIDwB+mKPr1oJz3B+lLnvzgd6AAdD/KlGc9T6Ug9sdKccfgKAE6Lk/dHBHtTgAAMABV4HFA6c8jHcdKAevt3FAmL34Ocnn3pQ2ORhQfXvR0BPJIGcDv9KBz6evIzVIkrYxnHC0vXBbJ9hQeG6N1IOetKe5wfTrTGIchu3uM0gwPunketOIJI7f1NNbk9T/gaLDQfwnufT3oBzgL16nI4ppKggEnOM8fzp3buQeeOlJIYN09MdPakPTIGR15o6jAHvmkOBg4qgFP3snGMD6imnoTnGKUHBByfbPem98AcdqYC55GemMU0McDeQO3FKAzMFCljnAAHWvO/HfxI/sa5m07wzbR6lfwpie5c5htpM4VD6k8j8K3oUJ13ywRSi5O0Vdnd6lqFnpli95qNzHbWocJ5jc7mJ4VR3Y14j401K78WWuo6peE2+l2l00VpamcxuIFBG9kHBYvg8mq154i1nxE+m/2zDJfX0e65aC3QIlk6naV2d1wOW6j1oudaim8N6joQtI3lluFFvIqBxdMWGMMRkgd+a9vC4J0GmtZfkvL/AD/JHVQo8rUpb/l/m/w6GX4U8TT+H9Tvkjg0pz5KQW2oTI8gkYctJFnjaR6DqKzPF+s3erXg1KxsLqLYrP5r3C5ZzhWBAXOCPXOK2xp2mHwla2CwXNx4vy7xRpI8n2ZQeFgGcKvPIOcVlT/2bf6Pa2ukaZeQeOLe6USRsGeO5jU5ZnIICgHqD/WvQjyczmo699Nu++39WNopKOqd/wCu/wCH9M5bTLOA6zDpN1aXkkLqAl1ZoyfZ1YbjkkFjgkgnjPanm2k/tGewtfDs1vNjy4Lu7usi3UtzIdo5JHHtXdXfi2/1PxJcnQr+41DVb5BBcyWCJFCzgYEEbEZ2Acbs+/NY2t2VxavHYDV9Nnlzi6stObzRbp/EWn7t6gcD0px55vV2+9/1r3S/QuMou0Zddkrfde17Lybf4FSw0qw01xCdIi1DUiPLEpkLpK/Zo0H3mHu2Par+u6J4l/s+GbWJZ7HSZpEiWzKxh2LHAAAUEA45GeKumS/1aDR7XTrC30qx0oPJYWtqT50m4EvIXPLZ64rpbDQ9Z8daRaal4h8QQ2+mI5nFtgK8eOMg9m+UdeB6VnOap2lK1uu7flb9el+o72Sbil6v/L+u9zhdc0V9Owk1hcaeYzJFs8p49x4xt2k5XOTzWYnmWtpcf2dbPbwkwxSo3XdtB3P/AHgzZ6EYrt9CvvEXiC/udEj8TfvQXNst3gGdBkDbLjpgf4VhX+n3mhWtzplxsS6jT7VChmE0cwHBHuDjPr71tCbvySauvXb+vU0jLmdpb+T1/L7v6Z2cH/CTeGvDyyy2llqekRKS6QOYpYM85Z1wX9cHP1rN8M6JqPj3UYrjVb0jSrIEtNcNmOJe4jAAG7oMc4qDWYbu38NeHFtdbF3BfMf+JamC8Ybn5gPmPsCeTirFnpOqW3h68jOoTRwrMYZtMLqsjK2CXjyMITgZAGcDrXK/di2mlJve1uvb9du/ciKunKKV36v/AD1/D161dS0vTbXxHIPDqI8K4gWSA8xM33xuxjOADkD+Iiva/DwtPDng20EUDrbxBpY4wvzSbicDAzz615neXF/4a8MXmiw29rcaWFWcX9vBk22egJH3m+tdp4H1Wa60SZVSWB3tg8V1PgIXI5YY4Rcc4rgxqlUpp7pPvv6+ZniLyh5X+/z/ABPP/iMlwI/7bs72D7bcyxGS3mzm2bcOH/vqR6Yx710PhHV7/RfDdppekCIz3MjSm5eDEMAbpkA5kOe/FYNss3jHxjp8Wqlbm0jf7MxRcRrH3II6seuT0rc8WOvgi5F/pto8ZsZBa29oZGkE6N92RySduMHmtalnGOHesvw7Jf18yppW9nLV9vS9v6t2uwv/AIp6zoUVqNb0CBtyybr6Z2t45ihAygweu4YHHeuj0zxzZ2OjWbeJrhYbm5YsjW7G4IU8/OAMgAHrXG+MPGuja5o9npL2U00EL77g3rA5LfeRWI9zz2wKm+Gc1qbrUls5ZoTbiO1SO4t1ZoYB90mQAFu4x6AVlUwsfZc06fK/J/8AD2Ob6vFRfutfe/z0/A9ATxn4Sv4o408Q6VIs8gjRZmKjf2GGHXPODW/HJDOVkiuLWU7cq6zqSR6jnpXz18VNMshrKSmCKQSETSwgY2EHbnaMcnpWlpvwm0k2oS/a6nCTedLHEojwpHKsw7DjpWM8Dh1CM+Zq/o/8hPCtbT+9f5Hu7EJNHA8sSSyA+UjON8mOTtXuPpQWAYKQMkEgZ5P+FeG6lNoHhkQNfX95e6pbKBYCSci5gVc7Ujfoo55yDnpWr8O73xtdWUe+4ttOtLi4e4djEJbgsxyDIGyFB9QBWE8u5Yc/NZeel/Tf+upDoTWzT/D+vz8up620qRoWlkjjTHLyOAPpk1NgrnjOOuDnivEPiZr3iT7fY2j31kdMe5S4Ef2dN26M4dFyPm6Fh3rsPDOqRXN/Z3WkpKlpKcR+a+ZWjA+YSA5GfQdqzngJRpqpff8AryG6E7Xf9fM73IPJP0HalXgjPBxya4n4d+Jb7WYNXfU5PtVtFfzR2d2sYQ7FA+RkAGMdj1NbGi+KdL1nVrnSLWWX+1LaITyxSJtGM8hT3IyMj3Fc1TDTg5K17bmcoSje62N4EFwoIBxkg+lOB+XnvTAcjI7/AKU4YOcZx0JrCxFh+efUU3ADc84NGScn8hjpTuRyCcUrCEAAJ4+vvR+IPegg4x6egpQPlxj34/pRYAByPTP6U4g5PX0ppGQeDxjHtSncxJU4b1PegQvfAP404DK9uBSDHI5x7Uq8kKRyOfamSKOu3gnGTijJB+U8UcgjGM85PvQobqNvP96qEVyccjgA/wCfrQeAAAOaaeWGc5HTHalDD6HpntmqGKeWx+bE80dG6j04FIDxnHfHNGd3rk+vp9aQyNkG4njDYP0p68jCkEjgijOe+aG4xnkZo6lDW+7z+NB4zkjOOlKOTnByenvTSdo3FiQDjI/z0piF6Z54798GmdSwC47Dvn3olkWKGSR22onLseij1rltX8d+H7K2VrXUbbUL2YvHb20UmT5gz/rMfcXIAyeueM1rTpTqO0FceuyGeLPFcNlputxWNz5FzYPFDLNIdp/eBivl9mztOR7GvL/Dd4dE1eS5urRpdOVAmoBQAN0mSJZj3Xk49Pxql4x13XNW8UTz6pYWjXlikcK6XDH5kbI2T5wyc7wcDnsafo2tJZwaxZ63iRNUjFneTbiZbYDlAB1CDPJ/wr6GhhfZUnHdvf8AA9ClBxg1bV/1v/XQ0otF07wz4ztjZ3k0eh6+jmTUEOxFyMCMf7JGBzWBDYQv4gTRodQk060inkiinMvmTrGMkJGx4XjgY7V2WmofFng660yUecyxeTceQf3YaM4SZP72QAeOteX6jDqNnqOoLqM6SXtsYZkmB+bYuMFR16V04a8nKMn7y0/yZcd/6/rX+tDrYJtQ8B+OrGKVT9o01t8Rk+V7u0fhwwHHmcg/hXO6/Np6P4kubKWe30fUpfJgt0kKznnOCo5wzH8cV0PizWdK1HwtbTxRahd6wjBZNRKnywxICtGTweD/ADrGhW3F9HptpDbS3cswKSyqWEWBl5nP8R5OB+HatqabXPNa7P5f16lU4ppzfb/Pp1KUGni51OBTbJYGysilybJyioP9s93PQ9hXeaB4P0v7LpUt9aStNEfNazgQsuSeMgcNj171x/hdWGrpHM0rW2qXJtYLoR7hI0bnBZBkgkYytexXerX2laTe3lmbRNSVGzHGNiQwL05P8RIzXNjKk4tQh/XQJzsvd6/1q/6sXdV0S7urSZ5IE2Ov3Im/fD6e/wDKvKZtAt7iPWZbma7t5YGTy4lQgaiM8rOg6YwBnvXpng7XtRu9NspL93u5Hk2TNJwxbsyeg9jir3i2+RLO9S5ijmNmvnz3Hkh8nPyIp9c9SeledRq1aE/Z/kZRqSi+SSv6eT/r9Dz6TW7+/ttRk1fw/pNxayRR26ReUyrbBR8rEdQOaxtJ0vT9Mj1CfWtLa60y+B8qe2Vll05l6MAeSnGeK2YvEF/qVxbtDp1oL4MZLluTCyYGFUY5I5yemaual4h1PUTKq2UFwzArG074CRg5xs6YP1rtSnD3Ukk99Td6aWt8/wDg/wDD+Z5tpUpj1mxv7R4mntZBIqBhkRg5Mx9WPp2r23S/EsM8I+xvp2qI8xyjQASRnH32A+Y9fvHsDXnWladp2p/D+9sGge08U6K7zrDGd3nxnlwB/d25B9K5x7a4sE0K9ljtV/tGLzrEwsySQdRtPGXXr83TNbVqMMU7S0a0/W/9eZnLkm7Pe9v6/wCAeya94kk027+xQadbXGrKPKjhgGI0Vx99/wC8v+zXIv4b1tNKvDc3M1vYRK25EkYQyEk/IvY564HTNUvCeqWVk14t/vN3Nlv7RnbO8r1hyM4PcetaV94quddVLDSp7qRriPYhuowHh7EooPy+me9c8aM6L5aa06sqMXB2S9b/ANev9aGTY61Fo2jmG0gt4pJNrGcb28qMHneg4JxkAjt1ruNJ12O8WKaa2hAZSYZZLgfa0jPQZ6OmAeO1Qy6LbxeHHt7GKG2ldjEjXQLPHKo+8z44XIxj0rmoPC2q20kURZLWKeJpPORma3kc9SoI4qJOjWTb0ZT5al+n3/1/XU65be3n0u4tDNBdR3JabZPAFlmRuCUPTjA6c8V53oHh7+0PGMlhb6jLCbcFGvrN+JcHjZ2DKMBvpWzc6t4j8Nadp0GpraTaepItbk5b7O5PBcAZHQ1n+G9Otm1q7uNfe7061EUtzbzwTGFrtyfn8s916cd60owlSjJp6Pa2v+X3f5E3cYNv+v69Cl4iV7fULuHWdRk1WeGMQw3UC5llYn7j56lRzx1q/fp41sPDceoTarD5Nqqq1u4XzY0LDDvjqQO3pVFZv+Ea8RRXGnQ3UmnWU5YyHMm1mOWLN03BTg5rur0N4wubLS9LubW40NAJL6cjy+MhhET/ABcjJ9hirqTcOV2Tj1bX6dGxysrX2PJNatL+DUo7/UUvLq9uUF0styoInjUjLKp5Hb5T2FdnZfEWEXA1CKC+EKY/fpMMu+BkFOpjH6dKvfFVprv+x9PspWnea4PkRRoPMUKABjuq+meKqeBPDNnqV1qcOuWJbVLabaIWbLqhA+bA6jrzVSqU6lFVKq/rYHZxTY/4heJ/DvibQ/8AQLndqoAmjgjhYFJF+824j5SR6dax9J8Yw6R4ImtrZhFq3n71lJ5SNujYPKuGwD2PWtHxL4Vn8PeXqWjzxfZYD50sV1khyp+UZAyOODnArPtdHHjXxCZfDGjW8cYtmmntGYK2X4EiseMAnle9TTVCNJWu4LW/Z9mFoqNr6eZ2/hG6g0vwCkkOEvEBa8jEoEgkLKA3sCzL8x4rgP8AhIL211zS7m0Z4tRs7uWfyZ/9ao+XdG7Dlg3PXjHSkm8M6xpkclnqKrEbYIJ4YpF85oyeABnqOvGQMVQstBm1rxBd6Xp+qrLZKC0N0obMh4+Vmxn1BNVTo0o8027p6+X9a/d13HGCafM7p/1/X3nt+n/E/wAN3GmyXerSzaLMh3fZ7n5y6/3oyvDLW7o3inQNcuHtdF1SKa5RFkCNGw+RsYYA9RzXzG0SRvPp19As4sZMKj3AEbL/ABFm+8RnIAA7Zr1fwBe6L4Y8Oza1qmowyJeKs0aQDADAYEJAyAV7DOa87FZZTpxvTvfp2/r5nFPDqKum/wCvkeuwXEc8twiOZJLZ9k+FIEZx056/hU/UhmI54H1ryhpfGuqhNafVLHRoWY3MVhbr5kseVIAlbHPyknHavSNCGpNpUI1eSGe9wCZ4V2iQHoxUcA/TNeVWw6pq6kmYSpyjqzQA9jjqfrRnjHG4HP0oZWRlBGOM4/xoLlRjaxy3OP51z2MxcY4xxTsZGPyBHIpu1gMN9cClxnJYkleevb0pWBjgxPToPTt9acBntnFNB54P0GeaRokmjCSDcoIYZ4yQcg/nTRLJFxkFevQHtQpUH5mIOPzoznljzk0ADA+XI7Z5prVklPPB6n3pRkDGOmCeKZ0wzdfrTvcHp/k0IsccfeBGcYpoP3gOT7dPwpMA9TkHvS9sgD2A6UDFzxjP4/1pACOB164B6+9J1HfP8vek44wRyepoQASMHv3o6YA5zxgCkY5PIOc9Qen0rF1DxXoGmXE8N9rNpBcwtsaNzzuI4GK1p05TdoK4Wb2MDxb8S9A8P3OqaZeR3M11bx+WxaL/AEdpHXiN26gc4zivOvhckOoXkj3lpYafKJVuJFgjyhIBJUnJxx0GeuK6zxFZaRr9zp+mWN0bu4uIDcTyNGubk9RIxPBx/dry5LsfDbxDJpUXl3Ucw3JLG5ZX5ztYY4Pv6V7+FowdJ04K0muv9aHfSgqaum9V+Pf+v+G39c1aMeLLjVp7SWBIHEk0dqQjvHyBknvkjgdfwrS+J76JqPhq01jRF238KrLHHt+YLn5i47g88GuI1NZDaXuqakBI19NHNJHbyea9rECQCD0Lc4xW+mgRWes2LeF9WttQ07VIZDc20suWiCqDtc9Q5yfSu10oRlGV2mvW2m6f+fU1naLV3/w39fcUdLvpfDuow6xZXjy6VekmZv8AlnGuP9YAMcKc8e1Y0d3YX/iKXU4YpJ4ZbgfZi6kmVweU9lb0PY1DJc28g8nTLFk095ED27szLNkD90q5yoBySQeuau3TxxpCgRbHToABNJbnPmHphB1JY8cY4NdSiou7Wr/r5lxhze89P6/Akna6WCGKRZZYbWdksLKIYT1JY55A5pxc217cXA1yS3W7AE5FvukXIwAAudg64FXtW03VY9GhvZIDpsN5cC1treUlp8bT+8K8BfQD3611Gh6br8Wnrpen2+l6LAB5t3feWZJ7gjgZL7uf5ZrGVeMY811/W/R/h16lzlHlSirr+tej/q1jz8Xd/a6MNEgvVl0aCb7Sl35ZWRJM5O0jlW9z+Vaa+ONVm0ltMuJ7dJbiN4t08O65kUnA3HoPYkV6np3gmwtbJEl+xs7gyM1y5DyMwznYD2OeTmsbxNYeGpdHu5Z7Gyk8viS4t3Y3DygYCAZ71hHG0qkuVQvr2/HsYKVNvRf5fnf5fg2N+H/iPSLaw0/Trvy7XUYFdGtss03n44Y54YYyaz/Fs2sXXiOHTkeCys/JEtukmVFzKTjLjuRn8M5rLi8I+KLBLfVEs0vr22OwQoQbmCPsGPQ8e2feofEmoeIBGqeKbO4k1SCVZrG+lXAi3f8ALN8cYIGOlEKdN1eenJO/mr38l2/pXDlalda/Pb+v8jv9E1ODyX0u6eODXoP3ctuV/wBaB08t8YdevpWw7sAFnWKGKIgu5AC7h/ePt6V5te6rqfi7SWtNI8NyyX9uFBuYZgotmBz8nfBz645q9Y2l94o1O+gvdY1BbKCNYZbNbcCXzSo3oeuVHUv1PbFc1TDRV5Tdu63/AKv5kOL6mR46ubF/EUYsWcXsCPHcTQMY0fdxsT1AGQfWsTSLdNU1uCwiFzBNMxtzNtJMUeCSkanlQccmuz8MaLZab461iwWVr5bSwjkjkucARhiNwX1ParvxBtzpPiLw9q0BVLmO5FsSSQzxupwWx9DXTGvGLVKHbR/K+xqqiiuVav8Ar/Mo6t4X0qz1bwpb2zyGDUJxb3VjAcMxXO0jPTk5LVdgtLbT/inrllFb20M0dnsjmWTylikKgs5Zs5Jz0GPat6GzS2+Kfhuzlb7VHYWlzem4dcBQQDz6EdMk968209Lnxzq+rz3Fytlb30rXm+VMx/KdsaFuoGFBwOtZU26ibm9OX83/AJL9GZwm5Ozelv10PY73UfsOn6dDasjSl/KnLJu5K/fzjkZ71xPh/wAQ6na+KbrSr6aNZN0hmYKZCpI+VdvQJ3yO9aXgG8uFsdUXVLa4Mtu506BwN+7j7uOw7g9feuUtdTSL4x3qQyzGVYxau7xgMWI5XHtjrXPSoL95C17K9wjFK6a/r+v6udPa6rbab44GiX0DyaXf2nnor4bbNzllz1BHGO2K871a1Wy8VTo8pligbzbW3U5jgzyAoJ9+ldx4w0u21TS5/O3w3tjmaC5XqhHJz7HFcEJZtShm1Caxea5mh3TRWyHCJtAWUtn5emfxrrwqjyua06P/ADNaafNdf1/w53HgnWNJ0HwpGdW1OIX0s7XU0Eo3g7uSpQD5ifqKo+G9V1bRdHeOXwzM+nm4kvoCMJiJjnLDqFHr2pvhnwZo2p+H7e6S+23gxM14g3FcH7pQ/eweDVq78bWmobdI1u3utMdWJvPIYhfL/uIxydr8Eg9OlZyjGU5KEebXW/6bCa1fW/4f1/XQr+DNe0q41zVNbudS8u7ll+z29vLG0kixEZ+TA+bkdu1WPFF1e3d7ZajoGi30txYbpDeyw+V50eTmIpu3MuRnoCKvvDb674ut9b8FXi2v2KzW2naS2V4I5CfkVAMc43ZP0rQv7Pxlb2bwzeJbOO9jWRluJIMM0Z7ZORjryBWcpxVVS0T7O7t9y/zIT1v+F7fp+JwGteLj4k0a4torRrN54/3kn8DNnBXd0C9vWsM6va2RgNgb9ns4VUMreX5TH7ygjqp981qeHfDV7r1vIbljBpkUgNwT8onlPTaOgB9fWugh8ATTCOC31G0h2q8sYnXzIzjhlJGDkeua3nWhTk6cGkl6v+v60O6KoUo2qXb7bfe7P7vxOG1C7m1m5t7LT1mt5bggXE87lnVSRnn6DJ57V6F8NbT7JZzzRRBUjnMSzhhtZVwB+eSePWq/gXw/Z6naarDras+q2s3kSbGIZoznaUAx8vBqx4XK+BvEcmk6lKr6TeMTaXU4xDGccr/vdB17VlVfMp007yVvmvLczr1Yyi1BWtut/wDIb4Ts4pfibr93FE++DASKeIEZYYIf0x1zTPFWmW/g/wAV6VqCjZDcXga50/buCyA5EqjpjH/6qr2uv6bonxA1idzO+iXiJFK6PvzJgDcD1Iz2zTdevLzx5qMdjpUCeVpx8xZ5pDubnG5scnHoMVXJP2vPLSHKr/dt9/8Aw5hduVulv6/X/hjt9f8AGul6PZxubiGd5CEjW0GfN7gsTwOe1cc3xQlRJHj0RknJKJbLKQQzcBgehXPJ6YzTPAulR6Z4/vtI1yGGe6ih+0Qybd0cjAjJVenAJ966Txp4etp1eSOzSSeTEL2UeVL7uRIpH3f/AK1YKGHpTVNxvfW9/wDhv67EKEF7rbuY2i/EDWtKvobG2sbCS1vLgQyy6ncFXtpdo3gsuRt3ZIPPBHSvSPAHie517SYRrdk9jqwJQgYZJwDw6EE4BHXt6GvA9Os4I/EIXxBbSXVmqtFcyRoSVjQ44UH756H1xXuXhTV7E6I40GxKW9vHvt0DfPJDu+cZOSNvpWeYUIJe5HV21/r9fUxrUEve1v8A1/WiO0UghjGQ204bHO0+h9KeOQp5Hoe9eSeOfGN1YXvhm702ZrdLrZdrFD88d2uQHRj3yD1PSvT9J1O01e0FzYTJLHnY6I2fKbupryquGlTipvZ/gc06coJN7MvHr0Izzj1pRxwM0DHO0jmlGNuR09c/pXPYyFXgjbknOcH2pM7TkMVzz0zThkEjJHOM00jgYJX8M1S3EUl5HG4D9ad97kZIPOTTTxjBHr7UhIBXduIY445/H6VJQ7nGWBPfrzTFBUBWOWPJPQGlIxkZ4zjijIBOAMdxTAD04z17/wAqCTgjOSOlJxgdCMde2KQk9+cdvWmhkN9dW+n2U99qE0dvZWqeZPM/3UX8OpPbFfOHiPWLnxl4l1TV9NfS4tNRhtS9to1kMGAA8jY6kg4B5xivXPiHbjXbvTNFaya90yEPe6g28qhwPkTj7x6nHTpXka2cIvvsulWkOkw3DMpV7fZKowCHYf3cnivdyynGKc/tP8F/wTpw1OV+e9jOtryWaGWwkaCylldXWa1uC8Vug5bac5Ukfwk49qtanfW3iC502xt7RItVuGW2S6M+xJYX6yN2HHB+tZVxpNzpWqSzaxaSXt9eRGSKR0/dM69WXH8JApPssNhZtPNp4fTMKyRSReaY2bkkSDOWPYHpXsqztJHdq1vZ/wBeepHqCzeG4oLeMsfIvfIvDCRtYZG0ADjnHD9qNYuIr/xNdS6fax6faykFreJ87cDhmPUnOSc9Sa0YrrT7eyuNI1COwRJrNrmK5tZd88EgIIiY/dJYdQD/ACrntNt47mzkzKTIQGxKuMHrgH17celb011fTr/X9eZyV6jekXv+ha0aNnvIQplkDq6QFsAlhyXx6V1nhS2vdY8Sw6h4eTTo5LSMrbf2mCI2lBw0kY6Er19sVyFmZEF3dRmM4QojoCCrdyPpXoPhyDxXfJoHhqS0+wu3/Eygv0XbcRQZwWUD1z3655rPEyST1S9e3XTqXByVFX6/l/Xby+eholtf+LPGs8OvapNrdvpamKOSMCBBIeWc4xwMfXpW7r3iKPQiltp15cy6i7ApGvIkj6Fj3XP58VyWi/29p2s6v4X0CU2wtLlne8AAk3EZPPQNgGuy8NeFbKzhhnhJlaWT5riYcyyHOVUHqeDmvMruEZJzd1ZWX+f/AACnGK+L4e3f/K5gGXXdTvIXsoDaPb5DXWSWi38gFv6nmqUWk62l5camTDu08LeCRsfvm3fw7eWf65r0HQdd0+8u9WSSGWX+zF3eZJxEpTjC54yDxnrWZpXjfWNQ8V2tvEiS6bJIEdIVyOfutzyqgc+9ZqtWXNyxSSWv5+e4KpLVKH9bmDH4t1hTdtDo0kJiXdLNDcMoWQ8lmOeMAHIrWs/Gs2oWflahol9NCYleY+SJUKnI8xiBnB7etdR41e9tJDLo2k2+oTSqfMBwqyDI+Vx3+g6nFcbp3jmR9QtYdV0KMKAftEsMDErt6BEAxxwMGpi1XhzKmvv1JXLNc0Yv79TiPEb6bo2vWt94abVdLTBFxuiaEIM9Y1P3gf7p44rd8P65L4D11rye/h16x1mP7XLc20o81RjHTswHGz8K7ddasNbaMTOnmysW2XaiUYz90jqvGDgetcv4g8EJpOqxa14d0u21Eo5kuNJI3wzcfdC8kHuARXTHERmvZVl069e1308tQfLLSS1/H5PTUij8UaNefEO+1DK29hLZxBBdja+4MCUI7ZxVL4ieIl8TatpsdnNMkMd0hlkiB8qJhkKisPvtyckdKyL+yvp/DGpeK7KBIdPeVofsUH39PXoFHfHYjtV/QtAsdY8RrbWOvzz6bp8EbebISEklkHzgkcrGMAZ9a29nRp/vV9lW72t+v57jSirPy/q5o+PvFEJ8TpDZX0xjm02S0le2IMiu2BtdeoX5Tz1ql8H7c3ni1NPkQXOl2tod/lk7cHkbvU55B/CqetaDb+Hb+Sz0SEazqN7G5NlGpSS12niWMr25I+bBNXvCFhr8umXOq+F9ctodYCiK6sHj+zuVA53bsZYdRilJQWHcIOyatd/m7LT1DSMGovXvt+P9a9kO1PU5rbxH4mlt9TuLGeN4/s8Vs25LlwMMWI6HbkmuWstGWHR28Q3rtamcGS1vUkMpefdnbKvVcgEgj05qJIIDo8sthNLFcElWluyAPMJ/eKT03Hmt3Wr19Tt/DVhoOix2Wm28ojSe7lDpI+OWZRxgckDvW6jyWjHbr8l+vz63NuTkSaV/Oy/r7yS88UT654YfTL0XI164Zd7oNkZj4w27pg9MfWvR/Amg3eneH7hFcQXjnB3EPFLgc7j0KgYA+leW+Blhv/GSxzQTzQxGUF4H/d7lIG5R2XJ6CvYJL+KDRxZ3LLa29orG4ePgyR9QPbPevNx6cbUqat1/pGU2lHlh1/r+vXc898WNP4fnv9a0Ix2ljlYDak7kyePMQdBk85FdLp9rpuj6GtzrHkwXEe2SWW5QSSSSuOXOc4UAn5RXOyaVe+OQ8yu+maMg2RDP7yRh049AeTiruihdOv8AV7bxRKLvWLWEy2F3NJj/AEcoV3R5+8wJHy9etE0pQUL6rdLfppfy+ZpJ6f1f+u5nW8N5bXup614K00SeHpnEUtq7ljcOOTKo67Tk9Kta546sbqw+yRQXceqOhtTbzdYgR/D6qK7PQvs8ej2+6CRJYbZVgjDENIxySeeR2JFed/FaSCfW9MhuRbNL5QW5aEiNl6kLkde1FCca1XllHb79O/cUeWc7Pf8Arf8Az/M6vwPZNH4cgaaaaL7YFi3ugaEDPJPYHsDXYXdrHaWMyWcclsfPCh5G3CXPBCk9q8q8Pa9r+l6Zvk0CbUtKLAeciPlZMYKrxllHvW7D450i4jImSa1mgbf9md/lRsYBYjow9Kxr4WrObcddejMqkZuV/P8Ar+mF3c/2V8S9N1FSI7e+i+zMfRx91m/u9xmo/ije2t5c6dpkrRiVbjzhG5DRxx45LduTWZqkVn4l8LXuvaprsAu4FMVnaRSKPM+YbWZc5LHn5aXwX4IGsafNeXjytaPnZBA+zOB8xZz1bOfl7VtanTtVqNpx0/q/r/XWo2T529tBngzwzF4nsbuW6tJPszSsltbwEBWdCQ7sfw4pbO0vvBvxEig8JyW5GqRvIkGovkx+Wp3Bm6g8H61d8CaDf2WsazZaVqrWv2V0NusiBgwdRgsvoRxxzmovGk+ueHr3RtSvNas9TvYZnit7VbYCSQkHdkDllP3Sabk51pU1JNNbO/VXXRrt+JUpOUnF2aJJbfxJf/Ey1eVdOOoQWLOpZdsMytgFEHXcSQM9q7zTtSi1aOK8hgubW+hPkTxTHabfZ1DD+R7ivLta8XeIbnXNOefT2tr/AAy2MTwszMr9SCRkY/SmX2ieK9d1W5vLy0uBfjbZvh/LMi4JyF7gZzk1FTDqaj7WUY6dP6tb8mS6Um03Zad/6/rT0qvqf23xPqt/pULXN1NdiGCGKQp5sg6kMP4vQda9G8J29zo+i674h1EJbOPNFvHG+XjO0gg+sgPVjyTXmXhzwnqOuxTmHURBFpt0bTylhyZpV/5aLj+MdzWn4u8NeKX0ya91HVDrFvCqs1lgx+Yqj5s9iy9eetbVo0qklS57bd7+S7DlaStp/Xl5m7eXEOm+GPDFjcReZOkyytErrG8UOC0p56Kcdu9dB4O1vS4L7T77BtW18SRXHyEIk8bDyyR0UMrEZ6EivNfDrXviZrmK4t4dZleBIxeaiMraxhhtWNOrc44Ndnf+E9F0yC0XxZ4k1e6hjYeTatKzBZuoVcdPQDturnxFKC/dSvfXb7/z/IU0nHlk/wCt9NO9m3oex4YNtcHgcrSjcM9/5kVgeDNck1/RVuLm2FndxSNDJas+94QPub++4jFbw4GcDr1PavCnBwk4voeY007McAOg5GacuT1OPf1qPBD5DHB4C9gfWlIPH8P6VBJTySe/HtTWIC89OmBQ3BPbvz1FBIHHII7e9ItBkdOM9s0gwcrgnPb1oPPLHg8YpDnHJ6elO4Bgt8oBZiD93vXK/EDX7rR9Hn/swhL0lEErHG1ic4XPXgEk9gKn+IFyLfwhqH7+S3aQYjlifY6yDkYPpxzXAXusaaun2uo+LQdV1fUYMyJbybYbOLjauD3Jxkjmu/CYZzam1dX27/p/Xmb0YKT5n9xlN4/1EavaXFvrEU0UhVvsyoxDR5w3zYwMkHqadq1tpup6tdX9tqskKTSEfZXkUsEYYAznB5z3yB2rM/tpU1gw2+lW0JWLEUbRlY0QA7m3dOQRxj8ayHl0y7tIFn0a+iik3ut9YfOJDn5SVI6DkcY6V70KKTTirfd/X6ncoNbK3y/Q7jTb7T444/Cvj6wMTyARQaiHLR7x054wfWsuGE+HY7jQfEBafw9cO0dnqMR3Rox4UNjpzjnsKoW2u3z6TfW8sFtrekWxEbG6QxyEsOq9T9Kx7O11HUNNntLSG+TS4izzwrIHSMEZ2jI5fGckdKqNG13J2X6912f4E8jf9fl/kN1JksfC8/hl9LshfrdCb+0xIDJNGOcpkYIPpnsa59xLbNI1mpTI+UbgwA9vQ9a35bu61KwURlLuyhIEIltcrEo/hDgg54NM1BdN1O2X+w9LexvlcSTxxzboPLAwXwRu3ZBOBwK7acuTRr1/4N/0Mp4dy16/1933GJbqHsRAPNS7eclY2+UmTHyx+4z1r1aeCHw5oLajd6ld6v4luYls4YGm/eh+ihQOiKcHHtXE6XbW+oapoNjcXYshO4aS8fjZGD8pBIOCx6E5rd0bSIoNL1nxEvnvr2h6qPNEkmS8O7ptxxlc5NYV5qVrv/g6237X3NKkFTtC+yX9f8E6L4fWE+jX+p6PeTNcXbNA95ceaCPNfPAzyfrXTeO9U33MOkWVxHbajPMLaCR1z5MePmkAHQnoO/WszRrldb8d+ILrTTbixulgWOWKMlTMoJKg+oGT6Vm+MLdrXU9Jn0lRDePN5CPICSXBzk5+pOa8tpTxF572/GxCXNJN6afobDCz8J+CbiFIZNssjQynh1L56OTjLN1wOgIqv8PNJH9rQXE8UQRAuG3HdG+MsCoHbkDNZ/iDSrjKz6tM18zXA2RrlU3k/wAK9Cfc9sV1llaSWunXsELbbqW0ldDHw7TMD8xPqO1TOSjTdndy6lT0i0nqzOvPiHINUuEXSy1tHcCJoZCN23puDDOWPYCtrX5orGzivdOgyiQtLHC/yRlSR1465zx3rjvAGlzavYWmp3F0ka2Em2KRQFiR8EEtnJkbBOOmDXU+Ifs82IDM0thax5RgS45/jI789c+tROFOFRQitt9/6/r74nGMZ8sem5xVpZC/uJC7RWwwJdsQ3HeeQEUcn+ldCms32kTrJ4jDKzMhilt0Jbjrvx6CubULY6hZXUpljkM4BmUfMqnggDtng/jXo9hbTSzyxhkE2C0LyAOJfYda2xE1H4tUaVZLrt/X9M8Z1m7X+yfFl/a621paS37Y00kBbstzlR1Xnk9q6O+8IN4Y8JL4k0jWJbHVBbJJvWQHkjldv3SDn17Ve8JaXoT654v0yQROrciSaMBtrqQ23dwACetYnwzsk1x4v7YmN9BpbNHaWqE7MA4G5T97vyfSuudVpNq6UbN6bprb/h/+AS2tV066HYeFdGh0/TYJoLKBdSntxcXF00xkeQtyXdiBj2A4rG8V6daaj4s0u1u7aI3MkZknuIG5mjUZGSMYftXoWnKnkToxhYsCDGnRFHYj+lcJ4mtR/bmi/wBlRXUmsvLmTO0b4+wA6ZxiuChVbqyk9N/y/ImEry3K+seD7Tw1Hp2vafpQuobaTzZ7MyCVLpD1yDwHUZI69K5U3Pgm/wBQ8S3kx1HT7Hej6YIImEMTbTwwGRy3bivS/FN7d6X4XuLnTo5I9kDPHDKuRGD8rMw75BJ61S0vT9Dm+FE+n2kReeWyeb7pyXUbvM546jpW1LESUOed3d2un0vcabdpO/bT9TzPQLq8tWuUsLT7LqN5aG1trSJSn7xmyXA9CPmzXd+MrpdP0XQPD0YE0l7Ci3d66E/In+sb+mT6VS8XeRf+BfDfiK3m8nWUeKMXAGM8EAjHUZXGKyNH0S41fQdQ8TX13dPfRu4SSM4RXX7yNGex9BxXRJxqWqT0s7W89l8ka6Sansv1PU9POlW0kFm8cQ0x4825UttCnseOPrXO+NbCwvPD2txak6v9kjD6ZfNHgxqpB2q/14wetXfDV9/avh2wvVXd+7LyxbQPK55+gHpUUZi8V3suZWOkabcBIItuIbubrvk9FUjgd682MXTqOTb916/f+v8AwTJO2rOQ074jSQaHbvqNpJLcrAqJJKjAM3IUggcsePTj6Umr+FdXl0H/AISHUGkuNWDLJeWjRggjqqqwzkhcE/WvQfFOmw3+i3GkARTvccrbgKmZezqccBQT+dUPBWr3mkufD3iMxR39rHmExHctzEBjejE4JHQg10Kv7vtKMbO+q7ry8v8Ah+hXtElzQRt2U6X2lxXtlOVnmVZY/mwsiFQQ2OnHf0715jew6HN8QI9Vv4ozoF2jiO5nykVxcx8uT6rkdwM1dudUtbHV73w3LqEcHhuUm5Nzb8/ZWb5mtw3YMScgZxnitRde0bX/ABlb2dm1l/Ymm2ahIyAyySuQCFB43AE06VKdHmaTs0/kunz/AC+ekR916mT428M6RBpVzrHhw2BigRbrMWGJkJAKEA42jgjuK0vD3hl5fDlnf6Xrd9Z30cfmmZJN8cjsf4oum0Hg4JPtWV8S9E02O+sbbQEZ9Xu5SZLS3yA0eP8AWOoO0EDPP6VkainiXwVDEkF+E06eTZHJAQ6RswAJ5HU/gK2inUpRgp+89de3bz8jVXnBWd/Ur6vrPiLTPFd5M1zZ/bzELad7JS6Tc8BBj5SD611XhfXfD2k2d/4k8U3x1PWbhxA6mP57Vu6Ip6D3q74L0PXvD9u7aXpWlXUs2Xne6LeamVBBbr8p68dCayfF8Vna+OfD19rkVvY200B86RcSKXQ/KcYGeQOeamU6dZ+yS0t03dum3kD5ZNx/H+tSxZarqdp4lvdd8V2V3aW80f2a0mwJfsSnlQ6jJG4DrW9qHjrRraaAWMZv7mHlI7LJD8feMh9O4pfFXiWOaxs7fw8bW5l1KAwKY2EhMeQHkYHuvYH1rR0HQ7LSbAaTbPBboyea08qrtB7sp65Oen1rmny2U6sbPsu23qQ3Frmen9anEeHvEt/oqakNQ0O68y6ujfxzW4JbBwS3TGAMe+c1J428awahot/bWtpqxnu5FbNxB5RWI/eHBxux0r1Ca18i0izqFk0HliMM/wAv5YzkH0rPvbaz1ZLrT7pF2MrQzoGwEBHBL4/EEVMcTTc1UcOvn/XyGqlNvmscF8JoHtjqSWzQiUCJ5EDgsm4ZQE9OCBnFN1y/ltvG17PcsqG2YRaXbyHcokKkszkZAX0J71wMby2Or3drZzpPlSY5YcrtUHlHx6+uas6PrUcb3QkihLyrtKzZZVXBDZbPIAJx05PtXpywr55VN7r+v6t5Gs7Xcr/1/X9LY9V+EOrXt/4hnecIgvbBnmhT5gk0cpHLdCSDnOeQRXrIIx3yB+deQ/CRrP8A4SW3/st5f7PmsHNur8EEEDnsc4JzXrinOMdu1fPZgkq7srHn4pL2mnZfkPXsedvvQC/8D7D3yc/SkXn7vrz6mlHJJ6Z5zt61xLVnO9ChnkDg4/WjPydjn1NBDHjPfkds0hOMkZA9KkoGGOMDn3phI9v5U4henOfr2pvrgk5OKdgMDxnpcOteHpre484pG25RDHvfPTp6dzXgl9baRb6zdahO76ncAr5ZjiO12PUhTkKFIHFez+PdZsTZXGjQS6jc6q6s72mmKcsoOPLlccorHggcnNeV3dzfaDrcsTmwsdX3q90yRiX7OSMrb7uS2B1YV7uWRlGLXfp+vVnZh5NrlLur+LBP9k0s2MaTWNt5ttbovM5YEEux7H09qh0HxV4m07RoNMu7awS3hAkijUAs+ck4xycZ6ViX08V6b+/s47SyaeRUjLSELEW4cKx++Tgcds1VstOs7G/tftx1A6ZHmKQWzD7TGxPzE45bjGK9ZUIctnH8Ov8AX9bHTypxu/6/r/hjrvDXhvVNfjl1m6vGgt7hBOso2q7qvA+QfKBxwCM+9Hh7xf8A8IfBPo19pwufLm+zpPCVbzI5Dy3Q5bHWuf1g6YNQmTwi+qnR/s5W4hlDhoT33H/a7+mak8F6rpGi6nd3N5bzG9iGLRoIg6Qx4xtKjoQOSe+KmdJzhJyV10jtb8SZRco+9t5b/wBf10161tdj8I+NNfa30m7vNAmuEe1htoswqxQbxjHU8dPSuJ8Y6xpur38WoWED2NrDcDzLgJsMSnrCB1Yk5JzXo9r8QNIh04m2tLu7C53XkVvIke/13Y7ZHNcv4jgu/E0ltqGjaK0RtZQft10VQzt3IXo4z/Eaww/7ualUjbpe/byIgrvVP+upy0Z0ma8nh1qW9gt3heW0a3JbfKpJj2j+5jGc9D6VsWmkC/8AD+maxc68w1DWtRjg1G280DcGfG5sdOOxrPs9P1LUJNX1hrB7t7KZnvraM7JYkH38AcBDzwOa6Lxdoej3mo+E4PBZWL+1Yt8gQbzt6Fie+OxrpnUSko3t3fRaX1/rWxpUknNWer8u39XNfw3eyeDG1m0X7Rd6BYalttrq3UMqPj5hJj+HHf2qr4q8QaTq+paVPaajmMXhknFspcwrjjaT1z6VNpGieIm/4SHwlpepwHTNMCyyQ3EQ3y/xFd3Y5AH0NQRTWXjgPbM1h4V0WwUPKyuvmzTgYwp/u8c461ypQ53U381vZrS6tq35aGScU3KT+en9fg/0fQ+O5tUaDStThKJp4cCNETDyHaArH06dK1jIJdOusSNH51pgGNs445GfUnvXBaU/i3xhYGzGuad9ltmMUT3JERbZ3A64xiqWoXl7aXUuh397BDBIUNx9jk3JIh5JU9sd8VKw10qd9Y9l0KjC6UVa68zpvCOpaXB4UsbPAV7bfvlX97GvOThe57fjW7p1/ZXaI0bB5Nu5oIvlfyyeGdR24rP8UeGtGg0bSX0Nl+13E8cX2mCYYeIn5+e7fWsbxBptx4J8RGS6lga1nYeXcgBXkX+5IR1b3rPlp1n7t1J3sn/X+QvdnrGXf+v6udBdaSbu8uJFmjeSVtoQ5Ck4GB7cVX8PH+wlFrezNaPIDcWTMSwdM4ce2Dn8Kpat4jtLzQ72C1LQSOQ+0xsu0A9Q3Y+3esfxP4muPFVto8cNsbTR7FxBJOXPmsTw3PbPpWlOlUkuWfw/1Ydpv3WtPyJZNMu/GIvrwGC1tluFWz+0Ao11Go/1WFxuVjwWq1qXiWyk8X2M2lWL6NNLamDUI2AQW8i42jHQjrz3zXoejPa20En2mUQeRD5EKMNqxxY42D1JxnFcdpWi6fqHizU7u5tdzQxpbz27NlZ35JZm6YAxx71nCupNucdIrT56f1frroQpRcnfp/X9bFga3BY2UlzqEii5dyNkY++cDAUj16+9Yd5qd7Hf2Wp3lncC0jDO7uu1lc8BgOg4xmtnwdokOmeJdasbl1NnGqSQMOSobJ2Kfw6jsBUGtz/8JNFqNhozxW+nW7C4lu8lg8qfdtwO/PU9qcXBTaS00u/XovMtOKdt/wDL+v8AIp6rfX3iXSrjTPD6lLcR777UDNlCvaEe/bFZsNleWWoW3hnxRq7xWawA28VnIRFdK2PkDdeO4Jrovha0MGiW10luiRzzPLJNJKC0jgED5T1HbNXNFkF74w1oSRWyR2VvFCqqwYiNjkvg98gfMPWm6rpucIrRfffbfXX9NLBJqN1bb8/62/q/HeJPDeg3kZn0HxA0cFqVDaejMzJIOkaIT1OM5HvVSz8TS6f4P1PSMFZbi4ZomJ2rbMeo3/mSD611vxSj0I6bciKwkbWDtNrcrhZNw7k9dmCPm6VH4TvdKsNNi0LSNMOr61MUeWV4y0LykZJd+gVc4z14rSNZuipSi3r1a087gneN5XfyS/rfcwPAugXmu6bdGPVZkst48qC2JDXJH3i5PG0cjjrXSXPhi68Pt5/hmZrZGCvPptw5kS9YdWz/AAnGfxrB8KarrVlrN94d0q3sLq5jlknjCSbIrdix3Ir9WU+nauzvdN8VX0EDf2nbQqAD5lvbjcpPBTew+YDoDWWInONX3ppRfTy9LfmOUve6W/r5/wBaGP4H1mPxLqWoavfW5+32bCBbENgW8P8AFx1bJAz9KvfECyt9WtYNNs7UtLd3kf2ScDa0PGXx3HbgVy/i/wAM33htF1PQdRuyFmWOdbx9sgc/3X/iGecDitY+DNZvDa3Os+Ibg6kimW1RG2xBz/fx7d6TVJTVeMrLorbW+f8AXmKyTUk9P68vv8jT8XeGNNtvAl/FpNnC13HD5yy9QjKMlz/t+5zTdQi8Ir4GsLvVbWxaBlW4ItFA3MRj5SuDuycYHenJ4Wa5sJ4L/XdbubF7cNKIZBD5ZxyGIxvFcFb6L/wiPjeZfJvbrStNCOHlh3/Zw65BKjo2cc0qMYVFy87bi79r+V73CPPLaWvz/r/hyTwGs3hvx7GdaW50+e8iY2z3TBVVM8RuT6jjPqRXT+K4B4z8Qvp1jLFBpmmlZtQkVhsXcPlSPs7DBOfesv4na14b8SeHVh06OO+1WXaEbzDiIk9R74ByDVjwNcW1h4EeKPULPTboSNI9xeJ5qI6ABWaLvxkADjoa3qKcksQ4tT2t+ttX5Ck/+XqX9f1t5+Rc1a/1HwgsEQuZNY0iRXaGaRmSeDHUO4P3cdAau+CrNvFt4+valalIo4vK0+O7iDRxwg/K8fqwOMk5zWd4k1ddU+HV/c2ontbW+CvNJKu1rjaxyQp/hzkgDtipfDlxr2teELdNNjttMs7C1Fqbi5kPmOSOHUD16gng1jOLdG7snezf/DdW99wWkeZKz7/1ou2n/AE8caLaafFNrlta2Fnd2E6M/kgxfbTnOIgDjtnp2q1Z+O7G909JmFhJM7AyJMRHt/4Ceh9q1YNMiNxBq2pyXOtSNGIo3uowsEb92iTonTkCual0PTtX+IUltPZJdWenwieQsPus2cJj+VTTlTnDlmr8ut/0+/8AroUnzfG9V/Vv6/4JLd+MNJtri2uJra2+xF2zbpKGc+pTAxnPUGsbxH41uLlfIdm0zTnIiuZEQ+dNCTkBQeMhePevTdO0C2ks4rpbTTLaB0ZCzQhgozjBPZhjrXLfEDWrGztW0ixdNT1K9hEUAnQNhBw7fgM4z+FOhVpyqJQh877fh0+8cZU5S5Um3/XyOR8faRpfhGKzTQb7K3DOZMnfJGGU43L3GTn8KzfAug6ZHdPca5cJFpduAEVxue4cgnJH90enfNZ2mSO+q+VFEUsrfbH5uNzJ/eTPqeue2K6zwn4ej1S4vr0O0enzTP5illklZVGNi9iOcn8a7ZyVOk4Sk/N9X/W3X16m8oyilzPVf1p6nWeD7/RoPF+jPBHqiIfMtYnmVEiLNyDsAyFxjGPavWV+XAPUfzrxG98OS2N1p+sRah9ot9PZYpIpx91c5QxMOhAOK9sim+0wpMoO2RQwOfX+teDjlFuMoaq1vuf/AATzsUve5r/19yJB0Hbn9aXazklGVfXJpOhBPOT16im4B4KjAHGeK4NtTlKeegHXg5pefl44ob73A47YpM+wA6eufpSSARuFJJGevIPA9KaeCMAKQePrTmxknnOeDmmqMsASP89atIVzjdT01Uu9VvNKszbag7q5mWUiW5kjcFAV6eWcDJzXlviDwtq9/e6lqE1ybq7u7jyLpmi3NEVIC7WHGOSMjnGa9JHjexXxElpMow6N9ov5D5aW/OVQA8+31qyPHOli7ktrUweQEaVZvMCqVHBLcHBzjAr1sO8RQ+CP9f1+h1wk47xu/wCv6/4B5nDpMmkrcTXeg2mrWyOsTWzMQ/y9THxkKeMk46VT1PTZj4vs7DT7SXSodZZfMtGyRCSPlAYdOnSur1bxtBc6j5gsWhgQ4e8gUMXTGQeSOprj5td1fX763NpFcWcsd2l3F5Kb5Sw4ViTgDgV6lJ1X70klp3+46/fkr2t/X3fqX9P1CTQLnXNN1fTZ5Zri2ktC0ZAktQAQXx1dSaueBPEmgafoC6fqEVtHPFH5BldgpE79ZM/xLjr6dKXX18Ualq+qXt1osKPdYjKJKEkTjt14x15rlNUFzp2mz6XqGnhYIpo5jdSwb5IkByVDrnIPTpVRjTrRtK13a9n/AF/wSeTmV1u/P+vzOr8J+NdJ0vQbzR9SaC6l+0tDGIomdDATnzAAPu9citbT9fm0W/1S18JaRLqulRFPs0/mbURWALRru98kY6ZqhqXjKOy0dINS8KpZahdIlzFOuw+fbZG3BHTIBGPeqvhvxBNYeI3itNE1aTTriY3NlAEw9uxUZUg8EccZIrCVNSUpuO/95We3axnyN3dmZurLr+m+IbvxDFDJoj3CCJldwyOpGNsnqPesTw1fT+HtV0rVtLuIZ9Y2SJ9ikYqECnGJOOfUYrpvHni3Vdf0qeF9NurKEkpI86DaVB/1Y+pzzV/RLXwVN4Sup2lj+0OI3LhwskcijOeTkknsOK6IzkqS9pG/Sy108/8Ahy21CP7xWvucmt5bahcya3rOovMb2+K3kNkSsskIB+mxC21QT6muk1Lwzp2m+FYvtDRP4jvpc2Gnxy72tAx+VRj72F5JOB1pv9mHSvEmueEbS3htpdQuI5xdja7RW4APlp6sTjjiu98P+CtJ0K8/tLUBJLcg7VkmffIfTPp9B09awxGJjBJpvukuq6ei/wAifactne3p17WMRfhzY/2ZA1x5rSrFuml37DI564X9PwrmJtC0ey8WCwvbx4bMx5VnUkvJ1EfGce+a7jxVrLJfKDhp1UyAE7VSKuZls5fFF9KLm1je3CZG19h3dmLY6+1Y0KlWzlUlo/60NITm1eTNPxJ4B0SGwnvdHlubZlDXOyEcn5SQAucKPeuVvrG/k8MabrOrX326xG1Wjnz50UTNgYPQnPcVLbeH9V/tptMtbyVIzGpdbiY/NHg/I3tW3BFrfhTToo3nttf0aUeVdadJHiVIueIm9s5BrSM3TSjz8z8+3a+tv61H70Utbv8AEn8SeB9NTwpdXNhasrpEHSaSbJYjkBgeBkHqa1tIis/EPhaO4miEGnzRRRukXHlHaP3g9wa5HULW80/wPqM3hW6XxB4QuMFop3P2uwJ4Jcd8YOK2LXxfpD+GWttFeeXECH7JtxOzKoXC9iOM54rGcajho27PfqvXt+XmYqblG9+v9fPyKnh2+1qWFrPTrm38i2laGPVrxSzOQePKU9SRwT0FWPDmu23g+LVbHW7mGO9hvJJd5jJNyXAOVHX+H6Vb0fU9N8HfDqSOcRTaiAdsQJYmXqXyRgDPOBVL4b6LDqIh1++khu9T1N3VJrgbzER1wvQZFVNxcZymvdvp3b/r/gDfK73VkY17qN9q2vtcyaZeaNoerLHaS3Iy7SgEnB/uliccV6RrF/pHh3w3thjs4UiUpDanKoHxyG9WHYdaxfiNMIfCl8V1F0hjZPJAAO+cE4C+mPpWN4U083Phy48WeL75Z7G2y8ELHcu7oWdcffz35qZKNaEaklZJ2SXXsD5ZJO9l/VjC8O+IJfD8UltJHby29/I0qox5yefkb+HA7d6k1C71nXdYvNW0nR5o5ogsImt3Hzxr1QsSAT3/AArpdC8PDVLiS91nRo3lmG2z06Q7fssJ5Vmx1JFNhW88FayssaiDRLuYxyWYy32V/wC8T02npnPet3XpubdNLn/M0bTbaX9f1/TOK1qK3v7GTVJ/FaXepp8j2JhdZCv9xiQDkH27VuaP4s/tTSNO8LJHb6dpc7BL65WUAsigZUHqM+p6V3Hj02kXhy7uIraCG5eEqAsSszlsbQD3PvWTrugeFtN8KWR1e1hivFtowUhbDibaMjb1LZ59OamOJjVjFTi27u22nn02M+aEkub8jWOj6FdaLY6ZYP5cED/aw8LjMLAfKwcdSOPqKwNJ8bTRo9rd2+oXk8TmNbywQlbo54Yj+E4HauP8JWNtda/cWuoSSwWquCkU7lEXPIbI5OT26CvWNOtI9JgjtYGNrbnIQqNwB6k59KxrRhQvGXvX1/pjlFR0lqzjPFV7ealJpGfDeoy2drcfa7gspM0y/QdFHB9eOldVL4m06LQGu/Nju4rqcgCMlpZieAoXqu3pzjpW4YoYbWOeK9lVh8y3St/rG9APQ+lcT4btLWLx94jVYraAwxpLOGYII94y3XOCeuRWcZwrR1j8P+fz7/10m8ZR8kdFLqU1vpKC0tZNUEAwlrGvliQ925wWA7isz4c6hZReFXv9RngR/Nc3E8rD52DZO4Njkdh6VKnie41XVGtvDAiMtr/qLxxttYCeu8n73HQDrWMngqKxCXsF61/fi4Mk8d5H/osrnqNo6HPQ80lCCg6dXRuz8/n2/O/QXLo09LnPazZ2PjP4iQQaBPa2CiIM1wYtoOTyUH8f1pus6Jf+DtWsm1E291Zm4MhBXbDJjouTgBj1APBwea6K4trrxX4lt7y1t/8AhGtQ0n/R52XB89j92KLHG0AE8+tVvHeka2mn2l/rN4NYs9NuDeXGnzoI1lhGBjcCcnrxxiuyFa0407pK1rb/AI+fqa88lo/u6mT448U6Vry2unRxSpYSTJLO0yMjR4x+76YBJ5x78Zr0+CWxe7S6miEzwWiRW0O0qXLEBVKnHP16V4bqc9vNqOpw2tu+kaPe+VOIbobvKTqMk8/ezgjPFa3/AAmGr2tpBbzasZbIKQ6rtMhhJwwD+u3O304rStg/aQjGnpb9f16DlSbiuX/g/wBf0j0rUfEJvdUktNPhuZdXtRsmDHZBp7gghmP8XoUGeM1xnn6p4L1aa91QW+oRao2bi6gbaob1XONreg6VpaH4ztfDtsljZaJdyeUdoFyAbhi3QNz827+9XLeMdaufE/2G3udPjgjid0lRZsRc9NwxkOOR+NRh6MlLlcfc9Vf+u1vx3Jp05J25dP6/r8+ppav48vVMj6FpjQEuBby3bktI+MMFToT33ZxzVLw9pwuYNT1G8u4rJLJfOVzb77m+kkP3VB4MYJ2+3fFVdP024uNTNnpEbT6nbQqXkuGzHZRDoEH8T9fwxS3/AIW1ptPS2u9fh+wlp54EdvJiUYLu+7GTuOcL6mulKmvcg0r283+v9Xt0NZRVN2vr/Xf/AC87XNOz8P3Ze3lb5LC5jEyTSyjfcW24EIidcdBnrzXdW3iPQ9OZ5NBsLieSJhBi3iLC2UjkZIABJwM/hVHRn8NppnhnVV1LzptFtlsUlnlAWCTZnbtxzkKcfQVq2fiewXUok02yvbpLzLK8EISE7u5zgnkdea8yvKU/ii9O+n3/AC/qxjKrKro18lcSTUvEeqkwJpKWMLxhRNdEMYjubOYlzliMcGux8MnGi2aBnICMoLxGMnDHt2HpUFnJqMLKdVuLa3IG5oY1Luy/3i1GneIIrrxDNpBTN3Gm9sMMquflLjtntjNebVbmnypWWun9f18zmm7xskbqjoOMdqEJA4RvwOKQEYznHPrTk3c7Cy+1cqvfQwKQ6ndxk549KbI+FY4OVGcKOW+nvQfl6545GP8ACjOBgEf/AF6aRAE8d8e46ex96aec4zx0HrQcNkA5pu9EDSTNujRS7c9QBVIDhvEngaLVvEF1dwSTWlzdDzd4hEtvNt7Sbs7T9OtcwfBWr2Ec73EFn58TRtAscBdbnscc9s1mXXirxCNSt7k+IpDbvNugSNgtsoz8sDgcnPC7vxr0rwX4kXxNaRrLbtb6xGztJbRnaARxgHtnNevJYjD0073X5Hoc9alD3rNK3qv6+fkzipPBsNvMZbpL+KGOTdM11gIYzzxjHfoK6KJoLoTXEci2VuoCLdYH7wgcIoGOgxWpf6/aTWF5FrGmXMAilaOOC5YA3W0As8Z7KOme5rk9Xgh1WKAWerW1toxKyW8akKIdwziUn3z9aISqVrc9/Xf/AD/rzCFV1F72n9f1v+htSSadE0Tx3k8uY1lDyKACP7351kya7oWlxuuo6lFcNIxeSGNfMOOykV59OsAuWUNLqJY7I2gBUOoPPJ4AH61HdR3c086xaVFZxgDdKHG6THTco5Nd8cHD7TZvGhdb/gbviHUJfGul6HaaFayXWsWTyzMihU+yRBl2AsRgg84FbtldfEWKzZ4pdIiABYo4LOx6bPr3/Guf8O69b6FYnT7bQrg+Z888vmAPJJ3PqF6YHbFd/wCHPFdtdWkPlS27NLk+TLhJEA4O4ev161FdVKa5YQTjfrZ/8N+H3mVROMbON15/ecj4tvvF2p2Y03XzYJpbKqz31lEZAq4yVIz2PBNUfCQ8ARaZfR6/cSrds6tNJJCEyQcrs44UHFek3t1ZKwuMppnmOIwZm4c4646DNee+K9b0nXI4bOO1eRTJ/pN60QDqFPHljHzEnj8aVCUq0eTlsvLT+v8AhhQfMuWKa9P6/UxNZbQtN8Q2d94VvZGtiRewPM53hwQDHz0LZ4znpXf6x4yS/wBOW9tGj/tF2XzbUoWMKnOSozyelch8P7NLm/upZtJs7+ymLReXO4SQEKThSeQDtAyOAcVmQXFxo16uq6XoWoWkcc/mql9k7o+Qyb+jHjitqlOE5qL3js2979H1KcVJqK1a/FHR3sV/HLam9t5YI7h/MLykMZgv3VP91R6V32gW0UyRwNuLtAZRhcBzjgj+dQXtlY+MPCianpDb7GeDDhRmSF/4h6hgc5rn/COq3Gl36aXqks7+Qnl2bO3BPoD349a8+o3XptbSjuief2kLxMbXpZ9O1gyW9z5kyYZd0Z/eZ+8PfFdJaeN7F7ZGvsQ5AX7M8O4gdypBziutu7S1kifUN8cZuIthZl457D0PrXDXV54a09p9Nu4o45Ex5jSR9M9MHtn+VEJxxEeVwbaK541Vs7mB40uNNa6a98K3LDUbtRE8FkMLPFjkMOmQPX3qOwZ/CU+janNd2N7aX1nJEDAo82MgH5Pov5k96qwxWep+NYNKsm8qzuJfkPmGPzZAB8oPYc9utYmo28Fve61aXN1dIbC6ZLNYB5kRw53lj2x+pr0oU48qpPa356fgaJ291dd/Nf13/AnXUDfy6bFrOoyvZJMvml4QhjZujY7Zzg5z1r0y6kt7WNWlljsNKgXzGaPEYdRxwfVs44ryyO5inuIwIJLkEYeEjeXXuzAdWI6elN1G2eWyZLYSPbKnyzuzPHbZP+rQE4DBd3HWnUoKo1zaf1/XctwT+Fqx2uk6XdeNtUa+vIWtrEoyWkMY2sQOh5yMAdWxk59qTTtBvW1+Xw5d3b3GjWESX4icAF8/wn1XOeKTV/FEt/qOi2PgiGZotNtlyuNwmBHKuB7hjn39qzdK8S20PjK+1K7tdsEtusbIpJEbKcYb1yQQax5azjLppou3b00MU5SWi06HsGnyx2lvvvp/LmlwCCMtHH2B9sVx3j+/m1K6tdGsn+bVpPLcMcGOFefmX1OOKw/F3isanfQz6Qk0Mi/PKwc4cMO6D+EDua5pJbfUbnUrjVtTurLULfa1rbtE8txeOfu+Ww6L2/GufD4NwftZb9v6+/8AMmNK3vy0/r0Nbxp4eOm6vY6Hod7c3N7IoLLLPvRG428/wng/lXodn4a0fRrdb6/mtxe7VmlnnlMhRwoDHLE8ZHQV5Pqek63pVjHeanp76WJ5FXzi/mb5DyCW+8CBnvxXodj4W0K50EXt3M+p70xumlZ3fAyWxnCrnmrxLvTgnNtbaa39Xt6FVLxS1/AwfEVjfaxbXPiCC0FtBFultpMfvXjTgtt6FWI4HvU9nB4j0fQLbXN0Or6SYxLOkTH5Nx/hBzz6+ldb4L1FNQ8KaffrB5cu8rBCfm3oDt+QVx1n4ztfC3hnWfDEytf3K3EltaNCAEaJ+7dsiohUqzvSjFOz28tvw73E5SfuqN7P+vmaFp43+2PBa+H9Fk1HUZwWiilO2K3f+LI/2Rg56HNYPiDwBfQaNd6tPeXGpakSZp1jXAuF/iUY7DoM0fDue9jkuDo+jS6pBIiWr3MDiMptOWyT1HIyPYV0Gu/Ea6t7WYXeg3VrIjmLLjbG5HCMG9OvHtWjVSnV5KCVuuur/UrlcJWgr93/AFobWkatpJ8LaTPbCxaJo8izU7RGQMbZPU/Wr1/4msIkjSSeGSMjL28algz9kB9c1y2gfDm0uvDclzo3iIy3U7G4mmgAkt5GxnZtOdp9xijwFKLq1lvLh1S8mUwiL+CNQfmUDsc9+vrXLOlRfNKN3Z7bfp6+fzMrRkr3v/X9f5i6Fc6zpt1qDNoN1tvLs3kOw73hwCNpB4ycj8KXxnq7eILmz8O6aH/taco7w3MflLDj5ijdevH6V31lCl6FkJl86MeUV8z7pxwxI6/WuO8TSvp+paRqSwLcXsEkv2nbkvNBwCzeuCPx/Cpp1VUqc3KuZfnbT8gTUpabmRqjz6x438Mp4y0X+y4V8xUiZlcSsvRW4GB6Z60yGw0yHU/FMFpoR1/RnnQg25VTDKR/qx7d+Ku/FbXNL1DwvaXQuI3V7iF1eF9zsu75iO4wPWrhjh0G0t/EnhcW9xYi2E11YxgL5gLAo6npuUY46kCuhSl7OL5bN6W1S0d+91941J8qt93/AATzTWkutO8WJcw2+p2MzSKlg0xEkkSDgLno4yQAOvPWraaLf+IRqviASwJfwTubnTHXbcSOijkR/Tn2rUv9YsPFfj6yN7cNDptuoeJzIYz5uQQQB90AjIHcin/EvS4dJ1e3v7LUZhqd87QPfqNrzIV5kKnjj7p9ciu5VZXjCStJr1+Wv49TVSaso6OxL4F0GTxPqN5Laak2m2TwwTXMIIzdkLnO7Hy7c4IHpUPia18Pae9vcalqE+uXyszQwrLugkYdtoxtjz75PrXPJH5V5pdtBeC20yWJkdlmMS+YoGcnPXBB/HFZ1na29mVvI4n1PQLcvCzbcpLJ0Emwdh79+aapPm5nJ26Lbytfz/rpa5Rk6re/XT0PSZNc8KToHtYbadJBHcvBBak7JFUkM69M8bfxrpH1u/UTXOjaPfXVrOqLDdIyxgj+JUQg7BnAz9az7LxFpOnm5v8A7TYiZIjCtqECOApAHyjuc9DV0+MdL1FYka7uYoZCN0gt8KcddoA49K8ucJXuqei73/SxhL3l1a/ryMnWrvUxfXc3iWK/0a2ni8uP7IfOt0UAczSfeAz/AHcVufDq3tr3X5dTsm82xtLMRR3PeaZjhmyeWAHAB6Vmya9falZu2hW00MKXfkXFzf5VNndVHqQQRmug+FdpbwadrTWXntbPeMFnlOfNbOSVHYDpj2rHENqi09Htpt/w/wA9rmdTSD+7+v8AgnbLgEY256YpyOEyCxHpjmmZAyTwD1wKkiBxjceAOleZSTc0o7nIyhnAPIPakzjG30GPWgHgMCB747UMfoPXFOxAjdu49DUN1OLeFnkcBcEHcMj8v6VK2QRgZycAVwXjvxDdLfHSdDngXysJfyy8eSOoKnpnnH4VtRourJRRdODm+VHO+JtP0++umn0tWElxMqagomxb2u4/K6oem79Ca43TNa1Gz0+5vmgk0zUZmktjO8RIaOMjAz1BxnLVsXl3aaTe3Fnb2UmoavfSFTbeZ8k3GTIX6Mg6ZFaHhfRrbU737Hq0t2ZCwnggg4gllX7xUnoAOD6170LUoe9ql/X9eXTQ9LmtHe6X9fO39MreIvEen+ITZG7nNxcyJFFEsJJWRFzlR3zk8mqL6ZcXWqpp2lwLLdsjyOyx5EEYPJUeorstX8PWd7o8lnFp0EEoLTW8owGuGyA0fsPcVzFuZNIuYDLHc2ghUxBy2ZLZScMrEdUOOp59qdGpFxtT0t0/r+vwKhP3bQ6HUaT4ct7DSRPPdo9vBhZr65OGRvRQPvGtiHQrDWPO1GyvoLho5mYNHAF/eH++faue8U6vbS29pp9nA99eRyhrNIVO2RcZLYPDfnXTfDSxuLHRrm3vWt2uZ385lizwCej8dR0rirc8aftZPX9DnnKUYc99fT+v6+8ytQsHW+lhvraMXEjCSRo0G1zjgj8AeKw77R9Kjt9Y+0WyrcLp0l0ksh3eW4I2kAdCeR+FdFq8UeqT6jbz3F0m6X5Vj42lRwSfT/69ebG2sW1O3OrX1w2mON0iqCEh+YrgEZ3E4/DNdOGTktX9xrC7W9vQXSvDeqeI7K0vpnCQT9FmJeRx3KDso6Z74r0Gw8BaRplut29uqtC4kE19IXdl6bWUZ+X2q1Z31tp9xa3Mc8EEEMRgt0dhtGRwo+lU4PH9mBD9suiZJZRC8UiAhGzjcxzgJ+vtU1amJrfBoiKlScl7q0M+58CeHprdY0mRHkmMqXCSlHweSgz0QDNc7p0F5qc+qWVgNT1nwyshhEc1xxGy4PmxbjjcMECu/wBTi03xXo+oN5MO62DRtNASU3Y+VkPsev1rD8GanD/ZcGlvGtpcWK+XIufmllznkdjg5op1qihK9210fT+vwEndXlrb8PM5n+zLuy1+PUPClvrNlkHy5Lx1SRmyQ+/JwwJz71LfanqMsgPiHT4oLgRP/Z72x2gzc46cFPUd69Wiv4l8ovbI10flV2UkD6Dsa4LxB/wlOt6u9la6Y0mm28gmtX2YV5Mfxt1A9BiilifaStUSSXVvX5NjjLmeq+ZS/wCE8sZNEaC3gbT7q1byo1J3xRN3J9F69an8Cx6E6apfeJpomvkVnMrtvVGOOIx/HkYxXI2941p4dutG1BBEPtDBrqVtzLg5dcAHdnoDnHNZUswlkQwWyW1vtLJ5XJ2LwMj15rtWFjKLhH3U30f9fcVNKMd7X+/+vUfO6oZQnyxpOXgzlfKJ6Lx0J6n647VDLNIkMiRuMAAhOoQnrlu/PWoPKkuJIsF5b0j92gUsSOy7R+PJxXVaX8O9c1A28jxLZxtyz3LbSB6lfSumpUp0VepKxLnUmrrRHN2k/wBruPs/202W4CJZ4Uw0QPVvXPpWjfXEPmXsmn+Y2lxyoq2LncrjoZH9GJ5B7V19z8LtVnhh0+xu7K5EQci4ZQjM57EjOR2rj7c3ul6ne6NqsQh523i7RukI+4VzjIz3FZRr0q1/Zu9ugUab5rxkn/w5b0d9Ru7fVNC8OmWO2lb7XPFIwQNs54kHOB6dK6Dwsp1jSm0nS7H7BZyYl1TVn/e3ByfuxnsG/TrWNomsz+EJNUS3httQF5bm3fL8Rk8scjkDDDPGOKv+DfEsWjaPJYJZ3GoKji4ikgGAdw6OP4QDwDWVeM5Rbgu1v830v2v6mtRNSen/AAT03QdC03Q7TybJPssKnBWMB5WX0kY9c+lcp48mjtX0e/LN/aMc2LdcbZZYx1QgdBg4qWI+ML66luSkOkIHDmJlLIjFcbiw4PX86p+Ebmw0jXtbm8V3Sx6lADG0rDzDNGecR+5xzjmvNp03GTqc3M10Wu5mrx96Rd8Z+KtVfQZLK58PSRtclYyboo8YLD5V4J59K57VvCOt+EPCou7rVGVGRTJp8DkbN3bPfPftV3X9dn8YLBZ6DpZttPWVXE8vBjkXO0E9ATn69OK0YNAvNURW8WXs94IpCyWyNhA3fPr7VtGXsIxTtHW7S1b/AB/UqKcIrSy6p/5FTRvB/iK50eKOPxLb2EE/SygbzGjyc4U9uOTVPwVY67ZeIdYj0SPRppLedUa7vIwxLkH7pHtknHcV0cnhbQ2HzW89uvLOLeRsHjj8D7dqoWeniw1+D+zpX0+F7Hzr2G3O5dgIwPUMePes1X54yV737pW/4I73T8/K35bklxceIPBGsa1rl1p1ldQajt+0Q2hKMCvAfHcHLZFXbzUfEmrzafrTW2n2VlZ/vktbh9zXSkYAyM4H9a39X0+CbSHhdpGgvItp3t8656Ef1rkvCniO20u3+w6jc2o1PTWeBjJkpJEAMZOMbscde1ZQk6sOeMby226Wt6eRmlGS5ra/Md4nn0eyhS5tLDU/Curx25jt5olH2clhkK23K5Oeprk/h9Lqf9vGGwt0uZ4EkuhDcS7JLgt99kY8Nyc4/GvS9el0rUtAmllMcNpJbyO8wdZFUFeoGeufXFcLea7o9/8ADDQWtp5LPW7SQLavGC9xuXjd2ypHWt8PKTpcnLu7d7b/AIfMcWnG3V9/6v8A5HTQ+IrWS/j025tbiy1khA9lMAoOT2buCMnPtXUQQRzx34WURumcJGf9WB0H+71/OvLtZvdT8Q6la2/jqM6PY2cqpdX8MWHMxU7DuH3QR07da1tQu9c0TWrPS7Say8Uo8RCeQcT7MZDSEZBwCBk4zis6mGTsotJ2v5fft99rdxOD2vr/AF8mF2LLSfiXpuqXekG+k1Cz8q1tIFC5m6DA6DK4yTWZpfg1rrxfJa68rW6amr3kVpZybYrZ933PbHc9KyU8TX+reMLG/uIIxfQBrW0tH+RNw4ZWPY57ivQNU0XWtQuodT1HVxaXMI2R/Zof3W49Vc5yyHoeK3qc1CybSbja+vTa3ki3zR66mD4f8M6JPonibSLu1kj+yXskQmnX5wNpZCG/hHB9jXGR2Wk3PhPTxolrqVz4pUE3j4ZrdYkZv73B4AIC571o+JbTW9Y0H/hKbm6jWXV5006CwtxtR05CuOeTwetb+l6n4msvAt6LXRtPNlo8nkz72IlDoBhioHbd681spOC5lK7b2vpfZ+uoa6O/XuvuOV0TSdU8RXV1Bo09nN5EQn3XUDNkMTkYIwpXHX3qCKWe/wBJDoptGaZ1eOIgEMv3lyeOoOK1vBnjS58EQX9/JYi5GrReYJETBEuSQMdlOcioGM+jWdlYlTqlxhNUuUhibzAzfMUPHzLk4LVs3NTeit0+7W/ztudcak+aUZbF+6t7CygiYw+ZenbI7OoiSBsHDMf4gPTmrNvp2uAJcQQtNpMzkTCKMrNMSOi7sYU8HA7U1fB+q6pave3V9byXl0pM8Eik/LjcBn1BA7dav6N4wvJ7WWfU4pJjEECTW/DMynaE2nG0jnkZzXM5Nx/dtS73/T8diJTk1aPzLJsZ3lst+k3hutGVlshDIJPMdvmMThSQRhurcV6R4E0u80nw2lvqMax3ksz3DQq24RAn5Vz9MVyP/CaaiYoxCiafcs4eS4uysUIBPCE55duwrtvC+pf2toUN5JCbe4DvHPCf4XDHOP5/jXk4z2nJaSSV+mvf/gs4K11G1rK5sDIZQp57ZNORgozuxn0FMHbacep/rSrg/wAQUfzrz4q8rHK9imMs317Gk6Zz06fWkHXgHjrikOeM8EdeKszHRqzSBUbYxyFbqF968e1uC8Phx9R1GyWexmnmjW4LZdNrkK5VQNzEjOD616zeIJ7O6iYuFmidCyD5gCP4e2fSuY0Oy0Xwl4eOnQyXcyBUmuIrxvNuXLjC5HQdMYGOldeHqez1Su7r+v6RtRlyvQ8ui02K3vLQfaH+xR2klvGyfM+6Rt2V7heeQOldT4KW6j055L2eI6daSG202RWG+JTw+4dSPeneJX0vTtVW+aD7LDbqfJuXXckkbDlxjow9K4/WbrTr5rT7FCbZwxna8jlYBl67VHRsnBOa9eLdeNuj+f8AT/qx2fF7v9anrV/e2YntoLdoltbYfvJTwyk9ChPueazdW0UXNnPZOY/Ku1OZ1kzk56se9cbHrN/rVvBHLpMuoW7jnyoioIHX5vXpzVa11LX9Dukmk0u4toJTm2hmIkDcnCnPTHXHvWUMI4u0ZJNea/r8CVSnFaFCM6h4e1pbRWMs9rKPLjBLFHbgeX3ww7HgZ611a+M5bNPM1DQNRtnkfBlQ7QeOOx+prhYfFE2n+JZNSinaXVJsxTtNFgkdCo7LzxmvStN8U6NcDfPcMtzGyx/YriTbKpbhuDwV5611YiErJuHN6b/8N/WhdWzSclcwJ/FukeVJcN517JLuEscL7WUYI2t65459qg0m0uLvQvBjX9tPHYSzXKNDtGyRFIZAx4xncRnP8NdhquhaJOkiyWaJIg+WIW4CjP8AtLjtmuB8YNc6Wv8AYF3qN1/wi8gW8WIt80BHQKTztJzxms6M41LRpq349OnnqEWpW5N/PTozvNQ0LRo9LtxPFp7OitI0Rc/uc88EtyQDXN6rr+gQ2Y0vStNTVZJodu2KLKZ/2m67h1rL8PeDk1+L+09SmvFtnP7mGRizSIOMtngDjFdN4StYbL+0bXTnSOCKdZcgfcJGCqt1x2qGoU73bk18kO3LpKVzI8HzeI/C+lTww6Y1yPKM8ADqoh3H5lK/xZ9O2KTVNX8O30c15NDNpmtbFPmGMgn1AHccAZPI4r0o32leWEe2ZZMbsCPcwPqG75riPiWrPoUs5sZobi2uIzE5AkZxycE+nHSsqVb2tX3o2be6diYtSle1rlOz1XxdNpLT2FkV5Aiu73CkD1K98DgVg634i8QQyXdneatfRboVW5s4mAQEjIkDAZwepHbpXrHh++ebTbKe/gWeaaISqwXO4+mDwB6mvEfG2ppq/iLV762RYoXBh3qvyzBTt+T1GeM104SftKkk4pJdfmKPLJu8e/n/AMAwUuSIkEkoEWfKjC8k/XOePeuq8D+HP7d1ERzDZZQNiRVz++Pdd3btVDwBoUfiLxJJa3CMEihG+QYDQoP4uevOBj3r3ayg0/wroltZaXDI0KqdgIy8mOWlf6A5/KtsfjPZfuqfxP8Ar7zOMny80ndsi0rwvo/hxZpdLsIxeuN4dn3MPoDyAK5e/wDE2rQvch7S2lgEvkxyyOS7n6dvpWBf6tcXOuXdzo0119kDq63j8hyvI8zuNxJxjAxiuw0zxZomuXMEWrCPTtXddysqfJKwPRexb1rz/Yzpe9Nc/fuvzNuSVuea5vv0/r/h1cwpvFtxAkH2jT32KxyYWILP6+30p3iPXvDXiLQzPrFm11qduvlwyR/JcA/3cd/rXZ2GlobVPsNxHcBPm8rywF5OeAe9cD8RtOtrfQpL23t5Bc/aFSSWH5Xj3ZG0e5/lmroTpVKiio2d907Erkb00aOR0+OSC9Rppks5lQmO5ZQ+0HqrjvkYH4GrGl6jqOgajcS6JeQLA+d1xIm+G4QdcjHY59BVC5TVoILK9+wG10maVbf7dIu7dg4OwdCM55PeustvA81zq2saC1xNHfW0KXcEhOEkhcA7So4yTngCvQnOCV5vT7/6t/SOqpOmtHr/AF/X+Y6bxB45nslnSWR4dokCpECrKeeR0yBzya5SGCG8nS41CabybqUym+uRtj2Dlwjf3j04A716D4B1W4vfDV1pF1EIZLSYLcQuMBowcBlPXJHBql4w+y6R4Mj02YfvrSbz9Lhb522Z4BTsgGRk+orCFVxqOmopNvp27/10MIy5dErM622vtNgvLLT9FCK11b/aFyQwkCgctzgHBHufWult3SWBXiSFGUjcB/D6/nXh9xpMnh6x0vxLY31lOl6yq6KhAiY5OOD06iu28NeOLO7E880ltY3JOBayqcOoHv0NcGIwTa5qWv53/MynB25k7nY6ndJBNDIpVLeNmB3cDd2A9+1ed6NrelDxBeQ3uVnn2otwCfKR9w4z0PvU+t6zpmrXFto+matFdG5YSvJB8whwM4yeM/yNanikWeneHrTRNOWC/wBXvIPs1pZ7FJwxHJx0I5O72op0vZJQmneXysu7LhaKt3I9c1uS7msLHR72L+1ppWjmlK7haxgf6wdiCOBW7o2kWSaMLS1jgWxtpS224QO7MOSxJGTkkkfWuGs/C1lbeLl0bzri5ktrEm6igl2uknHGRyQMk/hWtf6zougWd5Y6Te32qXVuBIhjVpNp6Hc2flA9adSkpKNOlfvt36/5f8ODS0UH/X9MwPiTYWttDbr5FvYXep3vmkRFtvlDqSmcYPpgc1o+KtS8NNFoB0Gxub2S1kUpLbW+0soGHXJ/HjFZPh5JpdaTXfEMVx9lmBFneOd8IKtzvz0GeAe9eoRywrGwvGkBILRtGo8kPj+Hb39autP2XKvi5b9dNf8ALbc0m+RpfkcX4g1jVNd0+/1bSbLyNDu0+x6h9tTdMShA3RxZ4KAtyTzn2o0vwrd+HbaPXfh3dRGcRhXSdw63MP8AePcHIPTp0rQTVrLwz4unhu2gj/teAXE0lzlgGwRs993UfSsHRrm6m1jUrDwUYv7MlTYJboEi1kbO5Yl98Z56UJS5bRVo6PXZrz7+W5movlcUtPw/r7u/rzd7qUlxp1za6qlncTyaib9riJCtxAwA3Io6YOP1qxb+MvE2p6aulWDbnnje2cun74Lg7uemcZ5FXfGvhaXwvp1lula43jdczlskXHRcn3PFXYvCcJ8P6dc6XPdf2rDCL2NpifLmc/MAfQn7vHrXZ7Wi4KdrpvTT8bdOh0S9m4pr+v8AgfgYWn6/qGj6v4e/tqN/7K0hsx27W+w8gguTyCRnitSW+u/GHjfVbfw7cTado2pWwn1MOVXzgmfnGc4yCB26V0mu+LdO8TeGodLeylvdSvP3D2Ma/vonCngnoCDg5rgPGOk6tpElrqOqRQvC8KW7PbKUXcMjZMF74Aye+Kml78vfXLN6fje6XrrfvsZJRlrazMqC0gOtXcVhNcHRBLHLCsjgsVTh2TP3gDnjjOOK9B8LeIdF06aewl1hbu1slKC9lXY1zBnIRGxnGOcGvNEMlulgZHgmTU2lNskPLIy8eWR2HHy4xjNd7pmoeHdY0Ww0weFb+71MIY50t4+jDny89F+tbYqCkrSu16pW89fu/pFztKKSvpe/5nSaj4tS/vorDwuofUGUCK52/uLaE9Wbux/rVzR/CWkR3BtQBcXIyXnuXZRI57KBx3Nee+B9TutAvUZ9PkmuboC0NpMPLZdpyNrn+FcYPqa62x8bW93DMXW1kWDKutvJnZMThcg8gdenoK4a1CcPdo7eu/r+nQiUZQ92Jc1PSY/D0QDWivpImWW7tLhPtDlxnDxg/Uc849K6v4cW9xF4clmutwa7u3mRWOSq9Ov4VzWneM7Z5pLW6eGe0gAZz5xaWz7Euw5GTnAzXo1k6yWVvIowrIMAjGB6Y9vXvXn4tzjHlmtX1/r1/Lpqc1SXu2ZZGT8o6dMZpw3HldpPfIpo6Y6A56DtT4iVHy5B6HmuOjHmmkc7M4kE5wST1HekYk7jnax7nnaaUHJ4J5pCeMduOOwosQYnjLXX8P6Il1bRrLfTzrb2yOcqHPLM3sACa8duvHumWfiOUzXyX1uzMxltlL+WCeGZxwSDnjtXsHjWOxfw7cy6st0beBvOU2uDLuwRwD29favlDUYLHV9a8nwvZyywbCb0Rvti3joVPYYxnHU5xmvWwEYOm3JeX9df66nXh4px03fr+Hp1/wCGPZtf1PTfEtrbwaaWlsdrSK7OfJdurHcPT060nht0vbsahe/Zore5t2iUT/JEhXk9enAwPXNVU0tIPD0thqLXFvb21rF9nNooLzEY2iTHQ9Pr3oEL6ai2l5FHdxTjMbTfeWb+649Mc/hXYlFx5I/18/62NoppW/r1/pnoE1xsFszk2qlQUgVgFVTwBs9TjNcd4v1qdrVtP06BWaQtl5BkyOP7h/gUdye9a8/hbaEbUNXvC7Rja8C7VDdcg+g6Vg6t4Rvfsd39jmn1CORVaUSShSCOcgnn6jvmscOqMZJt/ft/XqZwUX1JvCeu+G0WDT9TWAswPm3E5DxPIBk5z0Ht61zHjPTtOtmhms9WjcyyKPJRhK4B/h9/bPSux07xJpvk29pPbHRrh2EhF1b/ALnI6tn09q1tPXw7erc3eLS7O50MmnqpUkg5AUnJ4zzWntJUZuoou3rdflb8TVVOV63PP9P07Vr9rmbw2L6WwtXw0vntHswPm3Rk4wPQetYWTqM5W8MtxPLMCk4HypzjHpjjgV2Os2UfhhJr/wAL6pNBaECOeLIIKvwzFCc8cDGK5jw1DFF4g06IMskUcuHZRkEE5GAPzx2rup1OaLmnp077dS6b3krfr8z2rTbEW+lXNlAk+be1VBvIbcy9MdhXDeHNTmtp7ozJEbM7ftLNIqqrMcb89GwTzivSPDskcsd59lKyRebwDkZ4+bg84rzXXNMh0PVrq1MRTSZvuxgZCsTk8+3pXkYZqUpwluzKk0+aL8jo9W1AWFr8u+SSXAtViGfM55b2UD1rGS4ju9TtZ9aeS809HPlxWww0rY42jvjn8qq6bYW5069v4Z2RLfEcELEK91uIBAX0rotD0u8txLd3LQi5UbIo0X93Ep6j2OO9atQpJ2/4P9f16U+SKtuzmbXUzYGbSS91Bp1/cFI74yHzIgeTE393OcVW+KM2npaaFpelw2kcNmZsLAu7yYyCDvI9fXtXS+JtChvrVhpSRW00jKHnPIYZ+6R39c1meBfDZluPE0NyrGBkeytpyAA+wE5x2+Yc1rGrSS9s9109dL/cK8b8/wCBxfgG8mt/FGnywv5bOTFMseSGXGVBHuQK9p8RwxXunubzfaxzRNHF5Z3MrcHB+pHIrwy90+5tdsagJewTcqrfek6+YD7YHFer+GPE9rrOnw26tIb+MB7iJvlNtIOCwPdTwfaqx0HKUa0OgVKTp8vbuUfAassN3FiBJ0PmsCuHwBtOf7uMfyqz4z8PIlhb6xpDZhhw0kcShZEOch1P94frXPa5rK6V49vZdMeJwsaLPPw6FmHKllyASMc16Fol3HqFsFW3xZ3a4KsMkyHu3YVzV1OnJVl1/qxTnKL9otjk/C2tr9mWPUHNtdQIztfvLjzl65btkfrXO+OvEEmuxtb6fBM2nW77pL/bt86Yq20rntjNdN4q020v/EGixXkOGunaeeHZtSQoDg56YPTHvUfjIQ6/rth4Z0+ZLPTdPs5NQubgx8BlU4z6gcD8a2pShzqoo7pvyXp6sSlFTUv6X9dDG1u7u/EXgyDTNCs57jTdGt43uJEjYLIepQdyxJJJ6cVow+L7e213RtQnu5ABp32W4MEfz27dmePr14rW+Gmr2Oj6TBYXs5trTWIftNqCrODLyrjOP4gFIFM+HrRaNqk6pdxXmlXE7xTzzgMVYfcIPUAng9qmpNJTi4aK9vO++uut/wAfIh8qTTW343/D+rb6nJaFp8PijxtqVxLvt7SP5miiLIJVbo2ex/vD61s6jpWi6X4l8Nw6cTcyzSy75pmyLiNR0cnrtOMLV6fwwNY8WeIbV5poNMhuQLe2tyIzk8u+/wDu57d6p+LvDVhpunS2FjaOmt3LhbIwPvZ5R83GcbQADknFV7eM5qPM9tui0/TqUmn1/rzK/jS10nRvFOiTW0sS2obffWkjAALnIkKdEOTgd6l+KMOm+I/EukNo22Se8icXD26g+Yo+6XHYjpk0+3stH0z4bXOu38cuq388gjn85QX89vk2k54UEVFY6ePBPirRLnU7hmjng8t3ZPlVlAOD328/epwaumruUbpX69wi7PmT1V/n/Xoc/dtrVvLpumzadFDc20Mn2L7FaiV2U5BZto3MPrUnhWHUn8RJHZavb2OqGFk+16gCA/8A0zGfuEdgfSupbxPO/wASm1rSokvYLW0aFEU4U5GWfPcA0/TdB03xHFcalrMkF5fXkx867tmIWD+6pUfdxVSrShH31a66Lq/J/ru+hXNo01b8fwOe1S306007Ube/tr0eN4ATHcwzs5ugf+WiODwOxBrqPCuqaDL8PrrToTBaXUFsTcLL8vluRyWzznOT75rAe0vvhz4nN1cWkN/ZOuFnmJYPF3APY9OuM1neNNM1PWtJuPF82nxaZoyuEjVj+9uUY/fb6dB60+WFXlTfutpp369ktfu6fgLlvZN+j6en9f8ABNzwD4h0Sz8GxWOrEMUOxkmPK888d0PXHenx3N29zJJ4XNzZ6dIrMY5oj5Mj/wB+JP4Qe/1rZ0PQrSPSLUQCCKSWGKczTLuYMQCAv+FdDNcxBjLfXnyxsqkRptKsemAf1xXHUqxU5OEdX31/C1vzFKUU31Oc8LxWl3aRXcFy8+o3LiG4N1zJDIvIjBP8APIqteyx6D4o/tKZntdP1V/s2pkwEpbzpykuegz7V1Gk3GkSy3EtncvIxuCzrIBxKBy2ByAPU8c1T8Y6LeatBdWduYGtr1d6vO+F3gfdB/vHtWSqr2rU9E97/wBdOnoTzJycXt/X5foc8Lo+KvEbS6za3B0OGNnhZyUiup84Dj+9jjA7Va+GBeC01vw/dEi706fChn3fu87l+gBwOKveBJ2bw7F9piAe2WSyeFmzJBICQSeyg+v41xeqa7bWvxG0/ULOZIYYQtre3ES70cqPnbj7wABORnpmunllW56SVktvVf5/juXy814R6fp/X32N7RIU07xxrltIkcUhRp7ViPvK2Nzj647VL8TbU3Xhex0jS4Wu9QvpIyqR4P2iT5m2k9htVqm1PSJNXa21nQYUt9WEi3FvdSH93JFyCh/2COnvXPatrN/d6lK2oOPDR0RGuSbb949xcuNqJGp5wRu596dOPtKiqReq39dlp11/pCbbfMv6/M5q40a0vbvXdb8N6ekGmafGIntmc+ajFAsuD/DtYHBPXFbPwl8VwaXYxWGqSoVlU+SZiRGZQMNk9c9xUPgjWp9Ahulmg+2WmoxFru0RkMsrjO8tk8cnH4GsbRNDmnhN40hPmqcSZBW1uQuVIGc7WHHtmu2pFSjKFT4dLfd/n997anQoOUXTl9/9dTtvFl5Dr1mNI0dH1VzGzveo37u0VPmc7u7YBrQ8N6Hp0zNcXqWom1CAIWK/ukIxtLHu5x1rz3RbSxsYr7TrzURFHKhURRzYSabBIXd/DzjJ712nhObVbyHUZBYANp1uLpLjcAjKoIaPIOCSOhHvWFelyU3GLsv8/wCulvvuRNOEdy5rOi6jpf22zitIPL1OaLiJByyqBvb+8gA/MmvWLJPKs7SI/wDLOCNOO2FFcd4eLINGgefzPtSJdNBu3CJXJICnrlcYNdtk5OR3zyeteJipttRfT5eX6HFWnzJDs8ZIzx19Kkixz8u7gdKj+YcdgenvUkJXkNg+maxoO1RMxexnZHrx7fpSE4GTz3IpcEEg8noaQn1Un39aVjIxvE+jx65YQ20sjRGCcTowJ5OCMH2OaxLDwsLQ25KWqXEedzqgCnPsBg12MnKn+IdeOuR6iqd/cx2dnJcPtZukUZYDzHPRRW8Kk0uSJrCrJLlRRbQrU2gty8giaMROV48z3zXI+KdNt1s550U2qW8QSRFUyMjA8P8AX+maveHdduZ9e1WS7WSdGiVTDuA8vafvAY9B2rf1S0R51uAjbJNvnuWxkY+Vsd/pXTFzo1FzM2UpQlaTOK8BX0t1a3dhI4NpGqyoZHy6Z6/XPB9q7CERyvFA7bbxQfLZhhZR6H3FecalaXHhfUIbuSaB13tJLHGcsYyeG9h1/Ou9tbhNS0+3mtY2mjkQy7VOWUDoa3xUE2qkdmVNdVsyaUtLA8EqxSBR5R82Mcdu9cp4j0RbKFtc0CKKx1exXzsxpiOVB1RlzjBHetbXL69fS2urJv8ASYpQRDJHkXJPHl57Eism10HW9WLxa7fzSxO5L6fa4CIo/gkfGSR7UqK5Pfckl27iimil4hvNH8VeDbi7S3BuCAJJIl2GLaNxUk+hA+oNcnBfu3iOLXzaQwWywwSSNbg7UGNmQPVtuc9ua0PGWl6fpl3Nb2Uk62N/G8l3YrJjy9gGHDHuTx+NWvCGmXNj4sk065m3PcabC5TAMaK2SqMD1wuPzNejBQp0m47avXt1No2jFvuds+s6c8E9+lziC2xJJI3DAHpjH3h7im+KkbVdDW4WI3VxEVkVrYg5RuMkfxcHFcRf2kuka5c2KTQrZIhkiE6FuD1UY+6inPBzW14CvTY641k1zttZvmitCPvlh8+1vQcsB6CuSVBQj7SD21+Q/Z8q9pF7Eng2K2uXumkWB5reMRF5Gx5Kk8sB3PY4rrtTfRLOOO5jikuJFxHFbWm4mX3YH8a861OFfDfiVBPOgijmMluzA5ZSwGD7HOBn6130UFw0zf6Oi3TEy/uJDlUx6+lY4iCbVS+jFVXvXT0ZVvLhMT308cFhZ26+Y8POCw6ZP6VT8NOdG8Nanr1+sgnuA11JFjhXkOVRBnuDUfimee/0Sx06IQtHqlwlqwdcvtU/MV6Zx3NaXid4odHgmkcGztpJLrcRxKEB2DH1ANSl7qg+r/Bf5u5D2seOPfRya1J/aTfZ7ppCDGmWAbP3d3t3NL9ns01sNfXEiWg3QytEcsisOJCByVzjJrY1KOx0fUdIGsRGO2fTEEoRdzPcTMACW7AEgk+mazNI8LzJaXd5c3sS3Ol5tTbJ8zagJG+SNT2XhiTXtRnFrmvY6vaJw5f67Ho/gjSBbeHl0K/gsjNbBnlERDLfRkllkye+COPasjQri60TxDNoSQXN3HcETKGby/Jh/vn8ODXN6LqOr6TJZQ2M8UkckxtVtr8YSGQnG0uMEAdBmul1E+JfCvi6PWfFlnamK9jFufs8m/YVPARepHrXFKk1KSbT5rtLu/6/qxi04txl1H+NIr/TtZt9blvLZbeKMpBBKpEVuT0yep3euKb4Xge48GeKddvV86a+RoxKVILJjnA7Lx+lYfjjX7vxKrztbqkEQbyldtrk45Zl9AucD9a9Hiiik8IQ6YG2PJERiI9EEZwT7c1FVyp0oKW91f0WoO8Uro424ilufhbpnm28AMSRuGyV2KrHBB6gn+lb2kWaPaJmKAoQzGVerNnLcdCp6DpxWDbXJm+E+3y0jkX/AENHZ9wch+g9PxzW/qMxsPDatayQo8UccUQUFg8p42g+gqKl2uT+8x2va3f/ACKX/CXx6f4s1V3vobexu0SSKaVN7yMB8wCj+Ec4+lWvDPizRR4k1fVNSlxugxYT3KMC8A6hR/eJx09K4XQtO06+8aLcasY4bFFJjjm+VpmHLD274UYrsfFL2viX7HpvhJLeVI9pnupBtjsI9w+YMeMkZ49qupRpxfI09Urvt/wdBTjH4TGY6jounpLrOkFfC+pakb2JZnxMrgfL8o9eoFW4NVt/FfxCt7rxSWs9NhtT9kguh5ZnIzneD6elYt20K+IUXT9RuvEP2WUuk0Cs4gYAbSFYlWP3unpWZd6teXb6nq9+bbUmvGOmvcXQG9N2PnSMY2kZxn1BrpVHnV9m1vs1fyd+nzfYrk0v37f8E7/4cRCTSNQktjB9muNRl8sqNo2knGAecH0qPxRFNo+orqNlEY452X7Rs+VTx80e0dT3/CrENnH4X16LSrW7ik0jULcSWcxYMFuMcrx0J6810uoQ2N9GXkCw3MmVlaXPlu2RuK8/KTjqK8+dTlq89vdkQp+9zbpmRqGs6dL4ZLTXMMlgYnRIyd0mMfxjqADXmFyl/b6fBodwJBps88d7FZzMQZnYbVYHn5Plzt68+9dj4j0eztDYX3loImvEhmSEZLr/AHfcdOua0/iFpkNx4ZM8k4tZ9P3XDeYewY7VB7EjGAPSuijUhScYraTLjaLS7/gznNI1HXraUaG1oRfwTPEIZFIMa4yZGJ+6uOh5rZsfDHnedPNqE8126lkS2Qthv949R+FcJB4l1a21K31y8vm1O9vbd4bmB12tGqsVVJCOucAqe+a9Ft/Enje4geKHQY7aGPCEtIsTKfTIHPHpirxMKkNYWV99beu45OaV1oZWqaLf6fCs9pdm4iUgtdn91PG2clcdGAx0rdj8TabHAyXmq28YkZC0Ug3qSOsi4PX8utYu661zWbjTtetntY9OVZE0+1kJ85j1MjnnB9sYrdOkaB4cso11ODTxBcSeZ9iiXzXZSOE3dTz2GK56nLpGer8v6/4AptNe/ucM13pGueOtSNxe3Fj4cvm3Fog0a3TLwTu6DOPWuls9M0/xNcy22nWkNv4Z0tWt7VEGPNuCMGQP/Fj9aPDGraLaeAtVg1iznlXTZ5FNjcRhTGjsWVEHXoR1zzmqll4bubTws2teH9dFq6wtOYhIJIVMg+6FxwVBwTWspXdtY20Teq9fVq2opNN2va2n9eZg+GtE1XUtK1qaDxCLS00+aQMjPy4UE4Qds4+lLpvhu81/wfLr+n3gMot2Y2yDeYyCQqFic7yNxzj0pr+HrVPh/wCG/ESq0m65X7YVYjdFv+clO4zjn0zXU3N8tr44it/h3awXUV9B59zab8Rhl4WQns3P3enFbTrS1dN9XulZW3T9d0y3Ulf3X/XXUXRdF0vxP4BtkiMUfyxQ4VcSqcncQ2fvbs5Fcppumrc66PD17KYrM38oeRBtZtmeGOevHT0qbQ5Ne8P6nfxJYNLOspubiyLYB3Mf3sPq2d3HtWL4g8QQHxFqF1ElzDvuBc292w5D7cYK+5606VOfNKMXdPVeVy4JptN6HrMHg7S002C6/s+12wh2QAZbYwxvJJ5IznFctd6JdeEZ4brQtSuXgkJhhhd8De3IRhzuQ8n2IHrUVr41v5dP2w2trLNDhriRSyqp7qUJ49c9KmDXmqa1a3WpmC6WIbrwxybEtYfvKkS92YgZbriuaEKtNt1HddtzJ+0j8R03hvT93jO0V47gNaQr5jlQqFmGSuMnAB6YzXpAY5yApB5rifh3ayM1/qtyrbp2xES5OAf4TnuABXajPvn1968jFO9S3bT/ADOSu7yHDheT9D6e1SRHj723gds5qM5y3ZuuB3p0bbM5yDWVKymrmL2KIx0ByD0LUgPBIyDjp1pM55OGxgfWgZxjjHU89aoxK2ps8dhPKjSq0Q8wmJNzsF6qo9a831fxSdd08TQWJt4pCFa1uE5WMHO7ceh5r1FXZHDrgHrnNeZeM/DCwatFHpVncCPVRiW78zKW8uTwc/dHv3rrwjpqVp7/ANf13udOH5ebVFTQ7lJtZsTH+/jiEzyPJHgyR8jCgdPau602OaPwzEvlSNMys3lXHBVScgHPoOlcf4ZsLq3GoyXdsLO6JSxtIiceXAh/eNnphsEj612FzcB9Mto/NHmTfKTKfmKj19M1riGpStH+v6/rQuo7vTyMTXora4s1nk5lijZ0g8viTOAVLd+Ofwrzqzu4dHjM+lXN1NY+f5Dc7BbbgCPm7nOQU9APWu+8Xa1HYxYQxKygna+SEPQEjv7V5VrDPeSQ3N0u9CRE8CqI/wB2T8zj1Pua9DBQbj72zNaSvHXY9e0krcWiM9/9tYR/vnZBGFl6EKvt0FWLvWoNO0uRLm4ijgiXEjp94KR1PvXAadrdn4ffU7a3ca7dm7zYtGhYPGeAWPXjpx1rJ1nRvEF/HdXd3pFyDIgZoFf5lRvu7UHJx3rP6pFz/eOy+Sf/AAAVLm9Cpf6jfeJZ9Svo9OuprfZ9nEkabkjiXJ/4EfWtPT/ENufF51J18qK4tYLbzdwba6AYwPTGOnSu+8KR2N34HntmsyDHF5EsMh2NGMHIx1BPGa8t8MLFdeINLsJliSK5ZtPkdxmPBZtmM9MY61005xqKacbKOny/pGiakmv5T2OdUnurq609YWkkQTSwSKH+pUfxDuK881aK+029doS5mi3eXeuu0q2OGC+hXI/Gt7w8l74R1YaBrEkM162Z9PkU/wDLMMQxb06ZHarvjWyVVhltpVgtwN4ViWaUSdVHoRnIz6VxUmqdTlWqezFTlyy5Xqnp/X9fkXBbteQKZjvt7yGFsmMFnK9CM8Z5Na180Gn2stmlwAyKpurmY7fLQ5+XNYvw03PpVrJdXMlwbOKSO2gkA/dgEdPUgZGfesnxBdXGr6taaCz7FupPOuHVtqtGM/JzwW4x+NYez5qrg3ojNxblyvoWNKWXXNcj1YwMLCNTa6UrDawbPzyjHQ+hPWm/EC3fWrnSPDNm+yG7kAlcffSBPvN7BiMfjXVWaQ22nNPbwfYo1TyYLfcG+zLkg4PqcE/jXI6VeRS6tr3iE+UPsyNZ2TZz+6jHzHPcEg1VOTnJzXTb16Be7v2/r+vmcf4tuYtX8fSADyrNbmOEDooMfAPPbOKt+Op7ax10LYzKlwWh8yN4+IJQT/46wOQf9k1j6Okt3Np19cQgbrmNJi5wzktkOAeo4FdL8RNDFxLFeWknkyruEzEcIAQVk9dw969JuMKkIPZJo3futR8jnPHV2ljr11erClxFJCDd2r8o8bdWB7MDyPami1t2shOZb6fUWZHtNSkusx29vgNtCnkH2FQaDbXLRXGrzeZeebceWbpk2xCTaNp5/iP5V1U3hDVX0ZWv2t7S5mjMiCJi0KADO6TsMDoelXKpGlaDl/X9f8MU7KK591/W/wCf5kvw80mK6v73U9StgbV42tposBtryjDkZ649q6OTWLPS7y40zxBPHFqluqxGKCIu1zHztMSjrkdR7Vl+BdfsWli0DXE2Zcvb3qn5JnfrHKR0bPQ9KZNp81x8YraO9lLXER8y3G8hhEqttx6YJ/GuGpFyqy9r0V18v61/pmMnebvpb+vxMvQNKuf+Eo02w16BNPt73fJb25GUu/mO1h/dkX+IdelbXxBd4NItI90ai2uZGuJypVFOMLntyRxW54s/cjw/qZUyajZ6ijxyKcCNWyJMnvu4/Ksvxlqpvta06yutKc2EN95v9nwy+ZJqRA/dA4+UKD15qIzlUnGpbv8Ar+fnt6CU5OSsjnJNCi0bQote8QyrcXW8KtlIwALHjMgb+FfVcGpNE8Kya3JNc4v4NC1JvOjtoj5f2tgMbQP4Yhz17V0tr4QXVb68m8VPDqOqTnDRoCLa1GchFP8AER0ParOt+JbXSWbTtPgF3cx5jumhO1YlA4RR6ew5NX9YnJ8tN3l1e2nl/V/zL521yrV/gv679SXULyw0HSY7W1iSZ2kVYVhiG6aVQdscQ7IOcv8AX1rzi90C5tfEOn2l0bMXeqsJHugvEBdjviGeCR2Neh+A9IuJZV13V42S/mR1y5x5UPaONf4ehJ+tcf8AEsrcazZskYtI/ssjWwXhmwxAf8MZowslGo6cH3u/P/L+ttEQupuKepmwaNoWla7rmmeKDfxpalDBLZLmQHHIcDtjnNWNN8Sa5ZW7WVqwnhurhDDdXsbFlQHAOOnIJzSeHYWu9egkvr1dQu2jN5cXPl8TleFQr/dXrt7kV2PxHtNnhfUltDJdRxwxXiSHGQFYFxn+EYz9K2qVV7RU5a3tvt22f3lytdKerf4f16mP4xOtaWtrBe3ujXi3sgS3giXaY3YcOfTFYnj/AMP6rpllZy6rrz38KyxoYZDt8tyPvD1HHftitHxVo+i6T4PtNYsgV1Z0SWFWkLOC+MKCeSeM7unH0rJ8Q6fq9hfabe+LIjrFmsYdIXk+Zi44cg+jZHviqw7tyuLtv0Sbt27Cg07NW+459riBbl7SK7yzQiN4eRl8fKd3TcOvFer+AfEFjrOnTW2sskeoxMI3aRhndjqB79RXDeF47XT9Pmm1bTIdfs5b0JJp0WHnhO0fvCR1AHGfUVVjtfD9/wCMbSDwtcX+maeyuyyyAq8cijO1d33jxj2qsRTjWi4NNW1v/Wv4amlaXtG09LdT0LxLpk0NxJc2tyUvbS3MkdxEwCND1dX/ANo4H+TWN4Z1u1tdUi1LxZCsOo3B/wBGllXZbpBjgBui+p7mm+I9H8X2unMNZnGraNuR2a04mmUsOPdvb61YsvGmnvYz6ZZ+DtQ1LyVIMRtjI8TE4CPgHBx+tcajelZWkurTtZfPz6WsZ68vf0/r8PyLHhk6VqfjbVtUQ2skoljhgvCfNyNoLsqnPByQDWdrbWY1m+8OeCEmGp6rMTeFyPLUfxhl6DjPArlbvXr+y1e+vtKh/skMBbeTEMSqwGMHsD611nw7u7mPRFXRNG3X0su641W7mEaOW7f3j1xx0repRdL97fokk3ovXvbt3KlFx957f1/W5heJLLWfC+jW2iT6nDLpksjxbLYfvgFBJBHXy+D04ziut0/wtHb2p1LwdPcWt7PBHPCybXt3xwAyntnPTuTT9Pe+0nU7zxF4lhg1KxZFgEljl2s0z80fPRD/ABN3p8Au9B1O5HhaEX2jRj7a9vbnMtsrjpG3QrwTtzWU6s2uVPVdejfVP8FruS5tq1v8mVNP0S8lWTxLpuo3F34o0xylzbXjK0SPkmSIDHC4OVx61jeMrez1a7fxTpyqmk3EUZljQgvZTDG19n8/TvWy3iu1liRvC9hc3N8zgzpKoiDIOC8jdc5yAOvFcdqOn3mnyGxuLV9PlumafybU5W6BPMI7YPoa2oRlz803Z/jbt/kEE0+Z/l09P1+8vaiY9Rnlu7qwltdRhhCR3CL/AKNd+zH+Jm6Y6AE+lS6JFe2MurzG0kOnXsaeXLuyHk42pGp6Y+bP0WpY7+WDQ2W6uLZhZOi2Bkm2ybnOzG3qwG76Cux0bT47/wATQWLMXS2xcThT8km0D5iewyRgd6mtVdOLTWnz6Wf+XzuVKSje/T+v6/M7rRLV7TSbWG4BM+wNJnk7iOAffGK0FOfxHp3pD88jOQCSe/8AWnAngelfOtt6vc81u+ooLZyPwwP0p8bBBwOD74pnuB09TwKVWA+6obPPJq6LSmmxMpDOOB+A7UhPHBIOMA4pOMH5s++KXr9RTMhp9skemar3xu/7OvE0wQvfGI/Z0n/1bvjgN7VZdc8cdevqKZ1QkbccZH9aaYI88t/EMc8Ey63YajpN1bxlri3lXekhj/1jQn+6ME/Sor7xdLflzomlzXwPC3iRHYy9sZ9P511XjTw5H4otbON5jFPbOdkhJwUP3lIBHX3rC+Inimz8HaLHp1grw380AMMNuuBtBGTj1r0KMo1JJQjeT6dF+v4/odVNxdup5nrl7PcTO9w7vdJhGjPIQNnBb8j9M10/gjQ7WSFdXv4EvVdGsmiZiRFz6dz6GuQsLG5n0ufXbtvJuHmUs3mB2A/ut2OfTHFdRo+qalYwKYYnn063+/EiYNuWJILEdfavVr60+SDt/Wx0tO1l/X/BOh0yJLLxPfRLaC3sXjjjgkCDcrKBuQjrnOa6i5W2uIEaXel02AGUncv5dAa4rXNThl0Oy1hbmW1u7WbzbTI3NdhfvKfcgdxWVN4kvPEUSi1Bsb2MCdHtmIYfxYychgoBGMVwuhKolLa2jMpRcmnc6XR5tRg8d3lo4iksLuD7VG6rj5VIB3HqeSO1cF4h8PakLrxE2lzEjR5FvguAGEbHJdR/skH861dA+1XGs2OqzajBtl3mRpZPLDIPvRkc4JOCB3wa2PHtzNp7F7DYl9c6e8P24MB5MDn+NT949gPrzW0G6VVKO7Xbt/VjVXi7Lr/X9feUNd12CbWfDOvzyvJdzFfPuyMD7NtGQU9c5rofGE1mPDl5NcCK9imRUgkWQA5BBDKR0Iry157qLTrCyWa1azsZftEabCZ5GXg47bDjOK6S88M6b/YVrr2m6heXUaziQyyLiInPzIUz8uO1a1KMIuDbtr+unoN0+Wy/r/gHa+BGiGn6ZP5waUl4Jk3YwWH3cevHUVW8brNpsdhfRCF/sNyoLMCTEjEjOO496x/BepW51uaCFljWZQ6ecuWEi9AvpkFq77X9Pi1awjjkUAy5j3k42Bh/Q159X9zXvLZmc/dnqV7+dh4fnW2MTPDveMMdyuCMg46nrXElX074TQ/aWTzZA6qjLkneclB74PXtSabr8Wj6Nf6RdXxm1e08y2s5BEcPGBzJnvg5yakW1/tD4S6eUZQulrJ57ZJDswOwgnnOcfStI03Stzbcy+Y0raeZz+mQy6hf6ZburR27XcREpORnBYIvvgHiu58aXUFt4fv2MCzRTzxW2JerMZFGSfzrD8DWT2epaFfXkxNnq2nyzpZyLgwTJwZMepBwD79K7K70mDUdKbSdXP7q8jZYmz0Zun4ggH8aWIrR9rFvZf56/kE58zuU/HFpA3h6+tISIp4AZHQLwNnA4HXjvXJ6nr19B8LLX+xsQyvOunEFhISG6hQeSMHrVrQfEunx+HJdL1+/RNashJYvG6Ey3O0kLjHtiszwLoWn+KIL6e/murC7toxDCzMNqIR95VHHHXPWtKcPZR/ebJ3/AK7oEvd97o/6/QPEvhWTQbCBtOuWurOCL99553PDIORnHUZ79q6m0mXWvGmh69bGSBIrVra5VkDJO+3iNWByCcZzjsau+Db26vLFNI11IZNdswUu4gmC0HQT56MrZH0NedWuieJo9disNPW605xcOJGY4R4c5Ehc8IFGQMKSc0KXtE41JJNX17phzcyd90d7rayX2p6VpUcnlQrOby/lkz5SIBwhPr97gfpTtBmgXVb/AMTzSRQ2MEJsdGWUiMpDn95OfQMchRycYPeq3jOR7fwlqDXF8sjuFs0uwv7uPcwDbB1ZsAZY/wB6ta7NjI2oafJDGLW0iS3Yuu6IIsYKshxycYz71z7wXbb+vX9Ld7576IvSapek29xp8dnPpIidLhnBDrLgmMpxypOB+NeeeHmm1+WbxD4lUGeeTydPtY8r5xGQZCAO3bNdP4V1uxvPDen3VrdqQFCuIj/q1B6Mp9DWXo2uR+Gnm0/WLS+069jlk+yzm286OeJvmUKR346DpWlOMoKUYx1/G39b+RpT92/L/X5/gdtqOoNpbW8TqnyxojBugJzwT+FeX+Nzb3/iu0iFwkkEFu6yIp3gOxPy/QVe8UeL0n0CaWXSbwfam8t5b+AwxjHTYAcsTzgcfWudfSbjTo9NjLwpd6lbOwsIWDmEdVeR+xx25rbCUFTXM99TWhFQd5b/ANf1/mbuiXElt4I1ecRKjaTf20yyxjc6htokY4/hxnj05q1438SWlr4cvv7OK3VxIgjPlHdGu7+8eh+grn9F1KbR7u/u9NSC7WeGSya2UnKqRt80qeGbPGOPSlfwnf6LpENzJ9kmS3iU+TG5Jg3H5iw6Eg4z1/CtfZ01U5p99Pw/X8ypQ993Zo6/4PtdK03R9NsppL/xjqEatNAZCYoYSMkn/nmuduPesbxla6tour2+ha5eXd9ILeK9iihcfK65GG74H6+ldF4S8IXms2kmtWeuTW0lyCGeAAllyPlYtnnIBAHAxU/giSy0/XvEniHxBdtd3NoDYzXbjdsQqPnI+vB+mKI1XC/vczj0trdv8EtrIyUnHVtSseex6jcWE2mXOjJHa3+nB5bu8KBYmQsWi3ZP7xjkH8a7nxB4v8PeKdFdL/TZUv48/Zrq1Vd7TYyCgBwvIGST0zxXIeF/sUGqfYdXFteWXmeVaXEhOzzcZWQj1PHynpXo9/4N0DUrd7myvVMmF8+aAiN4sdWVehFXiZUoTi5xemzRpPkUk5Np/wBf1qYmieNdVl0W20y40/UbrUijlZYTtWTIwGHfgZyQDg034ZRWK2MiQeMLvSr+d5JriCGQK8pXjBZhjjk7ge5p2kfZ/DniC7i1mc2t4Yt9tqkrEL5TAgoB0QNwMYPJ610es+HdOuvC6Satb2CxWkJZUjTa9qWPyEkcsDnOPc1hVnCL5YqylbVf0+/kRPkScVpf5/gc54G0zRdX8M+IbO5mMl00rlbwPuZdvKMF6ntk/nUvw51mZHh8O6nBDb3unTFEecbFMA5Oc8b26jt71mR+FWt9TuNHeaSPdbJPFdxjy3ZMZdBjqM5/DFP8c+Em03Sn1O0ubq4kgCGRbxcPImQF5HVV9evFVL2VSTg5X59V5f16FyUZNq++39f8FHokep2k2rG3soHklg5e3tRnqDnzWPy9M/Lk1yWk22sWPizXNM0K4h0HTJLcXV493tlWMNnDg5+U8HisDTtU1rSdJWC0vbfTdNZiNrLvk81hksx64IB5JPapdG0jVNSs72eXT1ubi5fb9u1GRhvjxg7Y1xk9ME5HtURoxpKWqs9F1+eun4O3n1n2TSd/6/Ib4b1S08N3V5FoizatbyyqVvnQLJuBJZthPzKc1N4y8S2lxotxJbStOkVykzTyLtkE45SHb1XnH1rO1fQ9e03R47Ce3imvImWO2um+QLCOSNw6vzjJ9K0oNLgvJLPUvJgW6+cNc3QLLuPKFk+XcycDd7VvzUub2u779/X+vkVZNq2/9f12NC0W20dllWzSFiGluAyCRrliMooB4VQcNx6V3vgCwmt9DN3fHdPdr90rgKM5Ix2HSuO8OeEbjxFc2t5dXuNHsv3cUm4mZ3B+YMvbPb0HavWFCxoiRKEjQbUXrgDtXk42rH+GtX1/y/rbYwxEkvdW5Io5OeQcdOKUZPfB+tIOuBjHFOCkj1B56YrzmcgA8Z9zj3oTIGAcDtkZpMZ9Mk49aVNwGFKj6jNXSV6iH0Kf6Ed88ijHXqD159KCPm579MDP40DgZUcCmYIQ57/p6UhAIwQc9cetOGegBzyelB4z+eKLjGEdwThqq3el2F9PFNfWFvdTwDETyruKD2q6ccdcnv6U0/N04GfpUp9iotx2ZzGp+DdKn0mS0sbZbeNWe6W2GAktxjjeT2rz+w1DxB4Bkl/tS2hu4buD/SLezj3PbhiRlx7YyD0Oa9mdeMYznqMZpFJVyygByCNwHzAdPxrqpYqUE4yXMn3NVWdrS1Pn3YxknF3cXBsEAuIUUgSKxPKEd3bp6Cta9lvxqFuttbx6VpMkbpbtLHuw4+Y5I+62AQccV0vizwxpmhaPcalOst1YpGkUqgATKd2d2/ryeMVwdz4r1LxHfJbXWl/ZIPLkS1szJiON04ZVXu2MnPoDXsUqnt1zRWi7/wCXfrex0uUZWs2/6/r+rFzSmRFiuruyguFtpDsYNlN+Dgn+8R/WtHQtIm1+2TVtWLzQy3DZjc7d3bBXsPT8axrfS7i48LahLFcp9ksFCSooO4sSM7cf3ePzNd3pF1E2n2MtskMNhGIoriVs4jY5AYH39/WivPkT5N72/r1NZvtv/X/AOF8T6Euk6j9nsWuFhltz5EirkqepTJ6gVteFJrX+ytS0iWW4DantG1QDGzAfNgdjR8RZlh11LZ5J2e3y4JUbSeynthqwTPNZRXdxb21yI4Qjm3tY8zLJkDKnooA6gcGrV6lFcz3KUnJK50GhabBOkyaVJLc61ZXOFZo9gdV6RqehLDd9MV6LLeW13pDvsuLcooeS2uExMuOox3HbIrmvAWmavpcMl7DdwTaTdpujs548TLJ/fLDvyeKi+Jel+Jtams4NMiMmnsg+0ssgjKOP72eSnsO9ebVlGrW5XLTv/X9eZz1Heduxyl7q0F097MjRPcK+2fyXAitIT0jUnq2MEj3rpdFsdQvvhlqMUUU4LYurJeFaVlHIYd1PpTtD+HjxeDbi3v7eyGvXDl1WQ5tiOnzgevX1zXXeHdDfTND07Tbq5luGs4dnnKcHOc59T9KeIxVLltT6P8hTqaJX2MvxTANM8GaZqWlrKx0jZMIwhkeWN/lkjI64+b8MU3RfEWi65ZKthdYn3bIVbgxP12EnrjPWupa3ZdxhnYFpN7LIMqR3A/xri9e+GtjqN3JcadenTknbfNGsQPz/AN5T1HBPHfNc1KpSkuWq7dmRGSatJnE+MXlsPGGqsk6W6AI7X0Nsrs7Ko3RqTnJORzVPwRey6Rexava6fPd2kt59mu7OBN3lRv8AMmR6kEHjGOleh2nwq0O2iSJ9S1a4VFKhJ3DKgJz8oPTkmuv8PaTZeHtPFlo8bwwDBZ5Dl5D3Zj6111MfSVPkgr+uhq6sVGzd/v8A1B7dzJDNZRLHchNoeQY2xn+Ejvj+70qovh23eeSa8u7m5nkOXLyFl9sK2QPwFbXXdknJ55peDgEYHbtXlqrJbM5uZmdd6NpuoWLWN7apLbsjR/MMkE9815oE8VeFo5NMDSTQxIWSWeASxGMfxZ6g7ccV63tJ5YdsHbTj86GJxviYENG4+Vh6EVtRxLp3T1XmXCry/Ero8Ei8WPe+efsenbJYt3mQQtEpjAzggHoDx9auT+M5IbK3uLjTpJ57KTFlem7KwWxKkbgM/N+Oc123iX4a6bqtwLvSJzpFwRiSIJvhl9CR2/CuI8SfDnxLqIubNdEs9oiEUEizKbbCn72OqsRnkV68MRhprovJ6f1/Wh0RdGe/9fidHo8WmeKLQ3XijxT/AGvf7GU7cJFbgYYtEo4JGcE1y+qaZ4ftAJtBIuNOjIWWeGRjvmZiVHJJHGDgcc1ympfDi58OXFvHqeoXVskjqobYRgHqFfoef5Cux1C3mgsbbR4rVhBF80SE4klLceYzd+mPYAVdNK6lGTs/NW+Vv+BY1ScNnp+BHpN0to8F3OCIvP3PJtyY0z95gO2efauq+IOr6d/wjotdHvY7q5nBJa0TKCNRufcx6EgYweea4sPINHEV0jBjI6Mu0hTg4wSOj+3SoLq3Yaexhee6jjJVghAkbjBY44JAzV+xjKopvo/kW4c8lJvY2PD+jeJb/wAHaemm3kNhYyI89u0Jy8+f4T/cC4Jz15rI1LTptO1CLQ7JTetceQ0oTIjuJuSoOT0yScn0rp9I8Z2Gl6IbeGynkvfsyxJGsWQxGcH5eOeM59K47Tr1/wDhJEk8UvsDSrcXZtzuYkD5FGOOARwOgq6Xtbyclp0X9f1f8IjzXba0L/inQD4ejhuLiRL7TruUi8RhszKT85QDqCcjcOfetNdP1nTtUh0bSrmM6ddWf26ykdVlxASMqzEZCgkdea1vHkrXlnp3huwjt57nUZw0CuwbCZyW3dlA7965TStYv7PSole3zLpV1JBFcqS8aIc5t5B0wRkqexApQc50k3v5/gxc7lqt/wCrHR332y21NtV8aWcd7pskYti0a74YsDCuy9l56+9WNQgm8FXEJu5P7V0W9tv9CmaXLxyHnn+9Hg8Z9K3bfWdJv9PzLd2qW8a/Z7gyNsJiIyUZD3Hr34xXnUl2ZdOh0W3mRtNOoB7InPmCPOFRs8gcsfxFYU1Kp8aslv2t5drExvLTa2/9fp17G7d+JLK78VeHry9urmazt4ZbWdVj2bd4wNo7j39KPiJ4gg1jSI9PsbmW91GcA4i+VY4152HH3mOOlbuteGbDypUsoWtbu3B+z+Wdwz3yT19c+9cbg2NjoutaPYqBAksWuRyElY3Jx8jdQ56jHtRT9nJxnFO60X5r+l1HHkumh+iz6Le6volvqkf2bTCvkXOQf37gffPdRnFdfpWr2kMD3sty12EuJbeSJyVeK3GArbexPauMsdAOt2l1fTwLaW1+/mxSSIwklKKSAB0Uevviruk2t7eXCkXMMd+YxK6wkvHNGMgAseN4I59BRVhTknrt/X9ei9C52l1/r+vyOt8Yw/ZdBle32zaddRLuEsn7wxt0Qe+cnPasDw1ot/4vt7RdRuDFbRys7sM75I0bafwGMD1PNSafb6l4s1WGxvRDcWse2S6e3YfZLYLxtjz97OPqTmvV9PsrfTbFLKxTyrZXLhQPvMeSTXDVrPDR9mvi79v+D/XY55VHTVuv9bhY2ttYWqwWEIhgXtnLMe7Me5qzjAwDx796aPl9yacq5GAOnbsK8t7nK3fUdwfr046ZpT7fkfX1pAM4yfqMfypSM5Hbrwf50hATjrkZ6UKCRwMjsRSjJOQeM4P/ANahWz93A/HbV0n7yu7AU17dqU84yOcZ4o+Y5OBt6CgZwQeCD07UNmSEJAOTj3oPv+XYUZPJ5BI/SkGepB564pNjQZGcnjt9KDn+LGc4PNJnjAJP+FL1IwOuaAG4+U8DpjOc/hSE474+nrSjhQQTx6CjtwMn+dFxla/tYb+wurG5VWgnj2Orcj2JrypvAmu/ax/aj28tpFKWSO1Ugsp7O3U8cV64R8o3nHIpPm2jDMOPxFdFHEzo35Hua06rpnmOuabcQjT9BthZWc15K1xPFG4O2MLkBl6nOOvTpT/Cjo/gqcTzo1pc3OxskAW0asRhvqc12eseGdI1h7iS8t3S8nQI13CxWZAOm0/nxXP/APCvVtbhpdJ1d4H+Vh9oTejMBjJXp0x65NdUcTCUOWbt8v6f/DdTZVE1uYnimwtfEOq2egLHcrqMcglcIBs+zkD5twP/AI6a9MtoFtIEhtooECfeKIAGb1rM8KeG4dAS5nlu5tR1a7I+030i7cgfdRV/hAGPrW50ByegzXNXrKdoRei/pmM6l1ZbEYRcEOiFeuFHANP+79OuKXA/ungYz/SgAkD5jj1Haua5FwzkdiuMc00D7wLevNPxnG1ec9M0nOD1OO57/hSATGSSAuR2J6UcYyDgd80uAVIOSG/I0YPcEADgelGoXDAGSeB65z+VHQMT0/KnDjJwfX8KT8iTSGOAwSBwen0oVc4A6/XmjGTxuweARRn1PI6UxBgMMg4A4Oe1PPPIJwffk0YwvI59R3o7nGQc9fWmMFwQucex9KaAOgyO4ycY/GndAMA/jQTgkE5A6CmBV1Kxs9VspbHVLSO8spfvQy9M+vqD71wniL4YwXNmv/CNaxe6bciLySk7mVWTPCg/w49q9Fxx6HoT60hHB7np7E+1b0q86XwOxUakobM8d8ceF7vw5pOiywyyXdvJGtlfvBkkTY/1o44U9MmuSt72KKOa4uzFHan90kyMoWKQcsmCRlmx/jX0VJDFNbyQSoWt5BtdAeSK8r8f/C972O4udAtY7+CZ1lm0ppfKYuGBMkbYxuIyDkd69LC46LXJV37/ANf13OinWX2tzgF1OTVDDbQ6HrTx3scsun+bHHAspiA3HzN2Cgz9M4FN1KfU7LR4Z7P7Dp+owqp+yupmabcoPIAIDfj0xXWX+h+Kbue1sDpMwuEjPlW01yGEK8bY+BtVeMnB7CsK4064ttZuNC12/nsvEumwtd2zqV+yvEygu4cjPByMYOccV3QrRenMn5L8+v8AwehqqnK/ff8Aw3y/PYqaf5E0UUWowW2pyvH51yLV/szI2M7XY4Kqvt16Cm2moPa6Xqjx376fpN1G1sLGVWaW5A/1bhcYJDbQGz0qkZp7OxtYZUgm0u82K12kZjXBGRJz8xA9K1tVOoanpumNq0IhtBatBp7ug8xgDnII56gdR0rpVtLvT+um1zSVp+n9f8OdN4k02O08LeHj5EMcNmY2umUEzTKxGS7eo9/Wum8R6Na3mhT2tvDDa7dstgYFDMrHkAbc8HFRwSx6v4CdlVWtrmyKNkgHKjknqQcik8F3qReGbcXLGK5EKxRG0G7BBIXJPfB5b9K8mc5KKfWLf9fmZXk16F7wxqU2r6TFPKrLMqFZkb+FlOGx+IrM0qCzi1fW9L1C3juLS9uEuIIX4a4bHzsoOBgc07wI0NpqFxo0oYywXsgkmL5D+ZyQPpnn3zWf450aSXW7FZ5jFchvJM82fLSLd/qzjnLL0xUpL2sobJ7fmv63FZJtIj8J6yumXs2lauYXiinMdw8jh5Egc4BXB4UMVyRmnX/hbVpPHV5pFhbvbvOiBr5CVtorUZIKHsxzgjvmsDw/bX/iS4s9N0WwthqFmjCfUY4isUULOODuOQRjO05PFe+WqG3s4LVZnkjiQLvI++QPvUsVX9hO8Pie/l2f/Af/AA6qz9m79X/Vypoml22jaWLKzVAhO+V0Xb5j+uPTAAA9q0QMg0gxtGC2OvSnDjA/MV5LbbuzjbctWA5PHXp9aXnHYnpk0Anow5PA9qMcYAyOn0pWQrjs7entjPek3kXAiVJAWQt5gGUXHY993f6U4Hnnt1FOGQmM5z/Ok7ANA6HHbAXNGXx8jAfU07HzDJOTzkUBcklhn8aIR95JDuUcjdyCDnrR6nAIxzmkbOCADnoR6mlJ5P3jjn/9VDepkhMdOSfbNNJAB6Z9fSlYjqRjjijuRtbgZ4OT9akYE8dyevvig9s4FJj1PXk4PNO6Y6ep5pjG/hzj8qQ88AjpSkcA+2eaDuIHOPb/AOvTENIJOPXk5HagkdT1PPApRnOdpBJ9c/hSAnHpjuOtIYEEHggjtz3o4wTjOMdR0oIII3gjBpcYPb5f0o0GC9OuevJPek6KBkcCl4GQSePX+tOPUgkjmhi9Bo5POOcnr0pSu78+g/pSDJzxzRnnJOT6DtQxh12noW7+tKQQcnH40Y44HUdD3owCDjnv9KQAAPYNx360DGOc9eB2FKAeeCMEYGKAu7G3ufXpQMACB2Hbmjqpyc9BRnPC8r0A/rQD19OgBNACg8nBxjP4U7nOMD8O1NbB54/2j0oAJB446+lMBwyBnHPpmlyM9c4PIxg0nOPl5JxyKcT654/zijyATvwQB196DxnHU/5/KlwT7nPIH8qaMDPucY6CnewC9AcD3z6fSkyMZA4PWlweAM4z1PekH3jjHI/P60IAIzxkDuKaRk9uffBpwOFz90cnn+VJwAMrgY5ouAPkoRkYxyO5qpdafp99t+3adZXLABRJLEGkCjoN3UDrxVsEAHpk+nWkO3IVjktzgelUm0Hocv4t8I2WvXmkXbxkf2cwQ2UQCRTw5yQRjgiuM+KOka5B4gj1bS4TNDKggSOG3Li2wMBV5wD74r1s9hzgjqf8aVHaMkqzKevDV00MXOk090lY1hWcPQ8H8PT6ha2L6bY3dlHZOxWRJmHmkEHfjPRsnqc1Y8H2V+8Mf9iXNuLKKdrYxzbvLbHOUGQWPPsM169qOgaLqcwn1PR7O5lGSJCmCSepOOpNU9N8H6Hp2pjULWC5a6IAQy3Luq46AAnGBnpXVLMYyi/d1fkjoeIg07I8b1G5TQ/F92+lXcqvKpi/f8lJl+bftx1cnAHY17ZrGi2HiXTbFNZhmZVRZwpJjdHI5zg1o/ZbQ3KXUlnaNdI25LiSEM6n1DEZzU7ZLBjuJz82eST9fSuWvi3UcWlZrrfUxnVu049CnpGm2Wjacmn6Xbi3tEYsVDFmkc9Wdjyx+tXuQ3T6nrTQC3JAAyQfrThjJxkHpXI5Nu7Md2KvHTk9f8+1OU/LgADIOKYRkYIznqKfkZ/mRU3EC8D5cfj3pw/hJ9O1IM7ct1HP0oOQABn6UNgPU4YA4yacOT1GeccVGOCBhvwNPBPzYOfboKLhYVy/ljYgk5GVLbSR3Of85p6gA5Ic5HYU3GQCOfTBpyZySzqnbJPWqpv30Gx//9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Low power view of a colonic Peutz-Jeghers polyp shows a tree-like proliferation of smooth muscle lined by normal colonic cell types.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Robert Odze, MD.",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 518px\">",
"   <div class=\"ttl\">",
"    Normal colon",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 518px; height: 172px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCACsAgYDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD3ECnDJ6Uwe3SnD1r22cKHjpnOQPWpAe3eowOeaeuB3496hjHcnpRn5R/jR+XWgVIwGcYxQPrzQcZ4/nQfccY/KgLi5Jzjg0g4FGBnimgdz0FAxwz2pePSmjpx+FPPPBNACDnHOemcUh69aUYznNIPQ0DEXBYA08rwCTnimEHPNBc42/qKBiseMgH/AAFNyOp59qQnPTjPakPNNIBQSOlJmim0xi5BOBR2pOAc88Uh6cUwDqPxpAfxFI3TnmkyeeaYCg54puRz1pG780h5NUkAuc45/Wkz1xmkJA6mkJ/CnYBe1BPP8qTP5mk3DNBIpODnpQD7VGcZ70oP51VhD9aP/FLJz/y+D/0A1yvbGTiup1nnwshxnN4P/RZrlONx46dq6ML8D9WYVviF4zuPU0pPB64pvHPal75/DrXUZWFz27U0knvx6UHBGOg9qO9AIdnH0xSZP40lApDHHsADxTc89eaXPU4z9ab70DHZ60dqbQDkfjigQ7cQDg/nQODzxUaFizblwM8c/rTwfwoGOB5OT2pc9ecjNN3dhQM8c85pAOzntxQffp/Omk578noaXpjAyTQOw7PocfpS5H4g8Ui4OeevrTjknkUAL+HvmlBGBTQDjk5pQc57UhD88CjI4/pTc4pSaAD1NND9u/8AOlz6VR1FJpECW+WLkK/z7QF7n1ppXY0rjZtYtI7sWwkDS43YXuO+KuqwZQVPGOKzotKhghCRFmOchpDuINXSrqiKm3jGeO3tVadCpKP2SRj1G79KQ89OnrQcn29Pek4GetCIaDI7mmk8/wA+aD09qa2cYFMVhaKb19qKBnZg04HI6muF8ZeNP7Isx/Ylt/aV4JNssag4jXB/NjjgVwkXxG8Y39nHNDYJBJJu/dLGv7tV7sSD74FckMDUmr7ep6VLB1aiulb7/wDI92BHbmn8E+pr550b4jeLNQ1VrW4kmgKDzC6wqECk9OQNx9x/9euqTxh4htmjkad7iHcBh1TdJ7ADkZ9a0/syq9mvx/yNPqE/5l/Xqj17rxj3pSeeveuFn8cDT4ka90+5aVxkIny8evNRXvxO0qykP2i3nSE4xIzKuenY/Wud4Gv0iYrC1mubl0PQCf1oyMVwN58VfC9paRXE89ysT/dPk9fpzz+FdEvibS1uzaXF0Le4VVZlnG0KSM7S3QMPSspYWrHeLIdCot4m5jnk9qaenv3xVaG+tJ4WnhuoHhBILrKCoPpmpnmRIxK8iLGcYdmAB/GseVrSxDTW5IBg8jn1oyARzyelUrjUrK1K/aLy2izyBJKFz+Bqude0lsY1Sy4P/PZeDVKlN6pMpQk9UjV74B5pAeMdKpxalZSxh4r21dMfeWZSP50x9V09CQ9/arxnmZR/Wj2cuw1F9i/3x29KQjpVI6nYhN/221C9j5y/41Edb0sAn+0LTGcf60GmqU+iYKMn0NHPakJH0rjdc+IGk2EvlW+68mxn5GCxgDuWNcjrvxcig0p5YVjs7mNir+crOCfROma6YYGtJXtZeZvHDVJa2t6nrxYZwaXIzjmvBbX4yX1w4jhi86YANs+yHdIMdua6GP4o3EE6G/sYjFIUCqu9WG4cc4IOOQfStHl9XpZ/Mp4Spa6t956wTkkUhPBGcVymn+N9Iu3Eczy2knOROMKD6bhxSTeO/D8cu06gZBzykLkZ/KsHhqqduVmfsKt7cr+46rI/SmnqOPeucHjTw+VU/wBpxqG6BkYH8sVHqHiG0vNOnTQ9b02O/dR5TyuCBzz8p9qaw9TrFr5MXsp3tJW9TpiaaT14NVbabbboJZ0klVQruSFywHJx257dqgm1WyicpLfWiFRlg0yg/qalU23ZGduxfJOe/vTdwyOK5XWPHvh3S4y1xqKSbeW8gGTaPUkcVw2s/FrzmddL8q1hG799IPMkOBnO3ov05rop4SpPpb1NqeGqTdkreuh7C0mxCTkgDPBpqSLIu4dDXjlt4t1HWUgibUGJJBUbFjUkcgvjnA64OM0/+29eFpqM0OpW80GSNxYfMQOSucbR/OuhZfK2rNJYRxdnJf18j115HEqrHFuGMlywAH+JqUEc+teS6F421KytCs9pHcA4dd8hRsH8/WugtviRpghdr+Ge2aMhZNuJAp98dv8AGs54OotlcmeCrR6XO91rnwouAT/po/8AQDXKk84PWsD4teIob74QR3ekXcqRf2ysMhXKMf3DNtPfuprxHSPEer2h8621OdQhztdtyn8DTwtK0Wno7slZfOquZOz7H0bS/SuT8P8Aipb7RUu7qIo6ukchAyMnAz9K1L3xHpNlKYZ71PNUBiiAucHp0BrdU5X0RwTozhLla1Ng8ikJ4qhZavZ3tuJYZMKTgbhjmrgYhcuVBz+ApOLTszNpx3H0MegP6U0HK5x9KI2Yrll2n0pCHdTQKWkP/wCukAooA9elGfekBPpQMX3oPAorJ1/XrXQv7N+1xzP9vvYrCLygDiR84LZI+Xg9Mn2qW1FXYJXNc9f/AK1H16UA9zSgDcBzg0wAd+M0oGMUe/Bpe4GOaQxAQcnmnGk6k8c0p+p56UWC4D6ClHU8UnUDjn0pPp0oAUnrigsaQnnA7UgwegBxwKBj84z7UduaaBxx9aUYwO9ABkkY7UHODyfrS9etN9hkZpiAZGOc0h6kfNx39aX6UAcHr6UwGt/u/rTOnJ5/pT+2elNz35oATp2ooHGaKYjzjxTdXmhqkkX2pFhjEcFyxBjZnfBaUIOgAHzc4zg9aHtMz2q3ckgsbBVkmS1tWgT7QzlUXjlxkFjnAA5PUCr+j67f6hd7b2TT7KGZd8Atb4yJdeX/AAxqw+7z8xA5Ix2zWZ4p1e+07wlpcF9q0ey+knnlcRM27L/IVJy2BznPPTAGK7U3KyPoIyk2rvcz7ZNS1bXb6RHaSIMyKTEsMYY84X+JjwcHgVc0hU0rV47q6Uh7dxKQPmwccZ7D6GsrwRc6ZBDI13HazRMSsVzHGTGTjBDDrn39624NXj0pr6O13TWrjcpxhW4xnk5wPxroXvJo6FKo04KOjX5+Zra3fS6lP9oEezAHkSRnlV6//Xrk9PuJ/EN5dNqaWh06KUW48wYk88HBBBP3uPTBDGrMN3qOrWlt4atYpBHes7R3cGMwOvQEjt+X6V0cunWVtNvdo5EtZ4pmuJbUiOWcoQvlsCDK5PAzhfr1rNyUPdQub2SUGtv6/rzK62kVvff2Lp8Fk/iMFZbaKVTMkS5y0jBchRgcZI5xWbrzaZq1zazT3uoQahNO0Xy2ksbFycOShGB/vZ4rTt7dLXQtf0eK1ltkunRA91MsDXKk7mUOMkoCecZ6Yz3rQ0fT7hvGl2mmy6hPpFkq29xZXBKNDOoGPKLE/Iw5z3H1rB1OVtt/1/XQzdZuT5v6/E5HWdLGk2Xm3WtG007iJA0WdzH+J25JOM4GPxNVm0zW7zTkaz1mC6gQl42cfum6fLjsAMnjqeOK6PUdN8Q2+o2bWsH9o/bkmto42gCW8Z2HDMqcMOuWduOw9H+CtOsLPThbW82lwmRni+wszhp5VAExVZOq9QAOMHOav2ytuV7dX/4JgnRtVe7eVtYsYlb5IYxhw4DAkg+uMjjpxzVa90awsbSP7brU84Cm2mEcRZ3O8MMBeSy8dunWupv9JstMsr4f2roNrZwyCKG1llRI7OUHMg+RXffjkr+FbGgX17b6NcW/he0gudQsrg2+69k8yNZCcs+9OTkEHb2BAJ4pOu+XmX/AJ+srVR1froctD4Os5hNf28l1pyzpHavKYWjOBz8gxuy3c9q1NZ8O2t5biC4unY248z92DF1BALEnLcHpXQ+LDqUC2eqF7wTmN1uL6InNtH1Ihgwd5PTJ5ArAsk0bVLoO+gT6hdG8Ek2IfKa3YqNskoLDGeuF6dxmojVbXMONbRtrQzdNsrCNLe2s7tZIkxD5zYckg85Oef51VTSJ766mkm1i2Nhc7hbQWrANIu3HUfMMHJrupZPDd9vtW0mZJoZ2d2giCIrkfPJuYYI+brznnFYUPhmaDXYprO00fTdFNq8EdxG6s0jlTtVc8sMYOAR0/Oo1rb6FvEqaSatY5Wz0bSdcF1bI94Dax+W5uMq21MDeV6kE45PXFa9zo9u0FvE1tBLHFGF3uo4OeMDnjocjntVzUtXsraO7ga50yC7d1huHhi3klBnbI/ABwDjnjHSm6jqT6JbeRLZmCKZFeCfzQ8jjrgIfmVQOcnrWibdvM1pzUtu5z+k6K9kslzeQLZCEgAG4DKyc8scdB2zW/HYm9hhkS8ieB5FkR1KusqqeVBPAyPfIrgZ/Fs1yAbWKKWKYMsgu1ZoSoPcHAJPpXa2kumajFZrr7TwR3flrbWVupNqk65YMjbQV4GSDwB17UTdloOpUaWmq7mP4mtJNC+03to6mQkxtDPJtjDM3zHPdjwM5wO1c7YeKLmC8El3Y7bZpWid2RiyqFyT9c/p+ddtDaZvbm3srF5NLUM8rvIJ/tT43AW+WKj0IPT9KyLC4nuYdQC3FlBfzSki1vreRFES8BcgbmbryARngUczsR7VX0djHuNEubp/t9vayQ3MmQjSOQIs8BwPTqT9eKntfDGsx2NzcT3E09w+S0cSK3zHAUrn0H9TWhpWsXbXNlb22tPqN2qHbby2TCO43Lldz7RsAA6jtVw38ltezyS20ssJEUC2s0ixxPI33gsjEZHUD+Ic0nLqg9pDV9f67FVtG1RDIimNcPG3muNzMgA8zIHcnI/OszUdNv821vNcAXzt57ssWFZAclQO3BHU5J4rRW+uE89NIltobGwSGWO1tVkumliYnIDY67gRnr64q9aaXfXN5dtJdMt4WDtaCYq1urKrIkisMI+M5HP0p87b1ZUa0Vuyn4V0Ca6aa31NZYLUsG+0yj5jknIwM8dBxUep+EtMtp0vIv3kUDZQc4Zs9SD24rVifWtNmtx5crZgeOS1jMYQPn5pmy2/YFPYdB2q3q4i07wTfajLc3ZN35XlNJFtCIF58pTyASc8/pUSk7iVaLlZ6/ccVoFvfyalcWaoJ5jukbDKodicnjsBwAOp610Mz6ZGYJYreKG7ikw9sVOWx1Dtzn2Nc14L0VJLqS2+3fZ3kdm82R8GQj06c9en612Uej2pszZQQxf2iGxK7buP+mm4881uttTKpNXSm3bsv1OX8QX1495HbWMRVLhZSsSMCOnClvxP51uaP4WtI4xA0q/abqJFkjkk/1hC88kjJH9OawQn9neK0iluAJywRkWTg7TncD+fPua6bTrfTbq1sVudbtL2Sa8lNvchmjmRjwpiyMKqpnJOeeR0FZyk1ojSc401zR/rYu+N9JdvglJaWc0TzL4kG9l7FbYrg++APwxXjegkXL3WnagDDeRcAAfeHb9cc+9e5+LRZ6J8EYG014prU64jyTq5cS7rYkuG/iJyOa+f5tSmugxTYLgkbZ1GHbbkgE9PyrhpLWUk+r+ZzOr73MjpPDXi86cklvMXg2uIZUb51x6kevWuuvrvT4Ar6ZdwpGSPNbG4A+/69a8WkW4mupZCxMkq+YxJ+8e/9a1oVmg0u5sghImCzEd29efx/Stqc3K6aJU5c3Md54z1y+tVsbvTrpgkTNHMqHhtw+Vj+RrWHxDmu9NaK9soFuHjKbkl+U8EA47c44z/9fjvDWiXF4f3yyyW1xZ8pnsGxx7jiodSiS38SPFOZVtXRW2kAr045+o7VvG19UY1KCm+Znofg/wAQRNeQ3MLXUVohaKeB3L5bb94Dt83pXWaV4rWa6aPUo47Tdkxnfkf7jH+9+leEy2c+mXWj3wcmJizM6ZOcHv8AhXT6ZLLc+I7u01G4RPMUqFZcgseQPfsaUoKd7kzw9OestGez6Vq0WoySLbxsVQ/eHb0rQZsKTjI56c187aNqT22q3tnfr9laM/JLHIUxg9CcjqO9bk97BaNIUnuYQqfNJ57dDx2P0rN0U9UYfUG9VJHte7KqegP609SK8LsbiWKQS6ZqF7AxTcrCYtke6kkY+orqNM8X63bII9RtoL9CPlaHMcp/Dof0qHQfQieBqRV46ryPTa+fPiT8UEvdXtLBNGnh/sbVo7pjNcKHdoshoyFDBfmJG4M3TPevbfDmpf2nYCcq6ksRscDcvscV4H8cfCrxeP7N9Ltv+Q3tCKCiq9zuCsAOMZyhJbqXJz1x5WYupCn7nfUypRSm1I9t8A+IX8U+G4NWFm1kJXZRG8gl4ViuVIwcZB6gHIPBGCelIyBz9M+tZui6Pa6No9np+mrshtYxGhwAXx1ZsAAknJJwMkk1owsTEpZVDY5AORXXC6iuZ6mMt9CQdFB5NDcZ5FBwRnmg4H0+tUIcOuMdKRWBYgfjTGdd4XIDt0FKSOATgnp9aAsSjnrScdO3WoJrqG3XdNLHEuersBTPtsBTzBNEYwMl/MBUD65p8rHYmY/MB0z3x0pVGB/UVSGsaaYhINRs/KxnJnXGPXrWZceL9HilEUN2lzOxwsUJ3k/j0A96pQk9kVGLk7JHQqwIyDSFuKw7nxHbW4ImgmJHXZgj6AkisZvFl7NIkdjZRszsRk7jtHYHpzimqUmaRw1WSuonak5xigMCeSCcdM84+lcQviq6kVLqa3WIoCPIil3CTnnkgdPxriL7ULv+111rU5SJJiELxOY/Lj6AKQeMfzq1R7s3pZfVne+h7cDwPSms5DAY6968jl8Y3OLiBNYWWC3ADN8u8knABOM1pSa1fyXzQw38kkEQ3MVXBXAyc8c1SoeYLL6vdHpe4nP8z3piklQDjd3xXmkXxAMcqW18ZI5jzwnBHbJz6Vu23i6K4jngVVkuwuUjQ/eU8Bvpmk8PNK6MJYecZcr3OtDEj5cMPY0Vg2OtadZWqRTTCMp8rknOX70VLpyT0JdCpfSLZzWl6uurapp9zrrWVtcyRfZDbNG0MySF2wqjONjYOFwDxzXO/EHRdQku5Vm1C21LALxBSP3UfVRtXIx/nNehacLWeEC2tRLPBMuZ0VCqgqRuLA5Q4PPfB75rjL7wxLf/ANoK3h2SKOIbLHyb9VjmVj867zyADltuOK6aclBvtt0Pai+R26Hn+n319Y5iktflg+WRQeFOM59QMe1bWmDUdckc28TyJ5ij90ynKEZO9jwigc7jXUp4csrl01OBtWubO3mSFbGOIxzx8YLbpPvw8cHG4E12lroGoa4b3TbnSodI8OkgpFbIQ90mfuyMeQcgcCnLEKC3+82+stQ3fzM3QLKwjbUdA8Nm5FxOhlub4RMIgduSqv8Awr0579q57w9AdFtru5067sZ9ZlmWzV47iSeJGzl2di2wOwX5VXkdCeufSdSttUsVGlaK2nWGirbGJJS482G56KpVmG/g565rBvfsml3mn2Mel6bqytJGELW8ZlS5AxJNJyOmPvHJ9DXNGo5p29f+H/yORz9pIreGpXufsWrto1/LrT209qdRA2rE4OHCjJQnJ4fGPlJzzVe4sdU1PQ7i119rq6ggWSS2iedknuQuOW4GFJO3HQ549a6Gw0N77XLjUGgu1mEa6d8oKRqi4ciMNwV55bnnIFUbnTovsr29lpn2qxVGZmtrozb33kmNOeT+OO3FVCUeZu+v9eZceVXT/wAzG0+GOCAJPqd8k+lzrcPYQ3UeISQDteNML5ajPHfn3ro4dSsruye/3Qrdyho7Ge4jXEIcdWAJEm4/MFXrkcVzF7b6odWsbIaml1r12dkulWGAn2RlGBMGyqED7zHJxgD1rd07Tby9vTptlC+m2Fkr+bqKoLcjA2kQN821euXOCR0ok48t2yXJNMt6Dc293F9p0+1VLyZAJ7s6eIJWx/FtxncfU9KbH9gurq98NWNtf2tokYeW9s5FVYnJzsJwfnJ5Pr71xurfEjTvDGzSPDT3GoQ28jfaby9Yzvct/eR8jKj6fQVzM3xT164lfCwW0T5kWJQF3KRjoe+Oc96UYN+X9f1YtR512R7dd2Fpocx1XTNLutW1ggwjy5sKGI6nLbYx3JUVpLpi2OnwWSxW1lZsMTBned2HU+WTnuTyfyry3wL4v1XXvEy6WdXVLSSzKs1vGN8T44MRx98dwcjmu9ublL21vW8M6kt3LbP9lkNxuKrIuBI24DJOOcDgk44FYTpyjK0n89fl5fgZTi4SszkLq/1WMS6eZdC1FJ2MEmni98pY0xgsgYAgkHcc7jkHHtb1iFL3RrWwFhb31xatEj2yyuiQIeBLvONwAGfXkZ61p6HoMY8ttYudHM894wsJ44gJS2wkjj5S3UnHy+tOTUmv7oQq8k+mWcAT7XLlzcuASzbQPnwAOVGCxAHSt+dX93oaRs3ZMxRDYa4+pahrFn9ns9IZojh94faNwkVQNpfkcYx0zmvPPEt4dV1ZQ95KzB/LlZ2jWZj0JJ4xkcHaK9L17UtKtzJbX1haSMlss+n206v9ocvgvJOn3V+YKQOTwK87fQp9f1W5vbC2uvIMpG+6Cjc/HMXGf6V0UdVzNaHRSdrt6J9/69CGLw3HMGhuprONbeIrFGsZCZ6gnJByO/50eHbvXfKurOyliuNQjVQHmueApJJyo44z26gc11Nhp0F5avaJay/2jGSkzTHhPVsfptFctp1hHp/jKWK7vjYRxAyvcRT+XtUEEqePunGOfWtZpdDWUlrbddP1/wAjuLqyvtHnvJ9CeyutTntzJ/Zsc6H96CB5oj4PPJbnAxiuUjtphqra5rMV5cSrMXiaBmKIr5yUDEMgUDPp6CptdV9O8W6hqkWrDTpYZhPJLPF521ZGwItyjKqDwVB/Crd5pja3Po93psaXAlQyCO7LxxwhjzIoJDEE8bSeeB71hHTWRzOPK9eg62vtP1e60m7i1i7v75hLFHE2baG4RDgCRcYCjcMuepPPSrlvd6jY+HdRbS9OgvTHLtgtlsPKNu55LbnzvCnJDgEn2FRalf6rNc2lkNOtkbVF8o2NwjLOoUnJOGOwEDIX1OSa3vC+lWeoi1uf7RlmtrZlmgjWfMqSZ+dJZFJDrjClegxxUS+G7Mm1Yo6FDfzWU+naVqN1qRd2tr7UUuVgNpJtBIhwoGA3XB/iyKp2ejW9wtxZXzjWbeNObtpU2/alG3ZJt+dmAIbLk4GPpXYrpGn2OtR3C/ZoFkb7OsIlI8+QZdvl4UufvZx2qqmm6NfXkWpwS2LQ28jCQWoUiTJ+ZGJPLdMnAbjGcVCkriuuhjS6bqbaY0t9DNLKIFBaKVYo5XLKT+/bDHAU5IwNvGDWT8X9WRX0X7FcN+9hMplUeYHQkABOox8vHqK7mDR5tW1X+0fEken3Eao8NlawxMAsT9AdxwTjIJA9s4FeParJJceLyNQtV+zWgMMEdoR5EMa/KoGec4x3z1xVUm5yV90aUE3O/Yv6DqttBdiO80+5mWaMEyEAmPGeOe/PQVavJ0ttVbzYrmzs5QN0SyfMRjv/AIVbsZ4NQeCwt4nleWQBA44UZ6/lWnJBDbaldiztpLuKNzE0pcFyQB0z2rtvrudM5Ri25RabXf0OL1ptOm8RaeNLhERKk5ZTtA44JPIzg13Ph6HTrXw3o9/qy29wk1w/2ZIYGVYxKNoXGM4AyCx555rm55tLHjzRWjt7wFpRG4CbfmLAdPUZyfYV6rLbPcaNImh3dvDPGDHFLMWdevKsRz6HiuWvJKxzVZ+6ottevmupy/xyihsfgpbW1q8cUMOvRxKkG3agFq/yYHQfWvnK8mS2gCRxssvyyB1PB46j/Cvon4m6U3h/4C6Zaz/Zbt01pXuGYHZKxt5MnJ56454NeFwadDfywAxGGFULrIhLggn7vPXuK4aKupKL6szhFyVolvSNNEqGWXY0cqAgAEMoOM49q6G106KCCF41DvFwHkALEdTz6cmrlrDG8cCphE4Q8cADAz9K27HTvNRxDFJOqNkPGAAR7Z/nXcmo7nc1GCKFnO8Cr5B2Hrk/w56j8apaw6NAFuIRJk+SHx90H3rf/s6Tn7RAy/wxSk4AbPQjnNTPolx5aIIN24ZKlhnjHIz7+lHtI3JlOmUbCNDpdjF5W2eGYruxkFOoqKC3jub/AO0TriUP5iOOMcnnPcAZrp7G1W2Mq3lpIjlcJIGxsP4VjSxfvViD4l3FQpypI9TnpmkppmalGba6HM+KdNm1HT0+zBQzygDI5K/WifRIodJERbMqxIjEdMjqf8+ldeLD7OIEkaM+cDsAk3EY7+3esS7jS6kcO3yIxCtnHyj275qoyV7jtGeqOW8GQTvrUuImkhUFd2MbeeOfwrodevhpEiXNzbb4GYBZVfleOmP85rP8RS3lrY26WBZGeXezxjBwOg4rHvpZGs7sXjMY775Y1fJG4c7l9AKpNrUxnGycDvtJ1rUbUxSaSmHuyMRTYZZcD73B+UY75rqb5f7RvtLn1vTbV73TpvPiELrINxQjgsM4zhscfMintXm+jawunWOn23LXMEGzcThCrdt3YjjrVv8A4SPT1u0iu4rr7X/HHvUknsBzUypxqayRxVqOuiPVf+EgtV1CKzZZVeXGxmUhc/3SexrY3Edq8gu/EK2sguruJorUJ5SiY7nOTnkD6cY/OlbW7x7P7VZ312tuV8zbFM3T6HNZSop7CWBlJaaep6zdXltaRh7yeK3Q/wAUrhB+tU28RaKr+WdX0/fjOPtC/wCNeVz27XC+ZLJJOWXcXlkLkg9+a528hu1vIktbOFrLjjaM9e1L2CNf7OSV5S/A9n17xfpWlRP/AKRFdXmzMdtC29nPYEjOAfU15fL4k8RXd3LJdah5fmPuFuI1CKOyg9QPfNJaRxzPItp5QkGN0a4Uj0JFcp4t1VrSWMWxIkBIbAwQffNWoxpas6IYSjQjzS946bUN9/As2oytsQkBS+1F/H0+tVLi0t4ljkAj2scKE5B+gBwa56G8D6QyqVmuLlgZIGyQw6hgOxqxHpb3uiwiGZobhJMhC33D/TOP0rXm6nRCcbWhFDpL6xj1K4tJ4CsiZKtsHzkDOAPetHQtctA0V5bxyQuHETxKg5Yjg7vSrGm2Mo8qS+CT3UYB88rznp+PFbFtBbxqI4YIkAOfkjAyfXApJvqaclR6t2+Rm6xqWvSwI9vCrEPyQQx28cY96vy3N5/acMS48u4AdmJ4XIxg+vNXvJj+ZsA87lwcCptOsjdX6mJ40YttUuwVRjpk/wBKLi5FFXucdbaZqupX1hc3sjILG6O/JIypPUAdeRikv9CutRgSAX01xHPeead5yIY1zk9fw9OlemPpRtmZXZJJ9uf3LbgSTzk46+1UIbEwRDCYjjXa7Lgc5zjP1/pUXUkYx9m07HAa/oEWmQR39g8jhZ2laBlByecOx9j2oS+lfQra0kuXhubv97cTs2CIieB9T1rf1YfZyI5oslgW2sPvk9MA9qivNNjlMJuArTAhlAH3f88Y9K1g0vQ1eHvqnucHeSTa14kd4g8dtGFhQHnai8DI7k9ee9bDa1DpkywaWg3rxPPjcWA/hH8ia6WGBYXZreCIH5icICPc/wA+a43xQkFk+2wBimmfLNnp/h68Vmv3a01JlSdNN3NwX0+oWcdzcXDoS7DZHhNtFUdAuptFUxyJFN8gCho84HUnnuTRXTG1t7EpzSty3+aPoa10Qw3Vnqek6bBp85yZPtjsuUbGcxoQvmYAALZwBWpb2OqT20Q1eeyV2ZhJHahgpGfl2k88jqPWq6axd3+qX9kdMktZrMKVubhP3JVj1VjwWA5wPpmqV34tsNFa0stZuY77UZi4LW8W1Dt5JILHYAMd/pXkfvJPRa/ecPvN7a/eXRoOmaO9/qt1qGrXVssBBtPNZ44lA5McagHdgdQeO1c/ZeJoX0K4uLhJ9H0fyn+zJLMZLm+QfxRhm345Hv2rG/4WdqH2u6tk06zN/btvNuk5IePjDoxGM+xrX1GabxT9g1JB5N9tAst1qJZInYjJweOMEc5A61rCjNO9T+vl+poqU170jN8HeG7S50F7PxBZXeoW90PtZZ95ghBBCIoJ3BgCOCM5PWuj8M6GttBPqb6GYdWUfZo5JVHmyRp8qkkk7eOMeg5qW51eO61q+s7u5MQ0PYZpPtAgiZ5FwoYA4b1AOOTVh42sNP0XS7vXVubrmadpELNKnJYjYcDBICg8YHcipnKUnr19X5kuTdkYt5qviVNdlsrTULoTS+XNG7abmzjhXO6ISk8ueu7GBUWm6Te6JaXSnUbrVoQpW3skjRJGdmyz5BGWOSCxIAA710P9kXdzqtpJb3E0dmqES2sknyMOoYhRkt0GCcYHTNU/FvjDSvAFsqzwS3OpSrvESYXg5+Z2Jwo9B19u9Lmt7sFd+X6hdLRLUp22haP4T8M6nEgl0qxuV2zzeeZpEJGDHC2AQeeMfWvNfG/xEj1mOLRtAlk0zR48IGd/mmwMAMPSpft+p/EK4m1TU59ukQzBJLWMFJI0IzuUDqOgJ6nqPStxPCug2kF1ClnE0siF7eUsXZTwNo7HnHPvXZSpctnLV/1/X5G8HGLV9zhdE8JxT3KpqF08Edxhopim1AwHTJ4yeead4i063hiWG4YXSRJ5MNxyFaMcADHXv19K7u/knuvDTQzx2sL2xEZiHzOSjY4AHH696yvHuyXQ4JJ7iG9R9ypFbxqrZwPmPOSox04rpWu6OqMrOzXdd/ne3Uxvg1FJ/wALDtZ4Ink+zpIZUwcwjHDc9OMCvZ7y9ijtHW0toIbuVmhs4AcRy3ABblgvQdS2MDvXE/DTwpqNj4envTcLZ3WsW5itIwvz4Awrtk/KoPzADrx9K7ttA/tWSx0vUInu7W2gSW5vN+1JZRwECg5JJyxzlRgDkmvOrzhzczf9L+rHHWmrv+v6/wAyhFYalrIitpESxv4LfyWvbUD9wWA80Rk8Lkgc9eM1yOsePG055tB8KSS3N2C6zam4DmNhk7VAGAo9fXmnfF/xXNFfQ6DoF2sWnxfubtYD8zMeuWGeFHbuc+grH0XTbXQtQgudMlfUonBWbcmGI9uOR36VvRpc6UprTov8/wDI1p0+bVr5f5+pl6DDc3eoG+1WKfVVhy0kifMy7hySe9dTpmpWkN5dW2nXXlW7hJY4WX/loTtPXke/Pb2q3bT2y6pcvp8kcPnoreWI8hpBnqG6H9M1XV7VNbjkil2tcqRK86YHmememDzzXW9ehq/eupJrQr39jfLqRltriS4vJEZyYSFGBjkY/Adq5zwLbPqOqavfTrpv2mzicudTjcwpgjmZe4GCR7jntW/4h1ObwxcLMFVjdx7UWPKkEHr9PocGqOjuljoWoTatOEh1cpczNdwsYo4dwBR/Qu3CKM8LnvWdV+5buZyqylDW1rf19x0k1rpMuoLdWbOLa4uGe72FJIbiR03EybiSo7r3A7Gs/RYbmXxgptNSlexubNJVjnjCvcR5KrFGrfMqJ1zjknPpSeJv7HsoodTstOWe4ndLeKSF/JlV2HEqkjkBRjgd+tdhfaXHqGjB72zf7Q9sCTDdeXOzZ4XzF4UNzz2rmlLlRnL3dDE0670WXxRfTQafJNqFlE1k8iw5Mrnl4lJ5aTA/ADGeeblrocr2VxBN4ihttLOUia2gjieGXeCpJzj5fu7cc5Oa29Gt5LrTrLzbafTvLUia1aYO+/G075B99sYO7vWbpHiG2uJlsItEgtNOkcxwubdwJZFOXJQqNqjjDE5LdKxcm9FuYuTbLniBpINMstDtb23kv7tSk91K7JN5QT95MpQHa+OnI4rF0fSrqx0GwRrfTtTluxIbnVLZtsaKBhGCEZeQ4AzgH1Oa6rQre+toLsaveRyyT3ckiRbQFhhP3UPHJA7HNS3kMCWH+kXCrasGEkkb7Dt/2CP4u/ArJS5dv+HIi+VnE+MNRfSdPOtCy1G31ra1tDBLIoUDbjeUU5IXsCepyRXBeFW0Kewlk1yZjf3DE7kQgADpjnr61D4n1WDXtRg06wiltdMtF227Tu29VPO9myTuY8nd60mmWAs5xbXhkusfdeMh930969GjTfLqejSpe7q3fy/rodh4Yso7WS6vrGdZreJPJjJ4HmN23fT+dU3ttXtJPtFjMWeQ5cqysrH0wR9RVvV4ns9HtNLiVQyASyI3DknkAgcVy2p+KNU06xKCN9gO0eZHu2n0Ddq0TunL+rCipyTmmnfv2/rU0/Bwk1vxDqN/qJRrK2jGVT92EYcYJ/P9c126Pc6npyi1nXR7+5dHVEZZ2jB5zgEAllHXrz7Vy/wqsrhrMsFW5jvpXWYSsCUUDJBGMNksOvauvtrnwv4eEsyX9nAZpZDJO025pJABvwe+3gfLwBxXLVlrbqc9aWtjkviTMH+B0LR3F1d2tx4rKwm4TaUQwSYC46jIOM+pryrRpoIIIImKtK0hVABkEnnP4V7v8aNTsrn4MWd5ZSpNGdbQwylMgt9nc559s814HoV7DaSIpiZvtD7N2OFz1+n4Vz4Zu8m+7KovW53lpZCa0W5uZXijGJEdMfvNvO3HYHvWJoGh6/Z67aaveXpj+0EupEmEcEHA9OtdDe69bafJZpc6YbnTpFWMzw8snbIwM9a63wr4bg03SrpZtQN/BcSGVDLjaikcDHY45PStZvqyK2JUJe8iaxQtawyzRk3CqCNx+VyP5HNVNctdUudR+3w6fiaG2ZUcPkDIzxzz+VW7eaOCWeG3ljnijUHeANyMP4c9+Mc1Q1vxDc2WlzvFau12o3LHu4PfpUJtO6Oe0nK6VzI0zU7+00G6/tZme8hVpIi68kduKd4Y1O28TaMb14THLCwiuApx15B/GmLevqlhZau1lJbzMGE0DcgfgegNV9LtYNBN3Po8/leeRI9pKNyrjJGPpk1pJ36G8YNpOBN4rvINIsBfyaddw2M0ixh0X/Vpzk49T2zSyQW89taXdvcLLDIqiKNU2SsD7Dqfeur0DxXpOuW0tvNcW8lzGuJ4SNwI6Zx3FVmttFXUDrWlahFD9nQo6RSDyjxjoOhGO1ZqTvZoiGJnB2ktv63OZuYo5AyxKuSceVuyRjHGDVHV7GDU1MV3HgLgopO0g4/hI6HtSav4rU+NTpV/AYYePKnyTuYjIPupyK2ptKmt4kNzEqiZNzfMCATwMY6VrzaHZTqxktTltV8P+bFFNZP8wVcxMMIQOMZ+lUr/AES4/tibWVXzC6hwsSltrYAyPYV3EUMy2ixT20rKTkSdCje3qOlMs44LaCaC4Fx57sCs8WQgX6Yzinz38xOMXqcJe2F7dRfZ5Ij5EaLKj5/eSseox2x/SnTvqMF3YWdufLhhVNwXADdzkdx2ruX0+GREn+yv5xyVlUscjPXH9ajksGI3MjjHR2j7Gn7VdRxjF9TjZdX1vR9Y/wBIZpYZH+SIAEbOgI4pmoT6l/bdhb20Ey27hXKgZA55BPbFdwLVJX3GNgBk7+Ov9Kt/2ZNK6DySFC4wE5x13D1oVS3UTjFXTZ5rqGk3+kXd7qWnyzySSMRtaPJwT+tVrvTbrXLO3u7u136hG3lu+cZQdCR616VPppjlV5/MQAkDIwKkfSmPyrC3pkgjPak3Fqz2Hy0++jOBvdGfdbXkMUT6gu0yMG2gkYx7HAFa1jYJaCV4YX8yXlyCSOvOM+9djH4duI4mP7sp0xvySfWtTTPDwkiee9heQkElVcrv9OKXtEloN16NP3kc9omg3l/IRGQEB/1pGAB711Nn4KihXdLcGU4+6qYB9s5qtrt02lacrW8YtLWE+ZIi5BKjrjPWuE8JaZq3jPXH16PW5I7CGbAtS5LDuF25wBjv+lTdy1vZHJWxFWa5lKyOk1jXPDXh7UTbalCFnYfIsgLEehI/rWX4q8Qafoptbh7ETCc4SGJDtIx2xjvXR3Om6TP4ji1DVLa3klt1AEiEOc9BkHkkfStWTX9D+0R28kUiIQSWkiI2Y7Y6ik27aLUSnNbJvQwdHtjc2UNze26WD3Ee5IbiQq4HPJTrmp9K1DQblZLWO6hnuEPSGT51XPVgOBVxrnSNbkntLe3kDTI0YkkXbkEdAeoyK8q8aXkPhKAaT4d05raKRQ89wSS+4/wk+39aHJL4h3nP4tD0y30K3niN6ZI0bcQr3B3Mec5z347VXsNFjluXmtcXTwSfvA6YQsOcfjV/4c6mmseDbQxgPexIA4lXo3rVjUk8QT6tFb26Qw6aq5uZz8pb/ZXHsBk1V2pWuR9ZqJuLdjl/FWoXF1JsuAltbwAkRpt2n3yO1eU6rch9aSaKCS8I+55g2xRr247+uTXsPi/SoYNGS6gvvtQSQBsAYKk5HTrjpXll/tt9Ta4aW3vrwKPJsWyFTI79if8AZqotW00sdsXGVFcv9feaGn3Ul2Gad1C/wmNDj88YoqzoGvzfYgNQVYHH/LMIePoB0FFdtubVMmNSSXwMl1Dxb44S3V71UFlKxRBvyCRjK5z3z6VyN19puIbrUL2T95KFwkkRWKXB2kkg8NznnHQ/SvUJtKe6RRmUzAkx2xiwqqG5Kk8AfjXmniApPrMVvZNMnSJpIY2L7gecc/NjuK56kFCLaY5JKOjJtA0HVNRuDJp8fnTW4zvtZcYJUlTu6fNz1/HFfTXw/wBHuLTSIpb6WR7iVB+6PWI45Ga5D4W/DttIikvtTnbzbgDgZzIAfldgTwa9K1H7TZ6cWtopLqdsKqLiNfqx/hQdyOcVwVq3MvZxZzV6qS5IvXr/AF+ZzWnaPpup6Xqcp0Z/KurySa6hmZZjK8YwrYz0yOB+NXNHjW71N4dNeJ7KEg3N2pUl5evkqAMBR7VBZeHxq9jHC15YwaKxaa4tdIDIlxKTksZyQzDrnAGeM9K5n4g+P9J8H6fHoHhuJI5gCgW3G1Y/YN6n15oTc24w/wCG9fMzg224r/hvUteO/HK+Eftmm6bcpd6rw5RbYlbVOAXfBy7Y9wB6V5auk33jXUVvHnE19F82ZkKi8G7lsZIAPA9Ks+DoL60u5tZima9iJZbqC4wZGDdWB5wenPQ4NdaZrOJj/Zm20+7PbggqQH++uDwQcZ616NKj7PZa9zqhS5dErvv/AJlWPxE9zJFLp1lNBrEJMF1atH8u1R8ysRwQOqkc4NJYXE1xZm5ja+bUIiWiQANDGhPAw3Y8/lTpmIuxeeWI+vy8SAnGDn+8KVr/AFnTrN7m1iS8s0gMJ8k5bywSRx3x0rXl00N/ZqnFWtfz/If4d1tnmuYrq+gspXcvvkTazsevzdvoa5+30eLXPGN3aWQvNT03z1a4W0HMj4yWDE4Uc4zUOv6rpPiTTNLtdP06+ub2V9jNCCPl9M9zk9K9x8F+HLTwho8VrZbZLiVgHcj7xIycHvXPia6orTdmFScY3mla/T+ug2Hwxb6jZ26a5aIJbe4WaNbaRh5W37iBs5IC4B7E5xXP+P8AxLNc6k/hrwzeJb6juK3EzEIiDafkU9SfoOuB611fjjxHB4V8M3V9dXHl3LKUg+UMfMPAIXPO3Oa+efCs9i+pT3HiBJdUhucPHe4zIGzk7lzlfqK5MJF1X7Sey2OejGVR89rgvhLVtN1C4SeSQzOcIzDCS55+8fU+9dv4J0261G3YSZWwib5pmJV0YdVX1IGc+lS6PBPrF8thp+sT3OmSjc0dxHuESA8lW6k9BXU+INQiSNNHhuDaQlDG8gTCKMf6vd0XIPJ/qa7p1JJqEd/nojtnWlGKp21/LzOR1Ga1N87vv0mMHMFz5ZcM3pJ6ZrnNe1rUBYzWF1p8ctyvzQzRvlWGe34/zrrtXivNIs5P3huo4gA6zbZE24/vDkH65rznRo7nxF4xhax0e4ns45VJgh+bHPJUk4QcdTgY9eK15klzX0KhKLXN2/r1/Q1Phx4XvfFEw1XVrtlson8pIkHMjqRwOwX1Nd5d3Nrqms6zpYkvbucqsrgKVWIoANkGRtxnrnk0nie+t9JgiNqY0trmXZPb6ZB5hZc42hwcKeME1ujw7aXt8NQivNTM8siTzqr+Wsuxdqow9ADzjGSO9cc6j0nJ/wBf1/XbnlJ6SZzGg2djf+JLvS7nSHe4hYXu/VQ0jShjjdEo+VRxjGRnvW5DDa6f4sKado99JeNPF9tuB+7hji5wQW4cJx8i/XrXV3jS29u00t1DZWcYJ3tjAGOhJ7DrWL4bhtpraa7h1aXV0uJTIrvOJY4ug2oV4VeM7RXN7RyTfQwcuZGJpuo32lPqV74lNtp+mtO32WxRkV2Y9DJJnBLk5wT9a6Xw/qv9tQT3Y+zkwzfZnit5BKIWXqGbHLcjPb0qW/bT7XR7ufWRD/ZijzJFljWVWA6EDGSc9OOtS217FqPh2DUtKhksrd2EvlTW/lM4zjJXtngg9+Kick+nlciTu7Fqfc0sYeNTjOAwx9OfWvNvi3qNhp72rSEy6miPFAw4ECsAGCDpux3612Gt67HodsbzUDPPbyb5vmCgQHA2RjHXJzjPOMk9K+cb/VpvEmvm81RryK1kyqywqQVGewJxmtsPTbak9jbDQ97msdH4LeW0tpvsjwSJP80sdwCCTjpn/wDX0rr9D0+wkv5NWitW0/TrLDS72DEyY/hA4A7/AI1xVto9pYzxytqA1ODdmMlmimAPZl6dveut1XVbCDTLDRROYtPx5k8yDLO5ORkdwD/SvQldpW0O2VPS8E9d/Tr8yiqWWr3Us0t9NDdPIWwCFzzwOevGODWXq+ranPqS+GLeTT3+0Msa3EMX7wHsMdFPuBU+pTaZDpxjttZ027RssFcbZkI5wO9U/h94am12Z52/dQ3jiEOW2OsfWRlwM5xhfT5qUmkvIym4yXOnov0+49L8JabrukPDYLbwXEEqM02obgiJg8BUHzMW7k49ai0nRtMhunNxBp17cHfC0EapIIFLHKrxgAkktxnOa3tThsY9bgW3hhW+ESQ71J3iPPC59OKt2WgWmn3c1xZ29vayS5LNHGB1OefXqT+Nee6nV9Ti59Ly6mF8arNLr4R2sUqoA2sqVVV2jIt5AB+lfPWmxTGWzge0BS1cMu4ZDY6gnpXvfxwtZLf4QWyW91tb+3lfzJJDkgwScZ/p7V88S35sLqO2sYB9oYL5kmCy5OOVX05qMO0oyfmzopOKjd7fmd7Hpeo6g8Js76O0ihm8yeEBsrk/Ljjt6V2RjnsyDKYZbeZt0rru8z8B69Pyqp4Rlkvp3a8bbPJAsYZV+UcdfaujtryCLS5obqFI3th5bR7hhvQg9s1rOTvYxr1GptWOMvdWtU1DVm07VbeR4bdmEaRnz45On0x/Wl+GZmuNGfWdZcSRNIY4yzDLY65z71J4Z0bwnba5c3IEIvMOpPnMUOeuc9+taPiXRdG1Tw4un2yTrZscwtA2AjZ+8Qe31FS5O1miJN/BrcwvEMWsajrVs9gzWltu2oirgOM9iKveBtai8RRX2ny6dm5tHaO4kGPnwSAc468dPatHwzoUHhq1sLaO7e72lt3mkcBuoGOgB5ra8P6Zoug/aXsWEZuJN0ju5bJ+vpSlK60FVq2ilFHEL4at/C2sy31rab2eNkwMhNjcMp9CaxPCWiHw/wCM5reGU/2ddowMc7BQUKkgEf3gcc16ZKTd61E8qzC2t2J2GLcGJ/l9ap+LPAen+I9YsdX+1TW9xBtBWPBSVQc4x2PuKXMk1dFSrRSXOtTiLw6raWr/AGqxGorbSqLYmIM0S5ydrYJwPbI5FZ+o674j0ayvJNQjikty6C3hkBPlr15/Dg57mu38U+Er628PyPol5Kt1EMjM2DjPXd+P0qhpml6ywSHVY4bmBohJJISJFlbAzz/Me1a8yaumbKcJ6p/8Oa+i6nPeeHdL1F1eNSnzQg9Segweuax9U1eB9YisrbUTbahK+PsrAck/dBP5UvhzU7m88c/2Y8TfY7Fd80vSNTtz9AOcfga6jUtG0LULya/tbKzuNVUAxzbsjcO5Ge3rUt2dzJzVOXKtSkPDMusiDfqkkMcJ2tHGASxHXk+tZfi3wffy3Vpa6RqF5bGZyjMy5jUAEhnIOQCRjgHmrUnh+8v9Mjh1l1tFkOWSJjjIyQVYc9KisPDmoRXsdra6jq7RsQzGWTCKOSMA89vWk239orXVqehseH/Dd5oWnKmqXkeoPnBfbgY9Ofatu41WK3iKPZzpJ0GQMfUEHpWXY208l0lq+oTvLGxSQE7hnHVc9a17PQkFxK94pmbd+6kZiXA9/epb/mZhNxX8R3ObuPEVpqc5ijtYZ47bmYt1Vhxnj0rQa9lhkWW7lhgtcExxFgu7jvk5NacXh/SYJdiW6LKcPyfvHPU+tcf478Cadqtyb++ubqN1G3EbArgd8Hp+FVzx2RSnTl7sUbkVwjzYWYKsjfK6cgn0PvT5L+7SCZDIY5Y8uGB+V1Hpnp9K4uWUWWjrplk0sMKx4VmAPHsPX3p/h/ULO3h8i6d5ABjccnIz3FXynX9W05mijF4v1hbqddf03ybNs4uXcFRz/DuxnI7CvQdMtdMsbG3msoQsEq5AaArnuSAO/vXJ/EXw5B4ru7DUVvlWKBAojX1Jz0/Ku20O0cW1m2pXMcl3bKVG0Dayn2PQ0r3jd6HNUdop7L+vI4jTtd0zW/Ec1loekXUNyAytI6EAY4JB/h/Guht/DkUe+ecS3B3Ayuke4vt4wc9frWnrevzabrOnWlppzzQ3x2tdoQUjI7MoGTWlp82o3MZa7t4oYz0YMVY++OcUudpIh16ijdaL8TCOpWdjqkj3E6WsJVY0kuhtA46YP4c1oxaZJIz3sl5GzPg7lVSrL2PPWvK/F3gLVLrXbxo5xqQuWBVWlyIlz0J7Yz1rY8S6CW8Mabph1h7G9tHV0l+YhsDGFwenOadk1puaTg9HTe6Nnw/HqHhyG6tX1KHUxM7TR3DgiSJOcjGPn561tQ6gdT0O1hkkld72IhhGAZQD3x2FWIbuys/D9vNq8sSRBFD3LlUEhxjceeMmnWWt6JZ6cbyKSK1s9wQTEYV/TBHUU+j0vY5pTW/LqcB41ae8jtJ9JvreLRrItaT2aMN5k7ggcDHH+TXmF7bm1vWe1KRqTuluHAYgntz0r1TxHpnh7TvD9xd6BcSOuoXZuMBt6uwyG2gjgc/nXl0dpc3bFFtUWzZ90vmP83Xr65q46rVanq4f3qKsuv8AX/BOos9Hje3E1tdKY3I5CnBOKKhs7C6itES2t7jyF+7tBx/LNFdfPFHRHnS1miHxB4pc26wWct1HcKMRfMxADHkL6HpkGvRfgp4KltWl1nxDcAknzIYGAA9S7gjIx6H+VS+GvhA+nWyXUsscOpb8yiIiRtoJBCM3ALDBJIOK9AtrZLi0mt2jvdNmDlUt7qRWEqjoVIOMH65rhrV1UVlL7v6/E86daMlaMvu6GxBq9nqM8kOl6hZzyxqGkMUqybAenAPesvVZzq6zWFnqawwKxju7uzlVpYmHVB1CHsSe1cpqFhFqVtfaMka6PGSPt729qCXxggE8bgQCCRjBxgmqnxSvH0TwxpujaGgS91PEUZQKpSJcf99E8A5OcZrGNBRkkv68zGNJJpMo/Evx55kZ0LwxNCqiMq8juQ0qAYKxnpn3PftXD+EtEEMz38xa6uLYCZJZxu3ISeD6+me1bFpoNvo+nxWF5Es0xYSNao4kAcggvFJjKnPVW6VoRS6fotnEdUzekrtW3BKxRHI64+9njPbNenSpRpxSSO+lCMY3iv6/rqbFppCX1xFdWExttMkUSm5Hy7ecMg6dcZOeAapa1AEYHw8kb+U4PlXGWadCOq8dD64qjL4r36vZwahbp9kjYoLTYNnlsuA69mI560abqmjWVnpkN/qUYERktke4cqyfMSrZz02kDPtiqSlG7kxN1Kestv6+8pXGq6lpNtNdyL9p0qCRJ4gseDDnORnvnBFUv+E/utT1UWHgfT5p3vgQ0c6DAk/vgDgcdT0rT0m71nXb+70nR7Vks7vfHJc3MY8p0PV1I+7kDnqPTBr1Twn4Lh0FLJNIKWsandeSLCC90NpATJ5VcnJxycVz4msqXUxrVVrf+vvKnw48IxeEbAtcvHc65dNvuJUTCqcYIUDj6txnNbvim/1LTtNur/T4bRhaKpRZ2OGH/LQk9uOB1PU+1XG1O1TxHDpUaiSZ4jJMyyrmEDpuTO4g9AQMV458XPG0l0LjSLa6trOzhnDXHk3O6Zlzxnpg55IHQY5PNefShKtUUpLzd+xzxTqyuzndV1a58f62k3iW9ksNOh3JAEtW8lT7nORn1JGcVvJp0lpMBaWlrayMAqxlCYbtR/cPZx1B6888Ve0A2sOnRQ2l9Dd3s4VVi34lbI+8rHhl571Uisore3eDy7XfBI5MkdwdxPsgOMjI5HWvYhGMdInoQSXurYvadqLaZ5l3A62rkFTxsRCOCX7emT9Ki0ya+mv7jzb+OOa4If7PcxCRLj3DZwfoKo63DcXeiS+fdCTTRI0bNFlTvPVT/dz7jGa4HVtUghg/snTWuJYQQsC4O+Jv5g02lq2ayUeVtW/r5HYeIrfxQmqR6Jp+BbXrqqpb8naTgEq3zIOfpXYaFp6+G54tA8Oxm4vBF52r6koLkAN/qlGMZJ/rTfCOiz+E9Ca+1aSW48TX0Z8hp5C5gXGBnPI69K1lu8WSRPO4tUJRbaMBQ7Y5cnqeTmuOpNzem35mMKbmr/0/uOdvtFuNN8NagukXTS3UjG4uJJXG2BS3O1xwPlzwB1ru9H8rRdH0+0tX1DUnvJv3csgLldwzlnAwkY9T61yypPqUttpQ0ua6srsGCa6HEMMR+8e24/h1Nd4jxaTprqn+j2NsgUy54jjUdz9B1rnrzbXKyMU9eVGPremyXkyzWdnZXOuW9uYRJOzmCHceQFHBODz3OBTvDuiahbCB73UYpoI4vKNvb2awqsh5ZhjpxwP1q3oeq3OoWt80VsLa2bLWV+JFmW4DDIl2joOnBPNWNBj1SOO6bW7q0LtNuge2QqfKwMbweN2c9B3rGU5Ri4nG5tKyIBYafbanPqi2ZF7PGIWuHLEiMHIUA8DnB4HNZ+rm81HW9G8xzZ2trM80ySgk3KhcAAg4AOSeas6Hq76lqF1BqcAs7yNmlW2aZZCkAOFkYjgbuePxrMHiuK71PXJfJQeGdOtEdb/DYupG/hRjwVz8vHU04pp7agmk/M5P46eIIrXSrDTrbYJpgZsY4Vegbpz3xXHaPZxjR1Sx1aK+hYb5LSeArJux93A5Psao62bjxh4tl1HUJY7fSWfykvFLNHFtHCZUcdhzVvS55LTVLu1uYN04QeReQuV57Nkc59iK9TDQ5I2O+nGy5Vuv6ZoWsZtYkEZQrINxib51VT0J7ggjJBHamXKW5kmi1GFdQiY7lmSHep7HnGePar9v5cl2JTafumRswwThcsB13E89MkH1rEu9YutLu5W0tzYRj5vs8rbwT64554/St/kdEry922v9djkvFLWDajDDpcSKdoXZsIOB9ecfWvoH4a6TNo3hO2k1ENHeXK+YUcf8e6fwoPTjk+pNeU/DG1bxt40e81fy3e1VZNyxgfdPC8etewSX73PjGKAyxSQBJFWF0+cyKQWKHONoHXI61w1m5XivU8+vKU9Om7NhvKW9iN3IpuArPFCOydNzev1p8cUVvHIY3lGSWJMhPJOf61DdtdPbXlxbLD9qVNsC3BxEzf7ZHOB3/Sq9xNdRi1eWS0CNGDJ5SEndjouf4Sc8muVK+hzpN6HO/Hg26/B22+1ykqddTbJGpzu+zydc9e9eBaefKQQ29zGZohnzGTblcZwD1xXvnxeI1f4RWe6MGOLxAgZJkK5At36Djn5hXh2jSx3V5L5PmsuQoSVcbR6f4UYZNc1+7O7Dxa3Oz+G+r6hd6ZqoghQTwRP9mlxxI+04z+OPzqHRdN1DTPA63WtebLfz3DYR8koG7N78MfxFXNB1vSjdx6Qjr9rkcIAmQCc9CRWjdp/YkWpWXijX1t7HUZiLF0Yh0z1HTgdOenvWr0ldnJOfJUve7/Md4K0/TdQ0oy3ehpayiTCvIADJ/tY7V06wJZvIu5Ui2ZZABwR0x9f5155o+l6r4YvJLC51drwXB/cRnkgE/eOema19UnuYCILO3kuZgBudVLBW9M9OtS1zO5SpSn10Z0tjYi4YyXEiJGwysQAHfjJqHV9LvG1izi0oRLbNk3ayOcYx2HUfUUaW0pjs49SMMTzLmRV4ZD1GPy5rohaQLEo38LwGZsnNRzcruc1SbhLcyi506eBNRYJBKREjMxP4bv8AGprO2m0u8lmln86xmHYZMXpz3FZviCwW/RI9SYTWcTb/AJOASOgNLFJ/aNw1pbXiAxKCsfaQY4yfTpTtdFct43e3U6NbyzuAYzLE4cbdpP3vwqi2k2tpiW3iEIY5MafcJ/vYq9EYXhh+0x28cvRkyDhvY1CNLtxerLbp5WFO4xsfmJPeovY54tRdrtGH4l0fTdSsJLK+lezhYbibQ7Q2OmQOv41xU3gKO2ggvNC1K6s75QXCuxJdexHb8K9QvNEtLiEoTJFJgjzEbDc+vrVa00pkaOO4W2uYlG0y5KuR7r0zVRnbZm8KsOXcxtMS5NtDb6qyvdRfvPMVSu49hgd61rq/a2O7VJmhhAyEQ43H0J61a1O4h0iFBFZh5Gwq4G0Z/wBogcVgza3ZtBdXE8Uc1yn/AC6x4dvqSaavJ3sXG9RXS0HaTZzarctfJdodLA+SONCjhs9z39atNd2NrqAtg28v94JuZt3bvjNZ/hfxhJq1zJDDppt4VIG7+nHeul00IbxiqKhI4VB8h9/r2zTldPUTco35xL4sYyIrMxyKBtdiq4Hv6CuC1ODxdf38tto62ltahh5s8w3bsY4Geg9v5V6lKwRS7YwByawbjxPpEumXVzFeRGGElZJOiqR79/wqYydnZGdOcrWSPOfEm3TLdVuJlec8M69z7DsM54rlbe8ckCUDn+LpxRrmu2+p+ZKj5TkjK8n3x6VyD6qJiSgfz16DnkAVs6ihuz3VUjTiuZ3PQrHWpYLgwbwYnXDKT1H+NdJBr0T2JsLjVUg3nPmzOCU9AP8AGvGo7i6/4+plKNG3A7/j/jXQaXcadfY+0oIpmU7mPT8auM1Pcyny1V7uj8z3231TS10/ziLeRVjKpOjKwkwMHDDv0zXn3hb4qXEvi1dG1Gyit9PdzEpUHdGc8Z9v8av+DtJ0nVNKWwspkQQx/M6kEEE5x6g+9de3g3TJLaFovL+1Qt8t1sVmyD3NZyUYy1PMnGnBcs3qZHjq51bT1zpAnj81WhYRAt82fl+nFYWta14k0mHRLOSFLm98oPcmaASbix4X6jj8a9MMrxBlvLfDqoJdeUY+3pWNezNvmvngAhjjDOCw3g9Ac9hx19KIy0sVRqp2Uo7ficuug6j408IXtp4gSC2vY2kW0jCeWA6/cJI52Z4IAziuF1PUrfw54Qk0TxL4f1Cz1K3TfZxyXDPbTyHZu2uvYbyxUEjA27gTXpGneLIPEUqW+iX8XnW5UMQhOQeDjgcD1rP+MPgHVvFz2NzaanaRpZoy/Z50KqCcl5A6gkk4QbcY4zn15cV7WKdSjozOTcZK73/A4zXfGNjren2V3p8T20CQiA2x/wCWLgfMAeh6ghu4I4ByBH4ZhsLUxzzyiSOeQGSRznnHA+mTya8+n0XVNGuvLVopFfhikmFPPT5sfnjv9RXr3g+1s4dKEUyRhtoQlgrAZGTn3+hxXVl9SpUhapFqS8t/Q73Nwp8sovRWOlt7twM2rckYIbDZHqDRXN3Gn2jKEsIZldT8zxysoP4CivS5W9kcqoQerZ9Hj2zRJEkibZFV1znDDpXnQ+IsqMBPZQIxBKqsjOXx6cc/StP/AIT2KODdJpd5JNkDbAysv13EgAY55+leE8JWXQylgq8Fex0N7oFleTRSy+erxO0iFJivzFdvI6EYPAORXnHxf8I6pc/2PqdjJ9pg0uJo7hXO1jHkndx1x3xXp+lapZ6pZJd2VwkkLDIOcfmDzV4FXXghgfbrUQr1KUtehEKs6Uk30PmbQdQ02a1kgubu3sojCZ0mnGyQk9Bk9vbNWNU8R6JpjW8NmqarHMWhlCn5lDDo2eDz0YdhXtniDwF4Z17zDqWk27yMmzzI8oQOvGOAfwqvonw48L6JcvcWOnHzHAG6WQvjA7A9K9D+0oW6nTLGqerujxZfAviDxlp9nMstuNNVStm9w22SNc8plRmTA/i6cCu58EfCLTtEMsmszvqjsx2o6bEUe/dvp0r0O98NW1zfLeQ3FzbTLD5ISKQiIruyCV9e2Rg4rCax8UO8MCNe20qy7mukvEkgZATxhhuGR/DisXX9trGSX4f18hKqpr3ZWNuyv7H7Nc29m3kw2b+TIY4tqxEAHAGOmO4qaDXbGaxjvbe9gOnshkWeVsIyDOWDHtgc96tQ216Y2Sae32tncvk7vlPY9M8Vkala/wBnaCyXun6d/ZVrGxaKOM7YU5yQvOeOfWuZKnN2/X/gIwspPVnNeI/FU+ieHdW8Sf2dYtcuqQ212hVvtMZ+6ysOdoByFbmvEfDOnXup+dfXSi4+2SmFXkjXLu3BUk9D9a9M1jRrm/8AD8em3c/mJfXZ2T2zZitI8ZjwpAIXAwcZwc561yttb3vhu8lt9V01r/SY8NHPFJuRu3IUcE9a9ehTjDY9GhFQd0bf2X7dpFuniS1ULaK3k722pI6ZGVKAcjHc8808RxlrspdWi3tokcjxzkS+awGWZHH8HQcd65248RSXehy2Vp4W1AXTszQSh2EcSluuD6A496m8MeHr7xWLa51q9s7bTbRMie2nAPynkZHLA91xkVq5qKfQqN1foYF9r2sa/rH2DRJJblr1QskaDcmOQCTjIxnqa9Z+Fngi30Scz61YS3OrRjm4nX92jDHEYb5mx/fwB2HSn+Hl0jT7O5uPDelSIbyBla5ceVOwyfur0jz26dRWhbarDaRafplsbuzeJFVJFga6wvUo0nJPJ6k9q5KzqVE0tETUU5fCrIg1bTtQn8VXcNlqAvbuRvtBt7hGiFvHwAFYjDDnsc1o3fhSSSxnBntL68IDC3lDxws2ejsnzYxnGOven6x400+306eLVxOLdQI5JXygbI6Lj5s/QVd029gi06FNMguDuQJGNxZvYtnnPqWrButyrS1v63/4BPPXUeTb7jR/tfTbS4hsbm8tYbhysQhRgDvxnbjqBjpmp5Zo50kgjCyRFdjoVDB89QwPasL/AIR9ZpGuLnRLQXDSi4kuZI0aVnAwCeOWHbNUpPEGpWU98p0+6hihK4jFs5luMnHyOMrj1yOP1rFUVL4Hd+pgqd9nc62zs1VVEaoqABQqDAUY6AdMfhWPrN9FpqR29/O8VxNJ5UDCAnex+6oA69Oelc/ruv6jqMC2ekwR2VzcF0a2vVlWYxZ2b18s8ZOcHOenrVSA3Vlby6XDpFxPc2cKSwTapumTA+XK4JYKDkZxmrhSlvIqFN35pHR+EkuTHctqmq6fqTo5iZbODakTDqhbJyefQVyPxu1eCy0C0s4HUTM+YLZMYJAxux0+UZwPU+wrrLK7ubi0srX+0I7HUYAs09vp8KvGwB+ZdrDO0/gQe9eNfESdfEHxMvY76CZrC3VYjDt2smR/Cxxznk1pRpynVClGTnzMq+FPM8P26rr13Pbi8PmW82Q6NkDKspzg9Occ962DEQJ3il8xULID5AVNpx0B5U/Xp2qtbeGLfz7O2gRjZTLkLfNHIVYZOVw2fzx+NX9TuRa28CBwloh+W42/ffPdvwPPSvViraHdSsnoW5LS2t951GbzHBy0sKqyoScKcH76k8exrm/FF2bRPLlgKW77kVoUOJGI7A9KrX3iK3tJriOWxtdRnmbMYeM7j7fL/wDWrqvhZ4Wh1eNdd8Q27yqjH7LBI7OvB/h3dAD+frUVKippszlUdO7nqzq/hd4afwp4U86aIHULlfMZQPmHdV59u3rXQ6Np1ppUE8sKSm7vHMkvmtuZGbqo/uqOuBUU15bR3hvLm7LEKEitlkLQqM9cKOWNUJNQ1LUdJml0WKY3E4PkzSwMqKc46HkDAPPWvOcZTu31/qxwcspNt6f1+h0YZcqp/cxRDPzN1rEYQ392JLmO7WOOQ+WsUjKJR/eYDqPbNRarp/iK8a3EEsMNuqDzIniEnmOO5YnhfbGfepn8O3UtrFD9qe3UDBETGPbg/wAO3pmlBRjq5DioqOsjI+McEF58JrRAkix/2+hGCd2RbvySf89K8as5LFYfNvQYwDwyMWyRxzjr3r3Px7Yzp8KbWC8OGj1oEMJN5dfJfBJ4ryrTNLs7aX7G9vhHVnKtyo9OtGHslJruzspStDQ3vDI8PTarZ3draL9plUiG42EbmH3hj+9jnPvVLxtoUGv+M7C51GdTZ2cWWt16yEMfl/E4zW54TtFs7GJDAqorsVOd2PXHoagu7cPqLzPgI2VJPJXvn8aJ2k2ccIr2j5jCt/Duov4m1LxHqUyTLLE32e2V++PlyewGO1ZHhrTtb0/xHcaz4ivpodLiDGeR3ITkcAKev0ArttNvJP30ACvIRtDheT+H9a5bTtJ8UXviLytVuY7rSN/zxTsGQqOmE9fSj1KlFxTVjN8U+NP7T0kp4fU20zSbBJcAK8ieqe+ccVqeAtb1A3txoOtSo9/Eu7Mg4kU9Qc4zgHr1rZ8TfD7T9X1OO7YiCSNFHkgfIVHTpwv0pNasNE0bU9Gubu626xGpSGRusqDIw3qMHGaS956EqaskmdLpzta6bFZypiEEoqs29vz71zeuzXmkC6vbKKOW5QM+xUIOB2rD8QXXiiTXbaHSHiNq67gQoxju2cHp7V0MesWqadDBqmrW0d+hw8igop/2c468U0rM15XG777mHZ3CeMdOW400y6Rq8bDcy/MrN2yO4rf8P6Z4tihll1vULQg/IgTncnrkEbT9M1n6DbanLrbLJFops5Q3zWkg3xnB2lvX3OKsXF49mnlGALCoxIFJG5vY1bveyYRg6lknt/Xc7PTY9Qe2WNbmPzkb5mkPmNj0OPUCpr/Q7C9uTczNcCdFwTBMU49wK42y0OeyuZZotRkMFwobZGWEnI9Rx3//AFVLpGhtp2oxajbajK8SSfMpB3t6o3OPbms+VX3IlSSblGdvRfgdXp19bQuLW2uJGjjyXaVtzLjsT3q61vYWnmvKkCLId53AcnvXGa7rOk6VqIutREtqJiN6CNhux/8AWNczrviLxEdVLaXo1vd6S7AW1yyyNlT3OG4P4UnT6mLotvS53P8AZ2pXOpXrrJZw6I0YWAQJtf1JJH41FrnjzRvDVzBY309xcXLIGWOGPcQOgPYDp061k6tN4nt7DTTpkdhLI7/6S5UrGqcHauTniuqXRtNS6j1G5jgM6DatzKF3KOvBI4/nTl5kyWlpfIj8W6rYL4Onubu4ms4bqHEe4bJckdADyDXm97oQXwRHF5jm3MqzuuMFx2z+dd9rlhpniS0kifyr6a2YSIGY4DVznxI1OLR9BtYJY4kuJFyVRuABwoAqoSsrLqb4aMU1GXc8a1GdZluYY7cQscYYdcen0qxbhLHQySELuxZWByVH+RRc3TXwEJjiRs/IxGN/pzVmHQTcWY+1RyYjclfLBK+4Y4wa1SerSuzv5HOXNF/oZNnp84ijuY4tzyk4iPdT3p4SHzoonuGtJYskqMryOgyf/wBVekeAfsxW++ztEb5GCYPGxAP4R6UnjeK3ubS3SS3El4xO0vhmC4POevJqlRSWhk5Ln9nEz/hvrKweJYUgcKGYJJn7pHpnvzXpd/qUhstT0zTgNP1Z96whDlXIz8yV8+XkdzpaiXzPKCMpxHkENXb22v2d74t8J63rEl4kjlYSEOxVbOPMY++eQOuKyl2e/wDVhV7S96S2X6mp8I/ET6hqUGmapqE9zcxGSVYGGE2jqM55bPOMY4NeneIBZ2MV1M0Mkz3Ns8KnaTFtPUORxj61iN4b07Q/FK63b2UM7vKF8xW27GJILHHfOa63VWgn065tYmDN5ZPlL1/KobbSbOKcv3kWtUzivhV4ftdBvtTS2iG6VEJY8lRk4UGtn4jeIrfQ9HWCT5ru/wAwW6DrnHLH0AH86n8KW72lrPNcMWOAp2+3eub+KUGnXmlR6zLIsz2BwjxNkfN1Hpnim17yXQrljPFeV16HjV1NDf3Gye1uQYsoDG2ePdcV0Si3igiWEvhQMBvvYHrVHwtbW99dfa7y8laIMQwZ9pJ6gZ5zx6V28x06JCtnaxspIGQhYj15/wAa7YQdr9z0411GTbV2/Qg0/VLHyEVLs2bjO4PEGB6dCc0VB9nt53bbFGuP4dn9KKtp3MXhqcnfU1fA0V5rN7dQeI55bOS5XbZyK29GfPfk7fYDrmur0nwvrdrNJDvWd4mKu4/d4HbjuMdxXf2Hh7S7N5TDYwqZJPM5XO0+3p61sgDr39a8ueOab5dvM5nmDjpDVef/AADwuXw7qS6omnW1o1vLvEKzxuwMS4yN5OSy5PQEdeor2GwtLzRfDVtbQML+7tYgpMhK+djrzzg/nWsOmOR7U4HnjpmuavinWtdbGFfFutZNbDICzxq7qEYgNtJzin44zz+NC9+KRyVUlRuIB+XPU1y9TjvcdzzgdPSoDeW4MgaeEGMZfMg+Uep9K841q513UfHunwfYb6zjtLZ590Tt5chPAXeOGP8Asnp71ydjqdvDcSX2o3wuzazH7ZEjmUnec/NhQSRyAVGB36V6FLAc6u5HbTwil8Uj2uHV7KVvkkYjGQ5jYKR9cYq9FKk0QeNg6nPPrXiUmranZC2bTdRnuFuJ2NrsDiMJngSD+Ehc5zxx+Fd/Y+LkgtYzrTKgzg3I4Qjt+Pb3pVsDKKvDUutgmlenr+Y+58HyR6qlzoupNZWctyJr2zeISxzLtwUXP3M+1ZN38MLb+yYLHS9Z1OyMBZkmJWU8nO1geo5rsdO1vT9Qt1mt7tMEZKyHYy/VTyKmu9Ts7S1a5nnQRL1Ktu59OKyVfERdtb+hkp11K2tzjdL+GtjZnzbi4+23QyTNcQhzn2BO0D2xWwvhC2WPYJ9o6gx20S4PqABW7Z3ttexLJazxyqwDfKwJHGeR1H41aJAGW4A5JPAFTLFVr6v8hvEVU9X+ByF/4CsL5ZDNcSiZlIWURxgoT3Axg/jV/R/CtpptjFbyT3V2yrtaSSTZuGc/dTAFbcM8M8rxxTRSSIAXVXBKg9MgdAccVg+J/Eb6MrtFp9xcxQlRNIqsQu44AAAJPUc9BRGtXqvkT/QaqVqj5U/0NOPRNMiAC6dafK4cbog2GHRue/vV85z26YrnLXxFN5d5/aNkIZIAWXy51cScEhevBx36Gsebx7maWCCyjWeMKzxySneqt0JUDjNH1etN23+ZX1atOVt/mv8AM7k8r+NAJA4PFec/8J7fJdIslnbtAfnZhlflzjaCT179K6iz8V6PdzNGl35cgGdsyFOOecnjse9FTCVYboVTCVqe6+7U3D1znkd/SjJHes+TV9OitHvJL+1W1Q4aVpQFB9M+vtVC28W6Hc3zWkWoxC4UA4fKhge6k9Rnj61mqU3smYezm72TNSaytpX8xoU8z++Plb8xzXkHjvwPrOi3cOueEPtOo3KxiC4gkVZXlQHK7g33sDjI54FesPrOnRzNFJewCReo3jA/HpmroIIBBBB545FbQq1KT8hqU6e/4nzTa61d3DPpkul6jBfSuf8AQ1tSMy9tzEdP0xWfdeE/Hk1wYf7ElQSMUGXUhT6nnGPevqRiSQxPPTNNIOcfh1rqeYSfQ6Pr87WWh414K+EC226fxKlo8zENshycHvyOMV6VpXh+2sbJLZ3mu0jyE+0Nu2L/AHQOwraA5z2ox9cDjmsJ4mpPRs5pV5yILe3ht12wRJEvogwKl9cnNOxSYGeaxbvqzK7b1G47jrSYyfSngc8/hRjn1ouBxvxws7u6+FUUWnSrFcDVVdcrndiCTj6mvHfB0OpXOg3MOtxzG8hG6HcAGMeeh7nn9BXuXxWt7ib4fWQtZREU1dGck4yvkvx+orxBPBk1v4wt9XS8cwI4kEZJ3HgDaD6VvhdIN36ndSb5U0dB4Juvswu4ZYZ4ZRkpExB4H8QrVuWi07T5tRvroggcbl6H0x3qLRbmR5zFfQyRGMhVkOBla2dUtNJ1G2EV7AJoY3EhBJAyO5x2reb94mU7VLy67mN4dujrFt9pSERSKcsNmNwPQ5963btGjurRrdfnjBEmOykd6u28IWECJ0iULwqqOBXK3finTLLUzp17dxIx7ytj8z/jUXu9DNv2k24rTsburXtvb6RdT3JdI0jJZl9PavHY7BfiPHJIZpIJbDcsJjTcHQ849j0/Wur8fm61jwpO2imW4ET7ZUQEq4/Lnr2pfg7p99aeHrltSiSHdJiGNFwQuPmzjrzTtZWsaRh7KDbHfDfw7c6FC5u7l5pSxA44VcdOeeak0zwDpST381/JJexTEkBskAk5HHt6+9dmWZWMfl/u1P8AF396zNU1CO3hdoLiIMoyQvGfbOMVSbBOU5e6ed2F14Cjv5LZhLbXkchTLB0GVPtXoxuLa8gtZo/3kK7TFMmHB9gf8a4RfEmja3ra2t5FpiyA7SbmAb2b2bGB+ddXp9pFp9hJb6ayWO99z7Rvjf6Z6CnZ21NXHuzto5oltxIHRUAB3E9B7muZ8Q+JbfTNRW1lt0Fm8DTzXJOAAP5n261nQa6kOpQ6PezQxSzqSrDLB8d8dMVfvrCD+zpzq93ZtYkHzPMwUUduT0FTy23OeFKNOT59SHwx4q0vxFD5cUsd6YvmMcigsB2JBrpnmjuXEU0HzfwKTx+NcBo/hzR7PTb3VfArWd3crG3Ik8wZH8OCeCfQ074c654h8TwSXN/FDBFBJs+4VZuPT2NFkwlCMveR3Go6hLZ284W2jWZYi4VXBBIzj/OKxtCvP+El8LxT+INOwGYlUkBALDoRXM3Os6N4q1q50i+njuJ7bckaR74mdl6lXHHGD164qx8P76ytfGGoeFbGDUvIgg83fdzeauQBkAYwo54PeqtFR8yXDkXN2Oy8LWdvZWoW1U7pmLuSc/QZ9AOK8V+K95Hq/iOdY5kBibZHGx4Kjt7HOT+Neu6lLLotlfJIGX9w728qjKkj+Ejtx+lfMt/NLc6nPNkNK7MW2nOaV9bvU66Ks5VHrfQ6DQ4o7aUGdCyIwMiSDGOuSpr1OHUFaOPbMJYUUBHhbBjH0+lcr4CsbOTRo5dSijvLpWwsLsQoTGfmx/nit6XwzZS7zbQGxuCCy7HbYOOnPUV3QVlsXWlTk1F3VjB1xrZdVS4tGUTsCZWi4IPbkVTiF9czySRJNcXHZjljn1NdhoscMOl232WKKK4ClJ5MBizDg5J7HjgYqTQnFtvhdnjLMWJjwM5Pp7VaT1aNfrKhCyjdrucFreja9MFNwot7VuCZE6kep5qnaXE9vMEsmguTbfMslxGJF3Do2Dnoa9Rub20skWR76GUPwySD5j68emK8g13ZYy3cmnu0VtJIdsZPJXPC4rOSUfeZNOrKonK2n9aH0D4E1GTxP4SjvJ4Da3b7op4yuELg9Rn8D+dbGmPDfQy21xAkV5APLlRD0HYqfQ1498GfFsluPK1KSFUQfO0jYKxg9cetesxae1lrlxrEMizQXqouxP0Pp+Nclk0n0a09Tgq0+RtX31RfeGOJZbaRpBFONocHnLcHn1964H4lWMWgeDrK2tPltopDv8wb9+VOS3rXYXur2kWt6dBdOsX2hmji8zgs4/hA7H3rnvioDd+H5YvKMgtpA8wHTYc4/wD1URumisJzKtFPr/wx49o95B5xgtYbdUYb2EYIYkdODn8xXcaV5nlqf7JkOeM7id3vjtXn3h+7s4rtVgjaCQsAGdt2R6Z7V6rpdtdSxZMWN2ChfGG44wc13w0je56Fadqa2I5JRMSv9nzGQY+VQMD6UU7UXltvLNzGYsjhm4DUUaM51GTV4r8z3Xd1ySPxqRcZGe9Rg8E88VItfOM8lMeMY56jmnZGOlNz7jigdgefqKgY76fjSIoDs4Jy2Op4H0pD7jilBP4UCHEleM4H9a5i98CeHLq9mvH02JLqWYzvMmQxY9SOwzjmum6gAHg06qhUlTd4uxUZuDvF6nCa/wCHDZxo+mxyNCCfMAbOwAEg4PJ54rmLrRpkkaPT9NA0pAstzdmUyF2PPCn0PNexLjAxxVOKxWC/kuYGCJID5sYX77cYOe2Oa7aWPlFWl0O6njpL4tWjwecTO941zaSGzs2WQSzcpIOxUA5444NNn1lNLurbT4IBdrPGZ98EhZRk5OS3IOex6V7pqkbxwr9i06C6aSQRyK5ChVPVjxyBxkVHL4c0m5uFubnT7Y3IwzMq4BYdyBwcVv8A2gt2jsWZxavKP5f8A8vsoLyytX1dNJuRASqyMsWHPbOD1Hv0xXeNp8EmkxC9W7iilPEMUrO0hPr2xznGMV1XI656UE85HU/hXLUxsqlnaxyVcfKo07W9DzKy8DvYRK2kh5IoI1Cx3DFGkZW3BjjqwPQn3GK9ESNrvTRHeqytJHtkBODz1+lWqQ56cYPvWNXESq2v0MKld1LXWx5xrnw9ebVGubAwywvCYHE7lX2EYKkj7w9M9MU7xD4M1jURbTJqzQtbxrmKBQDORwN7kZYAcYr0ToQR/KqWm6fBp0MkVp5u2WZ5z5khc7nOTgnoPQdBWscZUsrvbyNFjJ6N2uvI8Rv7K78OyXM2uR6lNKZfNiSNA4I9E5wV9RntWdDPd29vD/Zrz3Qnk8yV9Qy86qQMoirgA/XgV9DywxypiWOOQejKGA/Os++0XT75ALi1iwFCgqu0gdcAjpXVDME9Jo645lBu84/czw++VLmJvt9zGbeGfzkidVCohG0BierHrn2wKbYztNrhtTbTuNhcXQjAiAPRSRycHnPrXpN34B0/fJLKk94DIGjiYqQg9uOxyc8msp/AWsu8sEWpQ2lo0gcNGSzFQclTxnJHHpXVHFUmtzrjjaNm07HNzRSWuow/Z1R55QsZilk2qwXkuCc/MAScY5rT0TxB4h0y6tbW8u5L5VgKb5/ukgjG/HO/ngg4wOea6/wb4bu9M0+VNVuGuJTO7xhsHy48/Knv9T615D4m1eTR/iHf6FqQmlsZQIlltE2GPzFzn5j82M9eMEVPtadaTg1cweIo1G4z6HURfF+6XWrqCfR4GtYZpIAkNwN5ZPmL7mwAqrnOe5GO9dheeNYH0d7jTIg148W+FJ8mPcRxuK9R9K+a/iFJJod5p8Okpcwac9rujeUZMu45dtx6kkc+nTpXd/BXxK/iCS5tNWt45JrdFKzINnmZJG0gcAjtjHSsHDD+09m07o5YwoX95fcesWHjeK4uY45bGSNW2qzo+4Ix9R6Z710dtqthcytHbXttLIp27UkBOfSuHu9CubhnS2stqSAg5JUYIwRms2DwVe6Do8P9gWsELRy+bPFKGkZwT820gkk8DH0onh6LejsXWo4d25Xb53PV1PBx264oB4rxR72+iu5JL6aQSW0rXFtHasd5JG3BB+8SCfl6Cug8PeJtWmVZHhvEeQ8W99CUY+49PzrOWCktmRPL5x1TR6OJEaTyldDIOqBssB9OtOB7EY/pXmmueGdQv7m4vhb3H2y4TypE8zagXsRyOnH1rR8OavqFnJaWV+zXMMcOJJNuZGfjjHYKAT3Jz7VLw3u3i7mU8N7vNB3Oy8WwLc+Co4jjnUB+H7pq8l1/SruDU7C/gusW4zHNBj7+R/8Aqr1XxEV1DwNaywu4Q6iG5BU4EbDpXLXFkssbK7Pk87s9COhrLDScE15sw5+Rq5y91qUGnxRPfXVtbhztAds4PcZ7kVqxzwNZRTWrJNbvw0wbdu7cdjXPeIPCn9trs1CN4Zd25ZomyOOM4P6iui8KaBb6Jpgs1JlUsWJfoenP6ZrofLa/U0qSilcj1S8t9OhgF9MkRf5URELOwHYKO3PWuB8QeAoL/Xf7Vv5JWt2ZCEUAZXsD39q9Pu9O83UILpBGzRnpIucD29KFgSa8kWX94qtuCkZwe1JSQQrRivzJtPszbwR+WREm0fu1XAXj07VBckJcgCZSFHK8A57mq3jTWbjQtClu7O3E86kAKTgKvVmP0Arkdc8QrZeFRqtyyw3Vyivg88t3/LtTUXbmexnSg6ju3uO8Z+JoYtPUCaRSx4EPVv8AOK8b8R6vLdPBullETZO1s+vU+tWtVnvnulmI+1Q3MZeKWOX5SMYO30IPY96cvg/UbjSluWulhRQSI5fmI/wrVqTj+7Vz0m4wjyR2OdFw7XASS1hBHIZcgkevWty31u4m0s27T3O/hQiSFT7c96w7iCS1njikPnnGN0fJx7fStC3uzY6W0bBbpZXBJcbRHjPGev8ASs6d1dSYozlF2Og8I2wXWLG+e4k8+3kO2K6bOPqRyB0NelW7aZ4sGo+Hb5pobzlvJONnHI2nr1wa8PikuHu5Lqydba3iX55eu/H15JJ7V6P4Rv7XUtdtr+1KpfW3yKZSVEg/u+x9PyrSNpXVv+COUVODUNGJo2rH4cwCK60Z7WK8uHgmdmLOdoGG+mGzx+teqiaLRdPzYxIZ5fmAdtgIz2z35zXM/EixbxNpVlaXsOxPtAxInzPExGM47jnke9ZupeHVi1+/bUvEaQadfLHHBay5MnmIqjIXpgYIz7496mz7aHPy81ufRPexDJZX83ja3ufD1lY2momXzLw4G5043bSeOmc45Oa9WtLeMXk9xCsQlYlGbaNwAPCk9elc/pt/pukWf2+RxLaYEcd0BkkDAIPvmtj7XFDcfbsTJazR/vC6EAY+63txRK70SMq6cneK0OY+LGoRWuiC0u5lje4IEJAOSe/6Zr54t4Ypr5ZbeQB1fcV6bue3ofavb/jG1uutaHdXnly2MUcgaNj98t0II7YryWf+yrh1trG2W3TeW3tKS59OvH5U4Quk2dVBfu4qx1UFxDFAjwzmKXoQB2PYium0zXrrV3S2uHjSWJfkkY/eA7D3rmP7Pje2WRbn96oHGMkj/Ira06az+zLb3FnEl2jZ8/cV+mO2frXoNNvVHXWhTkr2uzfnsXsrV5rR/MZVMrJJ0J77T/j3rDuILzVL2CS7ZbSPy8goM4Q89upPJ5qXVp5jDFHHdl1D/NAw6jPqO1RXur3AxcRWQiiiBO0PuwPbjpQlbcyowqKPMrN669vvLf8Awi+nOxYXpLg4JmUjd9D0H/1q5jXtGti88MCNcyRk5ZFLqox1yPrWfP8AEI3VwtubXyreQ7JHAyxX6dK9E03WLO0tUWK4T7KkeFRSA3vnHPNQuWonyu9jONerDf3vI8YtbZVvHit5RK0imFnHQA9/pX0r4Ct7m18G2tpcPuliQhN7Zwo+7n8q+bZJYTrkptjmA3JfJGBjOePpXvnwx8QyahpF/bXsWZLCQRg9TJEwBUn9a55xXs9DHFa07pdSv4w1WOG78J6xdRRqzTkeXIM7SeMj3wDzWz4lCImswvlo720Nwnf5kABA/DBqTUPD9prtrp7SqcWknmRgnAB7A/pU3iq1kbT4LiIhntyScjPBGD9fpUXVkvX/AIBnCpHnjH5fjdHzha2tydTjSL9+5bISXAb8B1rvG0vUbWNYpr3yWxu8tZTx7Y7GuMF/bWXij+0YDK00b4aMDPPQ9etd/F4sj1CD7NHpb3bFt6eYm2RF9CR0x611QtbQ9CU6kZNRV1/Xcr2WliQk3N7KWAwMDdgenPaitAaXrE6+bbaZiFjkKJlYj60VrzQQ/bvpNL5o+gQBnIxTwOnqKcUAP41IsYKA85r5ls8BIYARn/CnD6/XmnKg2g89M04qMipuBGo5PHAox/Op0jDcknNIUHB5pXERgUo6e9SCMbgMnrRGgPcilcCM/pS+5p6oCSOeKURj5uTxRcCI9eMZpe4p6qCx+tJt5x70XAaetGcYz3qRYx1564pAgxRcYz17ijtxTyoHr0BpfLGCcnjBoGRE49qbk4561IRk4pNuBjJP1phcjIOe/wBKQEEkd8VIFGe9AXtk96dwKcVu8d5cTG4lkWbbtibG2PA/h781N261KVGG68CkIwxHvTvcbk2REA9qy9S0HTNSn86+sbaa42bFmeMM6DqMEjjnnitZRu29aTAI5qoycXdMm5852/ws8Ty61rP9tWkN3ZMrNbeXdBY5ZQV2nBJKgjOeM9QMVzPhPwxJ4c+K2k6fd26XbLqCxma28wBG2huVx0G4H8D2r6vcDaD3zVa3sra1nuGtoI4nuZDNMyjBkcgAsffAArr+tc3xLVbGqqvW4iRncCXzjsR1NSjII9qm2AY68VGoHHHrXM3czbZAbeEvvMMe8dCUGR+NSEbsDqAPyp684B6EUD7pPocU7sLsj71AbK33u5gi3Scu20ZJ9frVsqMD6ZpuPkz74pqTWw02til4pc2fguzWAKFGpKoQ88eU2QPf/CsE9xgjHcV0Pim2S68Naajs6hNXVwUbBJET9fasFoBll3vgEAdP8PeqoK8X6sqorqJVulDR5Y42nj69Kgh3SzsN21VAwoPf1qxcRAMV3MQGxzRZwL9pnGWxvwPYYrYSjaJFqt9b6XYy3N3KkUSD7zHAz2FNs54xZRTuyJ55GwyMBuJGQB6n2FcL8brcXUvhrTnkkFtc3qpIFIBIJA/kTWl4/wBFtZfEXhrLSiGwjmnhgDDZuj2lcjGew79qrlsl5jjBNJdzkfFPiz7L4y1PTtf+bSUjRWjQfeJxgD/PY1wnjDxLFqJmgtoswxOFhjbmNUAI6dzXZ+ILGLWNIttSvtz3TXRYsMDOUNePahEtvdyxoTtDY5NVWlKEfwPRS9ktDRtV1TVoUWKKea3tl2r5KfLECc9unNdx4ei1vU7Sa2vb5YIIht3OMscjjj6etHwe1K5trXUIYXCxhgSMZ3ZHQ/lXX66iWf2HUoEVZ5cxyLj5HX3FdWFg1FSb3IjPXl6nI3PhttOv7C3S7ZxLuO8ptA9+e30rQ8J2enq13BLFBPqsRYTecituQ427c9OKtapcSDV7OEH5Yo3ZOeQSOv6VygRr3xTDO8skUs7JG5iO3IOBW0ko2fmb8sqlNIf8S9L06wSwbTojDPJkTRqwIx1DYHT6VzQ1GWza0bTYzbiJtzSb/vn1JPSvQ/Hfhiw06y8yBpy8mFYu+c9fb2FeXO5zJBx5QG7HriuWqmm2upCXLG6Z70vjiO1g0KOa3MsOpSCGW4RsGOXIwT2wcg/nS+J/BkGu6taahfzzwtDKQHjO7IDHqD0GR1FcX8JYY9et9U0zU1EtokPmIvQoycqQR0I/rXq3h67kubBZZgrPJuzx9Tmp/vEVIqN5LY5z4k6NqOqeHf7M0RUZoZEuIY4sJvXncB2znBr0jQDcS+HtNN+qi6NtGJlHQPtGR+dUZIVRdNlQlXZ1UkejHkVzfw/8Sajq/jzxdpl7IrWdg+23QDG0B9vXvxUNXOSu+aKfY85+M99d3WvXmn+Sv2XTxEsSjhiCCSwPr/QVyGkwW9wkiGPfIDuBdSMV6h8bIIpNUtwyDMkQDHvnJwc+tec2OQdjMz/7RPPX2ropJaM9XDxuoPyN6xtXuNsS3AifuB3/AArorGG7sEaNraK9iI+5Jkf5+lchdzSLcxRqxAK5z3robS6uF05XWeQEuFPPUV2RasdVanJ7PQuWKrcaoVgtltXk4MIO4D6emfStbdFYMLDVFe3jGfnVTuc/3SecDn/9VSfC5f7U1q5a6J3RQ/KVwCctzmt34i2McdjBOGcuHKckHjH51m568pxVKv79UHtoedy2vhmylkaL7LuDHLE5xVGa5spUdrFUBUcsvP8ALpRqWhWEt4Xmh81ic5ZjV21sLayGLSJYQVB+Qd8Hv1rZRaOmCcH5HnE4umvpZHAVmOfMHAA9uwr2/wCHanUPDPlRY3NtikmDcsofrkc8AkV5d4p0u3M4ncyOwXOGbIPGa7j4J3LzWWoW7hfLMbMMDG3tgVy2cFJM5ay5U7ep65YKbffCqq0MZPkn1HbNcj4C8VXPiXTdasNZtfs2p6ezpJGM/MhyAfqDx+Vda7GPRDKuN+0EE84NLDaxG4S+K/6S6bGb+8CO/wCVcr3Z5aa1b7/kfLniGGe2125M8EIDSfJIMD8/U10/gTxKumXEqarEmH6M4xk9sYrK+I7+R4xmgVVa3bLGJh8oPPT0rn9G1Ka8vY4J0iaFQdq7fu46Y71tTqKLt3PalGNRuL2Z7hDdvrJMmm6fK7HLMF+XPqee1FcVaa5qELrAk52LGMeo9s0V3pP7OxzywlRO0bW+Z//Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Low (left) and high (right) power views of a biopsy of a normal colon. Low power reveals straight crypts and mild lamina propria mononuclear cell infiltration. High power shows the surface enterocytes with interspersed goblet cells (arrows).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Robert Odze, MD",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_43_41658=[""].join("\n");
var outline_f40_43_41658=null;
var title_f40_43_41659="Proposed criteria for PV";
var content_f40_43_41659=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F77810&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F77810&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Proposed revised WHO criteria for polycythemia vera",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Proposed criteria for PV",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Major criteria",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Hemoglobin &gt;18.5 g/dL in men, 16.5 g/dL in women or other evidence of increased red cell volume*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Presence of JAK2 617V&gt;F or other functionally similar mutation such as JAK2 exon 12 mutation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Minor criteria",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Bone marrow biopsy showing hypercellularity for age with trilineage growth (panmyelosis) with prominent erythroid, granulocytic, and megakaryocytic proliferation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Serum erythropoietin level below the reference range for normal",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Endogenous erythroid colony formation in vitro",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Diagnosis requires the presence of both major criteria and 1 minor criterion or the presence of the first major criterion together with 2 minor criteria.",
"    <div class=\"footnotes\">",
"     * Hemoglobin or hematocrit greater than 99th percentile of method-specific reference range for age, sex, altitude of residence or hemoglobin greater than 17 g/dL in men, 15 g/dL in women if associated with a documented and sustained increase of at least 2 g/dL from an individual's baseline value that can not be attributed to correction of iron deficiency, or elevated red cell mass greater than 25 percent above mean normal predicted value.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Tefferi, Ayalew, Thiele, Juergen, Orazi, Attilio, et al. Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel. Blood 2007; 110:1092. Copyright &copy;2007 American Society of Hematology.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_43_41659=[""].join("\n");
var outline_f40_43_41659=null;
var title_f40_43_41660="Anticholinergic poisoning - Rapid overview";
var content_f40_43_41660=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F74091&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F74091&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Anticholinergic poisoning: Rapid overview",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        <span style=\"color: #ff0000;\">",
"         To obtain emergent consultation with a medical toxicologist, call the United States Poison Control Network at 1-800-222-1222, or access the World Health Organization's list of international poison centers (",
"        </span>",
"        <a href=\"file://www.who.int/gho/phe/chemical_safety/poisons_centres/en/index.html\" target=\"_blank\">",
"         www.who.int/gho/phe/chemical_safety/poisons_centres/en/index.html",
"        </a>",
"        <span style=\"color: #ff0000;\">",
"         ).",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Clinical and laboratory features",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Anticholinergic toxicity is almost always a clinical diagnosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Manifestations of anticholinergic toxicity include:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Flushing due to cutaneous vasodiation (\"red as a beet\")",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Anhydrosis (\"dry as a bone\")",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Hyperthermia due to loss of sweating (\"hot as a hare\")",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Blurry vision due to nonreactive mydriasis and paralysis of accommodation (\"blind as a bat\")",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Agitated delirium (\"mad as a hatter\")",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Urinary retention (\"full as a flask\")",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Decreased bowel sounds",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Tachycardia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Diagnosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Check fingerstick glucose, ECG, acetaminophen and salicylate levels, and a qualitative pregnancy test in poisoned patients",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        A serum creatine kinase and renal function testing (BUN and creatinine) are appropriate in patients in whom rhabdomyolysis is suspected",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        No laboratory findings or diagnostic laboratory tests can definitively determine anticholinergic toxicity",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        A trial of physostigmine (see Treatment below) will help establish or rule out the diagnosis of anticholinergic toxicity",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Treatment",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Secure the airway, breathing, and circulation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Patients who manifest",
"        <strong>",
"         both peripheral AND moderate central",
"        </strong>",
"        (moderate to severe agitation/delirium) anticholinergic toxicity,",
"        <strong>",
"         without contraindications",
"        </strong>",
"        to physostigmine, should be treated with this medication; dose: 0.5 to 2 mg (0.02 mg/kg IV, up to a maximum of 0.5 mg per dose in pediatric patients); physostigmine should be given by slow IV push, generally over five minutes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Treat agitation and seizures with benzodiazepines (eg, lorazepam 1 to 2 mg IV push; may repeat as needed);",
"        <strong>",
"         DO NOT",
"        </strong>",
"        use phenothiazines or butyrophenones (eg, haloperidol)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Give activated charcoal (1 g/kg; maximum 50 g) to patients with intact mental status or a secure airway and likely ingestion of an anticholinergic agent",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_43_41660=[""].join("\n");
var outline_f40_43_41660=null;
var title_f40_43_41661="Oxalate content food AGA";
var content_f40_43_41661=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F68231&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F68231&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Oxalate content of foods",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" colspan=\"1\" rowspan=\"2\">",
"        Food group",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"3\" rowspan=\"1\">",
"        For low oxalate diet, restricted to 40-50 mg daily",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        <p>",
"         Little or no oxalate &lt;3 mg/serving",
"        </p>",
"        <p>",
"         Eat as desired",
"        </p>",
"       </td>",
"       <td class=\"subtitle2\">",
"        <p>",
"         Moderate oxalate content 2-10 mg/serving",
"        </p>",
"        <p>",
"         Limit: 2 (1/2 cup) servings day",
"        </p>",
"       </td>",
"       <td class=\"subtitle2\">",
"        <p>",
"         High oxalate &gt;10 mg/serving",
"        </p>",
"        <p>",
"         AVOID completely",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Beverages",
"       </td>",
"       <td>",
"        <p>",
"         Apple or pineapple juice",
"        </p>",
"        <p>",
"         Bottled beer",
"        </p>",
"        <p>",
"         Colas (12 oz limit/day)",
"        </p>",
"        <p>",
"         Distilled alcohol",
"        </p>",
"        <p>",
"         Orange juice (4 oz)",
"        </p>",
"        <p>",
"         Lemonade or limeaid",
"        </p>",
"        <p>",
"         Wine, red, rose",
"        </p>",
"        <p>",
"         Milk, yogurt",
"        </p>",
"        <p>",
"         Coffee",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Cranberry juice (4 oz)",
"        </p>",
"        <p>",
"         Grape juice (4 oz)",
"        </p>",
"        <p>",
"         Nescafe powder",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Draft beer",
"        </p>",
"        <p>",
"         Juices containing berries",
"        </p>",
"        <p>",
"         Ovaltine and other beverage mixes",
"        </p>",
"        <p>",
"         Cocoa",
"        </p>",
"        <p>",
"         Tomato juice (4 oz)",
"        </p>",
"        <p>",
"         Instant coffee",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Meats",
"       </td>",
"       <td>",
"        <p>",
"         Eggs",
"        </p>",
"        <p>",
"         Cheese, cheddar",
"        </p>",
"        <p>",
"         Lean lamb, beef, or pork",
"        </p>",
"        <p>",
"         Poultry, seafood",
"        </p>",
"       </td>",
"       <td>",
"        Sardines",
"       </td>",
"       <td>",
"        <p>",
"         Peanut butter",
"        </p>",
"        <p>",
"         Soybean curd (tofu)",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fruits and vegetables",
"       </td>",
"       <td>",
"        <p>",
"         Asparagus",
"        </p>",
"        <p>",
"         Avocado",
"        </p>",
"        <p>",
"         Brussels sprouts",
"        </p>",
"        <p>",
"         Cauliflower",
"        </p>",
"        <p>",
"         Cabbage",
"        </p>",
"        <p>",
"         Mushrooms",
"        </p>",
"        <p>",
"         Onions",
"        </p>",
"        <p>",
"         Potatoes",
"        </p>",
"        <p>",
"         Radishes",
"        </p>",
"        <p>",
"         Sweet corn",
"        </p>",
"        <p>",
"         Bananas",
"        </p>",
"        <p>",
"         Cherries, Bing",
"        </p>",
"        <p>",
"         Grapes, white",
"        </p>",
"        <p>",
"         Mangoes",
"        </p>",
"        <p>",
"         Melons",
"        </p>",
"        <p>",
"         Nectarines",
"        </p>",
"        <p>",
"         Pears",
"        </p>",
"        <p>",
"         Pineapple",
"        </p>",
"        <p>",
"         Plums, green/golden",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Broccoli",
"        </p>",
"        <p>",
"         Cauliflower",
"        </p>",
"        <p>",
"         Cucumber",
"        </p>",
"        <p>",
"         Green peas",
"        </p>",
"        <p>",
"         Lettuce",
"        </p>",
"        <p>",
"         Lima beans",
"        </p>",
"        <p>",
"         Tomato, 1 small",
"        </p>",
"        <p>",
"         Turnips",
"        </p>",
"        <p>",
"         Eggplant",
"        </p>",
"        <p>",
"         Apples",
"        </p>",
"        <p>",
"         Apricots",
"        </p>",
"        <p>",
"         Black currants",
"        </p>",
"        <p>",
"         Cherries, red sour",
"        </p>",
"        <p>",
"         Fruit cocktail",
"        </p>",
"        <p>",
"         Orange",
"        </p>",
"        <p>",
"         Peaches",
"        </p>",
"        <p>",
"         Plums, red",
"        </p>",
"        <p>",
"         Prunes",
"        </p>",
"        <p>",
"         Squash",
"        </p>",
"        <p>",
"         Vegetable soup",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Beans",
"        </p>",
"        <p>",
"         Beets",
"        </p>",
"        <p>",
"         Carrots",
"        </p>",
"        <p>",
"         Celery",
"        </p>",
"        <p>",
"         Swiss chard",
"        </p>",
"        <p>",
"         Chives",
"        </p>",
"        <p>",
"         Collards",
"        </p>",
"        <p>",
"         Dandelion greens",
"        </p>",
"        <p>",
"         Endive",
"        </p>",
"        <p>",
"         Escarole",
"        </p>",
"        <p>",
"         French fries",
"        </p>",
"        <p>",
"         Kale",
"        </p>",
"        <p>",
"         Leeks",
"        </p>",
"        <p>",
"         Okra",
"        </p>",
"        <p>",
"         Berries",
"        </p>",
"        <p>",
"         Concord grapes",
"        </p>",
"        <p>",
"         Red currants",
"        </p>",
"        <p>",
"         Parsnips",
"        </p>",
"        <p>",
"         Sweet potato",
"        </p>",
"        <p>",
"         Tangerines",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Breads, pasta, cereal",
"       </td>",
"       <td>",
"        <p>",
"         Macaroni",
"        </p>",
"        <p>",
"         Noodles",
"        </p>",
"        <p>",
"         Oatmeal",
"        </p>",
"        <p>",
"         Rice",
"        </p>",
"        <p>",
"         Spaghetti",
"        </p>",
"        <p>",
"         White bread",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Cornflakes",
"        </p>",
"        <p>",
"         Sponge cake",
"        </p>",
"        <p>",
"         Spaghetti, canned in tomato sauce",
"        </p>",
"        <p>",
"         Bran cereal",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Grits, white corn",
"        </p>",
"        <p>",
"         Soybean crackers",
"        </p>",
"        <p>",
"         Wheat gem",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Miscellaneous",
"       </td>",
"       <td>",
"        <p>",
"         Mayonnaise",
"        </p>",
"        <p>",
"         Salad dressing",
"        </p>",
"        <p>",
"         Vegetable oils",
"        </p>",
"        <p>",
"         Jelly or preserves (made w/allowed fruits)",
"        </p>",
"        <p>",
"         Butter",
"        </p>",
"        <p>",
"         Soups made w/allowed ingredients",
"        </p>",
"        <p>",
"         Sugar",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Chicken noodle soup, dehydrated",
"        </p>",
"        <p>",
"         Fruitcake",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Nuts",
"        </p>",
"        <p>",
"         Pretzels",
"        </p>",
"        <p>",
"         Chocolate",
"        </p>",
"        <p>",
"         Pepper (&gt;1 tsp/day)",
"        </p>",
"        <p>",
"         Vegetable soup",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: the American Gastroenterological Association. Buchman, AL, Scolapio, J, Fryer, J. AGA technical review on short bowel syndrome and intestinal transplantation. Gastroenterology 2003; 124:1111.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_43_41661=[""].join("\n");
var outline_f40_43_41661=null;
var title_f40_43_41662="HCV testing algorithm";
var content_f40_43_41662=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F64362&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F64362&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 506px\">",
"   <div class=\"ttl\">",
"    Algorithm for hepatitis C virus (HCV) testing for asymptomatic persons",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 486px; height: 509px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     ALT: Alanine aminotranferase; Anti-HCV: Antibody to HCV; EIA: Enzyme immunoassay; RIBA: Recombinant immunoblot assay; RT-PCR: Reverse transcriptase polymerase chain reaction.",
"    </div>",
"    <div class=\"reference\">",
"     Centers for Disease Control and Prevention. Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. MMWR Morb Mortal Wkly Rep 1998; 47:1.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_43_41662=[""].join("\n");
var outline_f40_43_41662=null;
var title_f40_43_41663="Heel to buttock measurement";
var content_f40_43_41663=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F61856&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F61856&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Heel to buttock measurement",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 334px; height: 304px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The heel to buttock distance is measured to assess the ability to fully flex the knee. The knee is passively flexed and the patient's tolerance to the maneuver is noted. The distance between the posterior heel and the buttocks (arrows) is measured and compared with the opposite side.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Bruce C Anderson, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_43_41663=[""].join("\n");
var outline_f40_43_41663=null;
       